<SEC-DOCUMENT>0001437749-22-005677.txt : 20220309
<SEC-HEADER>0001437749-22-005677.hdr.sgml : 20220309
<ACCEPTANCE-DATETIME>20220309154652
ACCESSION NUMBER:		0001437749-22-005677
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220309
DATE AS OF CHANGE:		20220309

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39563
		FILM NUMBER:		22725292

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			GA
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			GA
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>govx20211231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:govx="http://geovax.com/20211231" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>govx20211231_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 3/8/2022 6:14:42 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0000832489</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">GeoVax Labs, Inc.</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
<ix:nonFraction id="c81558299" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c81558300" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c81558304" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c81558305" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.01</ix:nonFraction>
<ix:nonFraction id="c81558308" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c81558309" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">10,000,000</ix:nonFraction>
<ix:nonFraction id="c81558306" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction>
<ix:nonFraction id="c81558307" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction>
<ix:nonFraction id="c81558310" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81558312" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81558311" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction>
<ix:nonFraction id="c81558313" contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction>
<ix:nonFraction id="c81558316" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c81558317" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c81558318" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">600,000,000</ix:nonFraction>
<ix:nonFraction id="c81558319" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">600,000,000</ix:nonFraction>
<ix:nonFraction id="c81558320" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">6,381,541</ix:nonFraction>
<ix:nonFraction id="c81558322" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">6,381,541</ix:nonFraction>
<ix:nonFraction id="c81558321" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834,095</ix:nonFraction>
<ix:nonFraction id="c81558323" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834,095</ix:nonFraction>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c81558630" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c81558633" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember" name="us-gaap:DebtInstrumentTerm" id="c81558703" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81558762" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c81558801" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81558815" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81558825" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-Warrants2021Member" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81558842" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c81558934" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaid" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="i_2022-01-19_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_SubsequentEventTypeAxis-SubsequentEventMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81558984" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c81558559" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">149,705</ix:nonFraction>
<ix:nonFraction id="c81558560" contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">36,902</ix:nonFraction>
<ix:nonFraction id="c81558562" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">716,790</ix:nonFraction>
<ix:nonFraction id="c81558564" contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-UnitWarrantsMember" unitRef="Share" name="govx:WarrantsIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">300,001</ix:nonFraction>
<ix:nonFraction id="c81558566" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">300,001</ix:nonFraction>
<ix:nonFraction id="c81558568" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:DeferredCompensationLiabilityConversionToEquityAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,500,000</ix:nonFraction>
<ix:nonFraction id="c81558570" contextRef="d_2020-01-01_2020-12-31_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">177,626</ix:nonFraction>
<ix:nonFraction id="c81558571" contextRef="d_2021-01-01_2021-12-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="govx:ExtinguishmentOfDebtIncludingInterestAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">172,056</ix:nonFraction>
<ix:nonFraction id="c81558574" contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">126,042</ix:nonFraction>
<ix:nonFraction id="c81558576" contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-UnitWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">303,668</ix:nonFraction>
<ix:nonFraction id="c81558578" contextRef="d_2020-01-01_2020-12-31_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="USD" name="us-gaap:DebtConversionOriginalDebtAmount1" scale="0" format="ixt:numdotdecimal" decimals="INF">1,200,000</ix:nonFraction>
<ix:nonFraction id="c81558580" contextRef="d_2020-01-01_2020-12-31_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="USD" name="govx:DebtConversionAccruedInterestAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">14,667 </ix:nonFraction></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="govx-20211231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2021-01-01_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-03-09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-09</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-21</xbrli:startDate><xbrli:endDate>2020-01-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-25</xbrli:startDate><xbrli:endDate>2020-09-25</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_NatureOfExpenseAxis-UpfrontFeesCOHAndPNPLicensemember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:UpfrontFeesCOHAndPNPLicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:EquipmentAndFurnishingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:EquipmentAndFurnishingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-28</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2018-02-28_2018-02-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-02-28</xbrli:startDate><xbrli:endDate>2018-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-05-01_2021-05-31_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-17</xbrli:startDate><xbrli:endDate>2020-04-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-05-01_2021-05-01_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-26</xbrli:startDate><xbrli:endDate>2020-06-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-InsurancePremiumFinancingCostsmember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">govx:InsurancePremiumFinancingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-InsurancePremiumFinancingCostsmember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">govx:InsurancePremiumFinancingCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-01_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-01</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CapitalUnitsTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ManagementWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-29</xbrli:startDate><xbrli:endDate>2020-09-29</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-02-11_2021-02-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-11</xbrli:startDate><xbrli:endDate>2021-02-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-30_PlanNameAxis-StockIncentivePlan2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">govx:StockIncentivePlan2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:Warrants2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:Warrants2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_RangeAxis-WeightedAverageMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-RemainingLifeOnWarrantsOutstandingmember_RangeAxis-WeightedAverageMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RemainingLifeOnWarrantsOutstandingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-ConversionOfConvertibleDebentureMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionOfConvertibleDebentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-29</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-24</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-09-28_ClassOfWarrantOrRightAxis-Warrants2021Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:Warrants2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-NIHGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NIHGrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ResearchAgreementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:ResearchAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-19_2022-01-19_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-19</xbrli:startDate><xbrli:endDate>2022-01-19</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-01-19_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-01-19_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-19</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsFirstIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsFirstIssuanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-UnitWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-UnitWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000832489</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Washington, D.C. 20549</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2021-01-01_2021-12-31">10-K</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2611;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</b></p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">For the fiscal year ended <ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2021-01-01_2021-12-31">December 31, 2021</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission File No. <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2021-01-01_2021-12-31">001-39563</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Exact name of registrant as specified in its charter)</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2021-01-01_2021-12-31">Delaware</ix:nonNumeric></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(State or other jurisdiction of </i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>incorporation or organization)</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2021-01-01_2021-12-31">1900 Lake Park Drive, Suite 380</ix:nonNumeric></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2021-01-01_2021-12-31">Smyrna</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2021-01-01_2021-12-31">GA</ix:nonNumeric></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Address of principal executive offices)</i></p> </td><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2021-01-01_2021-12-31">87-0455038</ix:nonNumeric></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(IRS Employer</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Identification Number)</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2021-01-01_2021-12-31">30080</ix:nonNumeric></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>(Zip Code)</i></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2021-01-01_2021-12-31">678</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2021-01-01_2021-12-31">384-7220</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Registrant</i>&#x2019;<i>s telephone number, including area code:</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; ">Title of each Class</span></p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; ">Trading Symbol</span></p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; ">Name of each Exchange on which Registered</span></p> </td></tr>
<tr><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">Common Stock $0.001 par value</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">GOVX</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">Nasdaq</ix:nonNumeric> Capital Market</p> </td></tr>
<tr><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">Warrants to Purchase Common Stock</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">GOVXW</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">Nasdaq</ix:nonNumeric> Capital Market</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Securities registered pursuant to Section 12(g) of the Act:<b> None</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#x2610; <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2021-01-01_2021-12-31">No</ix:nonNumeric> &#x2611;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#x2610; <ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2021-01-01_2021-12-31">No</ix:nonNumeric> &#x2611;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2021-01-01_2021-12-31">Yes</ix:nonNumeric> &#x2611; No &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2021-01-01_2021-12-31">Yes</ix:nonNumeric> &#x2611; No &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#x201c;large accelerated filer&#x201d;, &#x201c;accelerated filer&#x201d;, &#x201c;smaller reporting company&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer &#x2610; Accelerated filer &#x2610; <ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2021-01-01_2021-12-31">Non-accelerated filer</ix:nonNumeric> &#x2611; Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2611;</ix:nonNumeric> Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric> No &#x2611;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">The aggregate market value of Common Stock held by non-affiliates of the registrant on June 30, 2021, based on the closing price on that date was $<ix:nonFraction name="dei:EntityPublicFloat" scale="0" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2021-06-30">30,365,310</ix:nonFraction>.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Number of shares of Common Stock outstanding as of March 9, 2022: <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2022-03-09">7,089,025</ix:nonFraction></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Portions of the registrant&#x2019;s definitive Proxy Statement to be filed with respect to its 2022 Annual Meeting of Stockholders are incorporated by reference in Part III of this document.</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Table of Contents</span></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PART I</b></p> </td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>1</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;">&#xa0;</td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:5%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 1.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>BUSINESS</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>1</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 1A.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RISK FACTORS</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>15</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 1B.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>UNRESOLVED STAFF COMMENTS</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>27</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 2.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PROPERTIES</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>27</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 3.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>LEGAL PROCEEDINGS</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>27</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 4.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MINE SAFETY DISCLOSURES</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>27</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;">&#xa0;</td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PART II</b></p> </td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>28</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;">&#xa0;</td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 5.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MARKET FOR REGISTRANT</b>&#x2019;<b>S COMMON EQUITY, RELATED </b><b>STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>28</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 6.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>RESERVED</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>28</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 7.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>MANAGEMENT</b>&#x2019;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION </b><b>AND RESULTS OF OPERATIONS</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>28</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 7A.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>34</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 8.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>34</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 9.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING </b><b>AND FINANCIAL DISCLOSURE</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>35</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 9A.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CONTROLS AND PROCEDURES</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>35</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 9B.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>OTHER INFORMATION</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>35</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 9C.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENTS INSPECTIONS</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>35</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 83%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PART III</b></p> </td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>36</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;">&#xa0;</td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 10.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>36</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 11.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>EXECUTIVE COMPENSATION</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>36</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 12.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND </b><b>RELATED STOCKHOLDER MATTERS</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>37</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 13.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR </b><b>INDEPENDENCE</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>37</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 14.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PRINCIPAL ACCOUNTING FEES AND SERVICES</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>37</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;">&#xa0;</td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>PART IV</b></p> </td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>38</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;">&#xa0;</td>
      <td style="vertical-align: middle; width: 83%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 15.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>38</b></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: middle; width: 12%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;"><b>ITEM 16.</b></p> </td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>FORM 10-K SUMMARY</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>40</b></p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: middle; width: 12%;">&#xa0;</td>
      <td style="vertical-align: middle; width: 83%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>SIGNATURES</b></p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>41</b></p> </td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       ii
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>This Annual Report (including the following section regarding Management</i>&#x2019;<i>s Discussion and Analysis of Financial Condition and Results of Operations) contains forward-looking statements regarding our business, financial condition, results of operations and prospects. Words such as </i>&#x201c;<i>expects,</i>&#x201d;<i> </i>&#x201c;<i>anticipates,</i>&#x201d;<i> </i>&#x201c;<i>intends,</i>&#x201d;<i> </i>&#x201c;<i>plans,</i>&#x201d;<i> </i>&#x201c;<i>believes,</i>&#x201d;<i> </i>&#x201c;<i>seeks,</i>&#x201d;<i> </i>&#x201c;<i>estimates</i>&#x201d;<i> and similar expressions or variations of such words are intended to identify forward-looking statements but are not the exclusive means of identifying forward-looking statements in this Annual Report. Additionally, statements concerning future matters, including statements regarding our business, our financial position, the research and development of our products and other statements regarding matters that are not historical are forward-looking statements.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Although forward-looking statements in this Annual Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us. Consequently, forward-looking statements are inherently subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in or anticipated by the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include without limitation those discussed under the heading </i>&#x201c;<i>Risk Factors</i>&#x201d;<i> below, as well as those discussed elsewhere in this Annual Report. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this Annual Report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this Annual Report. Readers are urged to carefully review and consider the various disclosures made in this Annual Report, which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operations and prospects.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><span style="text-decoration: underline; ">PART I</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">BUSINESS</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or &#x201c;the Company&#x201d;) is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer using novel proprietary platforms. GeoVax&#x2019;s product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company&#x2019;s portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 70 granted or pending patent applications spread over 20 patent families, which are discussed in greater detail in the &#x201c;Our Intellectual Property&#x201d; section.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Product Development Pipeline</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are currently developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The table below summarizes the status of our product development programs, which are discussed in greater detail in the following pages.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Indication</span></b></p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Product Candidate</span></b></p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Current Status</span></b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Coronavirus Vaccines</span></b></p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">COVID-19 (Primary vaccine for immunocompromised patients)</p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GEO-CM04S1</p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical - Phase 2</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">COVID-19 (Booster to mRNA)</p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GEO-CM04S1</p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical &#x2013;&#xa0;Phase 2</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Pan Coronavirus</p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GEO-CM02</p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Preclinical/IND-Enabling</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Cancer Immunotherapy</span></b></p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Solid Tumors (Advanced Head and Neck Cancer)*</p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Gedeptin&#xae;</p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical - Phase 1/2</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Solid Tumors (MUC1)</p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">MVA-VLP-MUC1</p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Preclinical/IND-Enabling</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><span style="text-decoration: underline; ">Other Infectious Disease Vaccines</span></b></p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Zika**</p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GEO-ZM02</p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Preclinical/IND-Enabling</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Ebola, Marburg, Sudan**</p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GEO-EM01</p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Preclinical/IND-Enabling</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lassa Fever**</p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GEO-LM01</p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exploratory</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Malaria**</p> </td>
     <td style="vertical-align: top; width: 28%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">GEO-MM02</p> </td>
     <td style="vertical-align: top; width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Exploratory</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>* Orphan Drug status granted, as described in greater detail in the </i>&#x201c;<i>Our Intellectual Property</i>&#x201d;<i> section.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>** Indication within FDA Priority Review Voucher program</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     1
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Coronavirus Vaccine Programs</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">COVID-19, caused by SARS-CoV-2, has rapidly swept throughout the world. The World Health Organization (WHO) declared COVID-19 a public health emergency of international concern and, as of early March 2022, has reported more than 425 million cases and nearly 6 million deaths worldwide.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are currently twenty-four vaccines&#xa0;authorized for use in one or more countries around the world, including three in the United States. These vaccines are primarily designed to induce antibodies specific for the S protein of SARS-CoV-2 but rely on different mechanisms for presentation or expression of the S antigen, including recombinant proteins, whole inactivated virus, defective adenovirus vectors (three different types) or mRNA. Antiviral drugs and mAbs currently have limited availability and effectiveness. According to the U.S. Centers for Disease Control and Prevention (CDC), estimates of COVID-19 mRNA vaccine effectiveness have declined in recent months because of waning vaccine induced immunity over time, possible increased immune evasion by SARS-CoV-2 variants, or a combination of these and other factors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">SARS-CoV-2 is an enveloped, single-stranded, positive-sense RNA virus belonging to the family <i>Coronavidae</i>&#xa0;within the genus beta-coronavirus. The genome of SARS-CoV-2 encodes one large Spike (&#x201c;S&#x201d;) protein that plays a pivotal role during viral attachment to the host receptor and entry into host cells. The S protein is the major principal target for vaccines against human coronavirus, including SARS-CoV-2. Neutralizing antibodies targeting the receptor binding domain (&#x201c;RBD&#x201d;) subunit of the S protein block the virus from binding to host cells. Over 90% of all neutralizing antibodies produced in response to infection are directed to the RBD subunit, and mAbs that have shown therapeutic activity target epitopes on the RBD.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>GEO-CM04S1 for Immunocompromised Patients </b>&#x2013;<b> </b>The CDC lists immunocompromised patients, including patients who have received therapeutic procedures for hematologic malignancy, as high risk for SARS-CoV-2 disease. SARS-CoV-2 infection is expected to be very serious in this vulnerable population of hematology patients, including autologous (auto) and allogeneic (allo) hematopoietic cell transplant (HCT), and recipients of chimeric antigen receptor (CAR)-T cell therapies. Given the serious impact of other respiratory viruses in this vulnerable patient population, it is anticipated that hematology recipients of cell therapy may develop severe clinical disease, profoundly impacting the therapy outcomes, such as morbidity and survival. There is very limited data and multiple critical gaps in our knowledge of the epidemiology and clinical manifestations of SARS-CoV-2 in hematology patients as no clinical trial of an approved vaccine has focused on immunocompromised patients. Thus, the efficacy and safety of a SARS-CoV-2 vaccine has not been established in the different immunocompromised patient populations and it is possible that candidate SARS-CoV-2 vaccines may differ in their efficacy and safety for these patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our vaccine candidate, GEO-CM04S1 (formerly referred to as COH04S1), is based on a synthetic, attenuated Modified Vaccinia Ankara (sMVA) vector expressing both spike (S) and nucleocapsid (N) antigens of the SARS-CoV-2 virus and was initially developed at City of Hope (COH) for immunocompromised patients. In a placebo-controlled Phase 1 clinical trial of healthy adults conducted by COH, GEO-CM04S1 was shown to be safe and immunogenic. In November 2021, GeoVax entered into a license agreement with COH, granting GeoVax exclusive worldwide rights to further develop and commercialize the vaccine.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GEO-CM04S1 is being studied in an ongoing Phase 2 clinical trial (NCT04977024) to evaluate its safety and immunogenicity, compared to the Pfizer/BioNTech mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy. GEO-CM04S1 is the only SARS-CoV-2 vaccine that includes both S and N proteins to advance to a Phase 2 trial in cancer patients. MVA-vector based vaccines tend to produce an immune response quickly &#x2013; in less than 14 days &#x2013; with only mild side effects. The trial is also the first to compare an investigational multi-antigenic SARS-CoV-2 vaccine to the current Food and Drug Administration (FDA)-approved mRNA vaccine from Pfizer/BioNTech in people who are immunocompromised. Such patients have often shown a weak antibody response after receiving currently available COVID-19 vaccines.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>GEO-CM04S1 as a Booster Vaccine</b> &#x2013; In December 2021, patient enrollment began for the Phase 2 portion of a Phase 1/2 trial (NCT04639466) of GEO-CM0461, evaluating its use as a universal booster vaccine to current FDA-approved two-shot mRNA vaccines from Pfizer/BioNTech and Moderna. The clinical trial, titled &#x201c;Phase 1/2 Dose Escalation Study to Evaluate the Safety and Biologically Effective Dose of COH04S1, a Synthetic MVA-based SARS-CoV-2 Vaccine, Administered as One or Two Injections or as a Booster to Healthy Adult Volunteers&#x201d; is being conducted at COH.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because GEO-CM04S1 is designed to stimulate potent humoral and cellular immune responses against both the S and N proteins of SARS-CoV-2, GeoVax believes its administration as a booster will provide additional antigenic targets to the immune system resulting in a broader immune response. The GEO-CM0461 vaccine&#x2019;s MVA backbone may also be more effective at inducing immunity since MVA is known to strongly induce T cell responses even in a background of immunosuppression. In addition, GEO-CM04S1 may offer greater protection against the significant sequence variation observed with the S antigen and durability of immunity, which is well established for MVA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Phase 1 portion of the trial was designed as a dose-escalation safety study in healthy individuals between the ages of 18 to 55, who had not been previously infected with SARS-CoV-2. The primary objectives were to evaluate the safety, tolerability and immunogenicity of the GEO-CM04S1 in healthy volunteers who were administered the vaccine at three different dose levels by intramuscular (IM) injection. Follow-up studies of the volunteers are continuing in order to better assess duration of immune responses. Scientific presentations and publications of the Phase 1 trial results are planned for early 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Phase 2 booster study, for which vaccination is ongoing, will include 60 healthy individuals, 18 years of age and older, who were previously vaccinated with the two-dose regimen of one of the FDA-approved SARS-CoV-2 mRNA vaccines, manufactured by either Pfizer/BioNtech or Moderna. The study is designed as a dose-escalation trial to specifically evaluate the safety profile and immunogenicity of COH04S1 as a booster. The immunological responses measured throughout the study will include the level of SARS-CoV-2 neutralizing antibodies against SARS-CoV-2 variants of concern (VOC), including the Omicron VOC, as well as specific T-cell responses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>GEO-CM02 as a Pan-Coronavirus Vaccine</b> &#x2013; First-generation SARS-CoV-2 vaccines were rapidly developed and have proven highly efficacious in the human population.&#xa0; Most of these first-generation vaccines were designed to encode the S protein of the SARS-CoV-2 virus with the goal of inducing high levels of neutralizing antibodies. However, potential limitations of narrowly focusing on the S protein are becoming apparent with emerging variants capable of partially escaping neutralization by vaccine induced antibodies, as has been seen with the Omicron variant. Thus, the effectiveness of these vaccines against new SARS-CoV-2 variants and future coronavirus spillover events remains of immense concern.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Using its novel Modified Virus Ankara - Virus Like Particle (GV-MVA-VLP<sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup>) platform, GeoVax has developed a design strategy for vaccines expected to induce broader immunity through inclusion of multiple, genetically conserved structural and nonstructural proteins from the target pathogen. The GV-MVA-VLP<sup style="vertical-align:top;line-height:120%;font-size:pt">TM</sup> platform is known to induce a balanced antibody and cellular (T-cells) response against the multiple encoded immunogens, potentially limiting immune escape by emerging variants. Expression of the SARS-CoV-2 spike (S), membrane (M) and envelope (E) proteins by MVA supports the <i>in vivo</i> formation of virus like particles (VLPs), which induce both antibody and T-cell responses. Incorporation of other sequence-conserved structural and nonstructural proteins will provide targets for T-cell responses to increase the breadth and function of vaccine-induced immune responses. This strategy provides the basis for generating a universal vaccine with augmented potential to alleviate the burden of disease caused by circulating coronaviruses. Unique compared to other vaccines approved or under development, the GeoVax vaccine candidates are therefore specifically designed to provide a broader and more long-lived level of protective immunity against SARS-CoV-2 which should protect against emerging variants while avoiding the potential side effects that can limit vaccine utility and acceptance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax&#x2019;s lead vaccine candidate (GEO-CM02) encodes the S protein as the antibody target and the M and E proteins as T-cell targets. The combination of S, M and E protein expression supports <i>in vivo</i> VLP formation and optimal immunogenicity. In small animal studies, the Company measured functional immune responses after a single dose that mediated protection from infection and pathogenesis, including protection against the more virulent Beta variant</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In January 2021, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded the GeoVax a Small Business Innovative Research (SBIR) grant in support of the Company&#x2019;s vaccine development efforts. The Phase 1 grant, titled, &#x201c;<i>Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,</i>&#x201d; is supporting the ongoing design, construction and preclinical testing of our vaccine candidate&#x2019;s evaluation, in preparation for human clinical trials. Scientific presentations and publications of the experimental results were delivered at multiple international vaccine conferences during 2021 and publication is planned for 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     3
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Cancer Immunotherapy Programs</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Gedeptin</b><sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup><b> </b>&#x2013; Gedeptin is a novel patented product/technology for the treatment of solid tumors through a gene therapy strategy known as Gene-Directed Enzyme Prodrug Therapy (GDEPT). In September 2021, GeoVax entered into an assignment and license agreement with PNP Therapeutics, Inc. (&#x201c;PNP&#x201d;), granting GeoVax exclusive rights to develop and commercialize Gedeptin. The Gedeptin technology was developed with funding support from the National Cancer Institute (NCI), part of the NIH. GeoVax&#x2019;s license to Gedeptin includes the rights to expand the use of Gedeptin to all human diseases and/or conditions including, but not limited to, other cancers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a very toxic antitumor compound, <i>in situ</i>. A cycle of Gedeptin<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>therapy consists of three intra-tumoral injections of Gedeptin over a two-day period followed by infusion of a prodrug, fludarabine phosphate, once a day for three days. A Phase 1 dose ranging study, evaluating the safety of a single cycle of Gedeptin therapy, found the therapy to be well tolerated, with evidence of a reduction in tumor size in patients with solid tumors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A Phase 1/2 trial (NCT03754933), evaluating the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumor(s) accessible for injection and no curable treatment options, is currently enrolling at Stanford University in collaboration with Emory University. The trial design involves repeat administration using Gedeptin followed by systemic fludarabine, as a way to gain additional information prior to expansion towards a larger patient trial. The initial stage of the study is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. The FDA has also granted Gedeptin<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>orphan drug status for the intra-tumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities. In January 2022, we engaged CATO SMS, a global provider of clinical research solutions, to manage the ongoing Phase 1/2 trial, and to assist with the expansion of clinical sites and acceleration of patient enrollment and evaluation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>MUC1-based Immunotherapy</b> &#x2013; Tumors are often able to inhibit the body&#x2019;s natural immune system by producing inhibitory factors as a mechanism of immune resistance, especially against the T cells that are specific for tumor antigens and can kill cancer cells. The field of immuno-oncology has received new momentum with the discovery and commercial launch of immune checkpoint inhibitors (ICIs), a type of monoclonal antibodies (Mabs).&#xa0; ICIs block the naturally occurring and tumor-induced immune checkpoints, thus allowing functional T cells to more fully restore cellular proliferation, cytokine production and killing of tumor cells.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Unlike conventional therapies (e.g. radiation, chemotherapy, antibody, etc.), therapeutic cancer vaccines have the potential to induce responses that not only result in the control and even clearance of tumors but also establish immunological memory that can suppress and prevent tumor recurrence. Convenience, safety, and low toxicity of cancer vaccines could make them invaluable tools to be included in future immunotherapy approaches in combination with ICIs for treating tumors. Currently, there are only a few vectored cancer vaccines being tested in combination with ICIs, all of which are in early clinical stages.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">We are developing our GV-MVA-VLP&#x2122; vaccine platform that is based on the aberrantly glycosylated forms of the cell surface-associated MUC1 protein that is expressed on a wide range of cancers, including breast, colon, ovarian, prostate, pancreatic, and lung, with the goal of raising therapeutic anti-tumor antibodies and T cell responses in cancer patients.</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We have produced a MVA-VLP-MUC1 vaccine candidate, demonstrated VLP production by electron microscopy using MUC1 immunogold staining, and showed that the VLPs express a hypo-glycosylated form of MUC1 in human cell lines.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We collaborated with Dr. Olivera Finn, a leading expert in cancer immunotherapy at the University of Pittsburgh, who was one of the first to show that many tumors express an abnormal form of MUC1 that is recognized by the immune system as foreign. Our collaboration with Dr. Finn has shown that a combination of our MVA-VLP-MUC1 vaccine candidate with a MUC1 synthetic peptide was capable of breaking tolerance to human MUC1 in transgenic mice and inducing immune responses with efficacy against challenge in a lymphoma tumor model.</p> </td>
    </tr>

    <tr style="vertical-align: top;">
     <td style="width: 27pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">In 2022, we initiated an IND enabling animal study with Dr. Pinku Mukherjee at the University of North Carolina at Charlotte n to define the optimal course and schedule of vaccination to define a protocol that can be evaluated in a Phase 1 clinical trial.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">We previously collaborated with ViaMune, Inc., which has developed a fully synthetic MUC1 vaccine candidate (MTI), with the goal of developing a MUC1-based vaccine that can produce a broad spectrum of anti-tumor antibody and T cell responses. The resulting MUC1 vaccine could be combined with ICIs as a novel vaccination strategy for cancer patients with advanced MUC1+ tumors. Preclinical studies of the combined MTI and MVA-VLP-MUC1 vaccines conducted by Dr. Pinku Mukherjee have shown the combination of our vaccine with MTI and ICI have significantly reduced the tumor burden in a mouse model for colorectal cancer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">MUC1-based cancer immunotherapy is a multi-pronged effort comprised of combinations of novel technologies and products.&#xa0; GeoVax believes our approach holds significant promise to be part of the continually expanding cancer treatment options in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Hemorrhagic Fever Virus Vaccines (Ebola, Sudan, Marburg and Lassa) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ebola (EBOV, formerly designated as Zaire ebolavirus), Sudan (SUDV), and Marburg viruses (MARV) are the most virulent species of the <i>Filoviridae</i> family, causing hemorrhagic fever illnesses with up to a 90% fatality rate in humans. Lassa fever virus (LASV), a member of the <i>Arenaviridae</i> family, also causes severe and often fatal hemorrhagic illnesses in an overlapping region with Ebola. In December 2019, FDA approved the first live recombinant Ebola vaccine for prevention of Ebola disease by Zaire virus. This rVSV-ZEBOV showed safety concerns in Phase 1 trials and by virtue of being replication competent could pose threats to immunocompromised individuals, such as those infected with HIV living in West Africa where recent Ebola epidemics started.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To address the unmet need for a product that can respond to future hemorrhagic fever outbreaks, we are developing vaccines utilizing our GV-MVA-VLP&#x2122; platform. The MVA vector itself is considered safe, having originally been developed for use in immunocompromised individuals as a smallpox vaccine. We expect our vaccines may not only protect at-risk individuals against EBOV, SUDV, MARV and LASV, but also potentially reduce or modify the severity of other re-emerging pathogens such as Bundibugyo, Ivory Coast, and Reston viruses, based on antigenic cross reactivity and the elicitation of T cells to the more conserved matrix proteins (e.g. VP40 or Z) in addition to standard GP proteins used by us and other manufacturers. Thus, the GeoVax GV-MVA-VLP&#x2122; approach could offer a unique combination of advantages to achieve breadth and safety of a pan-filo vaccine. In addition to protecting people in Africa, it is intended to prevent the spread of disease to the US, and for preparedness against terrorist release of any of bio-threat pathogens.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our initial preclinical studies in rodents and nonhuman primates for our MVA-VLP-EBOV vaccine candidate have shown 100% protection against a lethal dose of EBOV upon a single immunization. Recent studies in lethal challenge guinea pig models demonstrated that GeoVax vaccines MVA-VLP-SUDV and MVA-VLP-MARV conferred 100% protection from death. These vaccines were subsequently evaluated in a rigorous cynomolgus macaque infectious challenge model. Vaccination protected nonhuman primates from viremia, weight loss and death following challenge with a dose of Sudan or Marburg virus that is lethal in nonvaccinated animals. Evaluation of immune responses following vaccination demonstrated presence of both neutralizing antibodies and functional T cells, indicating a breadth of responses that combine for optimal protection. Likewise, our initial preclinical studies in rodents for our LASV vaccine candidate have shown 100% single-dose protection against a lethal dose of LASV challenge composed of multiple strains delivered directly into the brain. The nonhuman primate studies are ongoing in collaboration with NIAID and DoD and clinical development programs will be defined based on efficacy data and global priorities as potentially dangerous outbreaks occur.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Infectious Disease Programs</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>GEO-ZM02 for Zika</b> &#x2013; Zika disease is an emerging infectious disease caused by the Zika virus (ZIKV) and has been linked to an increase in microcephaly in infants and Guillain-Barre syndrome (a neurodegenerative disease) in adults. ZIKV is a member of the <i>Flaviviridae</i> family, which includes medically important pathogens such as dengue fever, yellow fever, Japanese encephalitis, tick-borne encephalitis, and West Nile viruses. Public health officials recommend avoiding exposure to ZIKV, delaying pregnancy, and following basic supportive care (fluids, rest, and acetaminophen) after infection.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To address the unmet need for a ZIKV vaccine, we are developing novel vaccine candidates constructed using our GV-MVA-VLP platform. MVA has an outstanding safety record, which is particularly important given the need to include women of child-bearing age and newborns among those being vaccinated. Our Zika vaccine is designed based on the NS1 gene product to eliminate the risk of Antibody Dependent Enhancement (ADE), which is a serious side effect observed when a vaccinated individual doesn&#x2019;t have a fully protective immune response which actually causes a more virulent reaction if infected.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our initial preclinical studies in rodents using our GEO-ZM02 vaccine candidate demonstrated 100% single-dose protection against a lethal dose of ZIKV delivered directly into the brain. In rhesus macaques, vaccination with GEO-ZM02 induced immune responses that effectively controlled the virus replication despite the fact the vaccine is not designed to induce ZIKV neutralizing antibodies. Further development of GEO-ZM02 will be dependent upon partnering support.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>GEO-MM02 for Malaria</b> &#x2013; Globally, malaria causes 228 million infections and 405,000 deaths annually. Despite decades of vaccine research, vaccine candidates have failed to induce substantial protection (e.g. &gt;50%). Most of these vaccines are based on individual proteins that induce immune responses targeting only one stage of the malaria parasite&#x2019;s life cycle. GeoVax&#x2019;s MVA-VLP malaria vaccine candidates incorporate antigens derived from multiple stages of the parasite&#x2019;s life cycle and are designed to induce an immune response with durable functional antibodies and CD4+ and CD8+ T cell responses, all hallmarks of an ideal vaccine-induced immune response.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have collaborated with the Burnet Institute, a leading infectious diseases research institute in Australia, for the development of a vaccine to prevent malaria infection. The project included the design, construction, and characterization of multiple malaria vaccine candidates using GeoVax&#x2019;s GV-MVA-VLP&#x2122; vaccine platform combined with malaria <i>Plasmodium falciparum</i> and <i>Plasmodium vivax</i> sequences identified by the Burnet Institute. The vaccine design, construction, and characterization were performed at GeoVax with immunogenicity and challenge studies in animal models conducted at Burnet Institute using their unique functional assays. Further development of GEO-MM02 will be dependent upon additional funding support via federal grants or other sources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>HIV </b>&#x2013; Due to our corporate refocusing of development efforts prioritizing our SARS-CoV-2 and cancer immunotherapy programs, and to a lack of continuing government support for our HIV vaccine development efforts, we recently decided to discontinue active development of these programs. Our technology and intellectual property in this will remain available for out-license or partnering, but we will no longer devote any corporate resources to the programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our GV-MVA-VLP</b><sup style="vertical-align:top;line-height:120%;font-size:pt">&#x2122;</sup><b> Platform</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax&#x2019;s GV-MVA-VLP&#x2122; vaccine platform utilizes Modified Vaccinia Ankara (MVA), a large virus capable of carrying several vaccine antigens, that expresses proteins that assemble into virus-like particles (VLP) immunogens in the person receiving the vaccine. The production of VLPs in the person being vaccinated can mimic the virus production that occurs in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines can elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vaccines typically contain agents (antigens) that resemble disease-causing microorganisms. Traditional vaccines are often made from weakened or killed forms of the virus or from its surface proteins. Some newer vaccines use recombinant DNA (deoxyribonucleic acid) technology to generate vaccine antigens in bacteria or cultured cells from specific portions of the DNA sequence of the target pathogen. The generated antigens are then purified and formulated for use in a vaccine. We believe the most successful of these purified antigens have been non-infectious virus-like particles (VLPs) as exemplified by vaccines for hepatitis B (Merck&#x2019;s Recombivax&#xae; and GSK&#x2019;s Engerix&#xae;) and Papilloma viruses (GSK&#x2019;s Cervarix&#xae;, and Merck&#x2019;s Gardasil&#xae;). Our approach uses recombinant DNA and/or recombinant MVA to produce VLPs in the person being vaccinated (in vivo) reducing complexity and costs of manufacturing. In human clinical trials of our HIV vaccines, we believe we have demonstrated that our VLPs, expressed from within the cells of the person being vaccinated, can be safe, yet elicit both strong and durable humoral and cellular immune response.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">VLPs mimic authentic viruses in form but are not infectious or capable of replicating and can cause the body&#x2019;s immune system to recognize and kill targeted viruses to prevent an infection. VLPs can also train the immune system to recognize and kill virus-infected cells to control infection and reduce the length and severity of disease. One of the biggest challenges with VLP-based vaccines is to design the vaccines in such a way that the VLPs will be recognized by the immune system in the same way as the authentic virus would be. We design our vaccines such that, when VLPs for enveloped viruses like HIV, Ebola, Marburg or Lassa fever are produced <i>in vivo</i> (in the cells of the recipient), they include not only the protein antigens, but also an envelope consisting of membranes from the vaccinated individual&#x2019;s cells. In this way, they are highly similar to the virus generated in a person&#x2019;s body during a natural infection. VLPs produced <i>in vitro</i> (in a pharmaceutical plant), by contrast, have no envelope; or, envelopes from the cultured cells (typically hamster or insect cells) used to produce them. We believe our technology therefore provides distinct advantages by producing VLPs that more closely resemble the authentic viruses. We believe this feature of our immunogens allows the body&#x2019;s immune system to more readily recognize the virus. By producing VLPs <i>in vivo</i>, we believe we also avoid potential purification issues associated with <i>in vitro</i> production of VLPs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Figure 1 below shows examples of thin section electron micrographs of actual viruses and VLPs for these viruses expressed by GeoVax MVA-VLP vaccines.</p>
  <div style="text-align: center;">
   <img alt="img02.jpg" src="img02.jpg" /></div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Figure 1. Comparison of MVA-VLPs and native virus structures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the MVA-VLP platform, we take advantage of MVA&#x2019;s large &#x201c;coding capacity&#x201d; to insert genes that encode multiple proteins, the combination of which is adequate to support the generation of VLPs by the MVA infected cells. Utility has been demonstrated for multiple vaccine candidates wherein the MVA-encoded viral matrix proteins and glycoproteins assemble into VLPs. MVA was originally developed as a safer smallpox vaccine for use in immune-compromised individuals. It was developed by attenuating the standard smallpox vaccine by passaging it (over 500 passages) in chicken embryos or chicken embryo fibroblasts, resulting in a virus with limited ability to replicate in human cells (thus safe) but with high replication capability in avian cells (thus cost effective for manufacturing). The deletions also resulted in the loss of immune evasion genes which assist the spread of wild type smallpox infections, even in the presence of human immune responses.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We collaborated with the laboratory of Dr. Bernard Moss at NIH/NIAID on four different generations of MVA vectors, spanning over 15 years of collaboration, to effectively express vaccine proteins that assemble into VLPs. These efforts led to the development of different shuttle vectors and the identification of multiple insertion sites for introducing foreign genes encoding the vaccine target proteins into MVA in a manner that optimizes each product for manufacturing stability. Each MVA-VLP vaccine has up to two expression cassettes, each encoding one or more antigens selected from pathogens of interest. At a minimum, each vaccine expresses two antigens required for VLP formation; in the case of HIV and hemorrhagic fever vaccines for example, a viral matrix protein and an envelope glycoprotein. We use a synthetic early late promoter that provides high, yet not lethal, levels of insert expression, which is initiated immediately after infection in cells of the vaccinated individual.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our GV-MVA-VLP&#x2122; vaccine platform affords other advantages:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Safety:</i></b><b>&#xa0;</b>Safety for MVA, generally, has been shown in more than 120,000 subjects in Europe, including immunocompromised individuals during the initial development of MVA and more recently with the development of MVA as a safer vaccine against smallpox. Our HIV vaccines demonstrated outstanding safety in multiple human clinical trials.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Durability:</i></b><b>&#xa0;</b>Our technology raises highly durable (long-lasting) vaccine responses. We hypothesize that elicitation of durable vaccine responses is conferred on responding B cells by the vaccinia parent of MVA, which raises highly durable responses for smallpox.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Limited pre-existing immunity to vector</i></b><b>: </b>Following the eradication of smallpox in 1980, smallpox vaccinations subsequently ended, leaving all but those born before 1980 and selected populations (such as vaccinated laboratory workers and first responders) unvaccinated and without pre-existing immunity to MVA-derived vaccines. A potential interference of pre-existing immunity to a vector may be more problematic with those vectors related to parent viruses used in routine vaccinations (e.g. measles) or constitute common viruses that infect people of all ages (e.g. cytomegalovirus).</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Repeated use of the platform for different vaccines used in sequence</i></b><i>. </i>In mouse experiments, we have shown that two of our vaccines (e.g. GV-MVA-VLP-Zika followed by GV-MVA-VLP-Ebola) can be given at <span style="text-decoration: underline; ">&lt;</span>4 week intervals without any negative impact on their immunogenicity (lack of vector immunity).</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>No need for adjuvants:</i></b><b>&#xa0;</b>MVA generally stimulates strong innate immune responses and does not require the use of adjuvants.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Thermal stability:</i></b><b>&#xa0;</b>MVA is stable in both liquid and lyophilized formats (&gt; 6 years of storage).</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Genetic stability and manufacturability:</i></b><b>&#xa0;</b>If appropriately engineered, MVA is genetically stable and can reliably be manufactured in either the established Chick Embryo Fibroblast cell substrate, or novel continuous cell lines that support scalability as well as greater process consistency and efficiency.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Support from the United States Government</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grants and Contracts</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have been the recipient of multiple federal grants and contracts in support of our vaccine development programs. Our most recent awards are as follows:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lassa DoD Grant. In September 2018, the U.S. Department of Defense (DoD) awarded us a $2,442,307 cooperative agreement in support of our LASV vaccine development program. The grant was awarded by the U.S. Army Medical Research Acquisition Activity pursuant to the Peer Reviewed Medical Research Program (PRMRP), part of the Congressionally Directed Medical Research Programs (CDMRP). In addition to the grant funds provided directly to GeoVax, DoD also funded testing of our vaccine by U.S. Army scientists under a separate subaward. The award, entitled &#x201c;<i>Advanced Preclinical Development and Production of Master Seed Virus of GEO-LM01, a Novel MVA-VLP Vaccine Against Lassa Fev</i>er&#x201d;, supports generation of immunogenicity and efficacy data for our vaccine candidate in both rodent and nonhuman primate models, as well as manufacturing process development and cGMP production of vaccine seed stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">COVID-19 SBIR Grant. In January 2021, NIAID awarded us a $299,927 Phase I SBIR grant in support of our development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The grant, titled, &#x201c;<i>Preclinical Development of GV-MVA-VLP Vaccines Against COVID-19,</i>&#x201d; has supported the ongoing design, construction and preclinical testing of our vaccine candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Federal Support</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have been the recipient of additional in-kind federal support through collaborative and intramural arrangements with CDC for our Zika vaccine program, the Rocky Mountain Laboratory facility of NIAID for our hemorrhagic fever virus vaccine program, and the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) for our hemorrhagic fever virus vaccine program. This support generally has been for the conduct or support of preclinical animal studies on our behalf.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Government Regulation</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Regulation by governmental authorities in the United States and other countries is a significant factor in our ongoing research and development activities and in the manufacture of our products. Complying with these regulations involves considerable expertise, time and expense.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States, drugs and biologics are subject to rigorous federal and state regulation. Our products are regulated under the Federal Food, Drug and Cosmetic Act (FD&amp;C Act), the Public Health Service Act, and the regulations promulgated under these statutes, and other federal and state statutes and regulations. These laws govern, among other things, the testing, manufacture, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of medications and medical devices. Product development and approval within this regulatory framework is difficult to predict, takes several years and involves great expense. The steps required before a human vaccine may be marketed in the United States include:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Preclinical laboratory tests, in vivo preclinical studies and formulation studies;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Manufacturing and testing of the product under strict compliance with current Good Manufacturing Practice (cGMP) regulations;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Submission to the FDA of an Investigational New Drug application for human clinical testing which must become effective before human clinical trials can commence;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Adequate and well-controlled human clinical trials to establish the safety and efficacy of the product;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The submission of a Biologics License Application to the FDA, along with the required user fees; and</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:3.5%;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;width:auto;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDA approval of the BLA prior to any commercial sale or shipment of the product</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Before marketing any drug or biologic for human use in the United States, the product sponsor must obtain FDA approval. In addition, each manufacturing establishment must be registered with the FDA and must pass a pre-approval inspection before introducing any new drug or biologic into commercial distribution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Emergency Use Authorization (EUA) authority granted to the FDA allows the FDA to help strengthen the nation&#x2019;s public health protections against certain threats by facilitating the availability and use of medical countermeasures needed during public health emergencies. Under section 564 of the FD&amp;C Act, the FDA Commissioner may allow unapproved medical products or unapproved uses of approved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions caused by threat agents when there are no adequate, approved, and available alternatives. This potentially may provide a faster pathway to market for our COVID-19 or other infectious disease vaccine candidates. This was the approval pathway followed by Pfizer-BioNTech and Moderna for their respective COVID-19 vaccines.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because GeoVax does not manufacture vaccines for human use within our own facilities, we must ensure compliance both in our own operations and in the outsourced manufacturing operations. All FDA-regulated manufacturing establishments (both domestic establishments and foreign establishments that export products to the United States) are subject to inspections by the FDA and must comply with the FDA&#x2019;s cGMP regulations for products, drugs and devices.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The FDA determines compliance with applicable statutes and regulations through documentation review, investigations, and inspections. Several enforcement mechanisms are available to the FDA, ranging from a simple demand to correct a minor deficiency to mandatory recalls, closure of facilities, and even criminal charges for the most serious violations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Even if FDA regulatory clearances are obtained, a marketed product is subject to continual review, and later discovery of previously unknown problems or failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Whether or not the FDA has approved the drug, approval of a product by regulatory authorities in foreign countries must be obtained prior to the commencement of commercial sales of the drug in such countries. The requirements governing the conduct of clinical trials and drug approvals vary widely from country to country, and the time required for approval may be longer or shorter than that required for FDA approval.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We also are subject to various federal, state and local laws, regulations, and recommendations relating to safe working conditions, laboratory and manufacturing practices, the experimental use of animals, and the use and disposal of hazardous or potentially hazardous substances used in connection with our research. The extent of government regulation that might result from any future legislation or administrative action cannot be accurately predicted.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>FDA Tropical Disease Priority Review Voucher Program</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Section 524 of the FD&amp;C Act authorizes the FDA to award priority review vouchers (PRVs) to sponsors of approved tropical disease product applications that meet certain criteria. To qualify for a PRV, a sponsor&#x2019;s application must be for a drug or biological product for the prevention or treatment of a &#x201c;tropical disease,&#x201d; must otherwise qualify for priority review, and must contain no active ingredient (including any salt or ester of an active ingredient) that has been approved in any other application under Section 505(b)(1) of the FD&amp;C Act or section 351 of the Public Health Services Act. Priority review means that the FDA aims to render a decision in 6 months.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The PRV may be sold. For example, a small company might win a voucher for developing a drug for a neglected disease and sell the voucher to a large company for use on a commercial disease. The price of the voucher depends on supply and demand. The voucher&#x2019;s value derives from three factors: shifting sales earlier, longer effective patent life due to earlier entry, and competitive benefits from earlier entry relative to competitors. Top-selling treatments can yield billions in sales each year, so being approved months earlier can be worth hundreds of millions of dollars to the voucher. Since the first voucher sale in 2014, the price of the vouchers has ranged from $68 million to $350 million.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax believes that its vaccine programs in Ebola, Sudan, Marburg, Lassa Fever, Malaria and Zika may each be eligible for a PRV and we intend to apply for a PRV at the appropriate time. There can be no assurance, however, that we will qualify or be approved for a PRV.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Manufacturing</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To be successful, our products must be manufactured in commercial quantities in compliance with regulatory requirements and at an acceptable cost. To date, we have not commercialized any products, nor have we demonstrated that we can manufacture commercial quantities of our product candidates in accordance with regulatory requirements. If we cannot manufacture products in suitable quantities and in accordance with regulatory standards, either on our own or through contracts with third parties, it may delay clinical trials, regulatory approvals and marketing efforts for such products. Such delays could adversely affect our competitive position and our chances of achieving profitability. We cannot be sure that we can manufacture, either on our own or through contracts with third parties, such products at a cost or in quantities that are commercially viable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not currently have the facilities or internal expertise to manufacture any of the clinical or commercial supplies of any of our product. Rather, our strategy is to rely on third-party contract manufacturers to produce vaccines needed for research and clinical trials. We have arrangements with third party manufacturers for the supply of our DNA and MVA vaccines for use in our planned clinical trials. These suppliers operate under the FDA&#x2019;s Good Manufacturing Practices and (in the case of European manufacturers) similar regulations of the European Medicines Agency. We anticipate that these suppliers will be able to provide sufficient vaccine supplies to complete our currently planned clinical trials. Various contractors are generally available in the United States and Europe for manufacture of vaccines for clinical trial evaluation, however, it may be difficult to replace existing contractors for certain manufacturing and testing activities and costs for contracted services may increase substantially if we switch to other contractors. Furthermore, there is currently a shortage of vaccine manufacturing capability due to demand for potential COVID-19 vaccines, which could affect our ability to have our vaccine candidates manufactured.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The MVA component of our vaccine is currently manufactured in cells that are cultured from embryonated eggs. We are exploring a number of approaches to growing MVA in continuous cell lines that can be grown in bioreactors more suitable for commercial-scale manufacturing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The raw materials and other supplies that are used in the production process for our vaccines and that we use in our research activities are generally available from a number of commercial suppliers and we believe we will be able to obtain sufficient quantities of such materials and supplies for all foreseeable clinical investigations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Competition</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our product candidates face, and will continue to face, intense competition from large pharmaceutical companies, specialty pharmaceutical and biotechnology companies as well as academic and research institutions. We compete in an industry that is characterized by rapid technological change; evolving industry standards; emerging competition; and new product introductions. Competitors have existing products and technologies that will compete with our pipeline candidates and technologies and may develop and commercialize additional products and technologies that will compete with our pipeline candidates and technologies. Because competing companies and institutions may have greater financial resources than us, they may be able to provide broader services and product lines; and make greater investments in research and development. Competitors may also have greater development capabilities than we do and have substantially greater experience in undertaking nonclinical and clinical testing of products, obtaining regulatory approvals and manufacturing and marketing pharmaceutical products. They may also have greater name recognition and better access to customers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face general market competition from several subsectors of the vaccine development field, including large, multinational pharmaceutical companies including Sanofi, GSK, Merck, Janssen, Mitsubishi Tanabe, Takeda, and Pfizer, Inc.; mid-size pharmaceutical companies and emerging biotechnology companies including Dynavax, Novavax Inc., Moderna, BioNTech, and Hookipa; and academic and not-for-profit vaccine researchers and developers including the NIH. The industry is typified by extensive collaboration, licensing, and merger and acquisition activity despite the intense competition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">More than twenty COVID-19 vaccines are currently authorized for use in one or more countries around the world, including three in the United States (from Pfizer/BioNTech, Moderna, and Janssen). All these vaccines are based on the S protein of the SARS-CoV-2 virus, but rely on different mechanisms for presentation or expression of the S antigen, including whole, inactivated virus, defective adenovirus vectors (three different types) or mRNA. Key companies in the space with late-stage clinical or pre-approval vaccine candidates include, Novavax, Inc., AstraZeneca PLC, CureVac N.V., Medicago Inc., GSK, Sanofi S.A., Dynavax, and Valneva SE.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A number of companies are developing various types of therapeutic vaccines or other immunotherapy approaches to treat cancer including Advaxis, Immune Design, Oncothyreon, Bavarian Nordic, Roche Pharmaceuticals, Merck &amp; Co, Bristol Myers Squibb, and AstraZeneca plc.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are currently no FDA licensed and commercialized Zika vaccines, or hemorrhagic fever virus vaccines (other than for Ebola) available in the world market. We are aware of several development-stage and established enterprises, including major pharmaceutical and biotechnology firms, which are actively engaged in vaccine research and development in these areas. For hemorrhagic fever viruses, these include NewLink Genetics and Merck, Johnson &amp; Johnson, Novavax, Inovio and GlaxoSmithKline. For Zika, these include NewLink Genetics, Inovio, Merck, Butantan Institute and NIH (NIAID). In December 2019, the FDA approved the first vaccine (ERVEBO<sup style="vertical-align:top;line-height:120%;font-size:pt">&#xae;</sup>) for prevention of Ebola, developed by Merck.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are currently no commercialized vaccines to prevent malaria infection. A first-generation infection-blocking malaria vaccine, RTS, S, is under regulatory review. It requires 4 doses and has been recommended by the WHO for pilot implementation studies. Since this vaccine is based on a single antigen and has modest efficacy (30-40%, depending on the age of subjects), the WHO has defined a Road Map for developing and licensing of next generation malaria vaccines. These vaccines are expected to contain multiple antigens designed to block both infection and transmission of malaria with at least a 75% efficacy rate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our commercial success depends in part on our ability, and our licensors&#x2019; ability, to obtain and maintain proprietary protection for our clinical product candidates, including our Modified Vaccinia Ankara-Virus-Like Particle (MVA-VLP) based vaccines, our in-licensed synthetic MVA Covid-19 vaccine candidate, and our in-licensed Gedeptin gene-directed enzyme prodrug therapy, and methods of treatment using the same.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We, and in collaboration with our licensors for our in-licensed assets, seek patent protection on each of our product and developmental candidates and, where applicable, on combinations with other therapeutic and/or antigenic agents and dosing schedules. Our success also depends on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. patent applications and, where appropriate, foreign patent applications covering our proprietary technology, inventions, and improvements that are important to the development and implementation of our business. We collaborate with our licensors to ensure the filing of U.S. patent applications and, where appropriate, foreign patent applications covering our in-licensed technology, inventions, and improvements that are important to the development and implementation of our business. We also rely on trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain our proprietary position. Additionally, we expect to benefit, where appropriate, from statutory frameworks in the United States, Europe, and other countries that provide a period of clinical data exclusivity to compensate for the time required for regulatory approval of our clinical product candidates.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We continually assess and refine our intellectual property strategies as we develop new technologies and product candidates. We plan to file additional patent applications based on our intellectual property strategies where appropriate, including where we seek to improve our basic technology, adapt to competition, or to improve business opportunities. Further, we plan to file patent applications, as we consider appropriate under the circumstances, to protect new technologies that we develop. Our patent filing strategy typically includes seeking patent protection in the United States and, wherein appropriate, in additional countries where we believe such protection is likely to be useful.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December 31, 2021, our owned, co-owned, and in-licensed patent estate, on a worldwide basis, includes 19 granted U.S. patents, 3 allowed U.S. patent applications, 10 pending U.S. patent applications; 56 granted foreign patents, 20 pending foreign patent applications, 4 Patent Cooperation Treaty (PCT) applications, and 4 U.S. provisional applications spread over 25 patent families. The term of individual patents depends upon the laws of the countries in which they are obtained. In the countries in which we currently file, the patent term is 20 years from the earliest date of filing of a non-provisional patent application which serves as a priority application. In addition, we plan to seek patent term adjustments, restorations, and/or patent term extensions where applicable in the United States and other jurisdictions. For example, depending upon the timing, duration, and specifics of FDA approval of our vaccine products, some of our U.S. patents may be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the &#x201c;Hatch-Waxman Amendments,&#x201d; and codified as 35 U.S.C. &#xa7; 156. 35 U.S.C. &#xa7; 156 permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally one half the time between the effective date of an IND and the submission date of a Biologics License Application (BLA), plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved vaccine product is eligible for such an extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. A similar kind of patent extension, referred to as a Supplementary Protection Certificate, is available in Europe. Legal frameworks are also available in certain other jurisdictions to extend the term of a patent. We currently intend to seek patent term extensions on any of our, or our exclusively licensed, issued patents in any jurisdiction where we have a qualifying patent and the extension is available; however, there is no guarantee that the applicable regulatory authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. Further, even if our patent is extended, the patent, including the extended portion of the patent, may be held invalid or unenforceable by a court of final jurisdiction in the United States or a foreign country.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current patent portfolio includes 5 patent families directed to various aspects of our DNA and MVA-based HIV vaccines, their genetic inserts expressing multiple HIV protein components, composition, structure, claim of immunization against multiple subtypes of HIV, routes of administration, safety and other related factors and methods of therapeutic and prophylactic use thereof including administration regimes. We have in-licensed patents from Emory University and the U.S. National Institutes of Health (NIH) relevant to our HIV-vaccine program. These patents will expire between 2022 and 2028, exclusive of any patent term adjustments or extensions. We wholly own one patent family, including one granted U.S. patent (US 11,098,086), directed to specific vaccine administration methods which, where issued, valid, and enforceable, will expire in 2037, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We wholly own one allowed U.S. patent application directed to preventive vaccines against Ebola virus, and one pending U.S. patent application directed to Marburg virus and uses thereof. These applications, where issued, valid, and enforceable, will expire in 2036, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We wholly own one U.S. patent application directed to preventive vaccines against Zika virus and uses thereof. This application, if issued, valid, and enforceable, will expire in 2037, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We co-own one patent family with Georgia State University directed to preventive vaccines against hepatitis B virus (HBV), and uses thereof, including one granted U.S. patent (US 11,052,148). These applications, where issued, valid, and enforceable, will expire in 2037, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We wholly own one allowed U.S. patent application directed to preventive vaccines against malaria and use thereof. This application, where issued, valid, and enforceable, will expire in 2038, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We wholly own 3 patent families, which includes one allowed U.S. patent application and one granted foreign application (AU 2017206102), directed to our immuno-oncology vaccine compositions and methods of use thereof. The patent applications of these families, where issued, valid, and enforceable, will expire between 2037-2040, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We wholly own two pending patent families directed to various MVA-based vaccines for the treatment of SARS CoV-2. The patent applications in these families, if issued, valid, and enforceable, will expire between 2041-2042, exclusive of any patent term adjustments or extensions. We have non-exclusively in-licensed from the U.S. National Institutes of Health (NIH) 3 patent families directed to certain aspects of our MVA-viral backbone used in our SARS-CoV2 vaccine, which will expire between 2023 and 2032, exclusive of any patent term adjustments or extensions. We have non-exclusively in-licensed from the NIH 2 patent families relating to coronavirus spike protein compositions relevant to our MVA SARS-CoV2 vaccine candidates. The patent applications for these families, if issued, valid, and enforceable, will expire between 2037 and 2041, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We wholly one pending U.S. application directed to MVA-based vaccines for the treatment of Zika virus. The patent application, if issued, valid, and enforceable, will expire in 2037, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We co-own one patent family with Leidos, Inc. directed to viral constructs for use in enhancing T-cell priming during vaccination. The patent applications in this patent family, if issued, valid, and enforceable, will expire in 2042, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are the exclusive, worldwide licensee of several patents and patent applications, which we refer to as the Emory Technology, owned, licensed or otherwise controlled by Emory University for HIV or smallpox vaccines pursuant to a license agreement originally entered into on August 23, 2002 and restated on June 23, 2004 (the &#x201c;Emory License&#x201d;). The in-licensed Emory University patents will expire between 2022 and 2028, exclusive of any patent term extensions. Through the Emory License we are also a non-exclusive licensee of four issued United States patents owned by the NIH related to the ability of our MVA vector vaccine to operate as a vehicle to deliver HIV virus antigens, and to induce an immune response in humans. These in-licensed NIH patents will expire in 2023, exclusive of any patent term extensions.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The MVA backbone that we have been using in our vaccines was provided to us by the laboratory of Dr. Bernard Moss of the NIAID, Laboratory of Viral Diseases (LVD). We have a non-exclusive commercial license to the NIH MVA backbone for our SARS CoV-2 vaccine with the NIAID of the National Institutes of Health NIH on behalf of the United States, which includes the use of certain patents and patent applications arising from the Moss laboratory and the provided materials. We also have a non-exclusive research and development license to use the MVA backbone for our other vaccine candidates. If we later decide to commercialize vaccine candidates that are under the research and development license, we will need to negotiate appropriate commercialization licenses. These in-licensed NIH patents and patent applications, if and where issued, valid, and enforceable, will expire between 2023 and 2032, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have exclusively in-licensed three patent families from the City of Hope in the field of vaccine products targeted for prevention, reduction, amelioration or treatment of COVID-19 pursuant to an Exclusive License Agreement entered into on November 9, 2021. The in-licensed patent families are directed to synthetic MVA vectors, including synthetic MVA vaccines encoding one or more SARS-CoV-2 antigens, and their methods of production and use, and encompass COH04S1, a multi-antigenic SARS-CoV-2 vaccine currently undergoing Phase 2 human clinical trials. These in-licensed City of Hope patent families, if issued, valid, and enforceable, will expire in 2041, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have exclusively in-licensed two patent families from the University of Alabama and the Southern Research Institute pursuant to an Assignment and License Agreement with PNP Therapeutics, Inc. entered into on September 28, 2021. The two patent families are directed to the use of tail-mutant purine nucleoside phosphorylase enzymes and fludarabine for the treatment of cancer, and cover aspects of the use of our Gedeptin clinical product candidate. These in-licensed patent families, where issued, valid, and enforceable, will expire between 2029 and 2032, exclusive of any patent term adjustments or extensions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We cannot be certain that any of the current pending patent applications we have or have licensed, or any new patent applications we may file or license, will ever be issued in the United States or any other country. Even if issued, there can be no assurance that those patents will be sufficiently broad to prevent others from using our products or processes. Furthermore, our patents, as well as those we have licensed or may license in the future, may be held invalid or unenforceable by a court, or third parties could obtain patents that we would need to either license or to design around, which we may be unable to do. Current and future competitors may have licensed or filed patent applications or received patents and may acquire additional patents or proprietary rights relating to products or processes competitive to ours. In addition, any claims relating to the infringement of third-party proprietary rights, or earlier date of invention, even if not meritorious, could result in costly litigation, lengthy governmental proceedings, divert management&#x2019;s attention and resources and require us to enter royalty or license agreements which are not advantageous to us, if available at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We also expect to benefit, where appropriate, from statutory frameworks in the United States, Europe, and other countries that provide a period of regulatory exclusivity to compensate for the time and cost required in securing regulatory approval of our clinical products. For example, in 2010, the United States enacted the Biologics Price Competition and Innovation Act (BPCIA). Under the BPCIA, innovator manufacturers of biological products may be granted 12 years of exclusive use before biosimilar versions of such products can be licensed for marketing in the U.S. This means that the FDA may not approve an application for a biosimilar version of our products until 12 years after the date the product is approved for sale (with a potential six-month extension of exclusivity if certain pediatric studies are conducted and the results accepted by the FDA), although a biosimilar application may be submitted four years after the date we receive approval from the FDA to sell our product. Additionally, the BPCIA establishes procedures by which potentially relevant patents may be shared and litigation over patents may proceed in advance of approval. The BPCIA also provides incentives to biosimilar applicants by providing a period of exclusivity to the first biosimilar of a product approved by the FDA. The 12-year data exclusivity provision of the BPCIA does not prevent a competitor from seeking marketing approval of one of our products, or a product similar thereto, by submitting its own, original Biologics License Application (BLA).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We intend to benefit, where applicable, from additional market exclusivity provisions in various jurisdictions that reward the treatments of rare diseases. For example, in the United States under the Orphan Drug Act of 1983, the FDA may grant orphan designation to a vaccine product intended to prevent or treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting a BLA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication; in the latter case, because health care professionals are free to prescribe products for off-label uses, the competitor&#x2019;s product could be used for the orphan indication despite our orphan exclusivity.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are not a party to any litigation, opposition, interference, or other potentially adverse proceeding with regard to our patent positions. However, if we become involved in litigation, interference proceedings, oppositions or other intellectual property proceedings, for example as a result of an alleged infringement or a third-party alleging an earlier date of invention, we may have to spend significant amounts of money and time and, in the event of an adverse ruling, we could be subject to liability for damages, invalidation of our intellectual property and injunctive relief that could prevent us from using technologies or developing products, any of which could have a significant adverse effect on our business, financial conditions or results of operations. In addition, any claims relating to the infringement of third-party proprietary rights, or earlier date of invention, even if not meritorious, could result in costly litigation, lengthy governmental proceedings, divert management&#x2019;s attention and resources and require us to enter royalty or license agreements which are not advantageous if available at all.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to patents, we rely upon unpatented, proprietary trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees, and consultants, and invention assignment agreements with our employees. These agreements are designed to protect our proprietary information and, in the case of the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that our commercial partners, collaborators, employees, and consultants use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>License Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>City of Hope License</b> &#x2013; On November 9, 2021, we entered into an Exclusive License Agreement (COH License) with City of Hope (COH), a California nonprofit public benefit corporation, under which the Company obtained exclusive worldwide rights to further develop and commercialize COH04S1, a multi-antigenic SARS-CoV-2 vaccine currently undergoing Phase 2 human clinical trials. The COH License grants GeoVax exclusive rights to key patents, know-how, regulatory filings and clinical materials for use against COVID-19. The terms of the COH License, include an upfront fee consisting of an initial payment to COH of $5,000,000 within 30 days of the effective date of the COH License, and additional payments of $3,000,000 and $2,000,000 on the first and second anniversaries, respectively, of the effective date of the COH License. The terms also include milestone payments due upon the achievement of selected development, regulatory and sales events. The Company will also pay COH an annual royalty on net sales of products covered by the patents licensed from COH on a country-by-country and licensed product-by-licensed product basis, subject to specified reductions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Gedeptin License</b> &#x2013; On September 28, 2021, we entered into an Assignment and License Agreement (the &#x201c;Gedeptin License&#x201d;) with PNP Therapeutics, Inc. (&#x201c;PNP&#x201d;) under which the Company obtained exclusive worldwide rights to key intellectual property, including Gedeptin patents, know-how, regulatory filings, clinical materials, and trademarks. The Gedeptin patent portfolio was originally licensed from the University of Alabama at Birmingham (&#x201c;UAB&#x201d;) and Southern Research Institute (&#x201c;SRI&#x201d;) by PNP. Under the terms of the Gedeptin License, the Company is the successor to PNP under the Exclusive License Agreement between UAB, SRI and PNP, and has acquired the exclusive rights to develop and commercialize Gedeptin, a novel patented product for the treatment of solid tumors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The terms of the Gedeptin License, include (i) an upfront payment at closing, (ii) milestone payments due upon the achievement of selected development and regulatory events, and (iii) quarterly support payments for the lesser period of three years or the Company&#x2019;s filing for FDA approval of its Biologics License Application on the use of Gedeptin for the treatment of head and neck cancer in humans. The Company will also pay tiered percentage annual royalties in the low-to-mid teens on Net Sales (as defined in the Gedeptin License) of products covered under the Gedeptin License on a country-by-country and product-by-product basis, subject to specified reductions. The Company also issued a warrant to PNP, exercisable at any time following March 28, 2022, and prior to September 28, 2026, for up to 100,000 shares of the Company&#x2019;s common stock at an exercise price of $13.00 per share. The Gedeptin License will remain in effect during the original term, which concludes upon FDA approval of a generic or biosimilar product, and then will automatically renew for 5-year additional terms, subject to customary termination rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>NIH Licenses </b>&#x2013;<b> </b>On November 25, 2020, the Company entered into a Patent and Biological Materials License Agreement for Internal Research Use (the &#x201c;Research License&#x201d;) with the U.S. Department of Health and Human Services (HHS), as represented by NIAID, in support of the Company&#x2019;s non-clinical development of vaccines against numerous pathogens. The Research License allows GeoVax to use these materials and patent rights owned by agencies of the HHS in combination with the Company&#x2019;s proprietary technology for the creation of preventive and/or therapeutic Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccines against Ebola-Zaire virus, Ebola-Sudan virus, Lassa virus, Marburg virus, Zika virus and malaria. The agreement also extends to the Company&#x2019;s research and development efforts in certain oncology areas. The agreement provides GeoVax with nonexclusive rights for the nonclinical development and manufacturing of its vaccine and immunotherapy candidates using HHS patents and materials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On October 22, 2020, the Company entered into a Patent and Biological Materials License Agreement (the &#x201c;COVID License&#x201d;) with HHS, as represented by NIAID, in support of the Company&#x2019;s development of a vaccine against SARS-CoV-2, the virus that causes COVID-19. The COVID License allows GeoVax to use these materials and patent rights owned by agencies of the HHS in combination with the Company&#x2019;s proprietary technology for the creation of a preventive Modified Vaccinia Ankara Virus-Virus Like Particle (MVA-VLP) vaccine that primes and/or boosts the immune system against COVID-19. The COVID License provides GeoVax with nonexclusive rights to develop, manufacture and commercialize its COVID-19 vaccine and includes access to NIAID&#x2019;s patent rights in the stabilized SPIKE protein, which is the protein that SARS-CoV-2 uses to gain entry into human tissue.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Scientific Advisors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We seek advice from our Scientific Advisory Board, which consists of a number of leading scientists, on scientific and medical matters. The current members of our Scientific Advisory Board are:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
   <tbody>
    <tr>
     <td style="width: 20%; border-bottom: 1px solid rgb(0, 0, 0);">Name&#xa0;</td>
     <td style="width: 3%;">&#xa0;</td>
     <td style="width: 77%; border-bottom: 1px solid rgb(0, 0, 0);">Position/Institutional Affiliation&#xa0;&#xa0;&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="width: 20%;">Harriet L. Robinson, PhD.&#xa0;</td>
     <td style="width: 3%;">&#xa0;</td>
     <td style="width: 77%;">Chief Scientific Officer Emeritus, GeoVax</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="width: 20%;">Stanley A. Plotkin, MD</td>
     <td style="width: 3%;">&#xa0;</td>
     <td style="width: 77%;">Professor Emeritus, University of Pennsylvania, Adjunct Professor, Johns Hopkins University</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="width: 20%;">Barney S. Graham, MD, PhD&#xa0;</td>
     <td style="width: 3%;">&#xa0;</td>
     <td style="width: 77%;">Senior Investigator, Vaccine Research Center, NIAID</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="width: 20%; vertical-align: top;">Scott C. Weaver, PhD</td>
     <td style="width: 3%;">&#xa0;</td>
     <td style="width: 77%;">Director, University of Texas Medical Branch Institute for Human Infections and Immunity Scientific Director, Galveston National Laboratory</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="width: 20%;">Olivera J. Finn, PhD</td>
     <td style="width: 3%;">&#xa0;</td>
     <td style="width: 77%;">Distinguished Professor of Immunology and Surgery, University of Pittsburgh</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Human Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently have eleven full-time&#xa0;employees. None of our employees are covered by collective bargaining agreements and we believe that our employee relations are good. We also engage consultants and independent contractors to fulfill key roles and/or provide expert services on both an ongoing and short-term basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive compensation, opportunity for equity ownership, and a robust employment package that promotes wellness across all aspects of their lives, including healthcare, retirement planning, and paid time off.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate Background</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The predecessor of our parent company, GeoVax Labs, Inc. (the reporting entity) was originally incorporated in June 1988 under the laws of Illinois as Dauphin Technology, Inc. (&#x201c;Dauphin&#x201d;). In September 2006, Dauphin completed a merger with GeoVax, Inc. As a result of the merger, GeoVax, Inc. became a wholly owned subsidiary of Dauphin, and Dauphin changed its name to GeoVax Labs, Inc. In June 2008, the Company was reincorporated under the laws of Delaware. We currently do not conduct any business other than GeoVax, Inc.&#x2019;s business of developing new products for the treatment or prevention of human diseases. Our principal offices are in Smyrna, Georgia which is in the Atlanta metropolitan area.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Available Information</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our website address is www.geovax.com. We make our SEC filings, such as proxy statements, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports available on this website under &#x201c;Investors &#x2013; SEC Reports,&#x201d; free of charge, as soon as reasonably practicable after we electronically file or furnish such materials to the SEC. We also make available our Code of Business Conduct on this website under the heading &#x201c;Investors &#x2013; Corporate Governance&#x201d;. Information contained on our website is not incorporated into this Annual Report.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>ITEM 1A.</b></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><span style="text-decoration: underline; ">RISK FACTORS</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Ownership of our securities involves a high degree of risk. You should carefully review and consider the risks, uncertainties and other factors described below before you decide whether to own our securities. Any of these factors could materially and adversely affect our business, financial condition, operating results and prospects and could negatively impact the market price of our common stock, and you may lose some or all of your investment. The risks and uncertainties described below are not the only ones facing our Company. Additional risks and uncertainties that we are unaware of, or that we currently deem immaterial, may also impair our business operations. You should also refer to the other information contained in this Form 10-K, including our financial statements and the related notes.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Risk Factors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business is subject to numerous risks and uncertainties, discussed in more detail in the following section. These risks include, among others, the following key risks:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Risks Related to Our Business and Capital Requirements</i></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We have a history of operating losses, and we expect losses to continue for the foreseeable future.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Our business will require continued funding. If we do not receive adequate funding, we may not be able to continue our operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Significant disruptions of information technology systems or breaches of information security systems could adversely affect our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Our business could be adversely affected by widespread public health epidemics or other catastrophic events beyond our control.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Risks Related to Development and Commercialization of Product Candidates and Dependence on Third Parties</i></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Our products are still being developed and are unproven. These products may not be successful.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We depend upon key personnel who may terminate their employment with us at any time. If we were to lose the services of any of these individuals, our business and operations may be adversely affected.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Regulatory and legal uncertainties could result in significant costs or otherwise harm our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We face intense competition and rapid technological change that could result in products that are superior to the products we will be commercializing or developing.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Our product candidates are based on new medical technology and, consequently, are inherently risky. Concerns about the safety and efficacy of our products could limit our future success.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We may experience delays in our clinical trials that could adversely affect our financial results and our commercial prospects.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Failure to obtain timely regulatory approvals required to exploit the commercial potential of our products could increase our future development costs or impair our future sales.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">State pharmaceutical marketing compliance and reporting requirements may expose us to regulatory and legal action by state governments or other government authorities.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We may not be successful in establishing collaborations for product candidates we seek to commercialize, which could adversely affect our ability to discover, develop, and commercialize products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We do not have manufacturing, sales or marketing experience.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Our products under development may not gain market acceptance.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We may be required to defend lawsuits or pay damages for product liability claims.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that they will be widely used.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Risks Related to Our Intellectual Property</i></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Our success depends on our ability to obtain, maintain, protect and enforce our intellectual property and our proprietary technologies.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We could lose our license rights to our important intellectual property if we do not fulfill our contractual obligations to our licensors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Other parties may claim that we infringe their intellectual property or proprietary rights, which could cause us to incur significant expenses or prevent us from selling products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Any inability to protect our or our licensors&#x2019;&#xa0;intellectual property rights in the United States and foreign countries could limit our ability to prevent others from manufacturing or selling our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The patent protection and patent prosecution for our product candidates is dependent in part on third parties.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Risks Related to Our Common Stock</i></p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The market price of our common stock is highly volatile.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">The sale or issuance of additional shares of our common stock or other equity securities could result in additional dilution to our stockholders.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Certain provisions of our certificate of incorporation which authorize the issuance of shares of preferred stock may make it more difficult for a third party to effect a change in control.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">We have never paid dividends and have no plans to do so.&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Public company compliance may make it more difficult for us to attract and retain officers and directors.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Our Certificate of Incorporation and Bylaws may be amended by the affirmative vote of a majority of our stockholders.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">Broker-dealers may be discouraged from effecting transactions in shares of our common stock if we are considered to be a penny stock and thus subject to the penny stock rules.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Risks Related to Our Business and Capital Requirements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have a history of operating losses, and we expect losses to continue for the foreseeable future.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a research and development-focused company, we have had no product revenue to date and revenues from our government grants and other collaborations have not generated sufficient cash flows to cover operating expenses. Since our inception, we have incurred operating losses each year due to costs incurred in connection with research and development activities and general and administrative expenses associated with our operations. We incurred a net loss of $18,570,317 for the year ended December 31, 2021. We expect to incur additional operating losses and expect cumulative losses to increase as our research and development, preclinical, clinical, and manufacturing efforts expand. Our ability to generate revenue and achieve profitability depends on our ability to successfully complete the development of our product candidates, conduct preclinical tests and clinical trials, obtain the necessary regulatory approvals, and manufacture and market or otherwise commercialize our products. Unless we are able to successfully meet these challenges, we will not be profitable and may not remain in business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business will require continued funding. If we do not receive adequate funding, we may not be able to continue our operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To date, we have financed our operations principally through the sale of our equity securities and through government grants and clinical trial support. We will require substantial additional financing at various intervals for our operations, including clinical trials, operating expenses, intellectual property protection and enforcement, for pursuit of regulatory approvals, and for establishing or contracting out manufacturing, marketing and sales functions. There is no assurance that such additional funding will be available on terms acceptable to us or at all. If we are not able to secure the significant funding that is required to maintain and continue our operations at current levels, or at levels that may be required in the future, we may be required to delay clinical studies or clinical trials, curtail operations, or obtain funds through collaborative arrangements that may require us to relinquish rights to some of our products or potential markets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may pursue additional support from the federal government for our vaccine and immunotherapy development programs; however, as we progress to the later stages of our development activities, government financial support may be more difficult to obtain, or may not be available at all. Therefore, it will be necessary for us to look to other sources of funding to finance our development activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that our current working capital will be sufficient to support our planned level of operations into the second quarter of 2023. We will need to raise additional funds to significantly advance our vaccine development programs and to continue our operations. In order to meet our operating cash flow needs we plan to seek sources of non-dilutive capital through government grant programs and clinical trial support. We may also plan additional offerings of our equity securities, debt, or convertible debt instruments. Should the financing we require to sustain our working capital needs be unavailable or prohibitively expensive when we require it, the consequences could have a material adverse effect on our business, operating results, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Significant disruptions of information technology systems or breaches of information security systems could adversely affect our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely upon a combination of information technology systems and traditional recordkeeping to operate our business. In the ordinary course of business, we collect, store, and transmit confidential information (including, but not limited to, personal information and intellectual property). We have also outsourced elements of our operations to third parties, including elements of our information technology systems and, as a result, we manage a number of independent vendor relationships with third parties who may or could have access to our confidential information. Our information technology and information security systems and records are potentially vulnerable to security breaches, service interruptions, or data loss from inadvertent or intentional actions by our employees or vendors. Our information technology and information security systems and records are also potentially vulnerable to malicious attacks by third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of expertise and motives (including, but not limited to, financial crime, industrial espionage, and market manipulation).</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While we have invested, and continue to invest, a portion of our limited funds in our information technology and information security systems, there can be no assurance that our efforts will prevent security breaches, service interruptions, or data losses. Any security breaches, service interruptions, or data losses could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business, and reputational harm to us or allow third parties to gain material, inside information that they may use to trade in our securities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business could be adversely affected by widespread public health epidemics or other catastrophic events beyond our control.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to our reliance on our own employees and facilities, we depend on our collaborators, laboratories and other facilities for the continued operation of our business. Despite any precautions we take, public health epidemics, such as COVID-19, or other catastrophic events, such as natural disasters, terrorist attacks, hurricanes, fire, floods and ice and snowstorms, may result in interruptions in our business.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Although the necessary work within our laboratory and of our collaborators has continued without significant interruption from the COVID-19 pandemic, we continue to monitor the situation and may adjust our current policies as more information and guidance become available, temporarily suspending travel and limitations on doing business in-person has and could continue to negatively impact our business development efforts and create operational or other challenges, any of which could harm our business, financial condition and results of operations.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the COVID-19 pandemic could disrupt our operations due to absenteeism by infected or ill members of management or other employees because of our limited staffing. COVID-19 related illness could also impact members of our Board of Directors resulting in absenteeism from meetings of the directors or committees of directors and making it more difficult to convene the quorums of the full Board of Directors or its committees needed to conduct meetings for the management of our affairs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Risks Related to Development and Commercialization of Product Candidates and Dependence on Third Parties</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our products are still being developed and are unproven. These products may not be successful.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To become profitable, we must generate revenue through sales of our products. However, our products are in varying stages of development and testing. Our products have not been proven in human clinical trials and have not been approved by any government agency for sale. If we cannot successfully develop and prove our products and processes, or if we do not develop other sources of revenue, we will not become profitable and at some point, we would discontinue operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We depend upon key personnel who may terminate their employment with us at any time. If we were to lose the services of any of these individuals, our business and operations may be adversely affected.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The success of our business strategy will depend to a significant degree upon the continued services of key management, technical and scientific personnel and our ability to attract and retain additional qualified personnel and managers. Competition for qualified personnel is intense among companies, academic institutions and other organizations. The ability to attract and retain personnel is adversely affected by our financial challenges. If we are unable to attract and retain key personnel and advisors, it may negatively affect our ability to successfully develop, test, commercialize and market our products and product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Regulatory and legal uncertainties could result in significant costs or otherwise harm our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To manufacture and sell our products, we must comply with extensive domestic and international regulation. In order to sell our products in the United States, approval from the U.S. Food and Drug Administration (the &#x201c;FDA&#x201d;) is required. Satisfaction of regulatory requirements, including FDA requirements, typically takes many years, and if approval is obtained at all, it is dependent upon the type, complexity and novelty of the product, and requires the expenditure of substantial resources. We cannot predict whether our products will be approved by the FDA. Even if they are approved, we cannot predict the time frame for approval. Foreign regulatory requirements differ from jurisdiction to jurisdiction and may, in some cases, be more stringent or difficult to meet than FDA requirements. As with the FDA, we cannot predict if or when we may obtain these regulatory approvals. If we cannot demonstrate that our products can be used safely and successfully in a broad segment of the patient population on a long-term basis, our products would likely be denied approval by the FDA and the regulatory agencies of foreign governments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We face intense competition and rapid technological change that could result in products that are superior to the products we will be commercializing or developing.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The market for vaccines that protect against or treat human infectious diseases is intensely competitive and is subject to rapid and significant technological change. We have numerous competitors in the United States and abroad, including, among others, large companies with substantially greater resources than us. If any of our competitors develop products with efficacy or safety profiles significantly better than our products, we may not be able to commercialize our products, and sales of any of our commercialized products could be harmed. Some of our competitors and potential competitors have substantially greater product development capabilities and financial, scientific, marketing and human resources than we do. Competitors may develop products earlier, obtain FDA approvals for products more rapidly, or develop products that are more effective than those under development by us. We will seek to expand our technological capabilities to remain competitive; however, research and development by others may render our technologies or products obsolete or noncompetitive or result in treatments or cures superior to ours.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our product candidates are based on new medical technology and, consequently, are inherently risky. Concerns about the safety and efficacy of our products could limit our future success.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are subject to the risks of failure inherent in the development of product candidates based on new medical technologies. These risks include the possibility that the products we create will not be effective, that our product candidates will be unsafe or otherwise fail to receive the necessary regulatory approvals, and that our product candidates will be difficult to manufacture on a large scale or will be uneconomical to market.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many pharmaceutical products cause multiple potential complications and side effects, not all of which can be predicted with accuracy and many of which may vary from patient to patient. Long term follow-up data may reveal previously unidentified complications associated with our products. The responses of potential physicians and others to information about complications could materially adversely affect the market acceptance of our products, which in turn would materially harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may experience delays in our clinical trials that could adversely affect our financial results and our commercial prospects.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not know whether planned pre-clinical and clinical trials will begin on time or whether we will complete any of our trials on schedule, if at all. Product development costs will increase if we have delays in testing or approvals, or if we need to perform more or larger clinical trials than planned. Significant delays may adversely affect our financial results and the commercial prospects for our products and delay our ability to become profitable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely heavily on independent clinical investigators, vaccine manufacturers, and other third-party service providers for successful execution of our clinical trials, but do not control many aspects of their activities. We are responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA requires us to comply with standards, commonly referred to as Good Clinical Practices, for conducting, recording, and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. Our reliance on third parties that we do not control does not relieve us of these responsibilities and requirements. Third parties may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The failure of these third parties to carry out their obligations could delay or prevent the development, approval and commercialization of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Failure to obtain timely regulatory approvals required to exploit the commercial potential of our products could increase our future development costs or impair our future sales.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None of our vaccines are approved by the FDA for sale in the United States or by other regulatory authorities for sale in foreign countries. To exploit the commercial potential of our technologies, we are conducting and planning to conduct additional pre-clinical studies and clinical trials. This process is expensive and can require a significant amount of time. Failure can occur at any stage of testing, even if the results are favorable. Failure to adequately demonstrate safety and efficacy in clinical trials could delay or preclude regulatory approval and restrict our ability to commercialize our technology or products. Any such failure may severely harm our business. In addition, any approvals we obtain may not cover all of the clinical indications for which approval is sought or may contain significant limitations in the form of narrow indications, warnings, precautions or contraindications with respect to conditions of use, or in the form of onerous risk management plans, restrictions on distribution, or post-approval study requirements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>State pharmaceutical marketing compliance and reporting requirements may expose us to regulatory and legal action by state governments or other government authorities.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Several states have enacted legislation requiring pharmaceutical companies to establish marketing compliance programs and file periodic reports on sales, marketing, pricing and other activities. Similar legislation is being considered in other states. Many of these requirements are new and uncertain, and available guidance is limited. Unless we are in full compliance with these laws, we could face enforcement action, fines, and other penalties and could receive adverse publicity, all of which could harm our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict, and may have a significant adverse effect on our business and results of operations. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States and foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. Among policy makers and payors in the United States and elsewhere, including in the European Union, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &#x201c;Affordable Care Act&#x201d;), substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act includes a number of provisions that are intended to lower healthcare costs, including provisions relating to prescription drug prices and government spending on medical products.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Since its enactment, there have also been judicial and Congressional challenges to certain aspects of the Affordable Care Act, as well as efforts by the former Trump administration to repeal or replace certain aspects of the statute. We continue to evaluate the effect that the Affordable Care Act and subsequent changes to the statute has on our business. It is uncertain the extent to which any such changes may impact our business or financial condition.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There has also been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products. There have been several Congressional inquiries and proposed bills, as well as state efforts, designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. In June 2017, the FDA issued a Drug Competition Action plan intended to lower prescription drug prices by encouraging competition from generic versions of existing products. In July 2018, the FDA issued a Biosimilar Action Plan, intended to similarly promote competition to prescription biologics from biosimilars.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures. For example, in September 2017, the California State Assembly approved SB17, which requires pharmaceutical companies to notify health insurers and government health plans at least 60 days before any scheduled increases in the prices of their products if they exceed 16% over a two-year period, and further requiring pharmaceutical companies to explain the reasons for such increase. Effective in 2016, Vermont passed a law requiring certain manufacturers identified by the state to justify their price increases.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that these, and other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and lower reimbursement, and in downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government-funded programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our drugs, once marketing approval is obtained.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be successful in establishing collaborations for product candidates we seek to commercialize, which could adversely affect our ability to discover, develop, and commercialize products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect to seek collaborations for the development and commercialization of product candidates in the future. The timing and terms of any collaboration will depend on the evaluation by prospective collaborators of the clinical trial results and other aspects of a product&#x2019;s safety and efficacy profile. If we are unable to reach agreements with suitable collaborators for any product candidate, we will be forced to fund the entire development and commercialization of such product candidates, ourselves, and we may not have the resources to do so. If resource constraints require us to enter into a collaboration agreement early in the development of a product candidate, we may be forced to accept a more limited share of any revenues the product may eventually generate. We face significant competition in seeking appropriate collaborators. Moreover, these collaboration arrangements are complex and time-consuming to negotiate and document. We may not be successful in our efforts to establish collaborations or other alternative arrangements for any product candidate. Even if we are successful in establishing collaborations, we may not be able to ensure fulfillment by collaborators of their obligations or our expectations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We do not have manufacturing, sales or marketing experience.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not have experience in manufacturing, selling, or marketing. To obtain the expertise necessary to successfully manufacture, market, and sell our products, we must develop our own commercial infrastructure and/or collaborative commercial arrangements and partnerships. Our ability to execute our current operating plan is dependent on numerous factors, including, the performance of third-party collaborators with whom we may contract.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our products under development may not gain market acceptance.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our products may not gain market acceptance among physicians, patients, healthcare payers and the medical community. Significant factors in determining whether we will be able to compete successfully include:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the efficacy and safety of our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the time and scope of regulatory approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">reimbursement coverage from insurance companies and others;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the price and cost-effectiveness of our products, especially as compared to any competitive products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the ability to maintain patent protection; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">the market demand is not readily known.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be required to defend lawsuits or pay damages for product liability claims.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Product liability is a major risk in testing and marketing biotechnology and pharmaceutical products. We may face substantial product liability exposure in human clinical trials and for products that we sell after regulatory approval. We carry product liability insurance and we expect to continue such policies. However, product liability claims, regardless of their merits, could exceed policy limits, divert management&#x2019;s attention, and adversely affect our reputation and demand for our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that they will be widely used.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Market acceptance of products we develop, if approved, will depend on reimbursement policies and may be affected by, among other things, future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will cover and establish payment levels. We cannot be certain that reimbursement will be available for any products that we may develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for our products. If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize products that we develop.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Risks Related to Our Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our success depends on our ability to obtain, maintain, protect, and enforce our intellectual property and our proprietary</i></b> <b><i>technologies</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In general, our commercial success will depend in part on our and our licensors&#x2019; ability to obtain, maintain, protect, and enforce our intellectual property and proprietary technologies, including patent protection and trade secret protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing, misappropriating, or otherwise violating the intellectual property rights of others. If we or our licensors are unable to obtain, maintain, protect, or enforce our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed, which could have a material adverse impact on our business, results of operations, financial conditions, and prospects. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technologies, nor can there be any assurance that the patents if issued will not be infringed, misappropriated, violated, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our intellectual property is uncertain. Only limited protection may be available and may not adequately obtain, maintain, protect, and enforce our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly obtain, maintain, protect, and enforce the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We cannot be certain that the claims in our in-licensed pending patent applications will be considered patentable by the U.S. Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that claims that may ultimately issue from our patent applications will not be found invalid or unenforceable if challenged. If we or our licensors are unable to obtain or maintain patent protection with respect to our product candidates, our business, financial condition, results of operations, and prospects could be materially harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We could lose our license rights to our important intellectual property if we do not fulfill our contractual obligations to our licensors.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our rights to significant parts of the technology we use in our products are licensed from third parties and are subject to termination if we do not fulfill our contractual obligations to our licensors. Termination of intellectual property rights under any of our license agreements could adversely impact our ability to produce or protect our products. Our obligations under our license agreements include requirements that we make milestone payments to our licensors upon the achievement of clinical development and regulatory approval milestones, royalties as we sell commercial products, and reimbursement of patent filing and maintenance expenses. Should we become bankrupt or otherwise unable to fulfill our contractual obligations, our licensors could terminate our rights to critical technology that we rely upon.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Other parties may claim that we infringe their intellectual property or proprietary rights, which could cause us to incur significant expenses or prevent us from selling products</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our success will depend in part on our ability to operate without infringing the patents and proprietary rights of third parties. The manufacture, use and sale of biologic products have been subject to substantial patent litigation in the biopharmaceutical industry. Such lawsuits often relate to the validity or infringement of patents or other proprietary rights of third parties. Pharmaceutical companies, biotechnology companies, universities, research institutions or other third parties may have filed patent applications or may have been granted patents that cover aspects of our products or our licensors&#x2019; products, product candidates or other technologies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Future or existing patents issued to third parties may contain patent claims that cover our products or their use or manufacture. In particular, the patent landscape in the COVID-19 vaccine space is crowded, and a large number of patent applications have been filed by numerous entities since January 2020, including for the use of certain SARS-CoV-2 antigens and antigenic combinations, including from Moderna, Janssen Pharmaceuticals, Inc., Sementis LTD., VaxBio, Inc., Oxford University, BioNTech, Ichan School of Medicine at Mount Sinai, Diosynvax LTD., The University of Alberta, and Tonix Pharmaceuticals. We expect to be subject to infringement claims from time to time in the ordinary course of business, and third parties could assert infringement claims against us in the future with respect to our current products or with respect to products that we may develop or license. Litigation or interference proceedings could force us to:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">stop or delay selling, manufacturing or using products that incorporate, or are made using the challenged intellectual property;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">pay damages; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">enter into licensing or royalty agreements that may not be available on acceptable terms, if at all.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any litigation or interference proceedings, regardless of their outcome, would likely delay the regulatory approval process, be costly and require significant time and attention of our key management and technical personnel.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     22
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Any inability to protect our or our licensors</i></b>&#x2019;<b><i> intellectual property rights in the United States and foreign countries could limit our ability to prevent others from manufacturing or selling our products.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We will rely on trade secrets, unpatented proprietary know-how, continuing technological innovation and, in some cases, patent protection to preserve our competitive position. Our patents and licensed patent rights may be challenged, invalidated, infringed or circumvented, and the rights granted in those patents may not provide proprietary protection or competitive advantages to us. We and our licensors may not be able to develop patentable products with acceptable patent protection. Even if patent claims are allowed, the claims may not issue, or in the event of issuance, may not be sufficient to protect the technology owned by or licensed to us. If patents containing competitive or conflicting claims are issued to third parties, we may be prevented from commercializing the products covered by such patents or may be required to obtain or develop alternate technology. In addition, other parties may duplicate, design around or independently develop similar or alternative technologies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Some of our patent families and our in-licensed patent families are in an early stage of prosecution and cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents are issued from such applications, and then only to the extent the issued claims cover the third-party technology. There can be no assurance that our patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technologies. There can be no assurance that the patents if issued will not be infringed, misappropriated, violated, designed around or invalidated by third parties. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. The degree of future protection for our intellectual property is uncertain. Only limited protection may be available and may not adequately obtain, maintain, protect, and enforce our rights or permit us to gain or keep any competitive advantage. These uncertainties and/or limitations in our ability to properly obtain, maintain, protect, and enforce the intellectual property rights relating to our product candidates could have a material adverse effect on our financial condition and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may not be able to prevent third parties from infringing or using our intellectual property, and the parties from whom we may license intellectual property may not be able to prevent third parties from infringing or using the licensed intellectual property. We generally attempt to control and limit access to, and the distribution of, our product documentation and other proprietary information. Despite efforts to protect this proprietary information, unauthorized parties may obtain and use information that we may regard as proprietary. Other parties may independently develop similar know-how or may even obtain access to these technologies.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furthermore, even if our or our licensors&#x2019; patent applications are granted, the patent term may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest United States non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates have been or are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing, and regulatory review of product candidates, patents protecting our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing biotechnology patents is costly, time-consuming, and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For example, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, signed into law on September 16, 2011, includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including post-grant review, <i>inter partes</i> review, and derivation proceedings. Further, because of a lower evidentiary standard in these USPTO post-grant proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation can increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first inventor to file system in which, assuming that the other statutory requirements are met, the first inventor to file a patent application is entitled to the patent on an invention regardless of whether a third-party was the first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013, but before we file an application covering the same invention, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates and other proprietary technologies we may develop or (ii) invent any of the inventions claimed in our or our licensor&#x2019;s patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent United States Supreme Court and Federal Circuit rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. For example, recent Federal Circuit rulings such as <i>Ariad Pharms., Inc. v. Eli Lilly &amp; Co</i>., 598 F.3d 1336, 1340 (Fed. Cir. 2010) (en banc), <i>Wyeth &amp; Cordis Corp. v. Abbott Labs</i>, 720 F.3d 1380 (Fed. Cir. 2013), <i>Enzo Life Scis., Inc. v. Roche Molecular Sys.,</i> 928 F.3d 1340 (Fed. Cir. 2019), and <i>Idenix Pharms. LLC v. Gilead Scis. Inc</i>., 941 F.3d 1149 (Fed. Cir. 2019), and <i>Amgen Inc. v. Sanofi</i>, 987 F.3d 1080 (Fed. Cir. 2021) have significantly heightened the standard for securing broad claims to pharmaceutical and biological products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to heightened patentability requirements, recent Supreme Court and Federal Circuit cases relating to biosimilar product approval under the BPCIA, have held that the &#x201c;patent dance&#x201d; provisions of the statute, which are intended to resolve any patent infringement issues before the approval of a biosimilar, are discretionary, and a biosimilar applicant can opt out by refusing to provide a copy of its application and manufacturing information to the biologic sponsor (see <i>Sandoz Inc. v. Amgen Inc</i>.,137 S. Ct. 1664 (2017). It may be that we do not learn of a biosimilar application until after FDA publishes its approval (see <i>Immunex v. Samsung Bioepsis</i>, 2:19-cv-117555-CCC-MF (D.N.J. Apr. 30, 2019). In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the United States federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The patent protection and patent prosecution for our product candidates is dependent in part on third parties.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We or our licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example, with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors, fail to establish, maintain, or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance, or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our license agreements. We have not had and do not have primary control over these activities for our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Pursuant to the terms of the license agreements with some of our licensors, the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our licensors fail to appropriately prosecute and maintain patent protection for patents covering our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using, and selling competing products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our technology acquired or licensed from various third parties may be subject to retained rights. Our predecessors or licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for non-commercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the research resulting in certain of our in-licensed patent rights and technology was funded in part by the United States government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The United States government also has the right to take title to these inventions if the applicable licensor fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to United States industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations, and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Risks Related to Our Common Stock</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The market price of our common stock is highly volatile.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The market price of our common stock has been, and is expected to continue to be, highly volatile. Certain factors, including announcements of new developments by us or other companies, regulatory matters, new or existing medicines or procedures, concerns about our financial position, operating results, litigation, government regulation, developments or disputes relating to agreements, patents or proprietary rights, may have a significant impact on the market price of our stock. In addition, potential dilutive effects of future sales of shares of common stock by us, and subsequent sales of common stock by the holders of our options and warrants could have an adverse effect on the market price of our shares.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the securities markets from time-to-time experience significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     25
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The sale or issuance of additional shares of our common stock or other equity securities could result in additional dilution to our stockholders.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In order to meet our operating cash flow needs, we may plan additional offerings of our equity securities, debt, or convertible debt instruments. The sale of additional equity securities could result in significant additional dilution to our stockholders. The incurrence of indebtedness could result in debt service obligations and operating and financing covenants that would restrict our operations. We cannot assure investors that financing will be available in amounts or on terms acceptable to us, if at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are obligated to issue additional shares of our common stock in connection with our outstanding warrants if the warrant holders choose to exercise them. There are outstanding pre-funded warrants exercisable for 2,360,000 shares at a nominal exercise price, and other outstanding warrants are exercisable for 5,884,115 shares at exercise prices ranging from $3.26 to $13.00 per share. The exercise of these warrants will cause us to issue additional shares of our common stock and will dilute the percentage ownership of our shareholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Certain provisions of our certificate of incorporation which authorize the issuance of shares of preferred stock may make it more difficult for a third party to effect a change in control.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our certificate of incorporation authorizes our Board of Directors to issue up to 10,000,000 shares of preferred stock. The shares of preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our Board of Directors without further action by the stockholders. These terms may include voting rights, including the right to vote as a series on particular matters, preferences as to dividends and liquidation, conversion rights, redemption rights and sinking fund provisions. The issuance of any newly issued preferred stock could diminish the rights of holders of our common stock, and therefore could reduce the value of our common stock. In addition, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell assets to, a third party. The ability of our Board of Directors to issue preferred stock could make it more difficult, delay, discourage, prevent or make it costlier to acquire or effect a change-in-control, which in turn could prevent the stockholders from recognizing a gain in the event that a favorable offer is extended and could materially and negatively affect the market price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have never paid dividends and have no plans to do so.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Holders of shares of our common stock are entitled to receive such dividends as may be declared by our Board of Directors. To date, we have paid no cash dividends on our shares of common stock and we do not expect to pay cash dividends on our common stock in the foreseeable future. We intend to retain future earnings, if any, to provide funds for operations of our business. Therefore, any potential return investors may have in our common stock will be in the form of appreciation, if any, in the market value of their shares of common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Public company compliance may make it more difficult for us to attract and retain officers and directors.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Sarbanes-Oxley Act, the Dodd-Frank Act, the JOBS Act, the FAST Act, and rules subsequently implemented by the SEC have required changes in corporate governance practices of public companies. As a public company, we expect these rules and regulations, and amendments to them, to contribute to our compliance costs and to make certain activities more time consuming and costly. As a public company, we also expect that these rules and regulations may make it difficult and expensive for us to obtain director and officer liability insurance and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be difficult for us to attract and retain qualified persons to serve on our board of directors or as executive officers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our Certificate of Incorporation and Bylaws may be amended by the affirmative vote of a majority of our stockholders. </i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Delaware General Corporation Law, a corporation&#x2019;s certificate of incorporation may be amended by the affirmative vote of the holders of a majority of the outstanding shares entitled to vote, and a majority of the outstanding shares of each class entitled to vote as a class, unless the articles require the vote of a larger percentage of shares. Our Certificate of Incorporation, as amended, does not require the vote of a larger percentage of shares. As permitted under the Delaware General Corporation Law, our Bylaws give our board of directors the power to adopt, amend, or repeal our Bylaws. Our stockholders entitled to vote have concurrent power to adopt, amend, or repeal our Bylaws.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     26
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Broker-dealers may be discouraged from effecting transactions in shares of our common stock if we are considered to be a penny stock and thus subject to the penny stock rules.</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The SEC has adopted a number of rules to regulate &#x201c;penny stocks&#x201d; that restrict transactions involving stock which is deemed to be penny stock. Such rules include Rules 3a51-1, 15g-1, 15g-2, 15g-3, 15g-4, 15g-5, 15g-6, 15g-7, and 15g-9 under the Exchange Act. These rules may have the effect of reducing the liquidity of penny stocks. &#x201c;Penny stocks&#x201d; generally are equity securities with a price of less than $5.00 per share (other than securities registered on certain national securities exchanges or quoted on Nasdaq if current price and volume information with respect to transactions in such securities is provided by the exchange or system). Our securities have in the past constituted, and may again in the future, if we are delisted from Nasdaq, constitute, &#x201c;penny stock&#x201d; within the meaning of the rules. The additional sales practice and disclosure requirements imposed upon U.S. broker-dealers may discourage broker-dealers from effecting transactions in shares of our common stock, which could severely limit the market liquidity of such shares and impede their sale in the secondary market.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A U.S. broker-dealer selling penny stock to anyone other than an established customer or &#x201c;accredited investor&#x201d; (generally, an individual with net worth in excess of $1,000,000 (exclusive of personal residence) or an annual income exceeding $200,000, or $300,000 together with his or her spouse) must make a special suitability determination for the purchaser and must receive the purchaser&#x2019;s written consent to the transaction prior to sale, unless the broker-dealer or the transaction is otherwise exempt. In addition, the &#x201c;penny stock&#x201d; regulations require the U.S. broker-dealer to deliver, prior to any transaction involving a &#x201c;penny stock&#x201d;, a disclosure schedule prepared in accordance with SEC standards relating to the &#x201c;penny stock&#x201d; market, unless the broker-dealer or the transaction is otherwise exempt. A U.S. broker-dealer is also required to disclose commissions payable to the U.S. broker-dealer and the registered representative and current quotations for the securities. Finally, a U.S. broker-dealer is required to submit monthly statements disclosing recent price information with respect to the &#x201c;penny stock&#x201d; held in a customer&#x2019;s account and information with respect to the limited market in &#x201c;penny stocks&#x201d;.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stockholders should be aware that, according to the SEC, the market for &#x201c;penny stocks&#x201d; has suffered in recent years from patterns of fraud and abuse. Such patterns include (i) control of the market for the security by one or a few broker-dealers that are often related to the promoter or issuer; (ii) manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; (iii) &#x201c;boiler room&#x201d; practices involving high-pressure sales tactics and unrealistic price projections by inexperienced sales persons; (iv) excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and (v) the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, resulting in investor losses. Our management is aware of the abuses that have occurred historically in the penny stock market. Although we do not expect to be in a position to dictate the behavior of the market or of broker-dealers who participate in the market, management will strive within the confines of practical limitations to prevent the described patterns from being established with respect to our securities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>ITEM 1B.</b></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><span style="text-decoration: underline; ">UNRESOLVED STAFF COMMENTS</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 2.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">PROPERTIES</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our principal executive offices are located in Smyrna, Georgia, where we lease approximately 8,400 square feet of office and laboratory space. Our lease for the premises is currently scheduled to terminate on December 31, 2022. We do not currently own any real property. We believe that our current facilities are adequate to meet our immediate needs and believe that we will be able to renew our lease without an adverse impact on our operations. In addition, we believe that if we require additional space, we will be able to obtain additional facilities on commercially reasonable terms.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 3.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">LEGAL PROCEEDINGS</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are not currently a party to any material legal proceedings. We may from time to time become involved in various legal proceedings such as those arising in the ordinary course of business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 4.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">MINE SAFETY DISCLOSURES </span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     27
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><span style="text-decoration: underline; ">PART II</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 5.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">MARKET FOR REGISTRANT</span></b><span style="text-decoration: underline; ">&#x2019;</span><b><span style="text-decoration: underline; ">S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Market Information</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our common stock is currently traded on The Nasdaq Capital Market under the symbol &#x201c;GOVX&#x201d;.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Holders</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On March 9, 2022, there were 12 holders of record of our common stock. The majority of our shares of common stock are held by brokers and other institutions on behalf of stockholders, and we are unable to estimate the total number of stockholders represented by these record holders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dividends</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have never declared or paid cash dividends on our common stock and do not anticipate paying any dividends on our common stock in the foreseeable future. We expect to retain future earnings, if any, for reinvestment in our business. We will not be permitted to pay dividends on our common stock unless all dividends on any preferred stock that may be issued have been paid in full. We currently do not have any plans to issue additional preferred stock. Any credit agreements which we may enter into may also restrict our ability to pay dividends. The payment of dividends in the future will be subject to the discretion of our board of directors and will depend, among other things, on our financial condition, results of operations, cash requirements, future prospects and any other factors our board of directors deems relevant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Sales of Unregistered Securities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were no sales of unregistered securities during the period covered by this report that have not previously been reported on a Current Report on Form 8-K or a Quarterly Report Form 10-Q.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Issuer Purchases of Equity Securities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We did not repurchase any of our equity securities during the fourth quarter of 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 6.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">RESERVED</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not Applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 7.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">MANAGEMENT</span></b><span style="text-decoration: underline; ">&#x2019;</span><b><span style="text-decoration: underline; ">S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following discussion and analysis of our financial condition and results of operations should be read together with &#x201c;Selected Financial Data&#x201d; and our consolidated financial statements and the related notes beginning on page F-1. This discussion contains forward-looking statements that involve risks and uncertainties because they are based on current expectations and relate to future events and our future financial performance. Our actual results may differ materially from those anticipated in these forward-looking statements because of many important factors, including those set forth under &#x201c;Risk Factors&#x201d; and elsewhere in this Annual Report.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview and Recent Developments</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax&#x2019;s product pipeline includes ongoing human clinical trials in COVID-19 and head and neck cancer. Additional research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for solid tumors. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GEO-CM04S1 License</i> - In November 2021, GeoVax entered into a license agreement with City of Hope (the &#x201c;COH License&#x201d;), granting GeoVax exclusive rights to further develop and commercialize GEO-CM04S1 (formerly referred to as COH04S1). GEO-CM04S1, a synthetic, attenuated modified vaccinia Ankara (sMVA) vector expressing Spike and Nucleocapsid antigens of the SARS-CoV-2 virus, was initially developed at COH for immunocompromised patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GEO-CM04S1 is being studied in an ongoing Phase 2 clinical trial to evaluate its safety and immunogenicity, compared to the Pfizer mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy. GEO-CM04S1 is the only COVID-19 vaccine that includes both SARS-CoV-2 spike and nucleocapsid proteins to advance to a Phase 2 trial in cancer patients. Such vaccines also tend to produce an immune response quickly &#x2013; in less than 14 days &#x2013; with only mild side effects. The trial is also the first to compare an investigational multi-antigenic COVID-19 vaccine to the current Food and Drug Administration (FDA)-approved mRNA vaccine from Pfizer/BioNTech in people who are immunocompromised. Such patients have often shown a weak antibody response after receiving currently available COVID-19 vaccines.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In December 2021, patient enrollment began for the Phase 2 portion of a Phase 1/2 trial of GEO-CM04S1, to study its use as a universal booster vaccine to current FDA-approved vaccines. GeoVax believes that the GEO-CM04S1 vaccine, when administered as a heterologous booster, will provide additional recognition elements to the immune system over a homologous boost from mRNA vaccines such as those developed by Moderna or Pfizer, which are directed only toward SARS-CoV-2 Spike protein. The COH04S1 vaccine&#x2019;s MVA backbone may be more effective at inducing COVID-19 immunity since MVA strongly induces T cell responses even in a background of immunosuppression. In addition, GEO-CM04S1 targeting of both Spike and Nucleocapsid antigens, may offer greater protection against the significant sequence variation observed with the Spike antigen.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Gedeptin</i>&#xae;<i> License</i> - In September 2021, GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc. (the &#x201c;Gedeptin License), whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#xae;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase 1/2 clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and no curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#x2019;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but not limited to, cancers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our corporate strategy is to advance, protect and exploit our differentiated vaccine/immunotherapy technologies leading to the successful development of preventive and therapeutic vaccines and immunotherapies against infectious diseases and various cancers. Our goal is to advance products through to human clinical testing, and to seek partnership or licensing arrangements for achieving regulatory approval and commercialization. We also leverage third party resources through collaborations and partnerships for preclinical and clinical testing with multiple government, academic and corporate entities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have not generated any revenues from the sale of the products we are developing, and we do not expect to generate any such revenues for at least the next several years. Our product candidates will require significant additional research and development efforts, including extensive preclinical and clinical testing. All product candidates that we advance to clinical testing will require regulatory approval prior to commercial use and will require significant costs for commercialization. We may not be successful in our research and development efforts, and we may never generate sufficient product revenue to be profitable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     29
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Change</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Grant and collaboration revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">385,501</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,823,658</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,438,157</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Operating expenses:</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 46.7%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">15,554,171</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,444,459</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">13,109,712</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,577,153</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,196,014</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,381,139</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total operating expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">19,131,324</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">4,640,473</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">14,490,851</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Loss from operations</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(18,745,823</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,816,815</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(15,929,008</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total other income (expense)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">175,506</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(141,253</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">316,759</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net loss</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(18,570,317</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(2,958,068</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">(15,612,249</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grant and Collaboration Revenues</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our grant and collaboration revenues relate to grants and contracts from agencies of the U.S. government and collaborative arrangements with other third parties in support of our vaccine development activities. We record revenue associated with these grants as the related costs and expenses are incurred. The following table summarizes our grant and collaboration revenues for the years ended December 31, 2021 and 2020:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Change</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lassa Fever &#x2013; U.S. Army Grant</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">85,574</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,438,465</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(1,352,891</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Covid-19 &#x2013; NIH SBIR Grant</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">299,927</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">299,927</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Malaria &#x2013; Collaboration Revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">385,193</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(385,193</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">385,501</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,823,658</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(1,438,157</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Grant and collaboration revenues decreased by $1,438,157 (79%) for the year ended December 30, 2021 compared to 2020, attributable to the differing mix of active grants and collaborations as shown in the table above, as well as the timing of expenditures related to such grants and collaborations. As of December 31, 2021, there was $81,526 of approved grant funds remaining and available for use during 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our research and development expenses can fluctuate considerably on a period-to-period basis, depending on the timing of expenditures related to our government grants and other research projects, and other factors. We do not disclose our research and development expenses by project, since our employees&#x2019; time is spread across multiple programs and our laboratory facility is used for multiple product candidates. We track the direct cost of research and development expenses related to government grant revenue by the percentage of assigned employees&#x2019; time spent on each grant and other direct costs associated with each grant. Indirect costs associated with grants are not tracked separately but are applied based on a contracted overhead rate negotiated with the granting agency. Therefore, the recorded revenues associated with government grants approximate the costs incurred.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our research and development expenses were $15,554,171 for the year ended December 31, 2021, as compared to $2,444,459 for 2020, representing an increase of $13,109,712 (536%). Of this increase, $10,000,000 relates to upfront license fees pursuant to the COH License ($5,000,000 paid during 2021 and $5,000,000 payable in future years), $1,864,300 relates to clinical trial expense and patent cost reimbursements pursuant to the COH License, and $459,825 relates to upfront license fees (inclusive of $209,825 of stock-based expense) associated with the Gedeptin License. Research and development expense for 2021 and 2020 includes stock-based compensation expense of $96,814 and $7,156, respectively associated with employee stock options, reflecting a $89,658 increase (see discussion under &#x201c;Stock-Based Compensation Expense&#x201d; below). The remaining $695,929 increase in research and development expense from 2020 to 2021 relates primarily due to expenditures related to our COVID-19 vaccine program, manufacturing process development, and a generally higher level of activity, offset in part by lower external expenditures related to our government grants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>General and Administrative Expenses</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our general and administrative expenses were $3,577,153 for the year ended December 31, 2021, as compared to $2,196,014 for 2020, representing an increase of $1,381,139 (63%). General and administrative expense for these periods includes stock-based compensation expense of $273,173&#xa0;and $57,307, respectively (see discussion under &#x201c;Stock-Based Compensation Expense&#x201d; below). Excluding stock-based compensation expense, general and administrative expenses were $3,303,979 and $2,138,707 for 2021 and 2020, respectively, representing an increase of $1,165,272 (54%). Approximately $360,000 of this increase is attributable to higher Delaware franchise taxes (which we expect will be no more than $200,000 in future years) with the remainder primarily due to higher legal, accounting and patent costs; insurance costs; consulting fees; and investor relations costs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation Expense</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The table below shows the components of stock-based compensation expense for the years ended December 31, 2021 and 2020. In general, stock-based compensation expense is allocated to research and development expense or general and administrative expense according to the classification of cash compensation paid to the employee, consultant or director to whom the stock compensation was granted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 18pt;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock option expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">269,427</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">18,730</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock issued for non-employee services</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">100,560</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">45,733</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">369,987</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,463</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result of the reverse stock splits enacted in April 2019 and in January 2020, we made adjustments and retroactive restatements to all of our outstanding stock options such that the balances in January 2020 were negligible. We therefore recorded no stock-based compensation expense related to our stock option plan for the majority of 2020. We re-initiated employee stock option grants in December 2020 and recorded a proportionate amount of expense for the year ended December 31, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the years ended December 31, 2021 and 2020, stock-based compensation expense was allocated as follows:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 18pt;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">273,173</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">57,307</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">96,814</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">7,156</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">369,987</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">64,463</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Income (Expense)</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest income was $4,736 and $2,271 for the years ended December 31, 2021 and 2020, respectively. The variances between years are primarily attributable to the cash available for investment and to interest rate fluctuations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest expense was $1,286 and $143,524 for the years ended December 31, 2021 and 2020, respectively. Interest expense for 2021 relates to the GRA Note and PPP Loan, and for 2020 relates to the GRA Note, PPP loan, financing costs associated with insurance premiums, and convertible debentures which were retired during 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During 2021, we recorded a $172,056 gain on debt extinguishment associated with the forgiveness of the PPP loan principal and accrued interest.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Accounting Policies and Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates its estimates and adjusts them as necessary. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our significant accounting policies are summarized in Note&#xa0;2 to our consolidated financial statements for the year ended December 31, 2021, which are included in this Form 10-K. We believe the following critical accounting policies affect our more significant judgments and estimates used in the preparation of our consolidated financial statements:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenue Recognition</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize revenue in accordance with FASB Accounting Standards Update 2014-09, <i>Revenue from Contracts with Customers</i> (ASU 2014-09), which created a new Topic, Accounting Standards Codification Topic 606. The standard is principle-based and provides a five-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grant revenue</i> &#x2013; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research collaborations</i> &#x2013; From time to time, we may enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive third-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU 2014-09 and revenue is recognized accordingly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#x2019;s fair value as calculated by using the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note 7 to our financial statements for additional stock-based compensation information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From inception through December 31, 2021, we have accumulated net losses of approximately $64.4 million and we expect to incur operating losses and generate negative cash flows from operations for the foreseeable future. We have funded our operations to date primarily from sales of our equity securities and from government grants and clinical trial assistance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following tables summarize our liquidity and capital resources as of December 31, 2021 and 2020, and our cash flows for the years then ended:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">As of December 31,</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 66%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liquidity and Capital Resources</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">11,423,870</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,883,796</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Working capital</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">6,193,756</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">9,424,839</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Year Ended December 31,</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 66%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash Flow Data</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash provided by (used in):</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(11,196,420</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,750,570</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Investing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(47,718</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(156,791</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Financing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">12,784,212</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">12,507,816</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,540,074</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9,600,455</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Operating Activities</i> &#x2013; Net cash used in operating activities of $11,196,420 for 2021 was primarily due to our net loss of $18,570,317, offset by non-cash items such as depreciation expense, stock-based compensation expense and the gain recognized on extinguishment of our PPP loan, and by changes in our working capital accounts. Net cash used in operating activities of $2,750,570 for 2020 was primarily due to our net loss of $2,958,068, offset by non-cash charges such as depreciation and stock-based compensation expense, and by changes in our working capital accounts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Investing Activities</i> &#x2013; Net cash used in investing activities was $47,718 and $156,791 for 2021 and 2020, respectively, and relates to purchases of property and equipment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Financing Activities</i> &#x2013; Net cash provided by financing activities was $12,784,212 for 2021, consisting of (i) net proceeds of $9,408,920 from a public offering of our common stock, (ii) $3,404,156 of net proceeds from the exercise of warrants, (iii) $1,000 expended for the repurchase of outstanding convertible preferred stock, and (iv) $27,864 in principal repayments toward a note payable to the Georgia Research Alliance, Inc. (the &#x201c;GRA Note&#x201d;); the GRA Note was fully repaid during 2021. Additionally, during May 2021 our PPP loan of $170,200, together with $1,856 of accrued interest, was forgiven by the lender and extinguished.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net cash provided by financing activities was $12,507,816 for 2020, consisting of (i) net proceeds of $11,158,496 from a public offering of our common stock and warrants, (ii) net proceeds of $300,000 from the sale of our convertible preferred stock, (iii) $170,200 of PPP loan proceeds, (iv) $888,500 of net proceeds from issuance of a note payable, (v) $2,500 in proceeds from warrant exercises, and (vi) $11,880 in principal repayments toward the GRA Note.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Funding Requirements and Sources of Capital</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our primary uses of capital are for salaries and related expenses for personnel, costs of conducting clinical trials, manufacturing costs for preclinical and clinical materials, third-party research services, laboratory and related supplies, legal and other regulatory expenses, and general overhead costs. We expect these costs will continue to be the primary operating capital requirements for the near future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We expect our research and development costs to increase as we continue development of our various programs and as we move toward later stages of development, especially with regard to clinical trials. We have entered into license agreements with City of Hope, PNP Therapeutics, Inc., University of Alabama at Birmingham, Southern Research Institute, Emory University, and with the U.S. Department of Health and Human Services (HHS), as represented by National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), for various technologies and patent rights associated with our product development activities. These agreements may contain provisions for upfront payments, milestone fees due upon the achievement of selected development and regulatory events, minimum annual royalties or other fees, and royalties based on future net sales. Aggregate unrecorded future minimum payments under these agreements (excluding milestone and royalty payments due upon contingent future events, and assuming neither party terminates the agreements) are approximately $174,000 in 2022, $128,000 in 2023, $128,000 in 2024, $28,000 in 2025 and $28,000 in 2026.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our research and development expenditures during 2022 and beyond will increase significantly as a result of the Gedeptin and COH04S1 clinical programs. We do not provide forward-looking estimates of costs and time to complete our research programs due to the many uncertainties associated with biotechnology research and development. Due to these uncertainties, our future expenditures are likely to be highly volatile in future periods depending on the outcomes of the trials and studies. As we obtain data from pre-clinical studies and clinical trials, we may elect to discontinue or delay certain development programs to focus our resources on more promising product candidates. Completion of preclinical studies and human clinical trials may take several years or more, but the length of time can vary substantially depending upon several factors. The duration and the cost of future clinical trials may vary significantly over the life of the project because of differences arising during development of the human clinical trial protocols, including the length of time required to enroll suitable patient subjects, the number of patients that ultimately participate in the clinical trial, the duration of patient follow-up, and the number of clinical sites included in the clinical trials.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that our general and administrative costs will increase during 2022 and beyond in support of expanded research and development activities and other general corporate activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are currently seeking sources of capital through additional government and quasi-government grant programs and clinical trial support, although there can be no assurance any such funds will be obtained. Gedeptin is in a Phase 1/2 trial, being conducted at Stanford University in collaboration with Emory University; the initial stage of the study (10 patients) is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During January 2022, we closed a private placement of our common stock and warrants for net proceeds of approximately $9.2 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe our existing cash and cash equivalents will be sufficient to meet our anticipated cash requirements into the second quarter of 2023. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties and is based on assumptions that may prove to be wrong; actual results could vary materially. We may need to obtain additional funds sooner than planned or in greater amounts than we currently anticipate. The actual amount of funds we will need to operate is subject to many factors, some of which are beyond our control. These factors include the progress of our research activities; the number and scope of our research programs; the progress and success of our pre-clinical and clinical development activities; the progress of the development efforts of parties with whom we have entered into research and development agreements; the costs of manufacturing our product candidates, and the progress of efforts with parties with whom we may enter into commercial manufacturing agreements; our ability to maintain current research and development programs and to establish new research and development and licensing arrangements; the costs involved in prosecuting and enforcing patent claims and other intellectual property rights; the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; the impact of any natural disasters or public health crises, such as the COVID-19 pandemic; the costs associated with any products or technologies that we may in-license or acquire; and the costs and timing of regulatory approvals.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We will need to continue to raise additional capital to support our future operating activities, including progression of our development programs, preparation for commercialization, and other operating costs. Financing strategies we may pursue include, but are not limited to, the public or private sale of equity, debt financings or funds from other capital sources, such as government funding, collaborations, strategic alliances or licensing arrangements with third parties. There can be no assurances additional capital will be available to secure additional financing, or if available, that it will be sufficient to meet our needs on favorable terms. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development of one or more of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Net Operating Loss Carryforwards</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At December 31, 2021, we had consolidated net operating loss carryforwards for income tax purposes of $75.2 million, of which approximately $48.9 million will expire in 2022 through 2037 if not utilized. We also have research and development tax credits of approximately $1.6 million available to reduce income taxes, if any, which will expire in 2022 through 2041 if not utilized. Section 382 of the Internal Revenue Code contains provisions that may limit our utilization of net operating loss and research tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or may occur in future periods.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Off-Balance Sheet Arrangements</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have no off-balance sheet arrangements that are likely or reasonably likely to have a material effect on our financial condition or results of operations, other than the operating lease for our office and laboratory space.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>ITEM 7A.</b></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#xa0;<b><span style="text-decoration: underline; ">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in the general level of United States interest rates, particularly because a significant portion of our investments are in institutional money market funds. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income received without significantly increasing risk. Due to the nature of our short-term investments, we believe that we are not subject to any material market risk exposure. We do not have any derivative financial instruments or foreign currency instruments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 8.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our consolidated financial statements and supplemental schedule and notes thereto as of December 31, 2021 and 2020 and for the two-year period ended December 31, 2021 together with the independent registered public accounting firm&#x2019;s report thereon, are set forth on pages F-1 to F-17 of this Annual Report on Form 10-K.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     34
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 9.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were no disagreements with our accountants on matters of accounting or financial disclosure, or other reportable events requiring disclosure under this Item 9.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>ITEM9A.</b></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><span style="text-decoration: underline; ">CONTROLS AND PROCEDURES</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Evaluation of Disclosure Controls and Procedures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We maintain disclosure controls and procedures designed to ensure that financial information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934, as amended (the Exchange Act), is recorded, processed, summarized, and reported within the required time periods, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding disclosure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We carried out an evaluation, under the supervision and with the participation of our management, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Form 10-K. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2021, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Management</b>&#x2019;<b>s Report on Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) of the Exchange Act. Management has assessed the effectiveness of our internal control over financial reporting as of December 31, 2021, based on criteria established in <i>Internal Control - Integrated Framework (2013), </i>issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). As a result of this assessment, management concluded that the Company&#x2019;s internal controls and procedures over financial reporting were not effective, due to a material weakness surrounding the Company&#x2019;s interpretation of a non-routine transaction. The Company&#x2019;s controls over non-routine transactions were not conducive to identify certain items with sufficient precision. Management has undertaken steps to design and implement more effective internal controls, including a more comprehensive review process of non-routine transactions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Changes in Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. The changes in the Company&#x2019;s internal control over financial reporting described in the previous paragraph will be implemented during the quarter ended March 31, 2022.</p>
  <p style="margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Limitations on Controls</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and fraud. Any control system, no matter how well designed and operated, is based upon certain assumptions and can provide only reasonable, not absolute, assurance that its objectives will be met. Further, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within the Company have been detected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>ITEM 9B.</b></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#xa0;<b><span style="text-decoration: underline; ">OTHER INFORMATION</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>ITEM 9C.</b></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><span style="text-decoration: underline; ">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not Applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     35
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><span style="text-decoration: underline; ">PART III</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 10.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information required by this Item is included in our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC under the captions &#x201c;Directors and Executive Officers&#x201d; and &#x201c;Corporate Governance&#x201d; and is incorporated herein by this reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Code of Business Conduct and Ethics</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our Board of Directors has adopted a written Code of Business Conduct and Ethics, a copy of which is available on our website at<i> </i><i><span style="text-decoration: underline; ">www.geovax.com</span></i>. The Company will provide a copy of the Code of Ethics upon request to any person without charge. Such requests may be transmitted by regular mail in the care of the Corporate Secretary. We require all officers, directors and employees to adhere to this code in addressing the legal and ethical issues encountered in conducting their work. The code requires that employees avoid conflicts of interest, comply with all laws and other legal requirements, conduct business in an honest and ethical manner, and otherwise act with integrity and in our best interest. Employees are required to report any conduct that they believe in good faith to be an actual or apparent violation of the code. The Sarbanes-Oxley Act of 2002 requires certain companies to have procedures to receive, retain and treat complaints received regarding accounting, internal accounting controls or auditing matters and to allow for the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters. We have such procedures in place.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company will post on its website,<i> www.geovax.com</i>, or will disclose on a Form 8-K filed with the SEC, any amendments to, or waivers from, a provision of the Code of Ethics that applies to the Chief Executive Officer or the Chief Financial Officer, or persons performing similar functions, and that relate to (i)&#xa0;honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships; (ii) full, fair, accurate, timely, and understandable disclosure in reports and documents that the Company files with, or submits to, the SEC and in other public communications made by the Company; (iii)&#xa0;compliance with applicable governmental laws, rules and regulations; (iv)&#xa0;the prompt internal reporting of violations of the Code of Ethics to an appropriate person or persons identified in the code; or (v) accountability for adherence to the Code of Ethics. Any waiver granted to an executive officer or a director may only be granted by the Board and will be disclosed, along with the reasons therefor, on a Form 8-K filed with the SEC. No such waivers were granted in 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 11.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">EXECUTIVE COMPENSATION</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information required by this Item is included in our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC under the captions &#x201c;Corporate Governance&#x201d; and &#x201c;Executive Compensation&#x201d; and is incorporated herein by this reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     36
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 12.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information required by this Item is included in our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC under the captions &#x201c;Security Ownership of Principal Stockholders, Directors and Executive Officers&#x201d; and is incorporated herein by this reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth certain information as of December 31, 2021 with respect to compensation plans under which our equity securities are authorized for issuance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 25%; border: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;">Plan Category</p> </td>
     <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 22%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of securities to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">be issued upon exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of outstanding options,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">warrants and rights<br /> (a)</p> </td>
     <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 22%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">exercise price of</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">outstanding options,</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">warrants and rights<br /> (b)</p> </td>
     <td colspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%; border-top: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of securities remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">available for future issuance under</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">equity compensation plans</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(excluding securities reflected in column (a))<br /> (c)</p> </td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 25%; border-left: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Equity compensation plans approved by stockholders</p> </td>
     <td style="width: 22%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center; border-right: 1px solid rgb(0, 0, 0); vertical-align: top;">962,300</td>
     <td style="width: 22%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); text-align: center; vertical-align: top;">$3.18</td>
     <td style="width: 31%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); text-align: center; vertical-align: top;">506,700</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 25%; border-left: 1px solid rgb(0, 0, 0); border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: -9pt;">Equity compensation plans not approved by stockholders</p> </td>
     <td style="width: 22%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: center; border-right: 1px solid rgb(0, 0, 0); vertical-align: top;">272,997</td>
     <td style="width: 22%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); text-align: center; vertical-align: top;">$5.00</td>
     <td style="width: 31%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); border-right: 1px solid rgb(0, 0, 0); text-align: center; vertical-align: top;">-0-</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A description of our equity compensation plans can be found in footnote 7 to our 2021 consolidated financial statements, which are filed as exhibits this document.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 13.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information required by this Item is included in our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC under the captions &#x201c;Corporate Governance&#x201d; and &#x201c;Certain Relationships and Related Party Transactions&#x201d; and is incorporated herein by this reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 14.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information required by this Item is included in our definitive proxy statement for our 2022 annual meeting of stockholders to be filed with the SEC under the caption &#x201c;Ratification of Appointment of the Independent Registered Public Accounting Firm&#x201d; and is incorporated herein by this reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     37
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b><span style="text-decoration: underline; ">PART IV</span></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 54pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 15.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: middle; width: 5%;"><b>(a)</b></td>
     <td style="vertical-align: middle; width: 90%;"><b>Documents filed as part of this report:</b></td>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">(1)</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial Statements</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><span style="text-decoration: underline; ">Page</span></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Report of Independent Registered Public Accounting Firm</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-2</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Balance Sheets as of December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-3</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-4</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Stockholders&#x2019;&#xa0;Equity (Deficiency) for the years ended December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-5</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-6</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes to Consolidated Financial Statements</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-8</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 90%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 5%; text-align: center;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">(2)</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial Statement Schedules</p> </td>
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following financial statement schedule is set forth on page F-17 of this Annual Report on Form 10-K:<br /> Schedule II&#x2014;Valuation and Qualifying Accounts for the years ended December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Schedule II&#x2014;Valuation and Qualifying Accounts for the years ended December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 90%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 5%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All other financial statement schedules have been omitted because they are not applicable or not required or because the information is included elsewhere in the Consolidated Financial Statements or the Notes thereto.</p> </td>
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 90%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 5%;">(3)</td>
     <td style="vertical-align: middle; width: 90%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exhibits Required by Item 601 of Regulation S-K</p> </td>
     <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Exhibit</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; ">Number</span></p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Description</span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095014408005004/g13992exv3w1.htm" style="-sec-extract:exhibit;">Certificate of Incorporation (3)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1.1</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095012310034714/c99234exv3w1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed April 13, 2010 (5)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1.2</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095012310039442/c99794exv3w1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed April 27, 2010 (6)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1.3</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774913009821/ex3-1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed August 2, 2013 (7)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1.4</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774915010019/ex3-1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed May 13, 2015 (8)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1.5</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774916033922/ex3-1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed June 14, 2016 (10)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1.6</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774917013827/ex3-1.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed August 4, 2017 (11)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1.7</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774919008334/ex_141886.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed April 30, 2019 (14)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1.8</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920000912/ex_169967.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed January 21, 2020 (16)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.1.9</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920020279/ex_205103.htm" style="-sec-extract:exhibit;">Certificate of Amendment to the Certificate of Incorporation of GeoVax Labs, Inc. filed September 24, 2020 (23)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3.2</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095014408005004/g13992exv3w2.htm" style="-sec-extract:exhibit;">Bylaws (3)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920018705/ex_201544.htm" style="-sec-extract:exhibit;">Form of Stock Certificate representing the Company&#x2019;s Common Stock, par value $0.001 per share (20)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1.1</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920020061/ex_204703.htm" style="-sec-extract:exhibit;">Form of Common Stock Purchase Warrant (22)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1.2</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920019373/ex_203004.htm" style="-sec-extract:exhibit;">Form of Representative&#x2019;s Warrant Agreement (21)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1.3</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920019373/ex_203004.htm" style="-sec-extract:exhibit;">Form of Warrant Agent Agreement (21)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1.4</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920019373/ex_203037.htm" style="-sec-extract:exhibit;">Form of Warrant issued to certain Management Creditors (21)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1.5</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920014012/ex_191614.htm" style="-sec-extract:exhibit;">Form of Common Stock Purchase Warrant, dated June 26, 2020 (19)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1.6</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921002520/ex_225848.htm" style="-sec-extract:exhibit;">Form of Underwriters Warrant Agreement dated February 11, 2021 (26)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1.7</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921022842/ex_287396.htm" style="-sec-extract:exhibit;">Form of Common Stock Purchase Warrant, dated September 28, 2021 (28)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1.8</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774922001326/ex_325631.htm" style="-sec-extract:exhibit;">Form of Pre-Funded Warrant Agreement (30)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">4.1.9</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774922001326/ex_325631.htm" style="-sec-extract:exhibit;">Form of Common Warrant (30)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">10.1 **</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774918016713/ex_123550.htm" style="-sec-extract:exhibit;">Employment Agreement between GeoVax Labs, Inc. and David A. Dodd (12)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">10.2 **</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000095012310022136/g22401exv10w2.htm" style="-sec-extract:exhibit;">Employment Agreement between GeoVax, Inc. and Mark W. Reynolds (4)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">10.2.1 **</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774913013257/ex10-3.htm" style="-sec-extract:exhibit;">Amendment No. 1 to Employment Agreement between GeoVax Labs, Inc. and Mark W. Reynolds (8)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">10.2.2 *&#x2019;**</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_339970.htm" style="-sec-extract:exhibit;">Employment Agreement between GeoVax, Inc. and Mark J. Newman, PhD, as Amended and Restated March 9, 2022</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">10.2.3 *&#x2019;**</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_339971.htm" style="-sec-extract:exhibit;">Consulting Agreement by and between GeoVax, Inc. and Kelly T. McKee, MD, dated December 22, 2021</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">10.5 **</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921026298/ex_303773.htm" style="-sec-extract:exhibit;">GeoVax Labs, Inc. 2020 Stock Incentive Plan, as amended and restated August 11, 2021 (18)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">10.5.1 **</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921006906/ex_234779.htm" style="-sec-extract:exhibit;">Form of Non-Qualified Stock Option Agreement (27)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">10.6</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000109690606001179/geovax8k100106ex10-2.htm" style="-sec-extract:exhibit;">License Agreement (as amended and restated) between GeoVax, Inc. and Emory University (2)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: bottom; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">10.7</p> </td>
     <td style="vertical-align: bottom; width: 2%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 88%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920021652/ex_208661.htm" style="-sec-extract:exhibit;">Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases, dated October 22, 2020 (24)</a></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.8</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920024573/ex_215829.htm" style="-sec-extract:exhibit;">Patent and Biological Materials License Agreement for Internal Research Use with the National Institute of Allergy and Infectious Diseases, dated November 25, 2020 (25)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.9</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774920006029/ex_178175.htm" style="-sec-extract:exhibit;">Office and Laboratory Lease between UCB, Inc. and GeoVax, Inc. (17)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.10 *</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_339972.htm" style="-sec-extract:exhibit;">Summary of the GeoVax Labs, Inc. Director Compensation Plan</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.11</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774921022842/ex_287401.htm" style="-sec-extract:exhibit;">Assignment and License Agreement by and between GeoVax, Inc. and PNP Therapeutics, Inc. dated September 28, 2021 (28)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.12</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/ix?doc=/Archives/edgar/data/832489/000143774921026180/govx20211109_8k.htm" style="-sec-extract:exhibit;">Exclusive License Agreement by and between GeoVax, Inc. and City of Hope, dated November 9, 2021 (29)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.13</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774922001326/ex_325629.htm" style="-sec-extract:exhibit;">Securities Purchase Agreement, dated January 14, 2022 (30)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.14</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774922001326/ex_325630.htm" style="-sec-extract:exhibit;">Registration Rights Agreement, dated January 14, 2022 (30)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">14.1</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774919005682/ex_138671.htm" style="-sec-extract:exhibit;">Code of Ethics (13)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">21.1</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/832489/000143774919021977/ex_162624.htm" style="-sec-extract:exhibit;">Subsidiaries of the Registrant (15)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1 *</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_343680.htm" style="-sec-extract:exhibit;">Consent of Wipfli LLP&#xa0;(U.S. PCAOB Auditor Firm ID <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AuditorFirmId">344</ix:nonNumeric>)</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.1 *</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_344528.htm" style="-sec-extract:exhibit;">Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934&#xa0;</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.2 *</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_344529.htm" style="-sec-extract:exhibit;">Certification pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934&#xa0;</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">32.1 *</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_344530.htm" style="-sec-extract:exhibit;">Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002&#xa0;</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">32.2 *</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_344531.htm" style="-sec-extract:exhibit;">Certification pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002&#xa0;</a></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.INS</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data Files because its XBRL tags are embedded with the Inline XBRL Document) (1)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.SCH</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document (1)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.CAL</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document (1)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.DEF</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document (1)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.LAB</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document (1)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101.PRE</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document (1)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inline XBRL for the cover page of this Annual Report on Form 10-K and included in the Exhibit 101 Inline XBRL Document Set (1)</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <hr style="text-align: left; height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt 0" />
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Filed herewith.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">**</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicates a management contract or compensatory plan or arrangement.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These interactive data files shall not be deemed filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, or Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under these sections.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed October 4, 2006.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed June 23, 2008.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Annual Report on Form 10-K filed March 8, 2010.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed April 14, 2010.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(6)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed April 28, 2010.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(7)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed August 2, 2013.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(8)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed October 23, 2013.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(9)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed May 14, 2015.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(10)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed June 16, 2016.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(11)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed August 4, 2017.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(12)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed September 7, 2018.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(13)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Annual Report on Form 10-K filed March 26, 2019.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(14)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed April 30, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(15)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Quarterly Report on Form 10-Q filed November 7, 2019.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(16)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed January 21, 2020.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(17)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Annual Report on Form 10-K filed March 24, 2020.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(18)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Quarterly Report on Form 10-Q filed November 12, 2021.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(19)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed June 26, 2020.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(20)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the Amendment No. 2 to registrant&#x2019;s Registration Statement on Form S-1&#xa0; (File No. 333-239958) filed August 26, 2020.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(21)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the Amendment No. 3 to registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-239958) filed September 8, 2020</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(22)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the Amendment No. 4 to registrant&#x2019;s Registration Statement on Form S-1 (File No. 333-239958) filed September 23, 2020.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(23)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed September 25, 2020.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(24)</p> </td>
     <td style="vertical-align: top; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed October 26, 2020.<br /> Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as the Company has&#xa0;determined (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to the Company if publicly disclosed.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(25)</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed November 30, 2020. Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as the Company has determined (i) the omitted information is not material and (ii) the omitted information would likely cause competitive harm to the Company if publicly disclosed.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(26)</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed February 11, 2021.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(27)</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Annual Report on Form 10-K filed March 23, 2021.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(28)</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed September 29, 2021. Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as (i) the Company has determined the omitted information is not material and (ii) the Company customarily A nd actually treats the omitted information as private or confidential.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(29)</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed November 10, 2021. Pursuant to 399 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted as (i) the Company has determined the omitted information is not material and (ii) the Company customarily and actually treats the omitted information as private or confidential.</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">(30)</p> </td>
     <td style="vertical-align: bottom; width: 3%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 91%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Incorporated by reference from the registrant&#x2019;s Current Report on Form 8-K filed January 20, 2022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 45pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 16.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b><span style="text-decoration: underline; ">FORM 10-K SUMMARY</span></b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     40
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;"><b>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">
   <tbody>
    <tr>
     <td valign="top" style=" width: 50%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
     <td colspan="2" valign="top" style=" width: 38%;"> <p style="margin-top: 0; margin-bottom: 0;"><b>GEOVAX LABS, INC.</b></p> </td>
     <td valign="top" style=" width: 12%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
    </tr>

    <tr>
     <td valign="top" style=" width: 50%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
     <td valign="top" style=" width: 3%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
     <td align="left" valign="bottom" style=" width: 35%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
     <td valign="top" style=" width: 12%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
    </tr>

    <tr>
     <td align="left" style="text-align: left; width: 50%;" valign="top"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
     <td style="text-align: left width: 3%;" valign="top"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </span></p> </td>
     <td align="left" style="BORDER-BOTTOM: #000000 1px solid width: 35%;" valign="top"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&#xa0;</span>David A. Dodd</p> </td>
     <td valign="top" style=" width: 12%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
    </tr>

    <tr>
     <td valign="top" style=" width: 50%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
     <td colspan="2" rowspan="1" valign="top" style=" width: 3%;"> <p style="margin-top: 0; margin-bottom: 0;">David A. Dodd</p> </td>
     <td valign="top" style=" width: 12%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
    </tr>

    <tr>
     <td valign="top" style=" width: 50%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
     <td colspan="2" rowspan="1" valign="top" style=" width: 3%;"> <p style="margin-top: 0; margin-bottom: 0;">President and Chief Executive Officer</p> </td>
     <td valign="top" style=" width: 12%;"> <p style="margin-top: 0; margin-bottom: 0;"><span style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&#xa0;</span></p> </td>
    </tr>

    <tr>
     <td valign="top" style=" width: 50%;">&#xa0;</td>
     <td colspan="2" rowspan="1" valign="top" style=" width: 3%;">(Principal Executive Officer)</td>
     <td valign="top" style=" width: 12%;">&#xa0;</td>
    </tr>

    <tr>
     <td valign="top" style=" width: 50%;">&#xa0;</td>
     <td valign="top" style=" width: 3%;">&#xa0;</td>
     <td valign="top" style=" width: 35%;">&#xa0;</td>
     <td valign="top" style=" width: 12%;">&#xa0;</td>
    </tr>

    <tr>
     <td valign="top" style=" width: 50%;">&#xa0;</td>
     <td colspan="2" rowspan="1" valign="top" style=" width: 3%;">Date: March 9, 2022</td>
     <td valign="top" style=" width: 12%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 248pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been duly signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
   <tbody>
    <tr>
     <td style="width: 21%;">Signature / Name&#xa0;</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">Title</td>
     <td style="width: 33%;">Date</td>
    </tr>

    <tr>
     <td style="width: 21%;">&#xa0;</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%; border-bottom: 1px solid rgb(0, 0, 0);">/s/&#xa0;David A. Dodd</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">Director</td>
     <td style="width: 33%;">March 9, 2022</td>
    </tr>

    <tr>
     <td style="width: 21%;">David A. Dodd</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">President and Chief Executive Offic9</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%;">&#xa0;</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">(Principal Executive Officer)</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%;">&#xa0;</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%; border-bottom: 1px solid rgb(0, 0, 0);">/s/&#xa0;Mark W. Reynolds</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">Chief Financial Officer&#xa0;</td>
     <td style="width: 33%;">March 9, 2022</td>
    </tr>

    <tr>
     <td style="width: 21%;">Mark W. Reynolds</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">(Principal Financial and Accounting Officer)</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%;">&#xa0;</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%; border-bottom: 1px solid rgb(0, 0, 0);">/s/ Randal D. Chase</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">Director&#xa0;</td>
     <td style="width: 33%;">March 9, 2022</td>
    </tr>

    <tr>
     <td style="width: 21%;">Randal D. Chase</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%;">&#xa0;</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%; border-bottom: 1px solid rgb(0, 0, 0);">/s/&#xa0;David A. Dodd</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">Director</td>
     <td style="width: 33%;">March 9, 2022</td>
    </tr>

    <tr>
     <td style="width: 21%;">David A. Dodd</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%;">&#xa0;</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%; border-bottom: 1px solid rgb(0, 0, 0);">/s/&#xa0;Dean G. Kollintzas</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">Director</td>
     <td style="width: 33%;">March 9, 2022</td>
    </tr>

    <tr>
     <td style="width: 21%;">Dean G. Kollintzas</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%;">&#xa0;</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%; border-bottom: 1px solid rgb(0, 0, 0);">/s/&#xa0;Robert T. McNally</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">Director</td>
     <td style="width: 33%;">March 9, 2022</td>
    </tr>

    <tr>
     <td style="width: 21%;">Robert T. McNally</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%;">&#xa0;</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="width: 21%; border-bottom: 1px solid rgb(0, 0, 0);">/s/&#xa0;John N. Spencer, Jr.</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">Director&#xa0;</td>
     <td style="width: 33%;">March 9, 2022</td>
    </tr>

    <tr>
     <td style="width: 21%;">John N. Spencer, Jr.</td>
     <td style="width: 12%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
     <td style="width: 33%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX TO 2021 CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 100%;">
   <tbody>
    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: middle; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Report of Independent Registered Public Accounting Firm</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-2</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: middle; width: 95%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: middle; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Balance Sheets as of December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-4</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: middle; width: 95%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: middle; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-5</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: middle; width: 95%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: middle; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Stockholders&#x2019;&#xa0;Equity (Deficiency) for the years ended December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-6</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: middle; width: 95%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: middle; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-7</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: middle; width: 95%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: middle; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes to Consolidated Financial Statements</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-8</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: middle; width: 95%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: middle; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial Statement Schedule:</p> </td>
     <td style="vertical-align: middle; width: 5%;">&#xa0;</td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: middle; width: 95%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">Schedule II &#x2013;&#xa0;Valuation and Qualifying Accounts for the years ended December 31, 2021 and 2020</p> </td>
     <td style="vertical-align: middle; width: 5%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">F-17</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     F-1
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">
   <tbody>
    <tr>
     <td style="width: 55%;">
      <div>
       <img alt="img01.jpg" src="img01.jpg" /></div> </td>
     <td style="width: 20%; vertical-align: top;">235 Peachtree Street NE<br /> Suite 1800<br /> Atlanta, GA 30303</td>
     <td style="width: 25%; vertical-align: top;"> <p style="margin: 0pt 0pt 0pt 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">404 588 4200</p> <p style="margin: 0pt 0pt 0pt 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">wipfli.com</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the Stockholders and the Board of Directors of GeoVax Labs, Inc.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Opinion on the Consolidated Financial Statements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We have audited the accompanying consolidated balance sheets of GeoVax Labs, Inc. and subsidiary (the &#x201c;Company&#x201d;) as of December 31, 2021 and 2020, and the related consolidated statements of operations, stockholders&#x2019; equity (deficiency) and cash flows for the years then ended and the related notes to the consolidated financial statements and schedule (collectively, the &#x201c;financial statements&#x201d;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Basis for Opinion</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b>Critical Audit Matter</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><b><i>Equity Transactions</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">As described in Note 7 to the financial statements, the Company has multiple equity instruments with various levels of complexity and volumes including warrants and stock options.</p>
  <p style="margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">The principal considerations for our determination that the complexity of the Company&#x2019;s equity structure should be a critical audit matter were based on the volume of equity transactions, including conversions to common stock, common stock issuance activity and warrant activity making it challenging to ensure adequate disclosure of all equity transactions. Auditing such estimates and activity required extensive audit effort due to the volume and complexity of these transactions and a high degree of auditor judgment when performing the requisite audit procedures and evaluating the results of those procedures.</p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The primary audit procedures we performed to address this critical audit matter included:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We evaluated the design effectiveness of controls over the Company&#x2019;s process for accounting for and recording equity transactions</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We tested the assumptions used within the Black-Scholes model calculation to estimate the value of stock options and warrants granted, which included key assumptions such as the estimated life of the stock options and warrants and volatility of the Company&#x2019;s stock price</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AuditorName">WIPFLI LLP</ix:nonNumeric></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have served as the Company&#x2019;s auditor since 2005.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AuditorLocation">Atlanta, Georgia</ix:nonNumeric></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">March 9, 2022</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td colspan="8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>GEOVAX LABS, INC.</b></p> </td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td colspan="8" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 70%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASSETS</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558270" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">11,423,870</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558271" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">9,883,796</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Grant funds and other receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558272" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:GrantsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF">49,006</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558273" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:GrantsReceivable" scale="0" format="ixt:numdotdecimal" decimals="INF">182,663</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558274" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">156,240</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558275" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">168,689</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558276" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">11,629,116</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558277" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">10,235,148</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558278" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">156,938</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558279" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">147,741</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deposits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558280" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DepositsAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">11,010</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558281" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DepositsAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">11,010</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558282" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">11,797,064</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558283" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">10,393,899</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Current liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558286" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,057,534</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558287" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">267,702</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558288" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">3,377,826</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558289" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">359,281</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Current portion of notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558290" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558291" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:NotesPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">183,326</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558292" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">5,435,360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558293" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">810,309</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">Accrued expenses&#xa0;&#x2013;&#xa0;noncurrent</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81559022" contextRef="i_2021-12-31" unitRef="USD" name="govx:AccruedExpensesNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,000,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81559023" contextRef="i_2020-12-31" unitRef="USD" name="govx:AccruedExpensesNoncurrent" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Note payable, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558294" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LongTermNotesPayable" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558295" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">14,738</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558296" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">7,435,360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558297" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">825,047</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Commitments (Note 6)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c81558299">&#xa0;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c81558300">&#xa0;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stockholders&#x2019; equity:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt; text-indent: -9pt;">Preferred stock, $<span style="-sec-ix-hidden:c81558304"><span style="-sec-ix-hidden:c81558305">.01</span></span> par value: Authorized shares &#x2013; <span style="-sec-ix-hidden:c81558308"><span style="-sec-ix-hidden:c81558309">10,000,000</span></span> Series B convertible preferred stock, $<span style="-sec-ix-hidden:c81558306"><span style="-sec-ix-hidden:c81558307">1,000</span></span> stated value; -<span style="-sec-ix-hidden:c81558310"><span style="-sec-ix-hidden:c81558312">0</span></span>- and <span style="-sec-ix-hidden:c81558311"><span style="-sec-ix-hidden:c81558313">100</span></span> shares issued and outstanding at December 31, 2021 and 2020, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558302" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558303" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PreferredStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-indent: -9pt;">Common stock, $<span style="-sec-ix-hidden:c81558316"><span style="-sec-ix-hidden:c81558317">.001</span></span> par value: Authorized shares &#x2013; <span style="-sec-ix-hidden:c81558318"><span style="-sec-ix-hidden:c81558319">600,000,000</span></span> Issued and outstanding shares &#x2013; <span style="-sec-ix-hidden:c81558320"><span style="-sec-ix-hidden:c81558322">6,381,541</span></span> and <span style="-sec-ix-hidden:c81558321"><span style="-sec-ix-hidden:c81558323">3,834,095</span></span> at December 31, 2021 and 2020, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558314" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">6,382</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558315" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558326" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">68,731,220</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558327" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">55,294,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558328" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">64,375,898</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558329" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">45,805,581</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total stockholders&#x2019; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558330" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">4,361,704</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558331" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">9,568,852</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total liabilities and stockholders&#x2019; equity</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558332" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">11,797,064</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558333" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">10,393,899</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>GEOVAX LABS. INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years Ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Grant and collaboration revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558334" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">385,501</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558335" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,823,658</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558337" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">15,554,171</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558338" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,444,459</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">General and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558339" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">3,577,153</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558340" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">2,196,014</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total operating expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558341" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">19,131,324</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558342" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingExpenses" scale="0" format="ixt:numdotdecimal" decimals="INF">4,640,473</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558343" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,745,823</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558344" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,816,815</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income (expense):</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Interest income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558346" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">4,736</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558347" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">2,271</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558348" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,286</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558349" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">143,524</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Gain on debt extinguishment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558350" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">172,056</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558351" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total other income (expense)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558352" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">175,506</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558353" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">141,253</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81558354" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,570,317</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81558355" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,958,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net loss per common share</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558357" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3.04</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558358" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2.14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average shares outstanding</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558359" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">6,099,933</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558360" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">1,383,829</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSOLIDATED STATEMENTS OF STOCKHOLDERS</b>&#x2019;<b> EQUITY (DEFICIENCY)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 7%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 7%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 7%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 7%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 9%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Total</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Preferred Stock</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 11%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Common Stock</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Additional</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Accumulated</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Stockholders&#x2019;&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Equity</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Amount</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Paid-in Capital</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">Deficit</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; text-align: center; margin: 0pt;">(Deficiency)</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558361" contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558362" contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">1,932,433</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558363" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">14,992</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558364" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">15</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558365" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">39,340,509</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">(<ix:nonFraction id="c81558366" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">42,847,513</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">(<ix:nonFraction id="c81558367" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,574,556</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Sale of convertible preferred stock for cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558368" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" format="ixt:numdotdecimal" decimals="INF">300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558369" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558370" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558371" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558372" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558373" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558374" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Conversion of preferred stock to common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">(<ix:nonFraction id="c81558375" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,686</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">(<ix:nonFraction id="c81558376" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,156,338</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558377" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">716,790</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558378" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">717</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558379" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,155,621</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558380" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558381" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Warrants issued in bridge financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558383" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558385" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558386" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">457,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558387" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558388" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">457,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common stock upon warrant exercise</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558389" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558390" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558391" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">286,902</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558392" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">287</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558393" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">2,213</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558394" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558395" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">2,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common stock upon debenture&#xa0;conversion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558396" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesDebentureConversion" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558397" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558398" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesDebentureConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">177,626</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558399" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558400" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">569,340</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558401" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558402" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueDebentureConversion" scale="0" format="ixt:numdotdecimal" decimals="INF">569,517</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common stock upon cancellation of accrued compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558403" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558404" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558405" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">300,001</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558406" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558407" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">1,499,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558408" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558409" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">1,500,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Sale of common stock for cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558410" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558411" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558412" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,310,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558413" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,310</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558414" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">11,156,186</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558415" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558416" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">11,158,496</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Issuance of common stock for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558417" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558418" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558419" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">26,581</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558420" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">27</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558421" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">94,373</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558422" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558423" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">94,400</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558428" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">18,730</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558430" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">18,730</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Roundup of shares following reverse stock split</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558431" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558432" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558433" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" scale="0" format="ixt:numdotdecimal" decimals="INF">1,203</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558434" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" scale="0" format="ixt:numdotdecimal" decimals="INF">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">(<ix:nonFraction id="c81558435" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558436" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558437" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueReverseStockSplits" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net loss for the year ended December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558439" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558441" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558442" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558443" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,958,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558444" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,958,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558445" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558446" contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558447" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558448" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">3,834</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558449" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">55,294,504</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">(<ix:nonFraction id="c81558450" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">45,805,581</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558451" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">9,568,852</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Sale of common stock for cash</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558452" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558453" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558454" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,644,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558455" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,644</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558456" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">9,407,276</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558457" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558458" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">9,408,920</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt; text-indent: -9pt;">Issuance of common stock upon warrant exercise</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558459" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558460" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558461" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">889,739</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558462" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">890</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558463" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">3,403,266</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558464" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558465" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="govx:StockIssuedDuringPeriodValueWarrantExercise" scale="0" format="ixt:numdotdecimal" decimals="INF">3,404,156</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Issuance of common stock for services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558466" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558467" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558468" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">13,707</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558469" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">14</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558470" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">71,827</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558471" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558472" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">71,841</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Issuance of warrant for technology license</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558474" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558476" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558477" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">209,825</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558478" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558479" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">209,825</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Repurchase of preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">(<ix:nonFraction id="c81558480" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">(<ix:nonFraction id="c81558481" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:numdotdecimal" decimals="INF">76,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558482" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558483" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558484" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">75,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558485" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">(<ix:nonFraction id="c81558486" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock option expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558488" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558490" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558491" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">269,427</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558492" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;"><ix:nonFraction id="c81558493" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">269,427</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net loss for the year ended December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558495" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">-</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558497" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558498" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558499" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,570,317</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558500" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,570,317</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; width: 24%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558501" contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558502" contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558503" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">6,381,541</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558504" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">6,382</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558505" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">68,731,220</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81558506" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">64,375,898</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558507" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">4,361,704</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 8pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>GEOVAX LABS. INC.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Years Ended December 31,</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash flows from operating activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558509" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">18,570,317</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558510" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,958,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558512" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">38,521</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558513" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">19,656</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Amortization of debt discount</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558514" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558515" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" format="ixt:numdotdecimal" decimals="INF">124,185</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558516" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">369,987</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558517" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">64,463</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Warrant issued for technology license fee</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558518" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" format="ixt:numdotdecimal" decimals="INF">209,825</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558519" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Gain on debt extinguishment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558520" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">172,056</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558521" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Changes in assets and liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Grant funds and other receivables</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558523" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">133,657</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558524" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInReceivables" scale="0" format="ixt:numdotdecimal" decimals="INF">114,060</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558525" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">16,270</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558526" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">24,702</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558527" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">6,810,233</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558528" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">137,956</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558529" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">7,373,897</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558530" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">207,498</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net cash used in operating activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558531" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">11,196,420</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558532" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,750,570</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash flows from investing activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Purchase of property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558534" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">47,718</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558535" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">156,791</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net cash used in investing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558536" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">47,718</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558537" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">156,791</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash flows from financing activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net proceeds from sale of common stock and warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558539" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="govx:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">9,408,920</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558540" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="govx:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">11,158,496</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net proceeds from warrant exercises</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558541" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:numdotdecimal" decimals="INF">3,404,156</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558542" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="0" format="ixt:numdotdecimal" decimals="INF">2,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net proceeds from sale of preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558543" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558544" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="0" format="ixt:numdotdecimal" decimals="INF">300,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net proceeds from issuance of note payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558545" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558546" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">170,200</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net proceeds from bridge financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558547" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558548" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromConvertibleDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">888,500</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Repurchase of preferred stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81558549" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558550" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock" scale="0" format="ixt:zerodash" decimals="INF" sign="-">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Principal repayment of note payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558551" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RepaymentsOfNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">27,864</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81558552" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RepaymentsOfNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">11,880</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net cash provided by financing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558553" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">12,784,212</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558554" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">12,507,816</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558555" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">1,540,074</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558556" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">9,600,455</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558557" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">9,883,796</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558558" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">283,341</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at end of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558581" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">11,423,870</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81558582" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="0" format="ixt:numdotdecimal" decimals="INF">9,883,796</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Supplemental disclosure of non-cash financing activities:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended December 31, 2021:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">149,705 shares of common stock were issued upon the cashless exercise of stock purchase warrants</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">$172,056 of principal and accrued interest related to a note payable was extinguished upon the loan&#x2019;s forgiveness</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">During the year ended December 31, 2020:</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">716,790 shares of common stock were issued upon conversion of convertible preferred stock</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">36,902 shares of common stock were issued upon the cashless exercise of stock purchase warrants</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">300,001 shares of common stock and 300,001 stock purchase warrants were issued in exchange for cancellation of $1,500,000 owed to current and former employees and directors</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x25cf;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">177,626 shares of common stock, 126,042 pre-funded stock purchase warrants and 303,668 stock purchase warrants were issued upon conversion of $1,200,000 convertible debentures and $14,667 of related accrued interest</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">See accompanying notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GEOVAX LABS, INC. </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Years Ended December 31, 2021 and 2020</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:NatureOfOperations" id="c2049117" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b>Description of Business and Recent Developments</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax&#x2019;s product pipeline includes ongoing human clinical trials in COVID-<em style="font: inherit;">19</em> and head and neck cancer. Additional research and development programs include preventive vaccines against&#xa0;Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for solid tumors. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GEO-<em style="font: inherit;">CM04S1</em> License</i> -- In <em style="font: inherit;"> November 2021, </em>GeoVax entered into a license agreement with City of Hope (the &#x201c;COH License&#x201d;), granting GeoVax exclusive rights to further develop and commercialize GEO-<em style="font: inherit;">CM04S1</em> (formerly referred to as <em style="font: inherit;">COH04S1</em>). GEO-<em style="font: inherit;">CM04S1,</em> a synthetic, attenuated modified vaccinia Ankara (sMVA) vector expressing Spike and Nucleocapsid antigens of the SARS-CoV-<em style="font: inherit;">2</em> virus, was initially developed at COH for immunocompromised patients.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GEO-<em style="font: inherit;">CM04S1</em> is being studied in an ongoing Phase <em style="font: inherit;">2</em> clinical trial to evaluate its safety and immunogenicity, compared to the Pfizer mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy. GEO-<em style="font: inherit;">CM04S1</em> is the only COVID-<em style="font: inherit;">19</em> vaccine that includes both SARS-CoV-<em style="font: inherit;">2</em> spike and nucleocapsid proteins to advance to a Phase <em style="font: inherit;">2</em> trial in cancer patients. Such vaccines also tend to produce an immune response quickly &#x2013; in less than <em style="font: inherit;">14</em> days &#x2013; with only mild side effects. The trial is also the <em style="font: inherit;">first</em> to compare an investigational multi-antigenic COVID-<em style="font: inherit;">19</em> vaccine to the current Food and Drug Administration (FDA)-approved mRNA vaccine from Pfizer/BioNTech in people who are immunocompromised. Such patients have often shown a weak antibody response after receiving currently available COVID-<em style="font: inherit;">19</em> vaccines.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> December 2021, </em>patient enrollment began for the Phase <em style="font: inherit;">2</em> portion of a Phase <em style="font: inherit;">1/2</em> trial of GEO-<em style="font: inherit;">CM04S1,</em> to study its use as a universal booster vaccine to current FDA-approved vaccines. GeoVax believes that the GEO-<em style="font: inherit;">CM04S1</em> vaccine, when administered as a heterologous booster, will provide additional recognition elements to the immune system over a homologous boost from mRNA vaccines such as those developed by Moderna or Pfizer, which are directed only toward SARS-CoV-<em style="font: inherit;">2</em> Spike protein. The <em style="font: inherit;">COH04S1</em> vaccine&#x2019;s MVA backbone <em style="font: inherit;"> may </em>be more effective at inducing COVID-<em style="font: inherit;">19</em> immunity since MVA strongly induces T cell responses even in a background of immunosuppression. In addition, GEO-<em style="font: inherit;">CM04S1</em> targeting of both Spike and Nucleocapsid antigens, <em style="font: inherit;"> may </em>offer greater protection against the significant sequence variation observed with the Spike antigen.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Gedeptin</i>&#xae;<i> License</i> -- In <em style="font: inherit;"> September 2021, </em>GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc. (the &#x201c;PNP License), whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#xae;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase <em style="font: inherit;">1/2</em> clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and <em style="font: inherit;">no</em> curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#x2019;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but <em style="font: inherit;">not</em> limited to, cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      F-
     <em style="font: inherit;">8</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2049118" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Summary of Significant Accounting Policies</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ConsolidationPolicyTextBlock" id="c81562663" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Principles of Consolidation</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c81562664" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Basis of Presentation</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January 21, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-<ix:nonFraction id="c81558616" contextRef="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:numdotdecimal" decimals="INF">2000</ix:nonFraction> reverse split of our common stock and on <em style="font: inherit;"> September 25, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-<ix:nonFraction id="c81558620" contextRef="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" unitRef="Pure" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" format="ixt:numdotdecimal" decimals="INF">20</ix:nonFraction> reverse split of our common stock. Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the <em style="font: inherit;">twelve</em>-month period following the issue date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We <em style="font: inherit;"> may </em>never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We believe that our existing cash will be sufficient to continue our planned operations into the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2023.</em> We intend to fund future operations through additional private and/or public offerings of debt or equity securities.&#xa0; In addition, we <em style="font: inherit;"> may </em>seek additional capital through arrangements with strategic partners or from other sources. There can be <em style="font: inherit;">no</em> assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#xa0;</p></ix:nonNumeric><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:UseOfEstimates" id="c81562665" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c81562666" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash and Cash Equivalents</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consider all highly liquid investments with a maturity of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c81562667" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fair Value of Financial Instruments and Concentration of Credit Risk</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c81562668" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Property and Equipment</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:c81558630">three</span> to <span style="-sec-ix-hidden:c81558633">five</span> years. We amortize leasehold improvements using the straight-line method over the term of the related lease.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases</i> (ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em>), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or <em style="font: inherit;">not</em> the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than <em style="font: inherit;">12</em> months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than <em style="font: inherit;">12</em> months, we made an accounting policy election to <em style="font: inherit;">not</em> recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">9</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c81562669" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Impairment of Long-Lived Assets</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be<b> </b>recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="govx:AccruedLiabilitiesPolicyTextBlock" id="c81562670" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Accrued Expenses</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have <em style="font: inherit;">not</em> yet been billed by our <em style="font: inherit;">third</em>-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c81562673" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Net Loss Per Share</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, calculated using the treasury stock method, totaled <ix:nonFraction id="c81558654" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">213,831</ix:nonFraction> and <ix:nonFraction id="c81558655" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,001,948</ix:nonFraction> shares at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="c81562671" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenue Recognition</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize revenue in accordance with FASB Accounting Standards Update <em style="font: inherit;">2014</em>-<em style="font: inherit;">09,</em> <i>Revenue from Contracts with Customers</i> (ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em>), which created a new Topic, Accounting Standards Codification Topic <em style="font: inherit;">606.</em> The standard is principle-based and provides a <em style="font: inherit;">five</em>-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grant revenue</i> &#x2013; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research collaborations</i> &#x2013; From time to time, we <em style="font: inherit;"> may </em>enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive <em style="font: inherit;">third</em>-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em> and revenue is recognized accordingly.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c81562672" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expense</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development (R&amp;D) expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to <em style="font: inherit;">third</em>-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred. During <em style="font: inherit;">2021,</em> we also recorded $<ix:nonFraction id="c81558668" contextRef="d_2021-01-01_2021-12-31_NatureOfExpenseAxis-UpfrontFeesCOHAndPNPLicensemember" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">10,513,825</ix:nonFraction> of R&amp;D expense for upfront license fees and warrant expense associated with the COH License and the PNP License.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">10</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:IntangibleAssetsFiniteLivedPolicy" id="c81563825" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Patent Costs</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b> </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="c81565271" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Period-to-Period Comparisons</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results for future periods.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c81565272" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Income Taxes</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will be realized.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c81565273" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#x2019;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note <em style="font: inherit;">7</em> for additional stock-based compensation information.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c81566659" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Recent Accounting Pronouncements</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Except as discussed above, there have been <em style="font: inherit;">no</em> recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standards if currently adopted would have a material effect on our financial statements.</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2049119" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">3.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Property and Equipment</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2049120" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and furnishings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558682" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">591,554</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558683" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">543,836</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558684" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">115,605</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558685" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">115,605</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558686" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">707,159</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558687" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="0" format="ixt:numdotdecimal" decimals="INF">659,441</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81558688" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">550,221</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81558689" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">511,700</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558690" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">156,938</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558691" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">147,741</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation expense was $<ix:nonFraction id="c81558679" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">38,521</ix:nonFraction> and $<ix:nonFraction id="c81558680" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DepreciationAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">19,656</ix:nonFraction> during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="c2049121" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">4.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Accrued Expenses</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020:</em></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c2049122" escape="true">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 18pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Accrued license fees&#xa0;&#x2013; current</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81559283" contextRef="i_2021-12-31" unitRef="USD" name="govx:AccruedLicenseFeesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">3,000,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81559284" contextRef="i_2020-12-31" unitRef="USD" name="govx:AccruedLicenseFeesCurrent" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Accrued license fees&#xa0;&#x2013; noncurrent</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81559285" contextRef="i_2021-12-31" unitRef="USD" name="govx:AccruedLicenseFeesNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,000,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81559286" contextRef="i_2020-12-31" unitRef="USD" name="govx:AccruedLicenseFeesNoncurrent" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558695" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedSalariesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">269,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558696" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedSalariesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">279,696</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558697" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">108,826</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558698" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">79,585</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558699" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">5,377,826</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558700" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">359,281</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:DebtDisclosureTextBlock" id="c2049123" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">5.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Debt</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GRA Note</i> &#x2013; On <em style="font: inherit;"> February 28, 2018, </em>we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a <em style="font: inherit;"><span style="-sec-ix-hidden:c81558703">five</span></em>-year Senior Promissory Note (the &#x201c;GRA Note&#x201d;) to GRA in exchange for $<ix:nonFraction id="c81558704" contextRef="d_2018-02-28_2018-02-28" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">50,000</ix:nonFraction>. The GRA Note bore an annual interest rate of <ix:nonFraction id="c81558705" contextRef="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">5</ix:nonFraction>%. During <em style="font: inherit;"> May 2021, </em>we repaid the remaining principal balance of $<ix:nonFraction id="c81558706" contextRef="d_2021-05-01_2021-05-31_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:RepaymentsOfNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">22,737</ix:nonFraction> and retired the GRA Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>CARES Act Paycheck Protection Program Loan </i>&#x2013;<i> </i>On <em style="font: inherit;"> April 17, 2020, </em>we received a $<ix:nonFraction id="c81558707" contextRef="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:ProceedsFromNotesPayable" scale="0" format="ixt:numdotdecimal" decimals="INF">170,200</ix:nonFraction> bank loan backed by the United States Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bore an annual interest rate of <em style="font: inherit;">one</em> percent. During <em style="font: inherit;"> May 2021, </em>upon receiving payment from the SBA, the lender forgave the full principal balance of $<ix:nonFraction id="c81558709" contextRef="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:ExtinguishmentOfDebtAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">170,200</ix:nonFraction> together with $<ix:nonFraction id="c81558710" contextRef="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="govx:GainLossFromInterestForgiven" scale="0" format="ixt:numdotdecimal" decimals="INF">1,856</ix:nonFraction> of accrued interest, and we recorded a $<ix:nonFraction id="c81558711" contextRef="d_2021-05-01_2021-05-01_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="0" format="ixt:numdotdecimal" decimals="INF">172,056</ix:nonFraction> gain on debt extinguishment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Convertible Debentures</i> &#x2013; On <em style="font: inherit;"> June 26 2020, </em>we issued convertible debentures in the aggregate principal amount of $<ix:nonFraction id="c81559494" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,200,000</ix:nonFraction> and warrants to purchase an aggregate of <ix:nonFraction id="c81559495" contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000</ix:nonFraction> shares of our common stock for gross proceeds of $<ix:nonFraction id="c81559496" contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember" unitRef="USD" name="govx:ProceedsFromConvertibleDebtGross" scale="0" format="ixt:numdotdecimal" decimals="INF">1,050,000</ix:nonFraction>. As discussed in Note <em style="font: inherit;">7,</em> in <em style="font: inherit;"> September 2020, </em>the convertible debentures and accrued interest were fully converted into our equity securities and were retired.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest expense recorded for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2019</em> was as follows:</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="govx:InterestExpenseDisclosureTableTextBlock" id="c2049124" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">GRA Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558713" contextRef="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">633</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558714" contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,727</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">PPP Loan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558717" contextRef="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">653</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558718" contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-PaycheckProtectionProgramCaresActMember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,203</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Insurance premium financing costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558719" contextRef="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-InsurancePremiumFinancingCostsmember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558720" contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-InsurancePremiumFinancingCostsmember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,743</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Convertible debentures (including $124,185 of debt discount amortization)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558721" contextRef="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81558722" contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">138,851</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558725" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">1,286</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558726" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">143,524</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CommitmentsDisclosureTextBlock" id="c2049125" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">6.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Commitments</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Operating Lease</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We lease approximately <ix:nonFraction id="c81558728" contextRef="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:numdotdecimal" decimals="INF">8,400</ix:nonFraction> square feet of office and laboratory space pursuant to an operating lease which expires on <em style="font: inherit;"> December 31, 2022. </em>Rent expense for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was $<ix:nonFraction id="c81558730" contextRef="d_2021-01-01_2021-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">166,242</ix:nonFraction> and $<ix:nonFraction id="c81558731" contextRef="d_2020-01-01_2020-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">166,577</ix:nonFraction>, respectively. Future minimum lease payments total $<ix:nonFraction id="c81558732" contextRef="i_2021-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="0" format="ixt:numdotdecimal" decimals="INF">176,356</ix:nonFraction> in <em style="font: inherit;">2022,</em> although the lease <em style="font: inherit;"> may </em>be terminated at any time by either party with <em style="font: inherit;">ninety</em> days written notice.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>License Agreements</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have entered into license agreements with City of Hope, PNP Therapeutics, Inc., University of Alabama at Birmingham, Southern Research Institute, Emory University, and with the U.S. Department of Health and Human Services (HHS), as represented by National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), for various technologies and patent rights associated with our product development activities. These agreements <em style="font: inherit;"> may </em>contain provisions for upfront payments, milestone fees due upon the achievement of selected development and regulatory events, minimum annual royalties or other fees, and royalties based on future net sales. Aggregate unrecorded future minimum payments under these agreements (excluding milestone and royalty payments due upon contingent future events, and assuming neither party terminates the agreements) are approximately $<ix:nonFraction id="c81558735" contextRef="i_2021-12-31" unitRef="USD" name="govx:LicensingAgreementFutureMinimumPaymentsReceivableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">174,000</ix:nonFraction> in <em style="font: inherit;">2022,</em> $<ix:nonFraction id="c81558737" contextRef="i_2021-12-31" unitRef="USD" name="govx:LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" scale="0" format="ixt:numdotdecimal" decimals="INF">128,000</ix:nonFraction> in <em style="font: inherit;">2023,</em> $<ix:nonFraction id="c81558739" contextRef="i_2021-12-31" unitRef="USD" name="govx:LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" scale="0" format="ixt:numdotdecimal" decimals="INF">128,000</ix:nonFraction> in <em style="font: inherit;">2024,</em> $<ix:nonFraction id="c81558741" contextRef="i_2021-12-31" unitRef="USD" name="govx:LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" scale="0" format="ixt:numdotdecimal" decimals="INF">28,000</ix:nonFraction> in <em style="font: inherit;">2025</em> and $<ix:nonFraction id="c81558743" contextRef="i_2021-12-31" unitRef="USD" name="govx:LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" scale="0" format="ixt:numdotdecimal" decimals="INF">28,000</ix:nonFraction> in <em style="font: inherit;">2026.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of <em style="font: inherit;"> December 31, 2021, </em>there were approximately $<ix:nonFraction id="c81558745" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">407,000</ix:nonFraction> of unrecorded outstanding purchase commitments to our vendors and subcontractors, which we expect will be due in <em style="font: inherit;">2022.</em></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PreferredStockTextBlock" id="c2049126" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">7.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Stockholders</b>&#x2019;<b> Equity</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Preferred Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2021, </em>we repurchased the remaining <ix:nonFraction id="c81558748" contextRef="i_2021-06-01_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100</ix:nonFraction> shares of our Series B convertible preferred stock for a total price of $<ix:nonFraction id="c81558749" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000</ix:nonFraction>. As of <em style="font: inherit;"> December 31, 2021, </em>there are <ix:nonFraction id="c81558750" contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:PreferredStockSharesOutstanding" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> shares of our preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      F-
     <em style="font: inherit;">12</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Common Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Public Offering </i>&#x2013;<i> </i>On <em style="font: inherit;"> September 29, 2020, </em>we closed an underwritten public offering (the <em style="font: inherit;">&#x201c;2020</em> Offering&#x201d;) of an aggregate of <ix:nonFraction id="c81558754" contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember" unitRef="Share" name="govx:ClassOfWarrantOrRightIssuedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">2,560,000</ix:nonFraction> units of our equity securities (the &#x201c;Units&#x201d;) with gross proceeds to us of approximately $<ix:nonFraction id="c81558755" contextRef="d_2020-09-29_2020-09-29" unitRef="USD" name="govx:ProceedsFromIssuanceOrSaleOfEquityGross" scale="6" format="ixt:numdotdecimal" decimals="-5">12.8</ix:nonFraction> million. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $<ix:nonFraction id="c81558756" contextRef="d_2020-09-29_2020-09-29" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-5">11.2</ix:nonFraction> million. Each Unit sold in the offering consisted of <ix:nonFraction id="c81558757" contextRef="i_2020-09-29_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember" unitRef="Share" name="govx:NumberOfCommonStockSecuritiesCalledByEachUnit" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> share of our common stock (or a pre-funded warrant to purchase <ix:nonFraction id="c81558758" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> share of common stock, all of which were fully exercised during <em style="font: inherit;">2020</em>), and a warrant to purchase <ix:nonFraction id="c81558760" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> share of common stock (&#x201c;Unit Warrant&#x201d;), exercisable at an exercise price of $<ix:nonFraction id="c81558761" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction> per share and with a <span style="-sec-ix-hidden:c81558762">five</span>-year expiration date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From <em style="font: inherit;">2016</em> through <em style="font: inherit;"> August 2020, </em>to help conserve the Company&#x2019;s cash resources, our executive officers and non-employee directors agreed to defer receipt of all or a portion of their respective cash compensation. Upon consummation of the <em style="font: inherit;">2020</em> Offering, $<ix:nonFraction id="c81558765" contextRef="d_2020-09-29_2020-09-29" unitRef="USD" name="govx:DeferredCompensationLiabilityConversionToEquityAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,500,000</ix:nonFraction> of accumulated deferrals were converted at the $<ix:nonFraction id="c81558766" contextRef="i_2020-09-29" unitRef="USDPerShare" name="govx:DeferredCompensationLiabilityConversionToEquityConversionPrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction> offering price, resulting in the issuance of <ix:nonFraction id="c81558767" contextRef="d_2020-09-29_2020-09-29" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">300,001</ix:nonFraction> units substantially similar to the units sold in the public offering, with each unit consisting of <ix:nonFraction id="c81558768" contextRef="i_2020-09-29" unitRef="Share" name="govx:NumberOfCommonStockSecuritiesCalledByEachUnit" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> share of our common stock and <ix:nonFraction id="c81558769" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember" unitRef="Share" name="govx:NumberOfWarrantsCalledByEachUnit" scale="0" format="ixt-sec:numwordsen" decimals="INF">one</ix:nonFraction> warrant substantially similar to a Unit Warrant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon consummation of the <em style="font: inherit;">2020</em> Offering, we issued an aggregate of <ix:nonFraction id="c81558771" contextRef="d_2020-09-29_2020-09-29" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">177,626</ix:nonFraction> shares of our common stock, <ix:nonFraction id="c81558772" contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">126,042</ix:nonFraction> pre-funded warrants to purchase common stock, and <ix:nonFraction id="c81558773" contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="Share" name="us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">303,668</ix:nonFraction> warrants substantially similar to a Unit Warrant upon the mandatory conversion of $<ix:nonFraction id="c81558774" contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember" unitRef="USD" name="govx:DebtConversionConvertedInstrumentPrincipalAndInterestAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">1,214,667</ix:nonFraction> of convertible debentures and accrued interest.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Public Offering </i>&#x2013;<i> </i>On <em style="font: inherit;"> February 11, 2021, </em>we closed an underwritten public offering of <ix:nonFraction id="c81558776" contextRef="d_2021-02-11_2021-02-11" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">1,644,000</ix:nonFraction> shares of our common stock, with gross proceeds to us of approximately $<ix:nonFraction id="c81558777" contextRef="d_2021-02-11_2021-02-11" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:numdotdecimal" decimals="-5">10.3</ix:nonFraction> million. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $<ix:nonFraction id="c81558778" contextRef="d_2021-02-11_2021-02-11" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">9.4</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrant exercises</i> &#x2013; During <em style="font: inherit;">2021,</em> <ix:nonFraction id="c81558780" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">740,034</ix:nonFraction> Unit Warrants were exercised for cash, resulting in gross proceeds to us of approximately $<ix:nonFraction id="c81558781" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="USD" name="govx:ProceedsFromWarrantExercisesGross" scale="6" format="ixt:numdotdecimal" decimals="-5">3.7</ix:nonFraction> million; net proceeds after deducting commissions owed to the underwriter of the <em style="font: inherit;">2020</em> Offering were approximately $<ix:nonFraction id="c81558783" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="6" format="ixt:numdotdecimal" decimals="-5">3.4</ix:nonFraction> million. During <em style="font: inherit;">2021,</em> an aggregate of <ix:nonFraction id="c81558785" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">215,672</ix:nonFraction> warrants were exercised using the cashless exercise feature of the warrants, resulting in the issuance of an aggregate of <ix:nonFraction id="c81558786" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">149,705</ix:nonFraction> shares of our common stock. During <em style="font: inherit;">2020,</em> <ix:nonFraction id="c81558788" contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">54,557</ix:nonFraction> warrants were exercised using the cashless exercise feature of the warrants, resulting in the issuance of an aggregate of <ix:nonFraction id="c81558789" contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">36,902</ix:nonFraction> shares of our common stock</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Common Stock Transactions</i> &#x2013; During <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> we issued <ix:nonFraction id="c81558792" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">13,707</ix:nonFraction> and <ix:nonFraction id="c81558793" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" format="ixt:numdotdecimal" decimals="INF">26,581</ix:nonFraction> shares, respectively, of our common stock pursuant to consulting agreements. During <em style="font: inherit;">2020</em> we issued an aggregate of <ix:nonFraction id="c81558795" contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" unitRef="Share" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" format="ixt:numdotdecimal" decimals="INF">716,790</ix:nonFraction> shares of our common stock, pursuant to the conversion of Series H and Series I convertible preferred stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Option Plan</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have a stock-based incentive plan (the <em style="font: inherit;">&#x201c;2020</em> Plan&#x201d;) pursuant to which our Board of Directors <em style="font: inherit;"> may </em>grant stock options to our employees. A total of <ix:nonFraction id="c81558797" contextRef="i_2021-09-30_PlanNameAxis-StockIncentivePlan2020Member" unitRef="Share" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" format="ixt:numdotdecimal" decimals="INF">1,500,000</ix:nonFraction> shares of our common stock are reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan. The exercise price for any option granted <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be less than fair value (<ix:nonFraction id="c81558800" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" format="ixt:numdotdecimal" decimals="1">110</ix:nonFraction>% of fair value for ISO&#x2019;s granted to certain employees). Options have a maximum <span style="-sec-ix-hidden:c81558801">ten</span>-year term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows:</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2049127" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average risk-free interest rates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558862" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">1.43</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558863" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="4">0.69</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558864" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558865" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c81558866" format="ixt-sec:duryear">7.0</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c81558867" format="ixt-sec:duryear">7.0</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558868" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">84.80</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81558869" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="4">38.16</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      F-
     <em style="font: inherit;">13</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">A summary of stock option activity under the <em style="font: inherit;">2020</em> Plan as of <em style="font: inherit;"> December 31, 2021, </em>and changes during the year then ended is presented below.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2049128" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Term (yrs)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558870" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">602,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558871" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.79</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558874" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">360,300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558875" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.82</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558878" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558879" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558882" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558883" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558886" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">962,300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558887" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.18</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81558888" format="ixt-sec:duryear">9.31</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558889" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="INF">499,660</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558890" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">200,661</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558891" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.79</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c81558892" format="ixt-sec:duryear">8.93</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558893" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="0" format="ixt:numdotdecimal" decimals="INF">166,549</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted-average grant date fair values of options granted during <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> were $<ix:nonFraction id="c81558806" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.87</ix:nonFraction> and $<ix:nonFraction id="c81558807" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.12</ix:nonFraction>, respectively. Total stock option compensation expense recognized in the consolidated statement of operations for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was $<ix:nonFraction id="c81558809" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">269,427</ix:nonFraction> and $<ix:nonFraction id="c81558810" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">18,730</ix:nonFraction>, respectively. As of <em style="font: inherit;"> December 31, 2021, </em>there is $<ix:nonFraction id="c81558811" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,420,144</ix:nonFraction> of unrecognized compensation expense that will be recognized over a weighted-average period of <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c81558812" format="ixt-sec:duryear">2.2</ix:nonNumeric> years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Purchase Warrants</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Summary of Warrants Outstanding </i>&#x2013; The table below presents summary information about our warrants outstanding as of <em style="font: inherit;"> December 31, 2021. </em>Additional information concerning the warrants follows the table.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c2049129" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant Description</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expiration</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2020 Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558894" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2020Member" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558895" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2020Member" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Jun 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2020 Unit Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558897" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,396,631</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558898" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2020 Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558900" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">128,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558901" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:numdotdecimal" decimals="1">5.50</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Mar 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021 Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558903" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">72,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558904" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">6.875</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Aug 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021 Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558906" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2021Member" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558907" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2021Member" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">13.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2026</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Warrants Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558909" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">2,816,631</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Exercise Price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558912" contextRef="i_2021-12-31_RangeAxis-WeightedAverageMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.35</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Remaining Life (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonNumeric contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RemainingLifeOnWarrantsOutstandingmember_RangeAxis-WeightedAverageMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81558915" format="ixt-sec:duryear">3.7</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Warrants</i> &#x2013; In <em style="font: inherit;"> June 2020, </em>in connection with the issuance of convertible debentures, we issued warrants to purchase <ix:nonFraction id="c81558814" contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">120,000</ix:nonFraction> shares of common stock, with a <span style="-sec-ix-hidden:c81558815">five</span>-year term and an exercise price of $<ix:nonFraction id="c81558816" contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">10.00</ix:nonFraction>. As a result of the <em style="font: inherit;">2020</em> Public Offering, in <em style="font: inherit;"> September 2020 </em>the exercise price was reduced to $<ix:nonFraction id="c81558818" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Unit Warrants</i> &#x2013; In <em style="font: inherit;"> September 2020, </em>in connection with the <em style="font: inherit;">2020</em> Public Offering, we issued <ix:nonFraction id="c81558821" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ConversionOfConvertibleDebentureMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">303,668</ix:nonFraction> warrants upon the conversion of convertible debentures, <ix:nonFraction id="c81558822" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">300,001</ix:nonFraction> warrants upon the conversion of amounts owed to current and former executive officers and directors, and <ix:nonFraction id="c81558823" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">2,560,000</ix:nonFraction> warrants to other investors in the <em style="font: inherit;">2020</em> Public Offering, with each of the warrants having a <span style="-sec-ix-hidden:c81558825">five</span>-year term and an exercise price of $<ix:nonFraction id="c81558826" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction>. During <em style="font: inherit;">2021,</em> <ix:nonFraction id="c81558828" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="Share" name="govx:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">740,034</ix:nonFraction> of these warrants were exercised for cash and <ix:nonFraction id="c81558829" contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember" unitRef="Share" name="govx:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">27,004</ix:nonFraction> were exercised using the cashless exercise feature of the warrant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Representative Warrants</i> &#x2013; In <em style="font: inherit;"> September 2020, </em>we issued <ix:nonFraction id="c81558831" contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">128,000</ix:nonFraction> warrants to the underwriter of the <em style="font: inherit;">2020</em> Public Offering, with a <ix:nonNumeric contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81558833" format="ixt-sec:durmonth">42</ix:nonNumeric>-month term and an exercise price of $<ix:nonFraction id="c81558834" contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.50</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Representative Warrants</i> &#x2013; In <em style="font: inherit;"> February 2021, </em>we issued <ix:nonFraction id="c81558836" contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">72,000</ix:nonFraction> warrants to the underwriter of the <em style="font: inherit;">2021</em> Public Offering, with a <ix:nonNumeric contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81558838" format="ixt-sec:durmonth">42</ix:nonNumeric>-month term and an exercise price of $<ix:nonFraction id="c81558839" contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">6.875</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Warrants</i> &#x2013; In <em style="font: inherit;"> September 2021, </em>in connection with a technology licensing agreement, we issued <ix:nonFraction id="c81558841" contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-Warrants2021Member" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">100,000</ix:nonFraction> warrants, with a <span style="-sec-ix-hidden:c81558842">five</span>-year term and an exercise price of $<ix:nonFraction id="c81558843" contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-Warrants2021Member" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">13.00</ix:nonFraction>.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      F-
     <em style="font: inherit;">14</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Additional Stock-Based Compensation Expense</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to stock-based compensation expense related to the <em style="font: inherit;">2020</em> Plan (see <i>Stock Options</i> above), during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> we recognized $<ix:nonFraction id="c81558847" contextRef="d_2021-01-01_2021-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">100,560</ix:nonFraction> and $<ix:nonFraction id="c81558848" contextRef="d_2020-01-01_2020-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">45,733</ix:nonFraction>, respectively, of expense related to the issuance of our common stock pursuant to consulting and investment banking agreements. As of <em style="font: inherit;"> December 31, 2021, </em>there is $<ix:nonFraction id="c81558849" contextRef="i_2021-12-31" unitRef="USD" name="govx:PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">19,947</ix:nonFraction> recorded as a prepaid expense for these arrangements, which will be recognized as expense during <em style="font: inherit;">2022</em> over the term of the related agreement.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="c2049130" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">8.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Retirement Plan</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We participate in a multi-employer defined contribution retirement plan (the <em style="font: inherit;">&#x201c;401k</em> Plan&#x201d;) administered by a <em style="font: inherit;">third</em>-party service provider, and the Company contributes to the <em style="font: inherit;">401k</em> Plan on behalf of its employees based upon a matching formula. During the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> our contributions to the <em style="font: inherit;">401k</em> Plan were $<ix:nonFraction id="c81558924" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">36,980</ix:nonFraction> and $<ix:nonFraction id="c81558925" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">27,511</ix:nonFraction>, respectively.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2049131" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">9.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Income Taxes</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At <em style="font: inherit;"> December 31, 2021, </em>we have a consolidated federal net operating loss (&#x201c;NOL&#x201d;) carryforward of approximately $<ix:nonFraction id="c81558927" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">75.2</ix:nonFraction> million available to offset against future taxable income of which approximately $<ix:nonFraction id="c81558928" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="govx:OperatingLossCarryforwardsSubjectToExpiration" scale="6" format="ixt:numdotdecimal" decimals="-5">48.9</ix:nonFraction> million expires in varying amounts in <em style="font: inherit;">2022</em> through <em style="font: inherit;">2037.</em> Additionally, we have approximately $<ix:nonFraction id="c81558931" contextRef="i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">1.6</ix:nonFraction> million in research and development (&#x201c;R&amp;D&#x201d;) tax credits that expire in <em style="font: inherit;">2022</em> through <em style="font: inherit;">2041</em> unless utilized earlier. <span style="-sec-ix-hidden:c81558934">No</span> income taxes have been paid to date. Section <em style="font: inherit;">382</em> of the Internal Revenue Code contains provisions that <em style="font: inherit;"> may </em>limit our utilization of our NOL and R&amp;D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or <em style="font: inherit;"> may </em>occur in future periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2049132" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62.2%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558939" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">18,449,694</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558940" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">14,737,240</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research and development tax credit carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558941" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" format="ixt:numdotdecimal" decimals="INF">1,566,293</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558942" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="0" format="ixt:numdotdecimal" decimals="INF">1,189,110</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558943" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:numdotdecimal" decimals="INF">129,475</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558944" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:numdotdecimal" decimals="INF">4,870</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued salaries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558945" contextRef="i_2021-12-31" unitRef="USD" name="govx:DeferredTaxAssetsAccruedSalaries" scale="0" format="ixt:numdotdecimal" decimals="INF">69,940</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558946" contextRef="i_2020-12-31" unitRef="USD" name="govx:DeferredTaxAssetsAccruedSalaries" scale="0" format="ixt:numdotdecimal" decimals="INF">72,721</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558947" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">20,215,402</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558948" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">16,003,941</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558952" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">30,945</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558953" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">28,274</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558954" contextRef="i_2021-12-31" unitRef="USD" name="govx:DeferredTaxAssetsBeforeValuationAllowanceNet" scale="0" format="ixt:numdotdecimal" decimals="INF">20,184,457</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558955" contextRef="i_2020-12-31" unitRef="USD" name="govx:DeferredTaxAssetsBeforeValuationAllowanceNet" scale="0" format="ixt:numdotdecimal" decimals="INF">15,975,667</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81558956" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">20,184,457</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81558957" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">15,975,667</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset after reduction for valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-<ix:nonFraction id="c81558958" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-<ix:nonFraction id="c81558959" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2049133" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. federal statutory rate applied to pretax loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81558960" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">3,899,767</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81558961" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">621,194</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558962" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" format="ixt:zerodash" decimals="INF">-</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558963" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">65</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81558964" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="0" format="ixt:numdotdecimal" decimals="INF">377,183</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81558965" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="0" format="ixt:numdotdecimal" decimals="INF">66,574</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance, net of expired items and other adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558966" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">4,276,950</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81558967" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">687,703</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reported income tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-<ix:nonFraction id="c81558968" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-<ix:nonFraction id="c81558969" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">15</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="govx:GovernmentGrantsandContractsTextBlock" id="c2049134" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">10.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Grants and Collaboration Revenue</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> we recorded $<ix:nonFraction id="c81558973" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-NIHGrantsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">385,501</ix:nonFraction> and $<ix:nonFraction id="c81558974" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NIHGrantsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">1,438,465</ix:nonFraction>, respectively, of revenue associated with these grants. As of <em style="font: inherit;"> December 31, 2021, </em>there is an aggregate of $<ix:nonFraction id="c81558975" contextRef="i_2021-12-31" unitRef="USD" name="govx:UnusedGrantFunds" scale="0" format="ixt:numdotdecimal" decimals="INF">81,526</ix:nonFraction> in remaining grant funds available for use during <em style="font: inherit;">2022.</em> During <em style="font: inherit;">2020,</em> we recorded $<ix:nonFraction id="c81558978" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ResearchAgreementsMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="0" format="ixt:numdotdecimal" decimals="INF">385,193</ix:nonFraction> of revenues associated with a research collaboration agreement.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2049135" escape="true">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">11.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Subsequent Events</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January 19, 2022, </em>we closed a private placement of <ix:nonFraction id="c81558980" contextRef="d_2022-01-19_2022-01-19_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">707,484</ix:nonFraction> shares of common stock, <ix:nonFraction id="c81558981" contextRef="i_2022-01-19_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">2,360,000</ix:nonFraction> pre-funded warrants to purchase common stock, and accompanying warrants to purchase an aggregate of up to <ix:nonFraction id="c81558982" contextRef="i_2022-01-19_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">3,067,484</ix:nonFraction> shares of common stock. The warrants are exercisable immediately at an exercise price of $<ix:nonFraction id="c81558983" contextRef="i_2022-01-19_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">3.26</ix:nonFraction> per share and will expire <span style="-sec-ix-hidden:c81558984">five</span> years from the date of issuance. Net proceeds after deducting placement agent commissions and other offering expenses were approximately $<ix:nonFraction id="c81558985" contextRef="d_2022-01-19_2022-01-19_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-5">9.2</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      F-
     <em style="font: inherit;">16</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="c2049136" escape="true">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>GEOVAX LABS, INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SCHEDULE II </b>&#x2013;<b> VALUATION AND QUALIFYING ACCOUNTS</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the Years Ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SummaryOfValuationAllowanceTextBlock" id="c2049137" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Additions (Reductions)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Description</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Costs and</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expenses</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Other</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accounts</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deductions</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for Deferred Tax Assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558990" contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" format="ixt:numdotdecimal" decimals="INF">15,975,667</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558991" contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">4,208,790</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-<ix:nonFraction id="c81558992" contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-<ix:nonFraction id="c81558993" contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558994" contextRef="i_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" format="ixt:numdotdecimal" decimals="INF">20,184,457</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558995" contextRef="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" format="ixt:numdotdecimal" decimals="INF">18,787,230</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81558996" contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">2,811,563</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-<ix:nonFraction id="c81558997" contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" scale="0" format="ixt:numdotdecimal" decimals="-3" sign="-">0</ix:nonFraction>-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-<ix:nonFraction id="c81558998" contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81558999" contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="0" format="ixt:numdotdecimal" decimals="INF">15,975,667</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-17
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>2
<FILENAME>ex_339970.htm
<DESCRIPTION>EXHIBIT 10.2.2
<TEXT>
<html><head>
	<title>ex_339970.htm</title>

	<!-- Generated by ThunderDome Portal - 2/25/2022 7:33:49 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.2.2</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="geovax.jpg" src="geovax.jpg"></p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>Employment Agreement</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Between</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>GeoVax, Inc. and Mark J. Newman, PhD</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Amended and Restated as of March 1, 2022</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This <b>EMPLOYMENT AGREEMENT</b> (the "Agreement") by and between <b>GeoVax, Inc.</b>, a Georgia Corporation ("Company"), and <b>Mark J. Newman, PhD </b>("Employee"; and with the Company, collectively, the "Parties"), is entered into and effective as of March 1, 2022 (the "Effective Date&#8221;). This Agreement amends and restates the original employment agreement between the parties dated August 25, 2020 (the &#8220;Original Agreement&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Employee will serve as Chief Scientific Officer of the Company. The Company and Employee desire that Employee be employed by the Company in the above capacity under the terms of this Agreement. Therefore, in consideration of the mutual covenants and agreements set forth herein, it is agreed:</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>1. </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Employment Duties.</u></b> Employee is hereby employed by the Company under the terms of this Agreement, and Employee accepts such employment. Employee shall serve in the capacity as defined above and shall perform the following duties (&#8220;Employees Duties&#8221;): such duties as are customary for someone in that position and duties that may be reasonably assigned from time to time by the President/CEO. Primary duties include but are not limited to: contribution to the overall focus of our company developing commercially viable vaccines for infectious diseases based on the GeoVax technologies. Assistance and contributions in the raising of equity and successful competition for grants (both as a PI and as a collaborator).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>2. </b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Term of Agreement.</u></b> The term of Employee&#8217;s employment pursuant to the Original Agreement commenced on or about August 25, 2020 and shall end upon the termination of Employee&#8217;s employment with the Company as provided herein. The Company may terminate this Agreement at will and at its sole discretion as allowed under Georgia state law, by giving written notice to Employee, and such termination shall be effective on the termination date described in such notice (or such earlier time as the Company and Employee may agree). Notwithstanding the foregoing, the termination of this Agreement shall not terminate the Company&#8217;s obligation to make any payments to Employee for services performed and expenses incurred prior to the date of such termination as long as the Employee is in good standing; and such termination shall not terminate Employee&#8217;s obligations under Sections 13-15, and 17-29 below. Employee shall have the right to terminate employment on one month written notice, and shall suitably perform all normal services during that one month period, if requested to do so by Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>3.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Base Salary.</u></b> The base salary will be $275,000 on a full-time annualized basis. Performance and salary reviews are at the discretion of the President/CEO and/or Board of Directors.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>4.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Performance Reviews.</u></b> Performance reviews will be conducted at least annually by the President/CEO or designee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>5.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Annual Bonus Potential.</u></b> An annual fiscal year bonus will be considered and recommended, if appropriate, by the supervisor and President/CEO and must be BOD approved. The targeted bonus will be 40% of base salary, but the actual amount shall be at the full discretion of the President/BOD based on Employee&#8217;s and the Company&#8217;s performance and achievement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>6.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Equity Stock Incentive.</u></b> An annual stock option grant will be based on a target of 75% of base salary, but actual option grants are performance based and at the discretion of the BOD based on Employee&#8217;s and the Company&#8217;s performance and achievement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>7.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Moving Expenses.</u></b> N/A</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>8.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Temporary Living Expense.</u></b> N/A</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>9.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Other Business Expenses.</u></b> N/A</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>10.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Benefits.</u></b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>a.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Group Insurance &amp; 401(k) Benefits.</u></b>&nbsp;&nbsp;Employee will be eligible for Company group benefit programs generally provided to other full-time employees of similar status, including group medical insurance and 401(k) benefits.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>b.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Vacation.</u></b>&nbsp;&nbsp;Employee will accrue four weeks of paid vacation per year on a full-time basis. Vacation time is accrued on a pay period basis subject to the Company&#8217;s paid time off policy as documented in the Employee Handbook.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>c.</b></p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><u>Holidays.</u></b>&nbsp;&nbsp;GeoVax will be closed on the following holidays: New Year&#8217;s Day, Good Friday, Memorial Day, Independence Day, Labor Day, Thanksgiving Day and the day after, and two days that include Christmas (to be determined by Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>11.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Termination.</u></b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>a.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Materials.</u></b> Upon termination, Employee shall immediately return Company issued computers, phones, files, emails, documents and/or other Company owned devices and materials (including laboratory materials) to Company and shall not delete or destroy anything prior to return to Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>b.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>By the Company with Cause.</u></b> If Employee is terminated with cause, Employee&#8217;s employment, compensation, and benefits will terminate immediately (unless otherwise provided by law), and Employee shall not receive any severance payments.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>c.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>By the Company without Cause.</u></b> Company may terminate Employee at will without cause consistent with Georgia state law by providing written notice. Company and Employee will discuss whether it is appropriate under the circumstances to have a period during which Employee continues to carry out his function for the Company for normal or adjusted compensation during that period, however, Company shall make the final decision at its sole option. Company shall pay Employee any amounts due up through the date of termination.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 54pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>d.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>By the Employee.</u></b> Employee may voluntarily terminate his employment on 30 days written notice to the Company, and Employee&#8217;s employment, compensation and benefits will terminate on the effective date of termination (unless otherwise provided by law). Employee shall not receive any severance payments or other payments due after the date of termination. Company shall decide whether to allow Employee to leave immediately, and if so, will not be obligated to provide any further compensation or benefits.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>12.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Record Keeping and Payment.</u></b> Employee shall keep and file with the Company an expense report for all business expenses for which Employee seeks reimbursement. Employee shall be reimbursed for such documented business expenses within thirty (30) days of submitting a request for reimbursement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>13.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Proprietary Information.</u></b> Employee agrees that all information, whether or not in writing, concerning the Company's business, technology, business goals, plans or strategies, relationships or financial affairs (collectively, "Proprietary Information") is and will be the exclusive property of the Company. By way of illustration, Proprietary Information may include information or material which has not been made generally available to the public, such as: (a) corporate information, including business or technical plans, strategies, methods, policies, resolutions, negotiations, or litigation; (b) marketing information, including strategies, methods, potential or present collaborator or vendor identities, or other information about prospects and prospect identities, or market analyses or projections; (c) financial information, including cost and performance data, debt arrangements, equity structure, investors and holdings, purchasing and sales data and price lists; (d) operational and technological information, including research goals, plans, potential products, implementations, viral vectors, inserts, specifications, manuals, forms, templates, software, designs, methods, procedures, formulas , discoveries, inventions, improvements, concepts and ideas; and (e) contract terms, licenses, license negotiation negotiations strategies, potential licensees or licensors; and (f) personnel information, including personnel lists, reporting or organizational structure, resumes, personnel data, compensation structure, performance evaluations, and termination arrangements or documents. Proprietary Information also includes information received in confidence by the Company from its collaborators, vendors, or suppliers or other third parties. Proprietary Information does not include information that a) is in the public domain or enters the public domain through no breach of this Agreement by Employee; b) information that is in Employee&#8217;s possession prior to receipt from the Company; or c) information that is disclosed to Employee by a third party who is not under a direct or indirect obligation of confidentiality to the Company with respect thereto.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>14.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Recognition of Company's Rights.</u></b> Employee shall not, at any time, without the Company's prior written permission, either during or after Employee&#8217;s employment, disclose any Proprietary Information to anyone outside of the Company, or use or permit to be used any Proprietary Information for any purpose other than the performance of Employee&#8217;s duties as an employee of the Company. Employee shall cooperate with the Company and use reasonable best efforts to prevent the unauthorized disclosure of all Proprietary Information. Employee shall deliver to the Company all copies of Proprietary Information in Employee&#8217;s possession or control upon the earlier of a request by the Company or termination of Employee&#8217;s employment.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>15.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Rights of Others.</u></b> Employee understands that the Company is now and may hereafter be subject to non-disclosure or confidentiality agreements with third persons which require the Company to protect or refrain from use of Proprietary Information. Employee agrees to be bound by the terms of such agreements in the event Employee has access to such Proprietary Information, provided that the Company has informed Employee that such information is subject to a confidentiality agreement with a third party.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>16.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Commitment to Company; Avoidance of Conflict of Interest.</u></b> While an employee of the Company, Employee will devote Employee&#8217;s full-time efforts to the Company's business and will not engage in any other business activity that conflicts with Employee&#8217;s duties to the Company. Employee will advise the CEO of the Company or his or her nominee at such time if any activity of either the Company or another business presents Employee with a conflict of interest or the appearance of a conflict of interest as an employee of the Company. Employee will take whatever reasonable action is requested by the Company to resolve any conflict or appearance of conflict which it finds to exist.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>17.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Inventions.</u></b> Employee will make full and prompt written disclosure to the Company of all inventions, discoveries, designs, developments, methods, modifications, improvements, compositions of matter, methods of use, processes of preparation, other processes, algorithms, databases, computer programs, formulae, techniques, trade secrets, graphics or images, and audio or visual works and other works of authorship, whether or not patentable or copyrightable, that are created, made, conceived or reduced to practice by Employee (alone or jointly with others) or under Employee&#8217;s direction during the period of employment for the Company (collectively &#8220;Inventions&#8221;). Employee acknowledges that all work performed by Employee is on a &#8220;work for hire&#8221; basis, and Employee hereby does assign and transfer and, to the extent any such assignment cannot be made at present, will assign and transfer, to the Company and its successors and assigns all Employee&#8217;s rights, title, and interest in all Inventions that (a) relate to the business of the Company or any of the products or services being researched, developed, manufactured or sold by the Company or which may be used with such products or services; or (b) result from tasks assigned to Employee by the Company; or (c) result from the use of premises, laboratories, equipment, physical space, or personal property (whether tangible or intangible) owned, leased, or contracted for by the Company (&#8220;Company&#173; Related Inventions&#8221;), and all related patents, patent applications, trademarks and trademark applications, copyrights and copyright applications, and other intellectual property rights in all countries and territories worldwide and under any international conventions (&#8220;Intellectual Property Rights&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>18.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Documents and Other Materials.</u></b> Employee will keep and maintain adequate and current records of all Proprietary Information and Company-Related Inventions developed by Employee during employment, which records will be available to and remain the sole property of the Company at all times.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">All files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic, or other tangible material containing Proprietary Information, whether created by Employee or others, which come into Employee&#8217;s custody or possession, are the exclusive property of the Company to be used by Employee only in the performance of Employee&#8217;s duties for the Company. Any property situated on the Company's premises and owned by the Company, including without limitation computers, disks, and other storage media, filing cabinets or other work areas, is subject to inspection by the Company at any time with or without notice. In the event of the termination of Employee's employment for any reason, Employee will deliver to the Company all Company property and equipment in Employee&#8217;s possession, custody or control, including all files, letters, notes, memoranda, reports, records, data, sketches, drawings, notebooks, layouts, charts, quotations and proposals, specification sheets, program listings, blueprints, models, prototypes, or other written, photographic or other tangible material containing Proprietary Information, and other materials of any nature pertaining to the Proprietary Information of the Company and to Employee&#8217;s work, and will not take or keep in Employee&#8217;s possession any of the foregoing or any copies.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>19.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Enforcement of Intellectual Property Rights.</u></b> Employee will cooperate fully with the Company, both during and after employment with the Company, with respect to the procurement, maintenance, and enforcement of Intellectual Property Rights in Company-Related Inventions. Employee will sign, both during and after the term of this Agreement, all papers, including without limitation copyright applications, patent applications, declarations, oaths, assignments of priority rights, and powers of attorney, which the Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Inventions. If the Company is unable, after reasonable effort, to secure Employee&#8217;s signature on any such papers, Employee hereby irrevocably designates and appoints each officer of the Company as Employee&#8217;s agent and attorney-in-fact to execute any such papers on Employee&#8217;s behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in any Company-Related Inventions. Other than with regard to signing these various papers, which shall be done without remuneration, any cooperation Employee provides to the Company after the term of Employee&#8217;s employment with the Company shall be provided at Company's reasonable expense.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>20.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Non-Competition and Non-Solicitation.</u></b><b> </b>To protect the Company's Proprietary Information and good will, during Employee's employment and for a period of one (1) year following the termination of Employee&#8217;s employment for any reason (the &#8220;Restricted Period&#8221;):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(a)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Employee will not directly or indirectly, whether as owner, partner, shareholder, director, manager, consultant, agent, employee, co-venturer or otherwise, engage, participate or invest in any business activity anywhere in the United States or elsewhere that develops, manufactures or markets any products, or performs any services, that are otherwise competitive with or similar to the products or services in the Company's Field Of Interest, provided that this shall not prohibit any possible investment in publicly traded stock of a company representing less than one percent of the stock of such company. The phrase, Company's &#8220;Field of Interest&#8221;, means research, development, and commercialization activities relating to vaccinia-based and modified vaccinia Ankara (MVA)-based vaccines that induce or enhance immuno-protection, or such other specific areas of research, development and commercialization as the Company may be engaged in during the term of this Agreement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(b)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Employee will not, directly, or indirectly, in any manner, other than for the benefit of the Company, call upon, solicit, divert, take away, accept or conduct any business from or with any of the customers or prospective customers of the Company or any of its suppliers.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">(c)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Employee will not, directly, or indirectly, in any manner, solicit, entice, attempt to persuade any other employee or consultant of the Company to leave the Company for any reason or otherwise participate in or facilitate the hire, directly or through another entity, of any person who is employed or engaged by the Company or who was employed or engaged by the Company within six months of any attempt to hire such person. Employee acknowledges and agrees that if Employee violates any of the provisions of this paragraph 20, the running of the Restricted Period will be extended by the time during which Employee engages in such violation(s).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>21.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Government Contracts.</u></b> Employee acknowledges that the Company may have from time-to-time agreements with other persons or with the United States Government or its agencies which impose obligations or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential nature of such work. Employee agrees to comply with any such obligations or restrictions upon the direction of the Company. In addition to the rights assigned under paragraph 17, Employee also assigns to the Company (or any of its nominees) all rights which Employee has or acquires in any Inventions, full title to which is required to be in the United States under any contract between the Company and the United States or any of its agencies.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>22.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Prior Agreements.</u></b> Employee hereby represents that, except as Employee has fully disclosed previously in writing to the Company, Employee is not bound by the terms of any agreement with any previous employer or other party to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of employment with the Company or to refrain from competing, directly or indirectly, with the business of such previous employer or any other party within the scope of the duties for Company. Employee further represent that Employee&#8217;s performance of all the terms of this Agreement as an employee of the Company does not and will not breach any agreement to keep in confidence proprietary information, knowledge or data acquired by Employee in confidence or in trust prior to employment with the Company. Employee will not disclose to the Company or induce the Company to use any confidential or proprietary information or material belonging to any previous employer or others.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>23.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Remedies Upon Breach.</u></b> Employee understands that the restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company and Employee considers them to be reasonable for such purpose. Any breach of this Agreement may cause the Company substantial and irrevocable damage and therefore, in the event of such breach, the Company, in addition to such other remedies which may be available, may be entitled to specific performance and other injunctive relief: without the posting of a bond. If Employee is found to have violated this Agreement by court of law, in addition to other remedies available to the Company at law, in equity, and under contract, Employee may be obligated to pay all the Company's reasonable costs of enforcement of this Agreement, including reasonable attorneys' fees and expenses.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>24.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Publications and Public Statements.</u></b> Employee will obtain the Company's written approval before publishing or submitting for publication any material that relates to Employee&#8217;s work at the Company and/or incorporates any Proprietary Information. To ensure that the Company delivers a consistent message about its products, services, and operations to the public, and further in recognition that even positive statements may have a detrimental effect on the Company in certain securities transactions and other contexts, any statement about the Company or its research or development activities which Employee creates, publishes, or posts during Employee's period of employment and for six (6) months thereafter, on any media accessible by the public, including but not limited to social media and networking services and sites, electronic bulletin boards and Internet-based chat rooms, must first be reviewed and approved by an officer of the Company before it is released in the public domain.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>25.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Survival and Assignment by the Company.</u></b> Employee understands that the Employee&#8217;s obligations under this Agreement will continue following the termination of Employee&#8217;s employment regardless of the manner of such termination and will be binding upon Employee&#8217;s heirs, executors, and administrators. Company will have the right to assign this Agreement to its affiliates, successors, and assigns in connection with the transfer of the area of business Employee is acting in, and Employee expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any parent, subsidiary, or affiliate to whose employ Employee may be transferred without the necessity that this Agreement be resigned at the time of such transfer.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>26.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Post-Employment Notifications.</u></b> For twelve (l2) months following termination of employment, Employee will notify the Company of any change in Employee&#8217;s address and of each subsequent employment or business activity, including the name and address of Employee&#8217;s subsequent employer or other post-Company employment plans.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>27.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Disclosure to Future Employers.</u></b> Employee will provide a copy of this Agreement to any future employer, partner or coadventurer prior to entering into an employment, partnership, or other business relationship with such person or entity, and can redact personal information such as salary, etc.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>28.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Severability.</u></b> In case any provisions (or portions thereof) contained in this Agreement shall, for any reason, be held invalid, illegal, or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect the other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal, or unenforceable provision had never been contained herein. If, moreover, any one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to duration, geographical scope, activity, or subject, it shall be construed by limiting and reducing it, so as to be enforceable to the extent compatible with the applicable law as it shall then appear.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>29.</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><u>Interpretation.</u></b> This Agreement will be deemed to be made and entered into in the State of Georgia, and will in all respects be interpreted, enforced, and governed under the laws of the State of Georgia. Employee hereby agree to consent to personal jurisdiction of the state and federal courts situated within Cobb County, Georgia and the Federal District Court for the Northern District of Georgia, respectively, for purposes of enforcing this Agreement and waive any objection that Employee might have to personal jurisdiction or venue in those courts.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>EMPLOYEE UNDERSTANDS THAT THIS AGREEMENT AFFECTS IMPORTANT RIGHTS. BY SIGNING BELOW, EMPLOYEE CERTIFIES THAT EMPLOYEE HAS READ IT CAREFULLY AND IS SATISFIED THAT EMPLOYEE UNDERSTANDS IT COMPLETELY.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;">The Parties hereto have executed this Agreement as of the day and year first written below.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-36pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td colspan="2" rowspan="1" style="width: 5%;"><b>GEOVAX, INC.</b></td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">By:</td>
			<td style="width: 45%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 5%; text-align: center;">Date:</td>
			<td style="width: 45%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%; text-align: center;">David A. Dodd / President &amp; CEO</td>
			<td style="width: 5%; text-align: center;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 5%; text-align: center;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 5%; text-align: center;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="width: 5%;"><b>EMPLOYEE</b></td>
			<td style="width: 5%; text-align: center;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 5%; text-align: center;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 5%; text-align: center;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
			<td style="width: 5%; text-align: center;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">By:</td>
			<td style="width: 45%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="width: 5%; text-align: center;">Date:</td>
			<td style="width: 45%; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%; text-align: center;">Mark J. Newman, PhD</td>
			<td style="width: 5%;">&nbsp;</td>
			<td style="width: 45%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.23
<SEQUENCE>3
<FILENAME>ex_339971.htm
<DESCRIPTION>EXHIBIT 10.2.3
<TEXT>
<html><head>
	<title>ex_339971.htm</title>

	<!-- Generated by ThunderDome Portal - 2/25/2022 7:46:08 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.2.3</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CONSULTING AGREEMENT</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">This CONSULTING AGREEMENT is entered into by Kelly T. McKee, Jr., MD, MPH, who is the President and Sole Proprietor of KTM BioPartners, LLC, a North Carolina Limited Liability Corporation, with offices located at 233 Valley Meadow Drive, Chapel Hill, North Carolina, 27516 (Consultant) and GeoVax, Inc, a Georgia Corporation with offices located at 1900 Lake Park Drive, Suite 380, Atlanta, Ga, 30080 (GeoVax).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The parties agree as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Scope of Work/Updates/Term</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Scope of Work</u>. During the Term (as defined below), upon the terms and conditions set forth in this Agreement, GeoVax hereby retains Consultant, and Consultant hereby agrees, to perform the consulting services set forth on Schedule A and Attachment 1 (collectively, the &#8220;<u>Services</u>&#8221;).</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Updates</u>. Consultant agrees to keep GeoVax updated promptly upon GeoVax request of any progress, problems, and/or developments of which Consultant is aware regarding the Services.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Scope of Services and Personnel</u>. Consultant agrees to make available the services of Kelly T. McKee, Jr., MD, MPH, in the performance of this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Term</u>. The term of this Agreement (the &#8220;<u>Term</u>&#8221;) shall be deemed to have commenced as of 15 January 2022 and shall continue until such time as GeoVax and/or Consultant propose and agree to terminate, change conditions, or otherwise modify the relationship between GeoVax and Consultant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compensation</u>. The Company shall compensate Consultant as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp; Consultant agrees to be available to GeoVax to perform duties as Chief Medical Officer and related activities for 10 hrs per week, at a bill rate of $400 USD/hr. GeoVax will pay Consultant a fixed fee of $4,000 per week ($400/hr X 10 hrs) for the Term of the contract. If additional hours are agreed between GeoVax and Consultant, the same bill rate ($400/hr) shall apply. Payment shall be made by check (mailed to Kelly T. McKee, Jr, 233 Valley Meadow Drive, Chapel Hill, NC 28306), or by direct wire transfer as follows:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;">Bank of America</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;">104 East Main Street</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;">Carrboro, North Carolina 27510</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;">Account Name: Kelly T. McKee Jr</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;">Account Number: 006010392899</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;">Bank Routing Number: 026009593</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 36pt;">Swift Code: BOFAUS3N (for wire transfer in US dollars)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Page 2</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Other Benefits; Taxes</u>. Except as expressly provided in this Agreement, Consultant shall not be entitled to receive any other compensation or any benefits from GeoVax. Except as otherwise required by law, GeoVax shall not withhold any sums from payments made to Consultant for US State and/or Federal taxes of any kind, and all required US tax payments in respect of the payable pursuant to this Agreement shall be the Consultant&#8217;s sole responsibility.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Confidential Information</u>. Consultant agrees that all information, whether or not in writing, of a private, secret or confidential nature concerning, without limitation, GeoVax&#8217;s business, business relationships, technology, clinical trials or financial affairs (collectively, &#8220;<u>Proprietary Information</u>&#8221;), is and shall be the exclusive property of GeoVax. Consultant shall not disclose any Proprietary Information to any person or entity other than employees of GeoVax, on a need to know basis, or such third parties as GeoVax may authorize in advance, or use the same for any purposes other than in the performance of its duties as a Consultant to GeoVax, either during or after the Term, unless and until Consultant can demonstrate in written records that such Proprietary Information has become public knowledge without fault by Consultant. Consultant agrees that its obligation not to disclose or to use information and materials of the types set forth above also extends to confidential and proprietary information, materials and tangible property of customers, suppliers, sales agents and distributors of GeoVax and other third parties who may have disclosed or entrusted the same to GeoVax or to Consultant (&#8220;<u>Third Party Information</u>&#8221;). Consultant agrees to treat Third Party Information in the same manner as Consultant is required to treat Proprietary Information.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Indemnification</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;Consultant shall indemnify and hold GeoVax and its officers, agents, directors and consultants harmless against all claims, losses, expenses (including reasonable attorney&#8217;s fees) and injuries to person or property (including death) resulting in any way, from any negligence or willful misconduct on the part of Consultant, in the performance or failure to fulfill any Services under this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;GeoVax shall indemnify and hold Consultant and its officers and directors harmless against all claims, losses, expenses (including reasonable attorney&#8217;s fees) and injuries to person or property (including death) resulting in any way, from any negligence or willful misconduct on the part of GeoVax, in the performance or failure to fulfill its obligations under this Agreement.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Term and Termination</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination by The Company</u>. This Agreement can be terminated by GeoVax with or without cause following 30 days written notice to the Consultant.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination by Consultant</u>. This Agreement may be terminated by Consultant with or without cause with 30 days written notice to GeoVax.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Page 3</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Compliance with Applicable Laws</u>. Consultant warrants that any materials supplied and work performed under this Agreement comply with or will comply with all applicable United States laws and regulations.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Independent Contractor</u>. Consultant is an independent contractor and represents and warrants that he is not and shall not be construed to be an employee of GeoVax and that his status shall be that of an independent contractor acting in his professional capacity as GeoVax Chief Medical Officer. Further:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 11pt; text-align: justify;">(1) Geovax shall provide professional liability coverage for the Consultant specific for services performed as GeoVax Chief Medical Officer.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 11pt; text-align: justify;">(2) The Consultant is not authorized to enter into contracts or agreements on behalf of GeoVax or to otherwise create obligations of GeoVax to third parties, except or unless authorized specifically by GeoVax.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 11pt; text-align: justify;">(3) The Consultant&#8217;s place of work is confirmed as being home based. At such time as this Contract terminates, or Consultant terminates services to GeoVax, Consultant will immediately return any computer or other corporate property that may be provided to him by GeoVax.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reimbursement of Expenses</u>. GeoVax will reimburse Consultant for all travel, lodging, meals, and other reasonable out-of-pocket expenses actually incurred by Consultant in connection with this Agreement, upon submission to GeoVax of an invoice and reasonable supporting documentation thereof. International travel (outside North America) will be via business class air; lodging will be in Marriott-brand hotels (or equivalent if Marriott is unavailable). It is expected that the Consultant is responsible for all cost related to maintain a professional office. Reimbursement shall be due within 15 days after receipt of the related invoice by GeoVax.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Reporting Obligations</u>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt; text-align: justify;">(a)&nbsp;&nbsp;&nbsp;&nbsp;None.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>General</u>.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">(a) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Severability</u>. Consultant hereby agrees that each provision herein shall be treated as a separate and independent clause, and the unenforceability of any one clause shall in no way impair the enforceability of any of the other clauses herein. Moreover, if one or more of the provisions contained in this Agreement shall for any reason be held to be excessively broad as to scope, activity, subject or otherwise so as to be unenforceable at law, such provision or provisions shall be construed by the appropriate judicial body by limiting or reducing it or them so as to be enforceable to the maximum extent compatible with the applicable law as it shall then appear.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Assignment</u>. GeoVax shall have the right to assign this Agreement or any rights and obligations hereunder to its successors and assignees, and all covenants and agreements hereunder shall inure to the benefit of and shall be binding upon said successors or assignees. Consultant may not assign this Agreement or any rights or obligations hereunder without the prior written consent of GeoVax.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Page 4</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law and Forum</u>. This Agreement and all aspects of the relationship between the parties hereto shall be construed and enforced in accordance with and governed by the internal laws of the State of Georgia, U.S.A. without regard to its conflict of laws&#8217; provisions. Any claims or legal actions by one party against the other shall be commenced and maintained in any state or federal court located in the state of Georgia, U.S.A. and the parties hereby submit to the jurisdiction and venue of any such court.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u>. All notices provided for in this Agreement shall be given in writing and shall be effective when either served by hand delivery, electronic facsimile transmission, express overnight courier service, or by registered or certified mail, return receipt requested, addressed to the parties at their respective addresses set forth below, or to such other address or addresses as either party may later specify by written notice to the other:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;"><u>If to GeoVax, to</u>:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">David A Dodd, President and CEO</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">GeoVax, Inc.</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">1900 Lake Park Drive, Suite 380,</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">Atlanta, GA, 30080</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;"><u>If to Consultant, to</u>:</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">Kelly T. McKee, Jr., MD, MPH</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">233 Valley Meadow Drive</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">Chapel Hill, North Carolina 27516, USA</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 99pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">1 919 214-2214 (phone)</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt 0pt 0pt 99pt;">mckeekt@ktmbio.com (e-mail)</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Nature of Obligations; Third Party Beneficiaries</u>. This Agreement is solely for the benefit of the parties and their successors and permitted assigns, and does not confer any rights or remedies on any other person or entity.</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt; text-align: justify;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement and Waiver</u>. This Agreement and any schedules and exhibits hereto shall constitute the entire agreement between GeoVax and Consultant with respect to the subject matter hereof and all prior agreements, representations, and statement with respect to such subject matter are superseded hereby, including without limitation any non-disclosure agreement previously executed between the parties. The terms of this Agreement shall control in the event of any inconsistency with the terms of any schedule or exhibit hereto. No failure of either party to exercise or enforce any of its rights under this Agreement shall act as a waiver of subsequent breaches; and the waiver of any breach shall not act as a waiver of subsequent breaches.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Page 5</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">IN WITNESS WHEREOF, the parties have signed this agreement on <u>22 December 2021</u>, effective as of <u>15 January 2022</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">GeoVax, Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By: _____________________________</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">David A. Dodd</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title:_President and CEO</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">____________________________</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consultant</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">By:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Kelly T. McKee, Jr., MD, MPH</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Title: President, KTM BioPartners LLC</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 43pt;"><b>In Lieu of Wet Ink Originals</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Page 6</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><u>Schedule A</u></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Scope of Services</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt 0pt 0pt 11pt;">The Consultant will report directly to David A Dodd, President and Chief Executive Officer, as Chief Medical Officer, and support him and GeoVax in line with GeoVax&#8217;s instructions and Standard Operating Procedures, by providing consulting services as Chief Medical Officer, and other related duties as requested or assigned, to include client meetings, Business Development activities, project / program strategy and support, protocol development, and other duties as described in Attachment 1. The Consultant will adhere to all local laws and regulations and ensure the services are provided in conformity with local law and regulations, institutional regulations and according to the Declaration of Helsinki as set out in the European Directive 2005/28/EC, the Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects, adopted by the General Assembly of the World Medical Association (1996) and any subsequent modifications or amendments thereto and applying consistently Principles of ICH Good Clinical Practice as required by EU/FDA regulations.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">Page 7</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Attachment 1 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>Chief Medical Officer </b>&#8211;<b> GeoVax, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Consultant, Leading to Potential Full-time Position)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;margin:0pt;"><b>Position Summary:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Chief Medical Officer (CMO) will report directly to the Chief Executive Officer. The primary role of the CMO will be to provide leadership and direction for GeoVax&#8217;s pipeline of clinical development programs in both infectious diseases and immuno-oncology.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The CMO will be responsible for the strategy, direction and execution of the company&#8217;s clinical development plans. The CMO will be a key member of the senior management team as a member of the company&#8217;s Executive Operating Committee which determines and oversees research and drug development at GeoVax and sets the overall strategic direction of the company. This is a unique opportunity to be a major contributor to the success of an exciting, well-positioned, well-financed growth stage biotechnology company.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;margin:0pt;"><b>Critical roles and activities:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Direct the development of clinical strategies and plans to integrate GeoVax products into the standard practice of oncology/hematology and infectious disease management/prevention;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Orchestrate and manage clinical aspects of regulatory strategies and interactions with health regulatory authorities;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Oversee the analysis and interpretation of clinical trial data and the reporting of clinical trial results;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Lead interactions with academic thought leaders, investigators, cooperative groups, and other clinical stakeholders ;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Provide clinical support and work with other members of the management team to develop and communicate the overall corporate strategy;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Represent the Company and its programs to external audiences, including the investment, medical and regulatory communities, as well as pharmaceutical or biotechnology industry collaborators/partners ;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to leading and supervising Clinical Development Operations, including external CRO relationships, the CMO will have direct responsibility for Patient Advocacy, Medical Affairs, and Biometrics operations</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;margin:0pt;"><b>Qualifications:</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The ideal candidate will offer:</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">M.D. or equivalent with Board Certification in Hematology/Oncology or Infectious Disease</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">15 years minimum experience in clinical practice treating patients and pharmaceutical and/or biotechnology industry experience as a sponsor working on investigational new therapies/vaccines</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Multiple years of management experience leading a clinical group including clinical/medical affairs and clinical operations</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A proven success record in Phase I-IV clinical development studies and trial design, successful submission of IND&#8217;s and marketing approval-directed filings (BLA&#8217;s, NDA&#8217;s and MAA&#8217;s) and lead interactions with regulatory agencies.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">Page 8</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;margin:0pt;"><b>Knowledge, Skills and Abilities: </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Knowledge of relevant FDA regulations and guidelines as well as those of the EU and other health authorities; experience in interactions with FDA personnel is essential; experience in interactions with other health authorities a plus;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Experience with, or strong knowledge of Oncology drug development or Infectious Disease vaccine development;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Experience in translational medicine, clinical pharmacology and early-stage development is desirable;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Must have a thorough knowledge of clinical research concepts, practices, and GCP and ICH Guidelines.</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The successful candidate will read, write and speak fluent English, possess excellent communication skills and will be capable of articulating the Company&#8217;s clinical and regulatory strategies and progress to a wide audience, internally and externally;</p>
			</td>
		</tr>

</table>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Must have excellent leadership and interpersonal skills; should have proven skills as an effective team player who can engender credibility and confidence within and outside the Company, including having outstanding executive presence.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>4
<FILENAME>ex_339972.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<html><head>
	<title>ex_339972.htm</title>

	<!-- Generated by ThunderDome Portal - 2/25/2022 2:41:31 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.10</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>GeoVax Labs, Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Summary of Director Compensation Plan</b><br>
<b>Effective as of January 1, 2022</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In an effort to attract and retain well-qualified directors, the Board of Directors (the &#8220;Board&#8221;) of GeoVax Labs, Inc. (the &#8220;Company&#8221;) has approved a plan of compensation for the Company&#8217;s non-employee directors (the &#8220;Plan&#8221;). A summary of the material terms of the Plan is as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Board Membership</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director shall receive an annual cash retainer of $25,000 for service as a member of the Board.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A non-employee Chairperson of the Board shall receive an additional annual cash retainer of $25,000.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the absence of a non-employee Chairperson of the Board, a non-employee director designated as the Lead Director shall receive an additional annual cash retainer of $10,000.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director shall receive an annual grant of options to purchase shares of the Company&#8217;s common stock. The Board, upon recommendation of the Compensation Committee, shall determine the amount and terms of such grants each year.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Audit Committee</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director shall receive an annual cash retainer of $7,500, for service as a member of the Audit Committee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Audit Committee Chairperson shall receive an additional annual cash retainer of $7,500 ($15,000 total) for service in such capacity.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Compensation Committee</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director shall receive an annual cash retainer of $5,000, for service as a member of the Compensation Committee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Compensation Committee Chairperson shall receive an additional annual cash retainer of $5,000 ($10,000 total) for service in such capacity.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Nominating &amp; Governance Committee</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Each non-employee director shall receive an annual cash retainer of $5,000, for service as a member of the Nominating &amp; Governance Committee.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Nominating &amp; Governance Committee Chairperson shall receive an additional annual cash retainer of $2,500 ($7,500 total) for service in such capacity.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Other</u></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All reasonable expenses incurred by non-employee directors in their capacity as such shall be reimbursed by the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash retainers shall be paid in advance in four quarterly installments.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex_343680.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_343680.htm</title>

	<!-- Generated by ThunderDome Portal - 3/5/2022 2:05:21 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 23.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We consent to the incorporation by reference in the Registration Statement on Form S-3 (File No. 333-252437) of GeoVax Labs, Inc. of our report dated March 9, 2022, relating to the consolidated financial statements of GeoVax Labs, Inc., appearing in this Annual Report on Form 10-K of GeoVax Labs, Inc. for the year ended December 31, 2021.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ WIPFLI LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Atlanta, Georgia</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">March 9, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex_344528.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_344528.htm</title>

	<!-- Generated by ThunderDome Portal - 3/8/2022 6:01:39 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO RULE 13a-14(a) or 15d-14(a)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OF THE </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, David A. Dodd, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this annual report on Form 10-K of GeoVax Labs, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" id="signature-table" style="text-indent: 0px; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 9, 2022</p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 39%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ David A. Dodd</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 39%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">David A. Dodd</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 39%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">President and Chief Executive Officer</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 8%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex_344529.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_344529.htm</title>

	<!-- Generated by ThunderDome Portal - 3/8/2022 6:04:10 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.2</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO RULE 13a-14(a) or 15d-14(a)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OF THE </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Mark W. Reynolds, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I have reviewed this annual report on Form 10-K of GeoVax Labs, Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(4)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(5)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="margin: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" id="signature-table" style="text-indent: 0px; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 9, 2022</p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 38%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Mark W. Reynolds</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 38%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Mark W. Reynolds</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 38%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chief Financial Officer</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex_344530.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_344530.htm</title>

	<!-- Generated by ThunderDome Portal - 3/8/2022 6:06:06 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO 18 U.S.C. SECTION 1350 </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO SECTION 906</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the annual report of GeoVax Labs, Inc. (the "Company") on Form 10-K for the year ended December&nbsp;31, 2021, I, David A. Dodd, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that to the best of my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The annual report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the annual report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="margin: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" id="signature-table" style="text-indent: 0px; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 9, 2022</p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 38%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ David A. Dodd</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 38%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">David A. Dodd</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 38%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">President and Chief Executive Officer</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex_344531.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head>
	<title>ex_344531.htm</title>

	<!-- Generated by ThunderDome Portal - 3/8/2022 6:09:48 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PURSUANT TO 18 U.S.C. SECTION 1350 </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AS ADOPTED PURSUANT TO SECTION 906</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the annual report of GeoVax Labs, Inc. (the "Company") on Form 10-K for the year ended December&nbsp;31, 2021, I, Mark W. Reynolds, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that to the best of my knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The annual report fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:0pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the annual report fairly presents, in all material respects, the financial condition and results of operations of the Company</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="margin: 0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" id="signature-table" style="text-indent: 0px; width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">March 9, 2022</p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 38%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Mark W. Reynolds</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 38%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Mark W. Reynolds</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 50%;" valign="top" width="50%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td align="left" nowrap="nowrap" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 38%;" valign="bottom" width="35%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chief Financial Officer</p>
			</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 9%;" valign="top" width="12%">
			<p style="margin-top: 0px; margin-bottom: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:72pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:72pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>govx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:28PM UTC 2022-03-09--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:govx="http://geovax.com/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://geovax.com/20211231">
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="govx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://geovax.com/20211231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://geovax.com/20211231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency" roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficiency)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-parentheticals" roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Statement - Consolidated Statements of Cash Flows (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-description-of-business-and-recent-developments" roleURI="http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 1 - Description of Business and Recent Developments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies" roleURI="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 2 - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-property-and-equipment" roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 3 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accrued-expenses-" roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 4 - Accrued Expenses</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-debt" roleURI="http://geovax.com/20211231/role/statement-note-5-debt">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 5 - Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-commitments" roleURI="http://geovax.com/20211231/role/statement-note-6-commitments">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 6 - Commitments</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity" roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 7 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-retirement-plan" roleURI="http://geovax.com/20211231/role/statement-note-8-retirement-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 8 - Retirement Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes" roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 9 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-grants-and-collaboration-revenue" roleURI="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 10 - Grants and Collaboration Revenue</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-subsequent-events" roleURI="http://geovax.com/20211231/role/statement-note-11-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 11 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-schedule-ii-valuation-and-qualifying-accounts" roleURI="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://geovax.com/20211231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-property-and-equipment-tables" roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 3 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accrued-expenses-tables" roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 4 - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-debt-tables" roleURI="http://geovax.com/20211231/role/statement-note-5-debt-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 5 - Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-tables" roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 7 - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-tables" roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 9 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-schedule-ii-valuation-and-qualifying-accounts-tables" roleURI="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-summary-of-significant-accounting-policies-details-textual" roleURI="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-property-and-equipment-details-textual" roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 3 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-debt-details-textual" roleURI="http://geovax.com/20211231/role/statement-note-5-debt-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 5 - Debt (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-debt-interest-expense-details" roleURI="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 5 - Debt - Interest Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-debt-interest-expense-details-parentheticals" roleURI="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 5 - Debt - Interest Expense (Details) (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-commitments-details-textual" roleURI="http://geovax.com/20211231/role/statement-note-6-commitments-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 6 - Commitments (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-details-textual" roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 7 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-stock-option-activity-details" roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 7 - Stockholders' Equity- Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 7 - Stockholders' Equity - Summary of Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-retirement-plan-details-textual" roleURI="http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 8 - Retirement Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-details-textual" roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 9 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-grants-and-collaboration-revenue-details-textual" roleURI="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 10 - Grants and Collaboration Revenue (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-subsequent-events-details-textual" roleURI="http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 11 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-schedule-ii-valuation-and-qualifying-accounts-details" roleURI="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="govx_AccruedExpensesNoncurrent" name="AccruedExpensesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="govx_AccruedLiabilitiesPolicyTextBlock" name="AccruedLiabilitiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_AccruedLicenseFeesCurrent" name="AccruedLicenseFeesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="govx_AccruedLicenseFeesNoncurrent" name="AccruedLicenseFeesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_CapitalUnitsTrancheOneMember" name="CapitalUnitsTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ClassOfWarrantOrRightIssuedDuringPeriod" name="ClassOfWarrantOrRightIssuedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" name="ConversionFromConvertibleDebenturesToConversionUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfConvertibleDebentureMember" name="ConversionOfConvertibleDebentureMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" name="ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConversionWarrantsMember" name="ConversionWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ConvertibleDebenturesMember" name="ConvertibleDebenturesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_DebtConversionAccruedInterestAmount" name="DebtConversionAccruedInterestAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" name="DebtConversionConvertedInstrumentPrincipalAndInterestAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_DeferredCompensationLiabilityConversionToEquityAmount" name="DeferredCompensationLiabilityConversionToEquityAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" name="DeferredCompensationLiabilityConversionToEquityConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="govx_DeferredTaxAssetsAccruedSalaries" name="DeferredTaxAssetsAccruedSalaries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" name="DeferredTaxAssetsBeforeValuationAllowanceNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_EquipmentAndFurnishingsMember" name="EquipmentAndFurnishingsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" name="ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_ExtinguishmentOfDebtIncludingInterestAmount" name="ExtinguishmentOfDebtIncludingInterestAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_GainLossFromInterestForgiven" name="GainLossFromInterestForgiven" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_GovernmentGrantsandContractsTextBlock" name="GovernmentGrantsandContractsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_InsurancePremiumFinancingCostsMember" name="InsurancePremiumFinancingCostsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_InterestExpenseDisclosureTableTextBlock" name="InterestExpenseDisclosureTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_June2020WarrantsMember" name="June2020WarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent" name="LicensingAgreementFutureMinimumPaymentsReceivableCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" name="LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" name="LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" name="LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" name="LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_ManagementWarrantMember" name="ManagementWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_NIHGrantsMember" name="NIHGrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" name="NumberOfCommonStockSecuritiesCalledByEachUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="govx_NumberOfWarrantsCalledByEachUnit" name="NumberOfWarrantsCalledByEachUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_OfficeAndLaboratoryLeaseAgreementMember" name="OfficeAndLaboratoryLeaseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_OperatingLossCarryforwardsSubjectToExpiration" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_PaycheckProtectionProgramCaresActMember" name="PaycheckProtectionProgramCaresActMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" name="PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="govx_ProceedsFromConvertibleDebtGross" name="ProceedsFromConvertibleDebtGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_ProceedsFromIssuanceOrSaleOfEquityGross" name="ProceedsFromIssuanceOrSaleOfEquityGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="govx_ProceedsFromWarrantExercisesGross" name="ProceedsFromWarrantExercisesGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_RemainingLifeOnWarrantsOutstandingMember" name="RemainingLifeOnWarrantsOutstandingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_RepresentativeWarrants2020Member" name="RepresentativeWarrants2020Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_RepresentativeWarrants2021Member" name="RepresentativeWarrants2021Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ResearchAgreementsMember" name="ResearchAgreementsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_StockIncentivePlan2020Member" name="StockIncentivePlan2020Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" name="StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodSharesDebentureConversion" name="StockIssuedDuringPeriodSharesDebentureConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" name="StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueDebentureConversion" name="StockIssuedDuringPeriodValueDebentureConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueReverseStockSplits" name="StockIssuedDuringPeriodValueReverseStockSplits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="govx_StockIssuedDuringPeriodValueWarrantExercise" name="StockIssuedDuringPeriodValueWarrantExercise" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_StockPurchaseWarrantsFirstIssuanceMember" name="StockPurchaseWarrantsFirstIssuanceMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_StockPurchaseWarrantsMember" name="StockPurchaseWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_UnitWarrantMember" name="UnitWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_UnitWarrantsMember" name="UnitWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_UnusedGrantFunds" name="UnusedGrantFunds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="govx_UpfrontFeesCOHAndPNPLicenseMember" name="UpfrontFeesCOHAndPNPLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_WarrantIssuedForTechnologyLicenseMember" name="WarrantIssuedForTechnologyLicenseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_Warrants2020Member" name="Warrants2020Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_Warrants2021Member" name="Warrants2021Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="govx_WarrantsIssued" name="WarrantsIssued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_WarrantsIssuedInPrivatePlacementMember" name="WarrantsIssuedInPrivatePlacementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" name="statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-3-property-and-equipment-tables" name="statement-statement-note-3-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" name="statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-4-accrued-expenses-tables" name="statement-statement-note-4-accrued-expenses-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-5-debt-interest-expense-details" name="statement-statement-note-5-debt-interest-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-5-debt-interest-expense-details-parentheticals" name="statement-statement-note-5-debt-interest-expense-details-parentheticals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-5-debt-tables" name="statement-statement-note-5-debt-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" name="statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details" name="statement-statement-note-7-stockholders-equity-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" name="statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-7-stockholders-equity-tables" name="statement-statement-note-7-stockholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" name="statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-note-9-income-taxes-tables" name="statement-statement-note-9-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" name="statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" name="statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="govx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>govx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:28PM UTC 2022-03-09--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="govx-20211231.xsd#statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="govx-20211231.xsd#statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLicenseFeesCurrent" xlink:label="govx_AccruedLicenseFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLicenseFeesNoncurrent" xlink:label="govx_AccruedLicenseFeesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="govx_AccruedLicenseFeesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="govx_AccruedLicenseFeesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-balance-sheets" xlink:href="govx-20211231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedExpensesNoncurrent" xlink:label="govx_AccruedExpensesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="govx_AccruedExpensesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-operations" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>govx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:28PM UTC 2022-03-09--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:href="govx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-" xlink:href="govx-20211231.xsd#statement-note-4-accrued-expenses-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments" xlink:href="govx-20211231.xsd#statement-note-1-description-of-business-and-recent-developments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-document-and-entity-information" xlink:href="govx-20211231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
	<link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
	<link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
	<link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
	<link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DebtConversionAccruedInterestAmount" xlink:label="govx_DebtConversionAccruedInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantsIssued" xlink:label="govx_WarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_WarrantsIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionAccruedInterestAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="govx-20211231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UpfrontFeesCOHAndPNPLicenseMember" xlink:label="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment" xlink:href="govx-20211231.xsd#statement-note-3-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-3-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt" xlink:href="govx-20211231.xsd#statement-note-5-debt" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="govx_ConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-6-commitments" xlink:href="govx-20211231.xsd#statement-note-6-commitments" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-6-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfConvertibleDebentureMember" xlink:label="govx_ConversionOfConvertibleDebentureMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2020Member" xlink:label="govx_RepresentativeWarrants2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2021Member" xlink:label="govx_RepresentativeWarrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2021Member" xlink:label="govx_Warrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ConversionWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CapitalUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_CapitalUnitsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ManagementWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ConversionOfConvertibleDebentureMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrants2020Member" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrants2021Member" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_Warrants2021Member" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PreferredStockTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-8-retirement-plan" xlink:href="govx-20211231.xsd#statement-note-8-retirement-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-8-retirement-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue" xlink:href="govx-20211231.xsd#statement-note-10-grants-and-collaboration-revenue" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_GovernmentGrantsandContractsTextBlock" xlink:label="govx_GovernmentGrantsandContractsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_ResearchAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="govx_GovernmentGrantsandContractsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-11-subsequent-events" xlink:href="govx-20211231.xsd#statement-note-11-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-11-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantsIssuedInPrivatePlacementMember" xlink:label="govx_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-significant-accounting-policies-policies" xlink:href="govx-20211231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLiabilitiesPolicyTextBlock" xlink:label="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables" xlink:href="govx-20211231.xsd#statement-note-3-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables" xlink:href="govx-20211231.xsd#statement-note-4-accrued-expenses-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt-tables" xlink:href="govx-20211231.xsd#statement-note-5-debt-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_InterestExpenseDisclosureTableTextBlock" xlink:label="govx_InterestExpenseDisclosureTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="govx_InterestExpenseDisclosureTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-tables" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:href="govx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="govx-20211231.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UpfrontFeesCOHAndPNPLicenseMember" xlink:label="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual" xlink:href="govx-20211231.xsd#statement-note-3-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt-details-textual" xlink:href="govx-20211231.xsd#statement-note-5-debt-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_GainLossFromInterestForgiven" xlink:label="govx_GainLossFromInterestForgiven" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromConvertibleDebtGross" xlink:label="govx_ProceedsFromConvertibleDebtGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="govx_ConvertibleDebenturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_GainLossFromInterestForgiven" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromConvertibleDebtGross" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-6-commitments-details-textual" xlink:href="govx-20211231.xsd#statement-note-6-commitments-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-6-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfConvertibleDebentureMember" xlink:label="govx_ConversionOfConvertibleDebentureMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NumberOfWarrantsCalledByEachUnit" xlink:label="govx_NumberOfWarrantsCalledByEachUnit" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromWarrantExercisesGross" xlink:label="govx_ProceedsFromWarrantExercisesGross" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2020Member" xlink:label="govx_RepresentativeWarrants2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2021Member" xlink:label="govx_RepresentativeWarrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2021Member" xlink:label="govx_Warrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ConversionWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CapitalUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_CapitalUnitsTrancheOneMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ManagementWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_StockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_ConversionOfConvertibleDebentureMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrants2020Member" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrants2021Member" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_Warrants2021Member" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfWarrantsCalledByEachUnit" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromWarrantExercisesGross" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual" xlink:href="govx-20211231.xsd#statement-note-8-retirement-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxesPaid" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual" xlink:href="govx-20211231.xsd#statement-note-10-grants-and-collaboration-revenue-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnusedGrantFunds" xlink:label="govx_UnusedGrantFunds" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="govx_ResearchAgreementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UnusedGrantFunds" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual" xlink:href="govx-20211231.xsd#statement-note-11-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantsIssuedInPrivatePlacementMember" xlink:label="govx_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="govx-20211231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals" xlink:href="govx-20211231.xsd#statement-note-5-debt-interest-expense-details-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="govx-20211231.xsd#statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_EquipmentAndFurnishingsMember" xlink:label="govx_EquipmentAndFurnishingsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="govx_EquipmentAndFurnishingsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="govx-20211231.xsd#statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLicenseFeesCurrent" xlink:label="govx_AccruedLicenseFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLicenseFeesNoncurrent" xlink:label="govx_AccruedLicenseFeesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_AccruedLicenseFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_AccruedLicenseFeesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details" xlink:href="govx-20211231.xsd#statement-note-5-debt-interest-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_InsurancePremiumFinancingCostsMember" xlink:label="govx_InsurancePremiumFinancingCostsmember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="govx_InsurancePremiumFinancingCostsmember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RemainingLifeOnWarrantsOutstandingMember" xlink:label="govx_RemainingLifeOnWarrantsOutstandingmember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2020Member" xlink:label="govx_RepresentativeWarrants2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2021Member" xlink:label="govx_RepresentativeWarrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2020Member" xlink:label="govx_Warrants2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2021Member" xlink:label="govx_Warrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_Warrants2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrants2020Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RepresentativeWarrants2021Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_Warrants2021Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_RemainingLifeOnWarrantsOutstandingmember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-balance-sheets" xlink:href="govx-20211231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedExpensesNoncurrent" xlink:label="govx_AccruedExpensesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssets" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="govx_AccruedExpensesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-operations" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredTaxAssetsAccruedSalaries" xlink:label="govx_DeferredTaxAssetsAccruedSalaries" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredTaxAssetsAccruedSalaries" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency" xlink:type="extended">
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantIssuedForTechnologyLicenseMember" xlink:label="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:href="govx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>govx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:28PM UTC 2022-03-09--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="govx-20211231.xsd#govx_DocumentAndEntityInformation" xlink:label="govx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="govx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DocumentAndEntityInformation" xlink:to="govx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherIncomeAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="govx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="govx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-significant-accounting-policies-policies" xlink:label="govx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-significant-accounting-policies-policies" xlink:to="govx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-3-property-and-equipment-tables" xlink:label="govx_statement-statement-note-3-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-3-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-3-property-and-equipment-tables" xlink:to="govx_statement-statement-note-3-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. federal statutory rate applied to pretax loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-4-accrued-expenses-tables" xlink:label="govx_statement-statement-note-4-accrued-expenses-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-4-accrued-expenses-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Accrued Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-4-accrued-expenses-tables" xlink:to="govx_statement-statement-note-4-accrued-expenses-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average risk-free interest rates</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-5-debt-tables" xlink:label="govx_statement-statement-note-5-debt-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-5-debt-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-5-debt-tables" xlink:to="govx_statement-statement-note-5-debt-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GrantsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant funds and other receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-7-stockholders-equity-tables" xlink:label="govx_statement-statement-note-7-stockholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-7-stockholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-7-stockholders-equity-tables" xlink:to="govx_statement-statement-note-7-stockholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-9-income-taxes-tables" xlink:label="govx_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-9-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-9-income-taxes-tables" xlink:to="govx_statement-statement-note-9-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:to="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:label="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:to="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-5-debt-interest-expense-details" xlink:label="govx_statement-statement-note-5-debt-interest-expense-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-5-debt-interest-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Debt - Interest Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-5-debt-interest-expense-details" xlink:to="govx_statement-statement-note-5-debt-interest-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-5-debt-interest-expense-details-parentheticals" xlink:label="govx_statement-statement-note-5-debt-interest-expense-details-parentheticals" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-5-debt-interest-expense-details-parentheticals-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Debt - Interest Expense (Details) (Parentheticals)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-5-debt-interest-expense-details-parentheticals" xlink:to="govx_statement-statement-note-5-debt-interest-expense-details-parentheticals-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon debenture conversion (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued during the period as a result of debenture conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:to="govx_StockIssuedDuringPeriodSharesDebentureConversion-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:label="govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:to="govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details" xlink:label="govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity- Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details" xlink:to="govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:label="govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stockholders' Equity - Summary of Warrants Outstanding (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:to="govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:label="govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:to="govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="locator"/>
    <link:label xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:to="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life of option (in years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatements" xlink:label="govx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="govx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NotesToFinancialStatements" xlink:to="govx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="govx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="govx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon debenture conversion</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross value of stock issued during the period upon Debenture Conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:to="govx_StockIssuedDuringPeriodValueDebentureConversion-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roundup of shares following reverse stock split</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in value of shares as a result of reverse stock split.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:to="govx_StockIssuedDuringPeriodValueReverseStockSplits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, weighted average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average remaining contractual term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Related To Consulting And Investment Banking Agreements [Member]</link:label>
    <link:label xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of expense related to consulting and investment banking agreements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_GovernmentGrantsandContractsTextBlock" xlink:label="govx_GovernmentGrantsandContractsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="govx_GovernmentGrantsandContractsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Grants and Contracts [Text Block]</link:label>
    <link:label xlink:label="govx_GovernmentGrantsandContractsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_GovernmentGrantsandContractsTextBlock" xlink:to="govx_GovernmentGrantsandContractsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_NIHGrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NIH Grants [Member]</link:label>
    <link:label xlink:label="govx_NIHGrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Grants from the National Institutes of Health (NIH).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NIHGrantsMember" xlink:to="govx_NIHGrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepositsAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deposits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssets" xlink:to="us-gaap_DepositsAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_InterestExpenseDisclosureTableTextBlock" xlink:label="govx_InterestExpenseDisclosureTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="govx_InterestExpenseDisclosureTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense Disclosure [Table Text Block]</link:label>
    <link:label xlink:label="govx_InterestExpenseDisclosureTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of interest expense, including, but not limited to, interest expense from investments, loans, and securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_InterestExpenseDisclosureTableTextBlock" xlink:to="govx_InterestExpenseDisclosureTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_InsurancePremiumFinancingCostsMember" xlink:label="govx_InsurancePremiumFinancingCostsmember" xlink:type="locator"/>
    <link:label xlink:label="govx_InsurancePremiumFinancingCostsmember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Premium Financing Costs[Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_InsurancePremiumFinancingCostsmember" xlink:to="govx_InsurancePremiumFinancingCostsmember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" xlink:type="locator"/>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Future Minimum Payments Receivable, in Three Years</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future payments receivable within the third year from the balance sheet date under a licensing agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" xlink:type="locator"/>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Future Minimum Payments Receivable, in Four Years</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future payments receivable within the fourth year from the balance sheet date under a licensing agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" xlink:type="locator"/>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Future Minimum Payments Receivable, in Five Years</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future payments receivable within the fifth year from the balance sheet date under a licensing agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent" xlink:type="locator"/>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Future Minimum Payments Receivable, Current</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future payments receivable within one year of the balance sheet date under a licensing agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" xlink:type="locator"/>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreement, Future Minimum Payments Receivable, in Two Years</link:label>
    <link:label xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future payments receivable within the second year from the balance sheet date under a licensing agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2020Member" xlink:label="govx_Warrants2020Member" xlink:type="locator"/>
    <link:label xlink:label="govx_Warrants2020Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants 2020 [Member]</link:label>
    <link:label xlink:label="govx_Warrants2020Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2020 warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_Warrants2020Member" xlink:to="govx_Warrants2020Member-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_GainLossFromInterestForgiven" xlink:label="govx_GainLossFromInterestForgiven" xlink:type="locator"/>
    <link:label xlink:label="govx_GainLossFromInterestForgiven-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_GainLossFromInterestForgiven</link:label>
    <link:label xlink:label="govx_GainLossFromInterestForgiven-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) from Interest Forgiven</link:label>
    <link:label xlink:label="govx_GainLossFromInterestForgiven-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents gain (loss) from interest forgiven.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_GainLossFromInterestForgiven" xlink:to="govx_GainLossFromInterestForgiven-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2021Member" xlink:label="govx_Warrants2021Member" xlink:type="locator"/>
    <link:label xlink:label="govx_Warrants2021Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants 2021 [Member]</link:label>
    <link:label xlink:label="govx_Warrants2021Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2021 warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_Warrants2021Member" xlink:to="govx_Warrants2021Member-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="locator"/>
    <link:label xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of debt</link:label>
    <link:label xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents amount extinguishment of debt including interest amount.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:to="govx_ExtinguishmentOfDebtIncludingInterestAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2020Member" xlink:label="govx_RepresentativeWarrants2020Member" xlink:type="locator"/>
    <link:label xlink:label="govx_RepresentativeWarrants2020Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Representative Warrants 2020 [Member]</link:label>
    <link:label xlink:label="govx_RepresentativeWarrants2020Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2020 representative warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_RepresentativeWarrants2020Member" xlink:to="govx_RepresentativeWarrants2020Member-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2021Member" xlink:label="govx_RepresentativeWarrants2021Member" xlink:type="locator"/>
    <link:label xlink:label="govx_RepresentativeWarrants2021Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Representative Warrants 2021 [Member]</link:label>
    <link:label xlink:label="govx_RepresentativeWarrants2021Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the 2021 representative warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_RepresentativeWarrants2021Member" xlink:to="govx_RepresentativeWarrants2021Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RemainingLifeOnWarrantsOutstandingMember" xlink:label="govx_RemainingLifeOnWarrantsOutstandingmember" xlink:type="locator"/>
    <link:label xlink:label="govx_RemainingLifeOnWarrantsOutstandingmember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Life on Warrants Outstanding[Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_RemainingLifeOnWarrantsOutstandingmember" xlink:to="govx_RemainingLifeOnWarrantsOutstandingmember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredTaxAssetsAccruedSalaries" xlink:label="govx_DeferredTaxAssetsAccruedSalaries" xlink:type="locator"/>
    <link:label xlink:label="govx_DeferredTaxAssetsAccruedSalaries-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued salaries</link:label>
    <link:label xlink:label="govx_DeferredTaxAssetsAccruedSalaries-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued salaries.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DeferredTaxAssetsAccruedSalaries" xlink:to="govx_DeferredTaxAssetsAccruedSalaries-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:label xlink:label="govx_PaycheckProtectionProgramCaresActMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Paycheck Protection Program CARES Act [Member]</link:label>
    <link:label xlink:label="govx_PaycheckProtectionProgramCaresActMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents loan designed to provide funds for small businesses to keep their employees on the payroll.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PaycheckProtectionProgramCaresActMember" xlink:to="govx_PaycheckProtectionProgramCaresActMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_June2020WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">June 2020 Warrants [Member]</link:label>
    <link:label xlink:label="govx_June2020WarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to June 2020 warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_June2020WarrantsMember" xlink:to="govx_June2020WarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UpfrontFeesCOHAndPNPLicenseMember" xlink:label="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:type="locator"/>
    <link:label xlink:label="govx_UpfrontFeesCOHAndPNPLicensemember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Fees for COH and PNP License[Member]</link:label>
    <link:label xlink:label="govx_UpfrontFeesCOHAndPNPLicensemember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents upfront fees for COH and PNP license.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:to="govx_UpfrontFeesCOHAndPNPLicensemember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debentures [Member]</link:label>
    <link:label xlink:label="govx_ConvertibleDebenturesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to convertible debenture.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConvertibleDebenturesMember" xlink:to="govx_ConvertibleDebenturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total adjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfConvertibleDebentureMember" xlink:label="govx_ConversionOfConvertibleDebentureMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfConvertibleDebentureMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Convertible Debenture [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfConvertibleDebentureMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to conversion of convertible debenture.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfConvertibleDebentureMember" xlink:to="govx_ConversionOfConvertibleDebentureMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ExtinguishmentOfDebtAmount</link:label>
    <link:label xlink:label="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAmount" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:type="locator"/>
    <link:label xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_DeferredTaxAssetsBeforeValuationAllowanceNet</link:label>
    <link:label xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount, before allocation of valuation allowances and after deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:to="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Reported income tax expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIncentivePlan2020Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2020 [Member]</link:label>
    <link:label xlink:label="govx_StockIncentivePlan2020Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to 2020 stock incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIncentivePlan2020Member" xlink:to="govx_StockIncentivePlan2020Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Member]</link:label>
    <link:label xlink:label="govx_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The conversion of a reverse stock split where there is a reduction in the shares outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ReverseStockSplitMember" xlink:to="govx_ReverseStockSplitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roundup of shares following reverse stock split (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromConvertibleDebtGross" xlink:label="govx_ProceedsFromConvertibleDebtGross" xlink:type="locator"/>
    <link:label xlink:label="govx_ProceedsFromConvertibleDebtGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ProceedsFromConvertibleDebtGross</link:label>
    <link:label xlink:label="govx_ProceedsFromConvertibleDebtGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt, Gross</link:label>
    <link:label xlink:label="govx_ProceedsFromConvertibleDebtGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to gross proceeds from convertible debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ProceedsFromConvertibleDebtGross" xlink:to="govx_ProceedsFromConvertibleDebtGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ClassOfWarrantOrRightIssuedDuringPeriod</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Warrant Or Right, Issued During Period (in shares)</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights issued during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:to="govx_ClassOfWarrantOrRightIssuedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on debt extinguishment</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Total</link:label>
    <link:label xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on debt extinguishment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod</link:label>
    <link:label xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Value of Stock Issued for Services During Period</link:label>
    <link:label xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the value of stock issued for services during period recorded as prepaid expense.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:to="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfExpenseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnusedGrantFunds" xlink:label="govx_UnusedGrantFunds" xlink:type="locator"/>
    <link:label xlink:label="govx_UnusedGrantFunds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_UnusedGrantFunds</link:label>
    <link:label xlink:label="govx_UnusedGrantFunds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unused Grant Funds</link:label>
    <link:label xlink:label="govx_UnusedGrantFunds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of grant funds available for use.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UnusedGrantFunds" xlink:to="govx_UnusedGrantFunds-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ResearchAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Agreements [Member]</link:label>
    <link:label xlink:label="govx_ResearchAgreementsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Agreements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ResearchAgreementsMember" xlink:to="govx_ResearchAgreementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInReceivables</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInReceivables-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Grant funds and other receivables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants issued in bridge financing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationAndAmortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromWarrantExercisesGross" xlink:label="govx_ProceedsFromWarrantExercisesGross" xlink:type="locator"/>
    <link:label xlink:label="govx_ProceedsFromWarrantExercisesGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ProceedsFromWarrantExercisesGross</link:label>
    <link:label xlink:label="govx_ProceedsFromWarrantExercisesGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises, Gross</link:label>
    <link:label xlink:label="govx_ProceedsFromWarrantExercisesGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of proceeds from warrant exercises before deducting costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ProceedsFromWarrantExercisesGross" xlink:to="govx_ProceedsFromWarrantExercisesGross-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantsIssuedInPrivatePlacementMember" xlink:label="govx_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="govx_WarrantsIssuedInPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Private Placement [Member]</link:label>
    <link:label xlink:label="govx_WarrantsIssuedInPrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the warrants issued in the private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_WarrantsIssuedInPrivatePlacementMember" xlink:to="govx_WarrantsIssuedInPrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockRepurchasedDuringPeriodShares</link:label>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodShares-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of preferred stock (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_SeriesBConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="govx_SeriesBConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to Series B Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_SeriesBConvertiblePreferredStockMember" xlink:to="govx_SeriesBConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockRepurchasedDuringPeriodValue</link:label>
    <link:label xlink:label="us-gaap_StockRepurchasedDuringPeriodValue-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of convertible preferred stock for cash</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of convertible preferred stock for cash (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new shares of common stock issued during the period upon exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Life (in years) (Year)</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock for cash (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock for services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of common stock for cash</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GRA Note</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-funded stock purchase warrants (in shares)</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant issued for technology license fee</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLiabilitiesPolicyTextBlock" xlink:label="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="govx_AccruedLiabilitiesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Policy Text Block]</link:label>
    <link:label xlink:label="govx_AccruedLiabilitiesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy regarding accrued liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_AccruedLiabilitiesPolicyTextBlock" xlink:to="govx_AccruedLiabilitiesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible debentures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt discount amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_EquipmentAndFurnishingsMember" xlink:label="govx_EquipmentAndFurnishingsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_EquipmentAndFurnishingsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment and Furnishings [Member]</link:label>
    <link:label xlink:label="govx_EquipmentAndFurnishingsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents equipment and furnishings.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_EquipmentAndFurnishingsMember" xlink:to="govx_EquipmentAndFurnishingsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="locator"/>
    <link:label xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_OperatingLossCarryforwardsSubjectToExpiration</link:label>
    <link:label xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:label xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="govx_OperatingLossCarryforwardsSubjectToExpiration-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $.001 par value: Authorized shares &#8211; 600,000,000 Issued and outstanding shares &#8211; 6,381,541 and 3,834,095 at December 31, 2021 and 2020, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeniorNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeniorNotesMember" xlink:to="us-gaap_SeniorNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantIssuedForTechnologyLicenseMember" xlink:label="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="locator"/>
    <link:label xlink:label="govx_WarrantIssuedForTechnologyLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant Issued for Technology License[Member]</link:label>
    <link:label xlink:label="govx_WarrantIssuedForTechnologyLicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrant issued for technology license.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_WarrantIssuedForTechnologyLicenseMember" xlink:to="govx_WarrantIssuedForTechnologyLicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</link:label>
    <link:label xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Valuation Allowance [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:label xlink:label="srt_WeightedAverageMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:label xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Warrants First Issuance [Member]</link:label>
    <link:label xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to stock purchase warrants, first issuance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, $.01 par value: Authorized shares &#8211; 10,000,000 Series B convertible preferred stock, $1,000 stated value; -0- and 100 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office and Laboratory Lease Agreement [Member]</link:label>
    <link:label xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to office and laboratory lease agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset after reduction for valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxesPaid</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxesPaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_StockPurchaseWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Warrants [Member]</link:label>
    <link:label xlink:label="govx_StockPurchaseWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to stock purchase warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockPurchaseWarrantsMember" xlink:to="govx_StockPurchaseWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grant and collaboration revenue</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development tax credit carryforward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments (Note 6)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLicenseFeesCurrent" xlink:label="govx_AccruedLicenseFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="govx_AccruedLicenseFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued license fees &#8211; current</link:label>
    <link:label xlink:label="govx_AccruedLicenseFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents current accrued license fees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_AccruedLicenseFeesCurrent" xlink:to="govx_AccruedLicenseFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLicenseFeesNoncurrent" xlink:label="govx_AccruedLicenseFeesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="govx_AccruedLicenseFeesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued license fees &#8211; noncurrent</link:label>
    <link:label xlink:label="govx_AccruedLicenseFeesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents long-term accrued license fees.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_AccruedLicenseFeesNoncurrent" xlink:to="govx_AccruedLicenseFeesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedExpensesNoncurrent" xlink:label="govx_AccruedExpensesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="govx_AccruedExpensesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses &#8211; noncurrent</link:label>
    <link:label xlink:label="govx_AccruedExpensesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents noncurrent accrued expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_AccruedExpensesNoncurrent" xlink:to="govx_AccruedExpensesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon warrant exercise</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross value of stock issued during the period upon the exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:to="govx_StockIssuedDuringPeriodValueWarrantExercise-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued payroll</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock</link:label>
    <link:label xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repurchase of preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from warrant exercises</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfCommonStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Units [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsMember" xlink:to="us-gaap_CapitalUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Warrants [Member]</link:label>
    <link:label xlink:label="govx_ConversionWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionWarrantsMember" xlink:to="govx_ConversionWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DebtConversionAccruedInterestAmount" xlink:label="govx_DebtConversionAccruedInterestAmount" xlink:type="locator"/>
    <link:label xlink:label="govx_DebtConversionAccruedInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related accrued interest</link:label>
    <link:label xlink:label="govx_DebtConversionAccruedInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of the debt accrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DebtConversionAccruedInterestAmount" xlink:to="govx_DebtConversionAccruedInterestAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion from Convertible Debentures to Conversion Units [Member]</link:label>
    <link:label xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the conversion of convertible debentures to conversion units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from bridge financing</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesBalance</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at Beginning Of Period</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at End Of Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_PreFundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label xlink:label="govx_PreFundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the pre-funded warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_PreFundedWarrantsMember" xlink:to="govx_PreFundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="govx_UnitWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unit Warrants [Member]</link:label>
    <link:label xlink:label="govx_UnitWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the unit warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UnitWarrantsMember" xlink:to="govx_UnitWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions Charged to Costs and Expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions Charged to Other Accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesDeductions</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:type="locator"/>
    <link:label xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ProceedsFromIssuanceOrSaleOfEquityGross</link:label>
    <link:label xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Gross</link:label>
    <link:label xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The gross cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:to="govx_ProceedsFromIssuanceOrSaleOfEquityGross-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:label xlink:label="govx_CapitalUnitsTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Units Tranche One [Member]</link:label>
    <link:label xlink:label="govx_CapitalUnitsTrancheOneMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the tranche one capital units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_CapitalUnitsTrancheOneMember" xlink:to="govx_CapitalUnitsTrancheOneMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:type="locator"/>
    <link:label xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_NumberOfCommonStockSecuritiesCalledByEachUnit</link:label>
    <link:label xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Common Stock Securities Called by Each Unit (in shares)</link:label>
    <link:label xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of common stock securities into which each unit may be converted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:to="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NumberOfWarrantsCalledByEachUnit" xlink:label="govx_NumberOfWarrantsCalledByEachUnit" xlink:type="locator"/>
    <link:label xlink:label="govx_NumberOfWarrantsCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_NumberOfWarrantsCalledByEachUnit</link:label>
    <link:label xlink:label="govx_NumberOfWarrantsCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Warrants Called by Each Unit (in shares)</link:label>
    <link:label xlink:label="govx_NumberOfWarrantsCalledByEachUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants into which each unit may be converted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_NumberOfWarrantsCalledByEachUnit" xlink:to="govx_NumberOfWarrantsCalledByEachUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]</link:label>
    <link:label xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about conversion of series H, Series I, and Series J preferred stock into common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="govx_UnitWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unit Warrant [Member]</link:label>
    <link:label xlink:label="govx_UnitWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the unit warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_UnitWarrantMember" xlink:to="govx_UnitWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:type="locator"/>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_DeferredCompensationLiabilityConversionToEquityConversionPrice</link:label>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share)</link:label>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The price per share for the conversion of deferred compensation liability to equity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="locator"/>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred compensation</link:label>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Compensation Liability Conversion to Equity, Amount</link:label>
    <link:label xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of deferred compensation liability being converted into equity in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfNotesPayable</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfNotesPayable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal repayment of note payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</link:label>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of note payable</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Notes Payable, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="govx_ManagementWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management Warrant [Member]</link:label>
    <link:label xlink:label="govx_ManagementWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the management warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ManagementWarrantMember" xlink:to="govx_ManagementWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per common share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of common stock and warrants</link:label>
    <link:label xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from issuance of common stock and warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantsIssued" xlink:label="govx_WarrantsIssued" xlink:type="locator"/>
    <link:label xlink:label="govx_WarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant issued (in shares)</link:label>
    <link:label xlink:label="govx_WarrantsIssued-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants issued in noncash financing activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_WarrantsIssued" xlink:to="govx_WarrantsIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:type="locator"/>
    <link:label xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount</link:label>
    <link:label xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Principal and Interest, Amount</link:label>
    <link:label xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of the financial instrument(s) that the original debt and interest is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:to="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance, net of expired items and other adjustments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for cancellation of accrued compensation (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares)</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new stock issued during the period for the cancellation of accrued compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</link:label>
    <link:label xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon cancellation of accrued compensation</link:label>
    <link:label xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of stock issued in lieu of cancellation of accrued compensation.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:to="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Permanent differences</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note payable, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">govx_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
    <link:label xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="govx_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>govx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 03:28PM UTC 2022-03-09--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:href="govx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-" xlink:href="govx-20211231.xsd#statement-note-4-accrued-expenses-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments" xlink:href="govx-20211231.xsd#statement-note-1-description-of-business-and-recent-developments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-document-and-entity-information" xlink:href="govx-20211231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
	<link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
	<link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
	<link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
	<link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DebtConversionAccruedInterestAmount" xlink:label="govx_DebtConversionAccruedInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:label="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:label="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantsIssued" xlink:label="govx_WarrantsIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsFirstIssuanceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_WarrantsIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ExtinguishmentOfDebtIncludingInterestAmount" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionAccruedInterestAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:href="govx-20211231.xsd#statement-note-2-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UpfrontFeesCOHAndPNPLicenseMember" xlink:label="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment" xlink:href="govx-20211231.xsd#statement-note-3-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-3-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt" xlink:href="govx-20211231.xsd#statement-note-5-debt" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="govx_ConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-6-commitments" xlink:href="govx-20211231.xsd#statement-note-6-commitments" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-6-commitments" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsDisclosureTextBlock" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfConvertibleDebentureMember" xlink:label="govx_ConversionOfConvertibleDebentureMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2020Member" xlink:label="govx_RepresentativeWarrants2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2021Member" xlink:label="govx_RepresentativeWarrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2021Member" xlink:label="govx_Warrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ConversionWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CapitalUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_CapitalUnitsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ManagementWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ConversionOfConvertibleDebentureMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrants2020Member" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrants2021Member" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_Warrants2021Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PreferredStockTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-8-retirement-plan" xlink:href="govx-20211231.xsd#statement-note-8-retirement-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-8-retirement-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue" xlink:href="govx-20211231.xsd#statement-note-10-grants-and-collaboration-revenue" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_GovernmentGrantsandContractsTextBlock" xlink:label="govx_GovernmentGrantsandContractsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_ResearchAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="govx_GovernmentGrantsandContractsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-11-subsequent-events" xlink:href="govx-20211231.xsd#statement-note-11-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-11-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NotesToFinancialStatementsAbstract" xlink:label="govx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantsIssuedInPrivatePlacementMember" xlink:label="govx_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-significant-accounting-policies-policies" xlink:href="govx-20211231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLiabilitiesPolicyTextBlock" xlink:label="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-significant-accounting-policies-policies" xlink:label="govx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="govx_AccruedLiabilitiesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables" xlink:href="govx-20211231.xsd#statement-note-3-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-3-property-and-equipment-tables" xlink:label="govx_statement-statement-note-3-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-3-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables" xlink:href="govx-20211231.xsd#statement-note-4-accrued-expenses-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-4-accrued-expenses-tables" xlink:label="govx_statement-statement-note-4-accrued-expenses-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-4-accrued-expenses-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt-tables" xlink:href="govx-20211231.xsd#statement-note-5-debt-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_InterestExpenseDisclosureTableTextBlock" xlink:label="govx_InterestExpenseDisclosureTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-5-debt-tables" xlink:label="govx_statement-statement-note-5-debt-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-5-debt-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="govx_InterestExpenseDisclosureTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-7-stockholders-equity-tables" xlink:label="govx_statement-statement-note-7-stockholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-7-stockholders-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-tables" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-9-income-taxes-tables" xlink:label="govx_statement-statement-note-9-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-9-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:href="govx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:label="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfValuationAllowanceTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:href="govx-20211231.xsd#statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ReverseStockSplitMember" xlink:label="govx_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UpfrontFeesCOHAndPNPLicenseMember" xlink:label="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="govx_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="govx_UpfrontFeesCOHAndPNPLicensemember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual" xlink:href="govx-20211231.xsd#statement-note-3-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DepreciationAndAmortization-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt-details-textual" xlink:href="govx-20211231.xsd#statement-note-5-debt-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConvertibleDebenturesMember" xlink:label="govx_ConvertibleDebenturesMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_GainLossFromInterestForgiven" xlink:label="govx_GainLossFromInterestForgiven-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromConvertibleDebtGross" xlink:label="govx_ProceedsFromConvertibleDebtGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="govx_ConvertibleDebenturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ExtinguishmentOfDebtAmount-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_GainLossFromInterestForgiven-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromConvertibleDebtGross-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-6-commitments-details-textual" xlink:href="govx-20211231.xsd#statement-note-6-commitments-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-6-commitments-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears" xlink:label="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:label="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:label="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="govx_OfficeAndLaboratoryLeaseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_CapitalUnitsTrancheOneMember" xlink:label="govx_CapitalUnitsTrancheOneMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ClassOfWarrantOrRightIssuedDuringPeriod" xlink:label="govx_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:label="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfConvertibleDebentureMember" xlink:label="govx_ConversionOfConvertibleDebentureMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:label="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ConversionWarrantsMember" xlink:label="govx_ConversionWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount" xlink:label="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredCompensationLiabilityConversionToEquityAmount" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredCompensationLiabilityConversionToEquityConversionPrice" xlink:label="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:label="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_June2020WarrantsMember" xlink:label="govx_June2020WarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ManagementWarrantMember" xlink:label="govx_ManagementWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NumberOfCommonStockSecuritiesCalledByEachUnit" xlink:label="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NumberOfWarrantsCalledByEachUnit" xlink:label="govx_NumberOfWarrantsCalledByEachUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod" xlink:label="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromIssuanceOrSaleOfEquityGross" xlink:label="govx_ProceedsFromIssuanceOrSaleOfEquityGross-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromWarrantExercisesGross" xlink:label="govx_ProceedsFromWarrantExercisesGross-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2020Member" xlink:label="govx_RepresentativeWarrants2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2021Member" xlink:label="govx_RepresentativeWarrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIncentivePlan2020Member" xlink:label="govx_StockIncentivePlan2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockPurchaseWarrantsMember" xlink:label="govx_StockPurchaseWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantsMember" xlink:label="govx_UnitWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2021Member" xlink:label="govx_Warrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalUnitsMember" xlink:label="us-gaap_CapitalUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ConversionWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CapitalUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_CapitalUnitsTrancheOneMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ManagementWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="govx_ConversionFromConvertibleDebenturesToConversionUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_StockPurchaseWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="govx_StockIncentivePlan2020Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_June2020WarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_ConversionOfConvertibleDebentureMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrants2020Member" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrants2021Member" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_Warrants2021Member" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightIssuedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromIssuanceOrSaleOfEquityGross-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfCommonStockSecuritiesCalledByEachUnit-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityAmount-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredCompensationLiabilityConversionToEquityConversionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_NumberOfWarrantsCalledByEachUnit-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_ProceedsFromWarrantExercisesGross-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual" xlink:href="govx-20211231.xsd#statement-note-8-retirement-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_OperatingLossCarryforwardsSubjectToExpiration" xlink:label="govx_OperatingLossCarryforwardsSubjectToExpiration-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_OperatingLossCarryforwardsSubjectToExpiration-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxesPaid-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual" xlink:href="govx-20211231.xsd#statement-note-10-grants-and-collaboration-revenue-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NIHGrantsMember" xlink:label="govx_NIHGrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ResearchAgreementsMember" xlink:label="govx_ResearchAgreementsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnusedGrantFunds" xlink:label="govx_UnusedGrantFunds-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_NIHGrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="govx_ResearchAgreementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_UnusedGrantFunds-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual" xlink:href="govx-20211231.xsd#statement-note-11-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_NoteToFinancialStatementDetailsTextual" xlink:label="govx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PreFundedWarrantsMember" xlink:label="govx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantsIssuedInPrivatePlacementMember" xlink:label="govx_WarrantsIssuedInPrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_WarrantsIssuedInPrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="govx-20211231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_SeriesBConvertiblePreferredStockMember" xlink:label="govx_SeriesBConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="govx_SeriesBConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals" xlink:href="govx-20211231.xsd#statement-note-5-debt-interest-expense-details-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-5-debt-interest-expense-details-parentheticals" xlink:label="govx_statement-statement-note-5-debt-interest-expense-details-parentheticals" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-5-debt-interest-expense-details-parentheticals" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:href="govx-20211231.xsd#statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_EquipmentAndFurnishingsMember" xlink:label="govx_EquipmentAndFurnishingsMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:label="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="govx_EquipmentAndFurnishingsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:href="govx-20211231.xsd#statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLicenseFeesCurrent" xlink:label="govx_AccruedLicenseFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedLicenseFeesNoncurrent" xlink:label="govx_AccruedLicenseFeesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:label="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_AccruedLicenseFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_AccruedLicenseFeesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details" xlink:href="govx-20211231.xsd#statement-note-5-debt-interest-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_InsurancePremiumFinancingCostsMember" xlink:label="govx_InsurancePremiumFinancingCostsmember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_PaycheckProtectionProgramCaresActMember" xlink:label="govx_PaycheckProtectionProgramCaresActMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-5-debt-interest-expense-details" xlink:label="govx_statement-statement-note-5-debt-interest-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="us-gaap_ConvertibleDebtMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="us-gaap_SeniorNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-5-debt-interest-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_SeniorNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="govx_PaycheckProtectionProgramCaresActMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="govx_InsurancePremiumFinancingCostsmember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:label="govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details" xlink:label="govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:href="govx-20211231.xsd#statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RemainingLifeOnWarrantsOutstandingMember" xlink:label="govx_RemainingLifeOnWarrantsOutstandingmember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2020Member" xlink:label="govx_RepresentativeWarrants2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_RepresentativeWarrants2021Member" xlink:label="govx_RepresentativeWarrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_UnitWarrantMember" xlink:label="govx_UnitWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2020Member" xlink:label="govx_Warrants2020Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_Warrants2021Member" xlink:label="govx_Warrants2021Member" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:label="govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_Warrants2020Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_UnitWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrants2020Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RepresentativeWarrants2021Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_Warrants2021Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_WeightedAverageMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_RemainingLifeOnWarrantsOutstandingmember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:label="govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-balance-sheets" xlink:href="govx-20211231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_AccruedExpensesNoncurrent" xlink:label="govx_AccruedExpensesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssets" xlink:label="us-gaap_DepositsAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_GrantsReceivable" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DepositsAssets" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="govx_AccruedExpensesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock" xlink:label="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInReceivables-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="govx_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-operations" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="govx-20211231.xsd#statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredTaxAssetsAccruedSalaries" xlink:label="govx_DeferredTaxAssetsAccruedSalaries" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_DeferredTaxAssetsBeforeValuationAllowanceNet" xlink:label="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-3" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredTaxAssetsAccruedSalaries" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_DeferredTaxAssetsBeforeValuationAllowanceNet-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency" xlink:href="govx-20211231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency" xlink:type="extended">
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:label="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:label="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:label="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:label="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_WarrantIssuedForTechnologyLicenseMember" xlink:label="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodShares" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedDuringPeriodValue" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="govx_WarrantIssuedForTechnologyLicenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueWarrantExercise" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesDebentureConversion" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueDebentureConversion" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="govx_StockIssuedDuringPeriodValueReverseStockSplits" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares-n8" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue-n8" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:href="govx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="govx-20211231.xsd#govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:label="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions-n9" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>geovax.jpg
<TEXT>
begin 644 geovax.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  K )H# 2(  A$! Q$!_\0
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MP*3MW>A]B?$?_@O;^RQ\-]ZGXEPZ_,F08]%TZYO<GT#A A_[ZKQ#QG_P=-?
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MO[%GAGQOH]N]VWPP\46^KWD:KD);.K1&0_[*R&')[ D]J^0RJ$)XRFJFU_\
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M0U(ND5KEL!I25X9F( XR68@#)-?$MU_P<W?LWV_BIK-8/B)-I*S>2=:30?\
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MXF_X)A?\$J]6_9.^('B;XL_%7Q=_PL3XV>-(S#?ZH-S6^G0L59HH68!F9MJ
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J(Y<!&MS+_:9N ""('FW&+;GROEV;\_>=?6O::**B;B[<JL5%-7N[G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img01.jpg
<TEXT>
begin 644 img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MHIKIZGN996J582<W?4^?_CQ_R/5G_P!@U/\ T;+7F=>F?'C_ )'JS_[!J?\
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M;_O]%_\ &Z/^%#^&/^?[5O\ O]%_\;HHK3^V<P_Y^LCZEAOY$'_"A_#'_/\
M:M_W^B_^-T?\*'\,?\_VK?\ ?Z+_ .-T44?VSF'_ #]8?4L-_(@_X4/X8_Y_
MM6_[_1?_ !NC_A0_AC_G^U;_ +_1?_&Z**/[9S#_ )^L/J6&_D0?\*'\,?\
M/]JW_?Z+_P"-T?\ "A_#'_/]JW_?Z+_XW111_;.8?\_6'U+#?R(/^%#^&/\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img02.jpg
<TEXT>
begin 644 img02.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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MU-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P# 0 "$0,1 #\ _OXHHHH
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M3_&ES0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4Q_ND9QGBGU7E<JID4?='.2!C^F.: ,F:[MK!'NY9&=<^65 SAN<\="V.
M0&[5SVOZU=WNF/\ V&A+N@82MB/<-V&C0D9$@//^[TZFNAN]/\V*>1!]H>91
MB&9A]F1N1NQM(^7@D%>0/SPM,CN;2QNAK"PW4]M]HG@AT^/8'@A0NL*1C:K2
M-MVJ.,G SFNRDZ:2JN+G.,XV@WH]K>[972=F[R2_)<T^?^'LI)ZI-<K5G=RU
MUULK+IULSS+QC\=_!'PVMO#NF^.?$-MIFK:@(1.FR25[6 DJUU<HBLRP;!\L
MIX=E)P<,*V'^T>,-5T3Q;X7\;6Z>#IK6VD2*T=9EU*VR6\V 1OEUF4M&3+'O
M4YP,C _.GXP^!_"?[5WQ&LO[2B^)_P )M1\^3P^^IQZ$E[H%]::>LSJ;BYN[
M>*/3[V0@Q1LBR1DLHW,?F/Z$^#3\(/V>/ASX)\$W_CCP[X=TBPM8])T6^\:>
M(=*TJ]UJ\,A>>17U*YMC<7,MQ*S/' I6+<J* N,^MBZ*RZG0FJ4X8VK"HJE*
M5.%2E&%:]Y0G:=/FCRVAR.37O-J+."A46-E./M%+#P=-PFG.E4<J;C92B^2H
MU+=W2BW97:T.K\4>,-/\&V4,]A9?VA/-=6Z?8VNK+2C]FGN(X)[[-]+;!X[5
MI4,SA6P74$[F KH;N]N+:ZM+NTFOM077/*MK2&&.*[TBQ:."2?[9/<0;6BMY
ME&&G\Z1&?RE4<@U\6?M3>.OBWX[\!_$/P?\  #X<7/B37=$FTS3=5UC6=/L/
M[*U[1M8M4NKK_A!K^>=[35)K=/)%S-\JPR K$?,5'/C/@[P/^T9K'P\^#I\6
M?%"]^!OB'PCXALV\8> ;*]M1;^,_#.EQ7KV'AR:RNKEX8(=5L<VEU-I6U;J\
MG2.7?<0PXZ*>30GEM+&U<5A*.)EB)T:F%JUU6Q=2C/#4Z]&M.C!N=.-[*/+2
MCS<]JDXWM'DEF;685<'"ABJE%8:-6GBH4'3PL:D*[HU*4*LDHSFU=R]^2]R\
M(N[9^BLNIOJ6H7=G)XA&EO#<VP2W5([2;5#91 ZG:6C7K%[K3GDE0K=Z:NY!
MD23MG MV7A]M-@EO_#TLDS:AJ-I->6T\L\\9M$?R98X?M%R_V:XA@+/*\;;9
MY(V+0,[(1^4W[6OQ^^-/P=^&WPR^+O[/GP7^'7C#X3:#-KT?Q'UKQF]KI-U\
M-M+@N[&"2[U&X>_-UHT!=;V#49$>XNXYUM4%MND0-!\%[C]H?X_76J_&?X9_
M'WP7XS^"GC#1M0F\)6%KJNLZGH5]J\DBZ?;:)#;QK;RP+X<\1*MK/J"3+<2M
M:!9(!#<NIVHY33JPJN68X7 0HW4Z>*2O4J4:D*3H2IT/:2C7:2JJ%645%N2C
M-PBZA-;,:M+V#C@,3C9UIJTL,](4ZD/:>T=2LJ=Z:E>G>G=M.-X)OE/UZ?7(
M?[/NI)K">>2UE6-=.MT\Z[F.]?\ 5Q$C<\>[>[$A JDY! SCV6K?9=2D-YX<
MN--U#69;AWNDMQ<PM9V.U('O[JV+K%-*C PQ/ENH89%8UOH7CS2O -L+[Q59
M#QK'HJ+K>OV^@K>)+J0L'B:YL=.0^85@O&CEA@&_?%$8V3FOS^\0_M.?#^RU
MCQW\'?$7C7XC_&7XM?#3P?9M\1;+X<)/H\4)U;4\6-K>Z/IDUO+:7]P4%O>"
M$/)'8R,'X?:OFX3 PQ4JM.A*G5<JRI1C3>(<YWM%3I\T:=!47449?O9^TDW#
MW(I2:[*V)G14)U85J<?9*K*4HTN6%FG*$U&4ZKJJ#EI3@X+EE[R;5_T#UCQ1
M'?7VE6^C:[:VUP]W,T\4,"3W+V%DH^UV:G,\;W&\AA#LCDC'^L ZUU\.HSB\
M-M>6KMI;62W$MY,50VSMRD,T2?-NE7GY %3H<5\1^!/B/X_AT!EO_ACX6\"6
M%QJ-G%IUA/J&JW6KIHVI0Q/']KO733X(M5*$I)(LL@\XI&TC."3[[I_CG6E6
M6&31KK6=+6-28H+:"WU?[2]P+:*U:)KPJRV46'N[R6,^9E2'=J,5@945&*A'
ME7.N9U*3F[.+NYTVXN7O6IIMWM>[*H8E5)-WE*7N>ZHS4>9IV7+))_9;F[*V
MB=ME[3;78GN;A8;9K>)0KF=SQ/ .(Y8E#'.>.&5>.O-3_;+U'6..$RQL_,@C
M*D G_>/;G.!UZ=*XK5=0F@2SLKR5-,F-O&MQ>1%'-G"\BF-9I9?+BDB9,(Z1
MJQ+] >#79V%[+<A/(\BXL%6-8[Z-SFYD VDHHR"H'4C@]!T->94A9*22::TN
MW+9))\UWONEU2OM<[X/=<S3O9W5FKVTZ;=>ET];W2VXT^4DEB7()R0?R]/<'
MITJ4# Q5.!XP9 90[!^%Y!&!R K8)  SGD>]6"Q8@H<KSR.F<C_/I7*S=;?\
M&_XV1+1112&%%%% !117Y4_\%=/VQOB%^R7^SIX>TSX%QVL_[1_[1/Q'\-?
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M\,?#E(OFN[OXB^-0/#'@Z&QB!W3W<&KZG!J$<2ABZV;C!'%?%?P$_:C^"_\
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M)J'M&G-*T.2,^=WVCR2C*^UG='Z3T5^8O[/O_!6W]D3]H;XFZ)\(-(U7Q_\
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M,CH<8S@@]\GJ<\UMK]T8_P G//ZU7'ERI^[(.<,K\$')QE>@Y(X]L?02H"5
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M+)%):7]C<^%&^T03*H,4T4Z@)*&W+*I*ON!-?O#K_P"Q;^S=K_[+FH_L:/\
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MYG,7[5QY$GPB!_Z^/$./_2&HFB_:S_AD^$/T-SX@_P#D$U].T4?4/^HW,/\
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M._\ M3Y&:#]M08VS_ T^N;CQ0/\ W&TTP?MK]IO@8/K<^*#_ .XT5Y=^W/\
MM$>,O@?XC_9T\.>&_B%X;^%VD?%?Q=XST;Q/XU\2>"]1\=QZ7;>'_#]EJNG1
M6>AZ;?Z?.\EU<SR0R2^:51=I*\5YG+^UW\0O \/[/4VG>*1^U!:?%KXH>/?"
M.H3?#CX7WOA#698/#WA2SU:PTS3='UG79(K:2UNY)IM0UK4+V"P:!HH\H_+'
M]G_]1V8?^%/I_<\OS[C6%=TUB,5KM^]_^U_X;<^F_(_;9_Y[? K_ ,"?%/\
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MBO\ P=_G$^BOLW_!1OM<_LS_ /@5XS_^5!IAMO\ @H_DXNOV9<=@;GQI_/\
ML>J/P0_;K\-_$?X,GX@0Z!XF\>WGA;PYX4B\;:K\/]%_M+0;CXB:]Y"7G@GP
M_+]J/VK5-'>XBEUV3=_9FA0NW]IZC;M#,J?0'[/?[2'A#]HFP\<2>'-*USP]
MK7PX\73>"O&?AWQ NGM?Z1KD=I!?QQB[T>^U/2;V"XLKF&XBGL+^YCVOL=DD
M5D#_ +-_ZC\S_P#"M_\ R'E_5V+ZK_U$8K3_ *??_:GA?V;_ (*0_P#/S^S&
M?K=^-A_+1OZ4PVW_  4ER<77[, '8?:O&W_RFK[^HI?V9_U'YG_X5O\ ^0#Z
MK_U$XK_P=_\ :GY^M:_\%*OX;O\ 9?Z]#<^-NG_@FIGV;_@I;_S]?LN_^!7C
M?/\ Z9<?K7Z"T4_[-_ZC\S_\*W_\AY?U=A]5_P"HC%?^#O\ [4_/<VW_  4Q
M)XN?V6U'O=^.#_+1C33;?\%-,\77[+&/^OKQS_\ *85^A5%+^S/^H_,__"M_
M_(!]5_ZB<5_X._\ M3\\OL__  4W[7'[+'_@9XY_^4IJ,VW_  4[[77[*WXW
M7CG_ .4U?HC11_9G_4?F?_A6_P#Y /JO_43BO_!W_P!J?G6;;_@J!_#<_LIG
MZW7CK^?]C=/\XIOV;_@J#_S\_LH_^!?CS_Y2U^BU?-_[7GQ \4?"S]F_XK?$
M#P7>1:?XH\,Z%9WNCWDUO'=QV]Q+KFE63NUO+^[ES;W4R!6XRP/44?V9_P!1
M^9_^%;_^0#ZK_P!1.*_\'?\ VI\\_9O^"H/_ #\_LH_^!?CS_P"4M*+;_@J#
MGFY_92_\"O'9^O71:^I?'_Q9E^&7P5C^)M]HEUXGNK7P_H%Y<:=97VD:,LUW
MJEO:"2YO-5UV]T[1M'TV"6=KB\O]0O8+:UMU9F8G:K?!Z_\ !4OPD_AR\O(O
MA[YOB#2OB3=?#?5F3XC^ /\ A7-OJ$.B-X@L[NW^*CZTOA"YCUFSC>VTFW^V
M1W%SJ(^S,B(1*3^S/^H_,_\ PK?_ ,@'U7_J(Q6G_3[_ .U/3OL__!3[_GZ_
M93_\"?'/_P I:/L__!3[_GZ_93_\"?'/_P I:FU/]OK2=/\ BEX&^&8^&6M)
M?>*_#?@CQ'<-JWB[P/HE_P#9_&US<6R1>$-+U#7HG^(;^'FMGF\0'PG+J/V>
MVDMI+3[69T0MN?V_?#^F?'KPK\&=;\$-I</C/XE'X5Z/J(\=^!;_ ,56_B"7
MS4TW5-:^'6GZY<>*=&\-:K/%Y5GJ5[:1S[)8;F:SBMW\T/\ LW_J/S/_ ,*W
M_P#(>7]78EA/^HG%O_N-Z?W?+\61^1_P4]_Y^OV4_P#P)\<?_*6C[/\ \%/>
MGVK]E//_ %\^./\ Y2UZI\0OBQXI^%7[3?@/2?%&K0I\&/BG\.O&5CIQFMHX
M_P#A'_B?X"@_X2TH^H+B1XO$?@N'7I([>;Y%F\/L83N=A7Q5X#_;I^(/AB/Q
MKXQ\<:%XM^(5WXV3X3>)_A3\,="MO#>CQ6/A?X[?&'QW\//A/IUGJFH7=I+-
MJNHZ5H6B:EKUQK,MM:6POT>%L"?8?V;_ -1^9_\ A6__ )#R_J[&L&WMB<7_
M .#NUO[O]7?<^@?L_P#P4^_Y^OV4_P#P)\<__*6C[/\ \%/O^?K]E/\ \"?'
M/_REKK8_VS8[#P3XY\2^+/AKKOAS7/AY\:OA_P# _P 3>%_[:T/59;;Q+X[3
MP5Y=W;ZKIMU/IEUI^ER>-+5+B6"X<W LYVMPX:,L_P"&G[:>E_$CX^^*?@C9
M> ]1TUO#/B#QAX9N=4U#Q1X3B\007O@^[6TEU35/A^=57QAI_ACQ!\USX7\0
M'2YK+4[0Q7$K6R7-N93^S?\ J/S/_P *W_\ (>7]78OJG_43B_\ P=Z?W?+\
M7W./^S_\%/O^?K]E/_P)\<__ "EH^S_\%/O^?K]E/_P)\<__ "EK]$J*/[-_
MZC\S_P#"M_\ R'E_5V'U3_J)Q?\ X.]/[OE^+/SM^S_\%/O^?K]E/_P)\<__
M "EH^S_\%/O^?K]E/_P)\<__ "EK]$J*/[-_ZC\S_P#"M_\ R'E_5V'U3_J)
MQ?\ X.]/[OE^+/SM^S_\%/O^?K]E/_P)\<__ "EI#;_\%/L<77[*?_@3XY_I
MHPK]$Z*7]F_]1^9_^%;_ /D/+^KL/JG_ %$XO_P=Z?W?+\6?G3]F_P""H/\
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M%960B='D!R8?_G]4_P#!,?+_ *?^;^X.:I_S[C_X,_\ M#^U:BOXO/C_ /\
M!0WX[> _$FG?%GX8_&#XT>._V=;A]#M?%4UIXS9!X-\1ZGIOGGPW<&X:#5;5
M_-( _M.Z,D[*6MKET*J?V(_9#^-L?QX\$Z5XHU#XF?$*Y35[!-4L2/B7XT5Y
MK%?W4S2-;:S! MPMWOA:)0-NP_>'-')A_P#G]4_\$KR_Z?>;^X.:I_S[73_E
MYZ?W>FOW;'[=$@<D@#WXI<]^U?G/XIBO=&\*:UX@TOQU\0X;[3A:W.FO/\1/
M&MW _P#Q,;.,B6VN=<EMYT9'='BECEB=6(92,BO2/VNOB?XCT#]FG]H/6?!&
MHZWX;\5^!]$DM-.US1H1?:M#?O:6UT+S2+2 -++<*DVR*%5\YGSM'2CV4&Z*
MA4;5:HZ2<H<K4HJ$GHI23TGW6S\B75<>?GC9QBI*TN;F5I7MHK6Y7>ZVU74^
MT**_G(_9P^(7[27QD^$^A>*K#XX^(M>O-6MM1AEC@\2>-HO%5I/8>9927%]I
M;>*+"TTN-+Z-HS-/9W6RY1A+:>6"K>M^+_B;XW^$_A;Q!J?C#XD?%*[U;P[H
MVDVL4&J_%G5=)L=4UK5%6UBEO;Z"X6#3+D7LF3 KFV<".0K%$7BC.7#_ //Z
MIZ^P7_RXKFJ?\^U_X,]/[O\ 5C]W**_(:;3/BUH.A:1#JGC;XRZA/+9VNI77
MB?\ X61J8T\V=WIL&IS@26&M2P7D]C).;".WMK>UDN@B7"2&)GEKQ70/B3XS
MUZ;7KOPW\:OB%XNM?#>HPZ?J-I:?$G6;:5=6N'41:#- VK)+9W/E1O*K/<SM
M<JY5#&\; G+0_P"?U3_P3']:R_K[PYJG_/N/_@S_ .T_JQ^\=%?C9\-- ^./
MQ;\2WEIIWQ7^*'AS0K=)[B_O5\=:_??8)6FFCM].M9!JEQ%-)Y:>:PD9I57!
M)=2KMP_C[PS^TY\)/B'%X3\0?'3Q_P")?!7B^T-SX?\ &=CXTUVTUWPWJMKY
M\TOA_4O#POW^TQ:C$L2:?J2>?G$R2)YJXHY*'_/ZIT_Y<Q\O^GWG^ 7J?R1_
M\&?_ &A^DW[1'[/&N_&?Q'\'_&OA+XFW7PP\8_!K7?$NM^']6B\*:9XPLKP^
M)])MM'OK74-)U2\L8F1+:V#0R1W"LLC$D$#!\[\2_LK_ !@\7'X:>(M=_:5N
M9?B-\(_%WB+Q1X0\56/PJ\-Z=ILD'B+0[?1;G0M<\,IJT\.HV")"UP)8K^TN
M7E95,FQ-K?E?>?'SQY_PGVN>"K?XT?%NUOO"[VFB:B;SQ?XF6PEN9I[=VU&5
MV=;A-1>&Z/[FVDDT^SBMU^UH)I<GUVWN/BW>?%2_\!Z%^T?\2O$5IIO@+3-9
MEU"U\::I);Q>)-=U.2TL[:_:"\R+2UA13*L3QS L&8$<$Y,/I^^J?^"%IM_T
M^\W]WF/GJ_\ /N/ISKKO?W.WJ?9VC_L(7?@@Z!XK^&OQGUWPS\7H#XZ7Q=\0
M]5\*Z1XA@\8P?$:[74/$*W/AE[FQM-,EM+Y([O0);2]8V$L,23I>('#<5+_P
M3&\%Z=X7U7P]X:^(^N0MJFL_#KQ%?Q^)M TSQ+X?\0ZQX#U#6M6NCXR\.-<6
M-IXDTOQ3J>O7MYJFE326]I RP1PI)''AOC;QC\5/B9X(U+QQX#UWXW^.H/B!
MI6FII^@I!XZ\5W>GOK3$7$M[=FVN&:#RK7E+-UF:>-LQKYH KG/ /BC]IF[M
M+4^*/C?\1+OQ T,E[+IMIXWU>QTQ;*ZE'V,7-O-<'6(IC&F(YC+ D7FC[1;M
M)\BG)A_^?U3_ ,$+R_Z?>;^X7-4_Y]Q_\&?_ &A^R/[+W[-6G_LT>'O'&B:?
MXF?Q+)X]\=WWC_5)4\.:1X4TW3]4U'3-,TR?3M$T/0PFGZ?H\$6EVXL[:--\
M2@K+)/(6F;Z>K\?OA;I/Q%\56NM6^J?'7XA3^(-%>::ZTR#XA>(45+68AX<S
M&\AR;=76(S*OERORJG) Y+QAXM\0>&Y+6"P^,_Q;U&:XUJ6SGAG\<Z_!]AMK
M1'DOI);QM2BMFW,GDZ9;LL4]T22"X1V!RT/^?U3_ ,$Q\O\ I\'-4_Y]K_P9
MUTW]WU[['[745_/K8_%#XJ[M:U'6OBQ\4]*TV.]?1K2.?QMK<"Z<]RP>SU:_
MD?7[B0(JQSH%(59_)F/EQ[HL^7:Q^V[IO@SXIK\&]8^,_P 5-0U*ZO\ 318^
M+KCQ5XXL])N?[5U"#3H]-LYEOH8K^YLY+J.6X2."'9'Y0DG4R@4<M#_G]4_\
M$K_Y;_5@YJG_ #[C_P"#/_M/TZ']+=%?SG?%GQI\:-"T71])\*?M"?'>'Q'>
M:A#J%[J#:_=7\O\ 9VI7JVEC;6D>Y=&MM(&Z2Y%UJ5\FH_9;<H?-DGCF'I>M
M^*/B_86>M:7-\7_BE8:W/:Z=::%K$7CW5[W1Q+;WL!UC5I&CU.2&W86XEM6@
MGGGCBG<%8CN&TY*%OXU3_P $Q\O^GWG^ <U3_GW'_P &?_:'[RD@=2!]:-P'
M)( ]<U_+=X?_ &E/C)X \7+X/^*7[4?B_5_'=GXO.IV&E>&M2\5W6CW/A75M
M5@TOPU8ZNMY+=*(1,0)[YRD-W=/+ \20(37]!WQ'^(EYIWPC^.&I::+JVUWX
M=_#+5-7COXI51Y=3E^'\OB6UNK4HR/#);RLGS%T_>+N5@,$*5.'[KDJ.2JU/
M9+FAR-3Y8RM93FGI*^ZVV%[1KF4X\KC'GLI<UU[VFRU]U^7F?0F<]**_@P^*
MW_!6?]HO0;^TM_!_QO\ B)K"2:987FH/IGCJ=8X[J>QB::TTV&]?47=XKAV,
MQGOGVNIB55# #R;3_P#@IY^W!-!=3)^U%\8)K<C^U4FO7B2[M+:/#2Z$;2TC
MDC%R#G_29II&:/#8BYK5T**;3KRT;7\%/M_T^\_P>Y*JS:3]FM;;U%?7_MW_
M (!_H445_ 9K?_!1[]MJW\*^'?%UI^U/\0M\]M(^H>'[?Q):/>7<X:98+:VM
M+JT34)9YX_*D06Y93,1'G8<USMI_P5!_;IO?#=_#%^T/X_'B>.\-A%#-KTUC
MJ :_2.2Q6VL95GM[B]LXY'>[ =HO+MI72(X,='L*/_/^?3_ERNMO^GWG^ _:
M5/\ GVO_  8O+^[Y_GV/]!6BOX__ -G?]HW]L[Q)X:TR]\;_ +0WQ U^\T^T
M@N-7N!J/B.R_M,7$;W!MD2PEM;<ZE$95L_)M9K:)V@CE&T2D']P?AY<W'BCP
M=;:HWQ1\>:QJ,-GY-[]A\??$.SGDOK40_:YUM+K7 WE*92+@PAXH61A%)(0R
M@]A15OW\]?\ IRO+_I];J_N%[6?_ #[7_@Q?_(^?]69]$_M>_LQZI^U/X-\*
M>"8/BCJWP[T30O&%AXLU[3+/0++Q'HWCR/2HI6TWP]XMTN[O-/\ M_A^WU%X
M=4ETX7:6]]=6MNEY'- AC/%WG[)'CSQE+X.D^*_QYN?&B_#^_P#%-WX3@T?X
M;>'_  5#80^*_AQXA^'%W9RI8:EJ"S16EGX@EU*T*^3LN+6&WQY+,1EV>BWR
MQV\<GBKXCW%V88_MD4GQ0\?XMY/*0W!$T&K[04F_U?F* T<R@@F(LV-J4$VC
MQ7LM_P",_B#;0P32B&YN_BWXVBA:-8XR1(\>L/&"7.V J6,K2H61 =M)4:+_
M .7\U_W!7EK_ !O-_=V'[6HO^7:^517^_EOU_JS.<N/^"9W@S2/ &H?#KX>_
M$76_!7A;6-.^',OB#PK;Z!IEWX+\3>+_ (<S?N/$VO>&$GM;2[B\6:>EMI_C
M31$FBLM=^Q6M[<,;E)#+]%?LM_LMZ?\ LT_\+4GL_$T/B&Z^+/C*R\;:O;:=
MX1T3P1X?T+4+70K+0VTWPWX?T$&TLM(,=DDT,,DDT\3,4>>;[Y_.?4_C=)X8
M\2P^&_\ A:WC+5[K4YKF.&+Q%\5_&&BW%I,UN\MK%;_9M42">WB($DTTKF22
M(ILB!8@?-UU/^W)X3BOM4U/]H74_%&G2ZU_:<]CI_P 1]:@UBQ\-232_9[/P
MM J[=68H8?.>_62:.(2 W'F+FFJ%!_\ +^?_ ()7E_T^\_P8>UJ?\^UK_P!/
M%Y?W?3^DS^EFBORK^&6J:YKO@'3M7\3>*?BI'KEK/%9ZH;?XI>+I8;J::/?;
M2QK#JT>T2QG,T:HOE2J5SBOG+X\:9^T_;^+D@^&WQ>^+&D>'-9\*WC0BP\9:
MIJ%YHVNP7,)LY88=7O;V6X>Z@9D=+H_8V)^66.3%+V%'_G_/_P $KR_Z?=+O
M[ON7M*G_ #[7_@Q>7]WS_/L?O#17XV_LY?#']H31O!-P/CO^T/\ %7Q=XQU2
M:YOK19/%&J:(-"L$EC2TLYSH6HBREFF16+N[R,?-.%4H /I[1O#5]J/VF.?Q
M7\3K>6U98QYOQ/\ ',4=P3EC-%-_;C+Y"1KF3> P;(4E<&CV-#_G_/I_RY76
MW_3[S_#[CVL_^?:_\&+U_E_K;<^]**_/[7-*G@M;BXTSQ;\2GGBMXI)K1OBA
MXZ=DD++&1;NFNE9%=B&.Z0E4;. !D_.WB?3OC7XDU33CX5\>_$WP;"D%_:ZU
MH-S\1O$\^K1220W+:7JEG<W=W?VDZ[_(:>,>;%TC"X):A4:+_P"7\UZT5Y?]
M/O-_<'M9_P#/M?\ @Q?_ ")^Q)8#J0,=<G%&0.I%?EI^S[H_QL\.?&;P-<>-
M/B]XG\6^'_$EEXEM+KPMK&N:O>PVEY9:$;M':WO[FYCN-LR>=#/FW> LT)25
M<.OG'[>OQQ^)-EX]^&&A_#6\\>V.E:G9^.M,U2#POXEUKPF8-8\-^,;OPP=5
MU._\/W:2R64DU@XLHKJ.Y4H^5ABD,@?&K"-.4$I\WM*?M(WCRNRG.#32E+5.
M/?9KS+A4Y[IKE:E:U^:_NQE=.RZ22MT/V2W#U'YUY?\ &KX6:-\;_A9XU^%&
MOZEJ6D:1XVT@Z3>:IHSVZ:K8*+FWO(;NP:ZAN+87,%Q:PNGGP2Q'!#QNI*G\
M(?A])^TCJEV\^M_&;XN2Z0NH-<3R3_$_Q[;S6^FE(9\13K=64*VL8,L:2W"/
M/, I&"&Q],0S>+-,M[:>^\6?'C5C>W36UE%#\8_B+YTT9.1=R1P:W"MO$$_>
M1[Y7#1D%^2*S-#Z@U+]A_4/%?@>_\ _$G]ICXR?$C0?-\+7_ (;MO$6G_#6W
MA\,:QX/O$N]'U""VT;P5IT.LQ%8UMKW3-=%_I]W JEX1*HDK-M?^"?/A73H/
M&DFF?&/XI6NK_$/Q.OBGQE>R_P#"'WVC:[=R:#-X<O=/O/!-UX:D\'2Z3)I\
MV[3K5M&\W1KE%GLK@,7#>$:[J%[ L-GI?C#X[/>7J)#'=-\5_B<]M:7K_>2<
MCQ49%CB^Z7-N(W?!63%/L/"7CJXMY9Y?B]\6$N514AM9/BY\2U21UC9YI'VZ
M^9%\LX4[793QTS0![SJW_!.[X6:II7A;P@?'/Q%3X<>'M.\,6%UX NM1T;5]
M(OIO">H3ZII^J:/>:IH]SJ?@;4;R[N9O[6D\%W.C17D(@BCBMOLT#H[1?^">
MWPZT7Q9X5\10_$'Q[)IO@;XR/\</"WA<KX5AT^'QC<:S+K=VNNZM;^'X_$?B
M;3WGN;N"T@U35F:QMYT$;O);6TD?S#9:CXDDF73/^$Z^,]S=^=Y9O3\7_B=%
M:LK%E5HA_P )  ?GCD!6256'RX\PDBNMTGP]XM-SNO/B=\7[N"YO'2."+XL?
M%-3!"F?-4WK:[:P!D)5%5HR7<!(Y')S0%S[U_:._9X\%_M,_#Q?AWXUU#6](
MM(/$&B^)-/UWPS>1V&O:7J&CW.Y_L%W)%.D46JZ;+?Z%JB&)OM.D:I?VWRF8
M.O%>*_V/?AAXJ\86GB][G6-(ET^U^!-AI^DZ5/;0Z58V'[/?C35?&_@BTMX'
MMW=(9+_5YK/45\P^98PP)$4="Y^1M?\ #OC&U^UVFF>.OC6;F"U;4DN9_B[\
M28;>2*$@"P4R^*'!NYRK8((09 W FN:GTGQ]'I?VZ3XD_%ZWF9"D44GQ<^(T
M<#W+&$PJS3^+8G1&61O.D1I5!1MG50 +L^L/B!^PWX-\?>./$OBF3XD_$?P_
MX?\ &7Q$\!_%KQ5\.]$OM%3PIK7Q#^'O]@1:/KT[W6D7&MQ0W=KX:TB'5-)M
M]5CL;N6U%SL1R4K>TW]CGPA:_&C0_C+JOCKQQXHO?"'B3Q9XL\$:!XAN='OX
MO"^K>-+:YL]8MK;Q,VE#QA?^'+>WOKV+1/#.H:W/I6CQ310P1/%8V*6_R[H.
MF:Q<Z7/JVI>/OC.9[:%'.F6?QH^(\XN6CBB%P;1X_$3F5?,/F8#%D64#)*X%
MCQ;HVKV>D6[:3\0_C(M]JFV2U\KXP_$R2>U61&D6&7S/$DT*R %0'> @A"I5
M20U 'ZN;AZC\Z-P]1^=?A+K.N>/M-M+^5?B?\9)I[ W"+;0_%GXA1/-YJHUN
MTTMWX@ \R('.VT25"A+GD%:^;9/B!\<;'5K#7I_CS\7M1\+AV2_TRQ^)'C>U
M$'DVHDF,EQ<ZI+=S*DI*M- \("@$0L&!H _ILW#U'YT;AZC\Z_F;A^*WQ(\7
MAY?!'[0OQ@MKB",F\L]=^(OCJ"RCD0_O5L[J75(KBX5  58(V]3E0:ZOX??%
MGX\^&/C+^SIIVK?$;XI>(+'QQ\;?!WAW5DO?B%XGUC09O#VHW4T5U#/IU_?3
M6]W;7:IB6.\@#P@!@2U ']'5%%% !1110 4444 %%%% !1110 4444 %%%%
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MB30Y]/\ %4"ZGX2T_3#=WEYJGB37-+Q!H%EI7AJ5)IX([FW2]DDO+U9#;*N
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M77Y6\P/VB6V24RR/%/?.)5MU2/;#:B *K0LLJ QRF)V=&;[LHC#-L!(J)#!
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MD63XS:N&56_XDWQ'SN3?\I^.7CO/&5ZG'.<"LL3_ !<'_P!@U;_U(E_P=/\
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MV[.GF1I.FFZ4T9=/XT#@94=1733WP'_8;5_],TCFJ[U/^O2_]R=[GYQ?L?\
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M+[5H+&22"6ZF$*7$=N4#">&PN)?LUU("K)-',,/L-? _QU^/<GQE^(.EZO\
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M5M':)HKV&I:II5[J36\E[J,3D6ULOD$F[EVY)BE5B2^ZEZO32R=O+=7?1O\
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M/'WAGX6MIO@&\UF/Q%J-T(-/M9M0@DBO8 T,3//<RNXB D.&$B@A$8(& &T
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MG2]-EL[4W]C?^/;OPW:0:=-:^&Y-^+*XO[9(Y8GU20>2(HF\UXRQ)5>O ?\
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MMP+<^"_VDK:<-MN/ 6FPRA6*,5E^$]LCJKCE&(8@,/NGD=*VC_S"=WC96O\
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MG$M9VUIJ< 2?5]2LXT,LUOJCA3MCL[EY$MX&E=0LC.(U9F! /X<OV7?V&O\
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M^(/BKXTZ;9Z5X.^#_P 6?%5AI_@W6?"5W\1[:^MK:[U."'5;:631;/2-5MK
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M\59SJWP;\!_!WX007R-;7>N3*^N7>G&91YCQW-_]JN9I(09-MK9 (NT,<L,
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M@ZI=?\% /V.? UI=W)M8OCU\/[O4WC,QM-0>&ZN%> OE8%^QMB1$V!Y0"1N
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M">L6ICL0>.O7'K74Q^7"067+913M1PJIYK;L)OZAADD\YP/0UO4_@X?TJ_\
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M$M^Z%W/:%\HC,/W<Q5Y$#-C:=M 'N/[%OP.==2F\:2Z>UOJ%]]EB((ANV-A
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MHHEN'TWQ)X.UBRUJ"R'VB:"/3M1\*ZW9//JC6B2I )K6XFEU [F%A:%<U?\
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MUUXDU/\ =Y."\WSY1  69SP%P>]7[&'7%UKK_IQ2\K_KW_SO]]I\/_@7IO\
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M_"@T?_XU1_PFOCG_ *)9JW_A0:/_ /&J^/CX=E+Q@>)/%(W@F.,>)=0223/
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M4&C_ /QJO-O"7C+QL/'?Q69/A?JS,VJ^%-Z?V_I(,9'A.Q ',6&W ;\KG&X
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M78Z_\2=7OM%M'MEEU(:U)'<:O*DI2/&FV[G]WYR*KF4 ;0W!P: /I[_@EO\
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MK8V$\M];*$$\L<+0%\^2[#FOUV'E@0R6[H8RSR.[LS>8!]Z-U[-_"!D$CJ*
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M7PY^P6NSX:>.P0 __"U=?\T!/+!E_L7P[YC;,D+EN=H. ,8P#@?<= !1110
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MR5,%NT3-Y_S<-E0-PC9NA:4J0".1E/7KRETDRQR:A:P*(X24F=2 22P(Y!)
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MD %?4/MO_".:G9ZI%9VEU+I9N(S>I+$SW5H98/\ 1GB)4RBW,L>W:/,VKO.
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MAB">1Q7W!7Q%^PFCQ_#OX@I))%*P^+?B0F2 #R'#:3X?8>259E,8!PI4X(Z
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M?+ (4*""K;23@,-WIDBE8LD<DDKO+)Y05 3M>-CPH5$8;UQ]_C))P2 :9?7
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MOQVD2:?J.H65W&KWEBJ0W,TMQ*/)D,#HR.GF*_R)XY_:>^*O@[P]XO\ @Z?
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MB<W!5)!\A;(- 'Z,?L%((_AAXW59S<K_ ,+3U\I,6W%XSHWATQG(X/RD8[X
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MYCQ)EL[NAR& Z5^I_P 0#M^''[3Q_NQ7W8'./#EEV/!STP:Z:?Q9?_V'S_\
M3=$YZOQ5._L7^53_ (!XK:WLCZ:BQD0DV=J/F?>5\VU@#'UW"0\*.%W<#'%?
M)G[8GBK4O"?[/?Q"\3B];RM'T66_OH9%6$K9VB[II3A1\RPK*[%\@@9/>OJB
MR3&G6&U8RYAL928S^\W^2A9FW=%)&" I SA<XX\?_: ^&LOQ8^#GQ,\$7FZ
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MV!GFC($C2*6Y8"/<%7>0J'' 'ID@'1M>[)!&TI#!5.%<(A*DJS!R<$?Q+Y;
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M_%"^N=$AO4UW1M D\/Q![C5$DBF:YAG@O$QJ$\5M%(@2WN/DE;Y9 JK7S/\
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MQ<\2#]Z59V/]D>'LNQ3Y?G.6P.F>:^UJ "BBB@ HHHH **** "BBB@ HHHH
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M0SM"I>'RB2OE2R!RJYX)) SFN%C\&:SIWB35=3\:B*.TTDVE_INDKN=-MVQ
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M07TTL=HH>.V161E8[HB!SYJDC/'(&#M%:3/!M-LS^9*2V6/F,B.P!W;B,.
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MH/'<A>(3:%-/$R+9>'6B9F"M$B:A(HCFD$  KK/A7#)=?&'01\1?%MYKLWQ
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M@6RW4"O#[M])_9[\#M;>(;"7Q''-;R_V3J<,T<\=A8&V"",3Q#<^W*LHE?S
MR$$#FO;K6VOM M;*/3;B,)J9@FN+N5H7>>WGCV()?,)0$,=HA3&U0#R:\<_:
MY\'77B'X*:GINE7@&OI;0ZCI4,68 9(Y76XW+$=TPE VI!@@DLP&#FHG\4O\
M3_-FT/@C_AC^2/#/"WQK_9TUG[3XAU'3=$N=5^Q7FG&74%L[W49=/F6074,P
MMMDJ3(^$@<*Q0-EI#@@_)G[;!T+XF?"'3=4\":/%>Z#HTQMM2AM=,DEN8Q=*
MD=GJ.78/%%;'-LCR%8V:42A"RBOCOX8?#WQ?H\LJR6MTT,6I7QFU Z?=22M
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M9L()&MH=.MKC%N\5NH9;BXE;9*\^W>0)2#A0*^GO@I:W6M_LO>+?B5\2=/\
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M10S7$R>*;EHH+?S!/-,OQNM3%'#Y7[P2O(%5-G.2 *TE_!I?]?JW_INB8?\
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MZI]AU6>:1!#%#+I\[0SO=2R+MV(K%V;;WH _/K]I?XX_!K]E?PQK7A#P=?\
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MO,%9?,2(+G)9M^X#CI7@>D^#;GPOJ<M[-XC75[^\C2."P,+:A'936\92V%U
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M/$E@]]KZ/XFUF^_L[4]'A22[U!=/N;LFYM];N[820:=N8?:+6"5_,:$("%&
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M)?$5GX,&BMK-G:ZK:ZGKFIF[EMT75=6MVU021R-%,^^./[-=7 W[L.(G?;C
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M(&QSQ]?HNW^#?[1#Z??P7_P?^*C2^6\:&S\,:A'->AB4)#O"4@3825#.G^T
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M;>-I/]ED..R@ 9'&!35"L]J<WMLN^WYH/:0_F1YO%;BXM$N&#H)/EPP!V/\
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MX3:!\0? GQ-O/$$]S)J%_'9?:8[*X>:YMC;1IYLD5Q)<?NX_)\V*WC,:.\2
MH7S(6;]PM/\ V"/VR+#3A_Q869M0B@N$AB/COX:,AEN[EF?,C>-_($(@2,2!
M;=6:14,9'S \IIW_  3J_;,N-4BO]8^ SVRVXCD@2T\=?##S$F!&]7*^,2CQ
M2*O[S<&,J.0PW1JRGL9]Z7_@^A_\L%[2/:?3_EW4Z[?8_KY'\VWQ0^+/QF\4
M_'?49!;3Z)9+J-GJ,]UI]JR(SF,LMNUPR Q1JX4A8S\IW8;[H'2:]\$?B/\
M$C7;+XO7BWTMKJ<36-Y(]\XGAP?LOE0:=B=Y8KD9G,@4*I&<\U^^/BG_ ()6
M?M6:I=7VLP?L_3W>H7TUV2C>/OA= UM&H#V;0F7Q:4QYQ8R;R[;'8L"P4#*T
M_P#X)M?MZ:=I-OI5I^S?:6L-L8BP'Q*^%ER))%<2_:(O-\6K&H#G][%Y2@<^
M4<<4>PGWI?\ @^C_ /+ ]I'M/YTJJ_.!^=7P=^ -KX0TC3M.U;4Y8='U.5I+
MO1VMFE%VC;HVC5V9T59%8ETFC$FX$IC  LWG[-7A;P;JC_\ "M[*73;'Q#>3
MW^HZA%LW(RH3=^09 [P[5^4IM5G4$[\KFON?XJ?\$O\ _@HSXJFTZ'PA\,;C
M0K:!X9+R;_A8/PP0-Y>)72"(^-'E@8S90.KX9?F 4<5U,W_!./\ X*-3Z5IN
MB2?!Y3;VUJ%U"]'Q"^&7FWTGEX:)XXO&5O(Y##B1IE4!CE'Z$]C/O2_\'T/_
M )8'M(]I]/\ EU5ZVM]CS1^7GQ?^"FMZQX:M)UU^[MS8WT4"2K++;B"T\^)[
M=XT"1K<S[1A9Y)8P%!;=AR3B:)X.\3I;2^'Y]85X8HYK8W%E=!M0D2X,$3SS
MBV1HYGBEW*6C)(@C;.YLD_KT?^";7[;FJZ-_9.L? >[A,+Z?)%-'\1/A9*+P
MVZB.YCOIO^$QD9P\0"0!8 L84^9O(!K,C_X)A?ME*UW##^SN^G126S0"6#XG
M?#20W0#[HRSGQ;]IBD=@KS!&5&3<F"SE@>QGWI?^#Z'_ ,L'[2/:I_X*J_\
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M@]\5_#=OJ:B6/38OA[XEO8;._ D,EY)<V%E(Y,X*1&&&!E11N+OC% '[;_\
M!*#0/#GA?]FS7M"\)V\]KH5A\6O&*6UO<DF6&9[/0GNXV)53\MR9,;ANYYR:
M_3BOA;_@GUX \7?#OX)ZQI7C+PUJWA;4]2^(/B'6XM.UJQN]-U":UN[/2(5O
MI;&_@MKVW6ZGMIV1;B")V"E]I#!C]TT %%%% !1110 4444 %%1R.5Z8Z#KG
MUQ4:RL<\+U'8]SCUH L45%O/M_G\:3S&^?@?* 1P?UYH FHKRCQEXVU;0?&/
MPZ\/V<&GR67BS6;_ $_4I+F&X>YA@M;![J-K)X[J***1I% =IH;A2F0J*WS5
MZO5.+2B_YDVODVM?FA)W<E_*[/[E+3Y-!1114C$P/0?E1@>@_*EHHN F!Z#\
MJ,#T'Y4M% "8'H/RHP/0?E2T4 )@>@_*C ]!^5+10 F!Z#\J,#T'Y4M%%P/G
M#XJ^+/CCHGB.:Q^'7@33==\/'2O#\XUZZF:6>VU.[O?$L6KV8TJ.:VDOHX[:
MTT*031W$'V+[6[2BX$JK'G0>,/C_ !^%Y[X^"=%N?$T7BB?P[!I=S'>6-E<:
M?IFEW4,GBF:YMKC4IXM(UW5X8-0T^**.XN++3;@6<PN+F-IF^H,>WZ?Y]3^=
M)@>@_*@#\Z_B'^T_^TK\+?#4?B'Q-\ -)OK:RT6YU?Q)>:#J'B:[T_1HWBTS
M[$Z2R>'U^T_9KF[NK?4K1WM]09[>(Z=;7:2N\.WX4^-'[3/Q3^&_BS7=)^&&
MA>$]1A_X0^_\$:A;W^OSCQ1I=[ -4UUH8==\)VHM#);QQ6EE,MMJ2HM\T5Y'
M9W]O+'%]\@ = !]!1@>@_*@#XUO/BG^T\E]J.AZ5\(/"UW?Z>V@H-3O[_P 5
MVFARI>B8ZE+'?CP[Y=\8$$$J+IWG^07>*_%M*!&+GBSXF_'W18_ASJ-I\/;>
M^N=6\.7UQXU\+:9H>OZM%I&LQ7!1;M?$D C$&EVEN!*VEC2+OQ#J9<#3;&4A
M]OU]@>@_*C ]!^5%P/BFU^+W[1FE6L[:W\)(]<MM8M+^X\-:AX=M/$"WEG>2
M,(=+TW7M%O\ 2H+S3EF=C<F[NDBCMK5?^)A]GF/EU@:'\;?VL=0U2PT ? G1
M$MY-*U!I/%NKWWBO1[:?4[7Y(0-)?PPSVT,,Q6*[^VWMD]YO%QH2:E:I+,GW
MK@>@_*C ]!^5 'Q!XA^+7[4-E!X+T[1/A+X<U.XU30=?OO%WB.9/&<%AH^L:
M1J-Y;VVFZ7H</A^>^NDN8;>"17OKVPDODN4N-$74XU:N^G^)OQ=G^-5UX,3X
M<36?POTBTT/4)/'L-MKES<:I+=F-+[35L9-'BLO(1;CSH[G3]1OKZW>RN(=1
ML+'? \OU#@>@_+UZTN/;]*+@?&?C7XH?%JS\4:II7@ZQNKQ[+4O$\-SIS_#C
MQ#X@L;+2M,TS2)=-O8_$6EWEI:+K$XO9M9LO#=]$LGB&"WGL+#4K2[-JEQY_
M_P +4_:I\P!O#(6V^U:A$UXOP@\322)I*Q;_  +KBV0\6B6:Y\?W?_$OU[0E
M<7OPPA/]I>)))8D,;?H9CV_2DP/0?E1<#XM'BC]J378;6]\)6/@VUTFW\/ZL
M+JZUW0KVZN=6UR+Q!JNEZ3<Z:EAKECF"?3+?3=8FA$!MWMY9?+OD+P@\MK_Q
M;_:T@AFN;3X266DV%M87VGW=U_95_P")=17Q9;W_ -IM'T[0=)U)+O4O"U[H
M\1M(-6$D$BZM>6[W-M!:P7#+]]X'H/RHP/0?E1<#XW\0>+/VEKOQ?K6C^%=*
MTJQT,>%-#U#2]4U+P1JMZNF>(K]K%)-+OYI?$6BV6L'][?W%_P#V3/)%HT-M
M$D\\]Q,T:>A>,?&7CS09/!]O907-[-J.D^+8-;DTCX>^*]<@76M-TV&31KOS
MK9XH]'MY[];E%LKUI%U)=D=GJ .R2;Z&P/0?E2X]OTH _.,?%S]K@^'UOY/!
MD<.K1Z7;WS:>OPI\4S+>6SR2>9>1RIXC,MIJ<CK':)X9GMOM]LTOVRYFCLU>
M5?9=5\5?M':;H/COQ!I_AW2?$*_V3HL_A'19]"ET36=$U"32$N]<6\M8-?UM
M_& MKV1;6"UTY-%N&D26./[0%5W^MZ3 ]!^5 'R%\.OB;\7/$'ASQY=^(/#^
MK:?K^F^'XY/#6B:K\,/%'AZ5O$0TJ[O'VW;ZAJ.EZ_I=Z8;::V6TO+"^M)KC
M^Q[V&+4DV5YUH?QP_:<L[:-M1^%HUZ*ZTO2KV?49/!_COP\=%DGL8?M]Q-HJ
MZ/JFH7UM'JI;3DTG3Y+WQ"AD&J26(T>"XNH_T#Q[?I28'H/RH ^)-#^,'[2]
MTVL:;J'P22VN[#P[::W9WMU/?+'<:U>:Q.L_AF=H;(:=+'::;+;B'4M)U#4)
MC]DNI;NR@,EOY^-XM^.W[5O@[2["YE_9_P##WB.^DUK5TOH] U;Q;-91>'=,
MF\J.ZBNAX6F,.J7R(UQ;PZE'8Z:T$T;-J*>3/L^],#T'Y48'H/RH ^ /@1^T
MY\;OC?%/J-O\(M&T?PO=>"?&FIZ;XE-SXK!3QEHVNZ_HVC>&[G3]2\.:?;2;
MH]/TR?5&BU83L]^QTN&\LHVNUZ32OB/^U+H5EX6T'5OAGHGB/6KRQU**[UK[
M5KH@DNM/FU"SCN]3N+'PS::9IHF>ULKYH&2WFN++5(!IUO<S6]XD/VW@'J!^
M5&!Z#\A0!\J)X[^/DG@*#4_$OA#1_"/B0>+M#LM1D\,Z-XB^(<-CX4U#2C=7
MFIP>'U_X1W6M1NK759+?1[A;7<MH))+]DDMH9FCXCPS\2OV@;G6-+B\0Z=>6
MGAN34/)U+6X/@SXH34(=16[*_P#",IH;^*'N3ILMBOVL^/!(^D13L]HMI<-&
MCR?<>/;]*3 ]!^5 'R=\5?'_ ,9-/\:C2_AGH]SJ^GCPTE\-)OOA]XCCBU'4
M9RQ46OQ DNXO#6FR6J*OVC3=3LA>,T@6(,JEA0T'XM_M ZN_BBRN?@[#H\VA
MVW@QM*GO'U<)K%]JK%/$]I(9-.MK7R-((+0WVE7>II(BR/)!#F!)/L&DP/0>
MG2@#\^_&_P"T?^TY\./"9\2^(_@)H6K?9%N;[5O^$<U;Q/<VVGZ-:V6JS3W#
MS3>'%V7=M/9V<DD-T+2&>UNR+2XENU2!]OX2_';X_?&+POXQU1/A?H/A>QD^
M'46N_#OQ-%>^)I$UWQ-?V$4MK;-I>M^&-+,=I'=O<PD0W%Y=V\^GR1WUI#'<
MVDD_W3@>@_*C ]!^7X?RXH#Y?U_21\2V'Q0_:EL$TCP]=?"?P_JNN36EQ%)K
M%S>^)$TR2*TO[_38->U74[/PQ%IEJ9196-Y?:/;I'JLL>NP76DZ=<6&GZA/;
M]#J/Q#_:1M=!\.:JWPNTBXUI-3UFQ\3^'-#GO+Z.[M;S1M&/A>_T?4M3?1FM
M8K+7];\G7Q>VKJUAHNM3VKH88!/]<X'H/RHP/0>G2@#\]8/C!^V#9G1=$G^#
M%IKVJ-:WNJ:UK-JM]H-@)K?Q#JEC;Z9:I>6^H:9%97&CVMMJ$;2:W)J^Z6"/
M[)Y-TMROKW@7XK_'?Q+XC^(%GK'P?LM \.>%;?7W\.:E=76NVE]XRN+-)DT:
MRLK6_P!'M8();NYMS]JG2:YL?LUU;2V5S<L)$7ZLP/0?E1@>@_*@#XI\+_&7
M]I&Z^'GCSQ;XH^#>D6/BG3=(T74?!G@73&\973ZI->7XLKR'4-4G\-6UR&2,
M/=&TM=).I6$6TWEH(668]2_Q*^)5M\,?".L^(M%U/PSXOU)KQO$5C;^%]0\0
MW6F7S:7<:AI>C6&DP"SDUZ2Z?9 (K*Y@GD>)H7DM;C>B_5N!Z#\J,#T'Y4 ?
M#%E\4OV@?)N+K4])GM[:V\-QZ@IM/@YXWN9;N1XK=[:_2U_M8:C'?7EX\NFW
M7A 6$FJ:4(SJ4UU-9J';9\%?%7XWZMXEUW3_ !7X/N="M8SKKZ/$GAF_"?8;
M;1'O=.FC6XNDO=;N3>+&DOV.&TM5:8Z>[B\7#?9V!Z#\J,#T'Y4 ?#=IXX_:
MMF\'Z?XHM_#%EJNIR^$]0FO/"8\#OH>J+KDNNM8:1?6[Z]X\L-JPZ45U>^\/
M7<=K</'"\46J12RQQBCX]^)_[4EEK&D+X.\):;-I=S\-FUO7H9_ ?BV^NO#?
MBB#0]2GEAFNHKZUL]9DDU\:5I4/AWP\^JZCL>YNA/+8@7B?>6!Z#\J,#T'Y4
M ?()^)/QMN?#GC=M.\,2Q>([#P5X1UK2(]=\#^)K"TT75=3\/ZE=Z];.MI)J
M*>.+NQU2#3D;0?#5U#J-F;M[29Y9(S,OBH^,G[9$=[HUI=_#J"&2[D\#W&J-
M#\/?$%[9V4&HZ7ISZ]HIOK77WC?5[S4)+^2UO%630_#<$(M?$=_:W 4S?I1@
M>@_+UZT8'H/RH @M9X[JWBN(TD595#!9[>6VE7V>"X2.:)O]F1%;':K&.V./
M3%%% "8'H/3I2X]NO7BBB@ _#VI,#K@9^E+10 8[XY]<4444 )@>@_*C ]!^
L5+10 F!Z#\J7\.G2BB@!,#T'Y4OX444 %'X444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430548212600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 09, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000832489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GeoVax Labs, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1900 Lake Park Drive, Suite 380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Smyrna<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">GA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0455038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">30080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-7220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,365,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,089,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WIPFLI LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Atlanta, Georgia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants to Purchase Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GOVXW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GOVX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430548104600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 11,423,870<span></span>
</td>
<td class="nump">$ 9,883,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grant funds and other receivables</a></td>
<td class="nump">49,006<span></span>
</td>
<td class="nump">182,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">156,240<span></span>
</td>
<td class="nump">168,689<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">11,629,116<span></span>
</td>
<td class="nump">10,235,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">156,938<span></span>
</td>
<td class="nump">147,741<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssets', window );">Deposits</a></td>
<td class="nump">11,010<span></span>
</td>
<td class="nump">11,010<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">11,797,064<span></span>
</td>
<td class="nump">10,393,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,057,534<span></span>
</td>
<td class="nump">267,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,377,826<span></span>
</td>
<td class="nump">359,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">183,326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">5,435,360<span></span>
</td>
<td class="nump">810,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_AccruedExpensesNoncurrent', window );">Accrued expenses &#8211; noncurrent</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note payable, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,738<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,435,360<span></span>
</td>
<td class="nump">825,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments (Note 6)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $.01 par value: Authorized shares &#8211; 10,000,000 Series B convertible preferred stock, $1,000 stated value; -0- and 100 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">76,095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value: Authorized shares &#8211; 600,000,000 Issued and outstanding shares &#8211; 6,381,541 and 3,834,095 at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">6,382<span></span>
</td>
<td class="nump">3,834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">68,731,220<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(64,375,898)<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">4,361,704<span></span>
</td>
<td class="nump">9,568,852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 11,797,064<span></span>
</td>
<td class="nump">$ 10,393,899<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_AccruedExpensesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents noncurrent accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_AccruedExpensesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430548165080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized (in shares)</a></td>
<td class="nump">600,000,000<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued (in shares)</a></td>
<td class="nump">6,381,541<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding (in shares)</a></td>
<td class="nump">6,381,541<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430550959240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Grant and collaboration revenue</a></td>
<td class="nump">$ 385,501<span></span>
</td>
<td class="nump">$ 1,823,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">15,554,171<span></span>
</td>
<td class="nump">2,444,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,577,153<span></span>
</td>
<td class="nump">2,196,014<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">19,131,324<span></span>
</td>
<td class="nump">4,640,473<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,745,823)<span></span>
</td>
<td class="num">(2,816,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">4,736<span></span>
</td>
<td class="nump">2,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,286)<span></span>
</td>
<td class="num">(143,524)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="nump">172,056<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">175,506<span></span>
</td>
<td class="num">(141,253)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,570,317)<span></span>
</td>
<td class="num">$ (2,958,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share (in dollars per share)</a></td>
<td class="num">$ (3.04)<span></span>
</td>
<td class="num">$ (2.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares outstanding (in shares)</a></td>
<td class="nump">6,099,933<span></span>
</td>
<td class="nump">1,383,829<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430546362808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Deficiency) - USD ($)<br></strong></div></th>
<th class="th">
<div>Warrant Issued for Technology License[Member] </div>
<div>Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Warrant Issued for Technology License[Member] </div>
<div>Common Stock [Member]</div>
</th>
<th class="th">
<div>Warrant Issued for Technology License[Member] </div>
<div>Additional Paid-in Capital [Member]</div>
</th>
<th class="th">
<div>Warrant Issued for Technology License[Member] </div>
<div>Retained Earnings [Member]</div>
</th>
<th class="th"><div>Warrant Issued for Technology License[Member]</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,486<span></span>
</td>
<td class="nump">14,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,932,433<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 39,340,509<span></span>
</td>
<td class="num">$ (42,847,513)<span></span>
</td>
<td class="num">$ (1,574,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of convertible preferred stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of convertible preferred stock for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,686)<span></span>
</td>
<td class="nump">716,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,156,338)<span></span>
</td>
<td class="nump">$ 717<span></span>
</td>
<td class="nump">2,155,621<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in bridge financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">457,833<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">457,833<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">286,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock upon warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">2,213<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesDebentureConversion', window );">Issuance of common stock upon debenture conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">177,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueDebentureConversion', window );">Issuance of common stock upon debenture conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">569,340<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 569,517<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation', window );">Common stock issued for cancellation of accrued compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation', window );">Issuance of common stock upon cancellation of accrued compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">1,499,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
<td class="nump">11,156,186<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 11,158,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">94,373<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 94,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Roundup of shares following reverse stock split (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueReverseStockSplits', window );">Roundup of shares following reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,958,068)<span></span>
</td>
<td class="num">(2,958,068)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">3,834,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,095<span></span>
</td>
<td class="nump">$ 3,834<span></span>
</td>
<td class="nump">55,294,504<span></span>
</td>
<td class="num">(45,805,581)<span></span>
</td>
<td class="nump">9,568,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in bridge financing</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 209,825<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 209,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">889,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodValueWarrantExercise', window );">Issuance of common stock upon warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 890<span></span>
</td>
<td class="nump">3,403,266<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,404,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Sale of common stock for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of common stock for cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,644<span></span>
</td>
<td class="nump">9,407,276<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 9,408,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,707<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">71,827<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 71,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock option expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">269,427<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">269,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(18,570,317)<span></span>
</td>
<td class="num">(18,570,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76,095)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">75,095<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,381,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,382<span></span>
</td>
<td class="nump">$ 68,731,220<span></span>
</td>
<td class="num">$ (64,375,898)<span></span>
</td>
<td class="nump">$ 4,361,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period for the cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesDebentureConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of debenture conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesDebentureConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueDebentureConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon Debenture Conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueDebentureConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in value of shares as a result of reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodValueWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodValueWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430548028072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,570,317)<span></span>
</td>
<td class="num">$ (2,958,068)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">38,521<span></span>
</td>
<td class="nump">19,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">124,185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">369,987<span></span>
</td>
<td class="nump">64,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Warrant issued for technology license fee</a></td>
<td class="nump">209,825<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="num">(172,056)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Grant funds and other receivables</a></td>
<td class="nump">133,657<span></span>
</td>
<td class="num">(114,060)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(16,270)<span></span>
</td>
<td class="num">(24,702)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">6,810,233<span></span>
</td>
<td class="nump">137,956<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total adjustments</a></td>
<td class="nump">7,373,897<span></span>
</td>
<td class="nump">207,498<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,196,420)<span></span>
</td>
<td class="num">(2,750,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(47,718)<span></span>
</td>
<td class="num">(156,791)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(47,718)<span></span>
</td>
<td class="num">(156,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Net proceeds from sale of common stock and warrants</a></td>
<td class="nump">9,408,920<span></span>
</td>
<td class="nump">11,158,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from warrant exercises</a></td>
<td class="nump">3,404,156<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Net proceeds from sale of preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Net proceeds from issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">170,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Net proceeds from bridge financing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">888,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock', window );">Repurchase of preferred stock</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal repayment of note payable</a></td>
<td class="num">(27,864)<span></span>
</td>
<td class="num">(11,880)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">12,784,212<span></span>
</td>
<td class="nump">12,507,816<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">1,540,074<span></span>
</td>
<td class="nump">9,600,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">9,883,796<span></span>
</td>
<td class="nump">283,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 11,423,870<span></span>
</td>
<td class="nump">$ 9,883,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430550961512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation', window );">Common stock issued for cancellation of accrued compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredCompensationLiabilityConversionToEquityAmount', window );">Deferred compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember', window );">Paycheck Protection Program CARES Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ExtinguishmentOfDebtIncludingInterestAmount', window );">Extinguishment of debt</a></td>
<td class="nump">$ 172,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember', window );">Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Convertible debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DebtConversionAccruedInterestAmount', window );">Related accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsFirstIssuanceMember', window );">Stock Purchase Warrants First Issuance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Common stock issued (in shares)</a></td>
<td class="nump">149,705<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember', window );">Unit Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_WarrantsIssued', window );">Warrant issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember', window );">Unit Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Pre-funded stock purchase warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Pre-funded stock purchase warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,042<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DebtConversionAccruedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the debt accrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DebtConversionAccruedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredCompensationLiabilityConversionToEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred compensation liability being converted into equity in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredCompensationLiabilityConversionToEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ExtinguishmentOfDebtIncludingInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount extinguishment of debt including interest amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ExtinguishmentOfDebtIncludingInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period for the cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_WarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_WarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsFirstIssuanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsFirstIssuanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556221368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Description of Business and Recent Developments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">1.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"><b>Description of Business and Recent Developments</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax Labs, Inc. (&#8220;GeoVax&#8221; or the &#8220;Company&#8221;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax&#8217;s product pipeline includes ongoing human clinical trials in COVID-<em style="font: inherit;">19</em> and head and neck cancer. Additional research and development programs include preventive vaccines against&#160;Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for solid tumors. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GEO-<em style="font: inherit;">CM04S1</em> License</i> -- In <em style="font: inherit;"> November 2021, </em>GeoVax entered into a license agreement with City of Hope (the &#8220;COH License&#8221;), granting GeoVax exclusive rights to further develop and commercialize GEO-<em style="font: inherit;">CM04S1</em> (formerly referred to as <em style="font: inherit;">COH04S1</em>). GEO-<em style="font: inherit;">CM04S1,</em> a synthetic, attenuated modified vaccinia Ankara (sMVA) vector expressing Spike and Nucleocapsid antigens of the SARS-CoV-<em style="font: inherit;">2</em> virus, was initially developed at COH for immunocompromised patients.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GEO-<em style="font: inherit;">CM04S1</em> is being studied in an ongoing Phase <em style="font: inherit;">2</em> clinical trial to evaluate its safety and immunogenicity, compared to the Pfizer mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy. GEO-<em style="font: inherit;">CM04S1</em> is the only COVID-<em style="font: inherit;">19</em> vaccine that includes both SARS-CoV-<em style="font: inherit;">2</em> spike and nucleocapsid proteins to advance to a Phase <em style="font: inherit;">2</em> trial in cancer patients. Such vaccines also tend to produce an immune response quickly &#8211; in less than <em style="font: inherit;">14</em> days &#8211; with only mild side effects. The trial is also the <em style="font: inherit;">first</em> to compare an investigational multi-antigenic COVID-<em style="font: inherit;">19</em> vaccine to the current Food and Drug Administration (FDA)-approved mRNA vaccine from Pfizer/BioNTech in people who are immunocompromised. Such patients have often shown a weak antibody response after receiving currently available COVID-<em style="font: inherit;">19</em> vaccines.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> December 2021, </em>patient enrollment began for the Phase <em style="font: inherit;">2</em> portion of a Phase <em style="font: inherit;">1/2</em> trial of GEO-<em style="font: inherit;">CM04S1,</em> to study its use as a universal booster vaccine to current FDA-approved vaccines. GeoVax believes that the GEO-<em style="font: inherit;">CM04S1</em> vaccine, when administered as a heterologous booster, will provide additional recognition elements to the immune system over a homologous boost from mRNA vaccines such as those developed by Moderna or Pfizer, which are directed only toward SARS-CoV-<em style="font: inherit;">2</em> Spike protein. The <em style="font: inherit;">COH04S1</em> vaccine&#8217;s MVA backbone <em style="font: inherit;"> may </em>be more effective at inducing COVID-<em style="font: inherit;">19</em> immunity since MVA strongly induces T cell responses even in a background of immunosuppression. In addition, GEO-<em style="font: inherit;">CM04S1</em> targeting of both Spike and Nucleocapsid antigens, <em style="font: inherit;"> may </em>offer greater protection against the significant sequence variation observed with the Spike antigen.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Gedeptin</i>&#174;<i> License</i> -- In <em style="font: inherit;"> September 2021, </em>GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc. (the &#8220;PNP License), whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#174;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase <em style="font: inherit;">1/2</em> clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and <em style="font: inherit;">no</em> curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#8217;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but <em style="font: inherit;">not</em> limited to, cancers.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556329656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">2.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Summary of Significant Accounting Policies</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Principles of Consolidation</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Basis of Presentation</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January 21, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-2000 reverse split of our common stock and on <em style="font: inherit;"> September 25, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-20 reverse split of our common stock. Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the <em style="font: inherit;">twelve</em>-month period following the issue date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We <em style="font: inherit;"> may </em>never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We believe that our existing cash will be sufficient to continue our planned operations into the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2023.</em> We intend to fund future operations through additional private and/or public offerings of debt or equity securities.&#160; In addition, we <em style="font: inherit;"> may </em>seek additional capital through arrangements with strategic partners or from other sources. There can be <em style="font: inherit;">no</em> assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;</p><p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash and Cash Equivalents</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consider all highly liquid investments with a maturity of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fair Value of Financial Instruments and Concentration of Credit Risk</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Property and Equipment</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:c81558630">three</span> to <span style="-sec-ix-hidden:c81558633">five</span> years. We amortize leasehold improvements using the straight-line method over the term of the related lease.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases</i> (ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em>), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or <em style="font: inherit;">not</em> the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than <em style="font: inherit;">12</em> months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than <em style="font: inherit;">12</em> months, we made an accounting policy election to <em style="font: inherit;">not</em> recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Impairment of Long-Lived Assets</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be<b> </b>recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Accrued Expenses</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have <em style="font: inherit;">not</em> yet been billed by our <em style="font: inherit;">third</em>-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Net Loss Per Share</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, calculated using the treasury stock method, totaled 213,831 and 1,001,948 shares at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenue Recognition</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize revenue in accordance with FASB Accounting Standards Update <em style="font: inherit;">2014</em>-<em style="font: inherit;">09,</em> <i>Revenue from Contracts with Customers</i> (ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em>), which created a new Topic, Accounting Standards Codification Topic <em style="font: inherit;">606.</em> The standard is principle-based and provides a <em style="font: inherit;">five</em>-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grant revenue</i> &#8211; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research collaborations</i> &#8211; From time to time, we <em style="font: inherit;"> may </em>enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive <em style="font: inherit;">third</em>-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em> and revenue is recognized accordingly.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expense</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development (R&amp;D) expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to <em style="font: inherit;">third</em>-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred. During <em style="font: inherit;">2021,</em> we also recorded $10,513,825 of R&amp;D expense for upfront license fees and warrant expense associated with the COH License and the PNP License.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Patent Costs</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b> </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Period-to-Period Comparisons</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results for future periods.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Income Taxes</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will be realized.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#8217;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note <em style="font: inherit;">7</em> for additional stock-based compensation information.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Recent Accounting Pronouncements</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Except as discussed above, there have been <em style="font: inherit;">no</em> recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standards if currently adopted would have a material effect on our financial statements.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556310120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">3.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Property and Equipment</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and furnishings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">591,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">543,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">707,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">659,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(550,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(511,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">156,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">147,741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation expense was $38,521 and $19,656 during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556274824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">4.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Accrued Expenses</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020:</em></p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 18pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Accrued license fees&#160;&#8211; current</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Accrued license fees&#160;&#8211; noncurrent</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">269,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">279,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">108,826</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">79,585</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,377,826</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">359,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556288888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">5.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Debt</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>GRA Note</i> &#8211; On <em style="font: inherit;"> February 28, 2018, </em>we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a <em style="font: inherit;"><span style="-sec-ix-hidden:c81558703">five</span></em>-year Senior Promissory Note (the &#8220;GRA Note&#8221;) to GRA in exchange for $50,000. The GRA Note bore an annual interest rate of 5%. During <em style="font: inherit;"> May 2021, </em>we repaid the remaining principal balance of $22,737 and retired the GRA Note.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>CARES Act Paycheck Protection Program Loan </i>&#8211;<i> </i>On <em style="font: inherit;"> April 17, 2020, </em>we received a $170,200 bank loan backed by the United States Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bore an annual interest rate of <em style="font: inherit;">one</em> percent. During <em style="font: inherit;"> May 2021, </em>upon receiving payment from the SBA, the lender forgave the full principal balance of $170,200 together with $1,856 of accrued interest, and we recorded a $172,056 gain on debt extinguishment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Convertible Debentures</i> &#8211; On <em style="font: inherit;"> June 26 2020, </em>we issued convertible debentures in the aggregate principal amount of $1,200,000 and warrants to purchase an aggregate of 120,000 shares of our common stock for gross proceeds of $1,050,000. As discussed in Note <em style="font: inherit;">7,</em> in <em style="font: inherit;"> September 2020, </em>the convertible debentures and accrued interest were fully converted into our equity securities and were retired.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest expense recorded for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2019</em> was as follows:</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">GRA Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">633</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,727</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">PPP Loan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">653</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,203</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Insurance premium financing costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Convertible debentures (including $124,185 of debt discount amortization)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">138,851</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,286</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">143,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556289448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">6.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Commitments</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Operating Lease</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on <em style="font: inherit;"> December 31, 2022. </em>Rent expense for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was $166,242 and $166,577, respectively. Future minimum lease payments total $176,356 in <em style="font: inherit;">2022,</em> although the lease <em style="font: inherit;"> may </em>be terminated at any time by either party with <em style="font: inherit;">ninety</em> days written notice.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>License Agreements</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have entered into license agreements with City of Hope, PNP Therapeutics, Inc., University of Alabama at Birmingham, Southern Research Institute, Emory University, and with the U.S. Department of Health and Human Services (HHS), as represented by National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), for various technologies and patent rights associated with our product development activities. These agreements <em style="font: inherit;"> may </em>contain provisions for upfront payments, milestone fees due upon the achievement of selected development and regulatory events, minimum annual royalties or other fees, and royalties based on future net sales. Aggregate unrecorded future minimum payments under these agreements (excluding milestone and royalty payments due upon contingent future events, and assuming neither party terminates the agreements) are approximately $174,000 in <em style="font: inherit;">2022,</em> $128,000 in <em style="font: inherit;">2023,</em> $128,000 in <em style="font: inherit;">2024,</em> $28,000 in <em style="font: inherit;">2025</em> and $28,000 in <em style="font: inherit;">2026.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Commitments</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of <em style="font: inherit;"> December 31, 2021, </em>there were approximately $407,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, which we expect will be due in <em style="font: inherit;">2022.</em></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430553057720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">7.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Stockholders</b>&#8217;<b> Equity</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Preferred Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2021, </em>we repurchased the remaining 100 shares of our Series B convertible preferred stock for a total price of $1,000. As of <em style="font: inherit;"> December 31, 2021, </em>there are no shares of our preferred stock outstanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Common Stock</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Public Offering </i>&#8211;<i> </i>On <em style="font: inherit;"> September 29, 2020, </em>we closed an underwritten public offering (the <em style="font: inherit;">&#8220;2020</em> Offering&#8221;) of an aggregate of 2,560,000 units of our equity securities (the &#8220;Units&#8221;) with gross proceeds to us of approximately $12.8 million. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $11.2 million. Each Unit sold in the offering consisted of one share of our common stock (or a pre-funded warrant to purchase one share of common stock, all of which were fully exercised during <em style="font: inherit;">2020</em>), and a warrant to purchase one share of common stock (&#8220;Unit Warrant&#8221;), exercisable at an exercise price of $5.00 per share and with a <span style="-sec-ix-hidden:c81558762">five</span>-year expiration date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From <em style="font: inherit;">2016</em> through <em style="font: inherit;"> August 2020, </em>to help conserve the Company&#8217;s cash resources, our executive officers and non-employee directors agreed to defer receipt of all or a portion of their respective cash compensation. Upon consummation of the <em style="font: inherit;">2020</em> Offering, $1,500,000 of accumulated deferrals were converted at the $5.00 offering price, resulting in the issuance of 300,001 units substantially similar to the units sold in the public offering, with each unit consisting of one share of our common stock and one warrant substantially similar to a Unit Warrant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon consummation of the <em style="font: inherit;">2020</em> Offering, we issued an aggregate of 177,626 shares of our common stock, 126,042 pre-funded warrants to purchase common stock, and 303,668 warrants substantially similar to a Unit Warrant upon the mandatory conversion of $1,214,667 of convertible debentures and accrued interest.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Public Offering </i>&#8211;<i> </i>On <em style="font: inherit;"> February 11, 2021, </em>we closed an underwritten public offering of 1,644,000 shares of our common stock, with gross proceeds to us of approximately $10.3 million. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $9.4 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Warrant exercises</i> &#8211; During <em style="font: inherit;">2021,</em> 740,034 Unit Warrants were exercised for cash, resulting in gross proceeds to us of approximately $3.7 million; net proceeds after deducting commissions owed to the underwriter of the <em style="font: inherit;">2020</em> Offering were approximately $3.4 million. During <em style="font: inherit;">2021,</em> an aggregate of 215,672 warrants were exercised using the cashless exercise feature of the warrants, resulting in the issuance of an aggregate of 149,705 shares of our common stock. During <em style="font: inherit;">2020,</em> 54,557 warrants were exercised using the cashless exercise feature of the warrants, resulting in the issuance of an aggregate of 36,902 shares of our common stock</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Common Stock Transactions</i> &#8211; During <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> we issued 13,707 and 26,581 shares, respectively, of our common stock pursuant to consulting agreements. During <em style="font: inherit;">2020</em> we issued an aggregate of 716,790 shares of our common stock, pursuant to the conversion of Series H and Series I convertible preferred stock.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Option Plan</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have a stock-based incentive plan (the <em style="font: inherit;">&#8220;2020</em> Plan&#8221;) pursuant to which our Board of Directors <em style="font: inherit;"> may </em>grant stock options to our employees. A total of 1,500,000 shares of our common stock are reserved for issuance pursuant to the <em style="font: inherit;">2020</em> Plan. The exercise price for any option granted <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be less than fair value (110% of fair value for ISO&#8217;s granted to certain employees). Options have a maximum <span style="-sec-ix-hidden:c81558801">ten</span>-year term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows:</p>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average risk-free interest rates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">84.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">38.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">A summary of stock option activity under the <em style="font: inherit;">2020</em> Plan as of <em style="font: inherit;"> December 31, 2021, </em>and changes during the year then ended is presented below.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Term (yrs)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">602,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">360,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">962,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">499,660</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">200,661</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">166,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted-average grant date fair values of options granted during <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> were $2.87 and $1.12, respectively. Total stock option compensation expense recognized in the consolidated statement of operations for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was $269,427 and $18,730, respectively. As of <em style="font: inherit;"> December 31, 2021, </em>there is $1,420,144 of unrecognized compensation expense that will be recognized over a weighted-average period of 2.2 years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock Purchase Warrants</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Summary of Warrants Outstanding </i>&#8211; The table below presents summary information about our warrants outstanding as of <em style="font: inherit;"> December 31, 2021. </em>Additional information concerning the warrants follows the table.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant Description</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expiration</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2020 Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">120,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Jun 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2020 Unit Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,396,631</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2020 Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">128,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Mar 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021 Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">72,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">6.875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Aug 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021 Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">13.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2026</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Warrants Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,816,631</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Exercise Price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Remaining Life (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Warrants</i> &#8211; In <em style="font: inherit;"> June 2020, </em>in connection with the issuance of convertible debentures, we issued warrants to purchase 120,000 shares of common stock, with a <span style="-sec-ix-hidden:c81558815">five</span>-year term and an exercise price of $10.00. As a result of the <em style="font: inherit;">2020</em> Public Offering, in <em style="font: inherit;"> September 2020 </em>the exercise price was reduced to $5.00.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Unit Warrants</i> &#8211; In <em style="font: inherit;"> September 2020, </em>in connection with the <em style="font: inherit;">2020</em> Public Offering, we issued 303,668 warrants upon the conversion of convertible debentures, 300,001 warrants upon the conversion of amounts owed to current and former executive officers and directors, and 2,560,000 warrants to other investors in the <em style="font: inherit;">2020</em> Public Offering, with each of the warrants having a <span style="-sec-ix-hidden:c81558825">five</span>-year term and an exercise price of $5.00. During <em style="font: inherit;">2021,</em> 740,034 of these warrants were exercised for cash and 27,004 were exercised using the cashless exercise feature of the warrant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Representative Warrants</i> &#8211; In <em style="font: inherit;"> September 2020, </em>we issued 128,000 warrants to the underwriter of the <em style="font: inherit;">2020</em> Public Offering, with a 42-month term and an exercise price of $5.50.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Representative Warrants</i> &#8211; In <em style="font: inherit;"> February 2021, </em>we issued 72,000 warrants to the underwriter of the <em style="font: inherit;">2021</em> Public Offering, with a 42-month term and an exercise price of $6.875.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Warrants</i> &#8211; In <em style="font: inherit;"> September 2021, </em>in connection with a technology licensing agreement, we issued 100,000 warrants, with a <span style="-sec-ix-hidden:c81558842">five</span>-year term and an exercise price of $13.00.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Additional Stock-Based Compensation Expense</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to stock-based compensation expense related to the <em style="font: inherit;">2020</em> Plan (see <i>Stock Options</i> above), during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> we recognized $100,560 and $45,733, respectively, of expense related to the issuance of our common stock pursuant to consulting and investment banking agreements. As of <em style="font: inherit;"> December 31, 2021, </em>there is $19,947 recorded as a prepaid expense for these arrangements, which will be recognized as expense during <em style="font: inherit;">2022</em> over the term of the related agreement.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556305368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">8.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Retirement Plan</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We participate in a multi-employer defined contribution retirement plan (the <em style="font: inherit;">&#8220;401k</em> Plan&#8221;) administered by a <em style="font: inherit;">third</em>-party service provider, and the Company contributes to the <em style="font: inherit;">401k</em> Plan on behalf of its employees based upon a matching formula. During the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> our contributions to the <em style="font: inherit;">401k</em> Plan were $36,980 and $27,511, respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556349144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">9.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Income Taxes</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At <em style="font: inherit;"> December 31, 2021, </em>we have a consolidated federal net operating loss (&#8220;NOL&#8221;) carryforward of approximately $75.2 million available to offset against future taxable income of which approximately $48.9 million expires in varying amounts in <em style="font: inherit;">2022</em> through <em style="font: inherit;">2037.</em> Additionally, we have approximately $1.6 million in research and development (&#8220;R&amp;D&#8221;) tax credits that expire in <em style="font: inherit;">2022</em> through <em style="font: inherit;">2041</em> unless utilized earlier. <span style="-sec-ix-hidden:c81558934">No</span> income taxes have been paid to date. Section <em style="font: inherit;">382</em> of the Internal Revenue Code contains provisions that <em style="font: inherit;"> may </em>limit our utilization of our NOL and R&amp;D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or <em style="font: inherit;"> may </em>occur in future periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62.2%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">18,449,694</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">14,737,240</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research and development tax credit carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,566,293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,189,110</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">129,475</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,870</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued salaries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">69,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">72,721</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">20,215,402</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">16,003,941</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">30,945</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">28,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">20,184,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(20,184,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(15,975,667</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset after reduction for valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. federal statutory rate applied to pretax loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(3,899,767</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(621,194</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(377,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance, net of expired items and other adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">4,276,950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">687,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reported income tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556255144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Grants and Collaboration Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_GovernmentGrantsandContractsTextBlock', window );">Government Grants and Contracts [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">10.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Grants and Collaboration Revenue</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> we recorded $385,501 and $1,438,465, respectively, of revenue associated with these grants. As of <em style="font: inherit;"> December 31, 2021, </em>there is an aggregate of $81,526 in remaining grant funds available for use during <em style="font: inherit;">2022.</em> During <em style="font: inherit;">2020,</em> we recorded $385,193 of revenues associated with a research collaboration agreement.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_GovernmentGrantsandContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_GovernmentGrantsandContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556422136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 45pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><em style="font: inherit;">11.</em></b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>Subsequent Events</b></p> </td></tr>
</tbody></table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January 19, 2022, </em>we closed a private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock, and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. The warrants are exercisable immediately at an exercise price of $3.26 per share and will expire <span style="-sec-ix-hidden:c81558984">five</span> years from the date of issuance. Net proceeds after deducting placement agent commissions and other offering expenses were approximately $9.2 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556237480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>GEOVAX LABS, INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SCHEDULE II </b>&#8211;<b> VALUATION AND QUALIFYING ACCOUNTS</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the Years Ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Additions (Reductions)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Description</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Costs and</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expenses</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Other</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accounts</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deductions</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for Deferred Tax Assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,208,790</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">20,184,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,811,563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430548084968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Principles of Consolidation</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Basis of Presentation</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January 21, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-2000 reverse split of our common stock and on <em style="font: inherit;"> September 25, 2020, </em>we effected a <em style="font: inherit;">1</em>-for-20 reverse split of our common stock. Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the <em style="font: inherit;">twelve</em>-month period following the issue date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We <em style="font: inherit;"> may </em>never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We believe that our existing cash will be sufficient to continue our planned operations into the <em style="font: inherit;">second</em> quarter of <em style="font: inherit;">2023.</em> We intend to fund future operations through additional private and/or public offerings of debt or equity securities.&#160; In addition, we <em style="font: inherit;"> may </em>seek additional capital through arrangements with strategic partners or from other sources. There can be <em style="font: inherit;">no</em> assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results <em style="font: inherit;"> may </em>differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash and Cash Equivalents</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consider all highly liquid investments with a maturity of <em style="font: inherit;">three</em> months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Fair Value of Financial Instruments and Concentration of Credit Risk</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Property and Equipment</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from <span style="-sec-ix-hidden:c81558630">three</span> to <span style="-sec-ix-hidden:c81558633">five</span> years. We amortize leasehold improvements using the straight-line method over the term of the related lease.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases</i> (ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">02</em>), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or <em style="font: inherit;">not</em> the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than <em style="font: inherit;">12</em> months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than <em style="font: inherit;">12</em> months, we made an accounting policy election to <em style="font: inherit;">not</em> recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Impairment of Long-Lived Assets</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be<b> </b>recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_AccruedLiabilitiesPolicyTextBlock', window );">Accrued Liabilities [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Accrued Expenses</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have <em style="font: inherit;">not</em> yet been billed by our <em style="font: inherit;">third</em>-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Net Loss Per Share</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, calculated using the treasury stock method, totaled 213,831 and 1,001,948 shares at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue from Contract with Customer [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenue Recognition</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize revenue in accordance with FASB Accounting Standards Update <em style="font: inherit;">2014</em>-<em style="font: inherit;">09,</em> <i>Revenue from Contracts with Customers</i> (ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em>), which created a new Topic, Accounting Standards Codification Topic <em style="font: inherit;">606.</em> The standard is principle-based and provides a <em style="font: inherit;">five</em>-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Grant revenue</i> &#8211; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research collaborations</i> &#8211; From time to time, we <em style="font: inherit;"> may </em>enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive <em style="font: inherit;">third</em>-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU <em style="font: inherit;">2014</em>-<em style="font: inherit;">09</em> and revenue is recognized accordingly.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expense</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development (R&amp;D) expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to <em style="font: inherit;">third</em>-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred. During <em style="font: inherit;">2021,</em> we also recorded $10,513,825 of R&amp;D expense for upfront license fees and warrant expense associated with the COH License and the PNP License.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Patent Costs</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Comparability Adjustment [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Period-to-Period Comparisons</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should <em style="font: inherit;">not</em> be relied upon as predictive of the results for future periods.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Income Taxes</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than <em style="font: inherit;">not</em> that some portion or all of the deferred tax assets will be realized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Stock-Based Compensation</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#8217;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note <em style="font: inherit;">7</em> for additional stock-based compensation information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Recent Accounting Pronouncements</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Except as discussed above, there have been <em style="font: inherit;">no</em> recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but <em style="font: inherit;">not</em> yet effective, accounting standards if currently adopted would have a material effect on our financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_AccruedLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_AccruedLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556340888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment and furnishings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">591,554</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">543,836</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">115,605</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">707,159</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">659,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(550,221</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(511,700</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">156,938</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">147,741</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430552957096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 18pt; margin-right: auto;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Accrued license fees&#160;&#8211; current</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">3,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;">Accrued license fees&#160;&#8211; noncurrent</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">2,000,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">269,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;">279,696</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">108,826</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">79,585</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">5,377,826</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">359,281</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556428424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_InterestExpenseDisclosureTableTextBlock', window );">Interest Expense Disclosure [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 68%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">GRA Note</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">633</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,727</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">PPP Loan</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">653</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,203</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Insurance premium financing costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,743</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Convertible debentures (including $124,185 of debt discount amortization)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">138,851</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">1,286</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">143,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_InterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense, including, but not limited to, interest expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_InterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430552424456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average risk-free interest rates</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.69</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of option (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">7.0</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">84.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">38.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Average</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Remaining</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Contractual</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Term (yrs)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Aggregate</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Intrinsic</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Value</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">602,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">360,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited or expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">962,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">3.18</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">9.31</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">499,660</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">200,661</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">8.93</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">166,549</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 55.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Warrant Description</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">of Shares</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Exercise</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Price</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expiration</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2020 Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">120,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Jun 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2020 Unit Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,396,631</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2020 Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">128,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5.50</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Mar 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021 Representative Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">72,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">6.875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Aug 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021 Warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">100,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">13.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><em style="font: inherit;">Sep 2026</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total Warrants Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">2,816,631</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Exercise Price</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5.35</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-Average Remaining Life (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556241528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62.2%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">18,449,694</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">14,737,240</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research and development tax credit carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,566,293</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,189,110</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Stock-based compensation expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">129,475</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,870</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued salaries</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">69,940</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">72,721</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">20,215,402</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">16,003,941</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax liabilities</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Depreciation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">30,945</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">28,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">20,184,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(20,184,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(15,975,667</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td colspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax asset after reduction for valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2021</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">2020</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. federal statutory rate applied to pretax loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(3,899,767</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(621,194</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(377,183</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(66,574</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance, net of expired items and other adjustments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">4,276,950</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">687,703</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reported income tax expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556359672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfValuationAllowanceTextBlock', window );">Summary of Valuation Allowance [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Additions (Reductions)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 40%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Description</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Beginning</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Costs and</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Expenses</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Charged to</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Other</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Accounts</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Deductions</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Balance at</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">End</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Of Period</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Allowance for Deferred Tax Assets</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">4,208,790</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">20,184,457</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Year ended December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">18,787,230</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(2,811,563</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">-0-</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">15,975,667</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfValuationAllowanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfValuationAllowanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430551081000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Summary of Significant Accounting Policies (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 25, 2020</div></th>
<th class="th"><div>Jan. 21, 2020</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,831<span></span>
</td>
<td class="nump">1,001,948<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,554,171<span></span>
</td>
<td class="nump">$ 2,444,459<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=govx_UpfrontFeesCOHAndPNPLicenseMember', window );">Upfront Fees for COH and PNP License[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,513,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=govx_UpfrontFeesCOHAndPNPLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=govx_UpfrontFeesCOHAndPNPLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=govx_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556321880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation, Depletion and Amortization, Nonproduction, Total</a></td>
<td class="nump">$ 38,521<span></span>
</td>
<td class="nump">$ 19,656<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430548035144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 707,159<span></span>
</td>
<td class="nump">$ 659,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="num">(550,221)<span></span>
</td>
<td class="num">(511,700)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">156,938<span></span>
</td>
<td class="nump">147,741<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_EquipmentAndFurnishingsMember', window );">Equipment and Furnishings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">591,554<span></span>
</td>
<td class="nump">543,836<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 115,605<span></span>
</td>
<td class="nump">$ 115,605<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_EquipmentAndFurnishingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=govx_EquipmentAndFurnishingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430548037912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_AccruedLicenseFeesCurrent', window );">Accrued license fees &#8211; current</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_AccruedLicenseFeesNoncurrent', window );">Accrued license fees &#8211; noncurrent</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Accrued payroll</a></td>
<td class="nump">269,000<span></span>
</td>
<td class="nump">279,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Other accrued expenses</a></td>
<td class="nump">108,826<span></span>
</td>
<td class="nump">79,585<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 5,377,826<span></span>
</td>
<td class="nump">$ 359,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_AccruedLicenseFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents current accrued license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_AccruedLicenseFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_AccruedLicenseFeesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents long-term accrued license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_AccruedLicenseFeesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430548233624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Debt (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Jun. 26, 2020</div></th>
<th class="th"><div>Apr. 17, 2020</div></th>
<th class="th"><div>Feb. 28, 2018</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 170,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,864<span></span>
</td>
<td class="nump">11,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172,056<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=govx_ConvertibleDebenturesMember', window );">Convertible Debentures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromConvertibleDebtGross', window );">Proceeds from Convertible Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember', window );">Paycheck Protection Program CARES Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from Notes Payable, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 170,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_GainLossFromInterestForgiven', window );">Gain (Loss) from Interest Forgiven</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt, Total</a></td>
<td class="nump">$ 172,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_GainLossFromInterestForgiven">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents gain (loss) from interest forgiven.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_GainLossFromInterestForgiven</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ProceedsFromConvertibleDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information related to gross proceeds from convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ProceedsFromConvertibleDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=govx_ConvertibleDebenturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=govx_ConvertibleDebenturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=govx_PaycheckProtectionProgramCaresActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430548045304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Debt - Interest Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">GRA Note</a></td>
<td class="nump">$ 1,286<span></span>
</td>
<td class="nump">$ 143,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">GRA Note</a></td>
<td class="nump">633<span></span>
</td>
<td class="nump">1,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=govx_PaycheckProtectionProgramCaresActMember', window );">Paycheck Protection Program CARES Act [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">GRA Note</a></td>
<td class="nump">653<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=govx_InsurancePremiumFinancingCostsMember', window );">Insurance Premium Financing Costs[Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">GRA Note</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">GRA Note</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 138,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=govx_PaycheckProtectionProgramCaresActMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=govx_PaycheckProtectionProgramCaresActMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=govx_InsurancePremiumFinancingCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=govx_InsurancePremiumFinancingCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556289448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Debt - Interest Expense (Details) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Debt discount amortization</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 124,185<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556484280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Commitments (Details Textual)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent', window );">Licensing Agreement, Future Minimum Payments Receivable, Current</a></td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears', window );">Licensing Agreement, Future Minimum Payments Receivable, in Two Years</a></td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears', window );">Licensing Agreement, Future Minimum Payments Receivable, in Three Years</a></td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears', window );">Licensing Agreement, Future Minimum Payments Receivable, in Four Years</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears', window );">Licensing Agreement, Future Minimum Payments Receivable, in Five Years</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Unrecorded Unconditional Purchase Obligation, Total</a></td>
<td class="nump">407,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=govx_OfficeAndLaboratoryLeaseAgreementMember', window );">Office and Laboratory Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="nump">166,242<span></span>
</td>
<td class="nump">$ 166,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, to be Paid, Year One</a></td>
<td class="nump">$ 176,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future payments receivable within one year of the balance sheet date under a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future payments receivable within the fifth year from the balance sheet date under a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future payments receivable within the fourth year from the balance sheet date under a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future payments receivable within the third year from the balance sheet date under a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future payments receivable within the second year from the balance sheet date under a licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=govx_OfficeAndLaboratoryLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=govx_OfficeAndLaboratoryLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430540863704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Sep. 29, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 28, 2021</div></th>
<th class="th"><div>Jun. 01, 2021</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
<th class="th"><div>Jun. 26, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromIssuanceOrSaleOfEquityGross', window );">Proceeds from Issuance or Sale of Equity, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfCommonStockSecuritiesCalledByEachUnit', window );">Number of Common Stock Securities Called by Each Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredCompensationLiabilityConversionToEquityAmount', window );">Deferred Compensation Liability Conversion to Equity, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredCompensationLiabilityConversionToEquityConversionPrice', window );">Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation', window );">Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">1,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,408,920<span></span>
</td>
<td class="nump">$ 11,158,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 9,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,404,156<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,707<span></span>
</td>
<td class="nump">26,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod', window );">Prepaid Expense, Value of Stock Issued for Services During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,947<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfExpenseAxis=govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember', window );">Expense Related To Consulting And Investment Banking Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,560<span></span>
</td>
<td class="nump">$ 45,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">269,427<span></span>
</td>
<td class="nump">$ 18,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,420,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member', window );">Stock Incentive Plan 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock, Capital Shares Reserved for Future Issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember', window );">Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember', window );">Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount', window );">Debt Conversion, Converted Instrument, Principal and Interest, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,214,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantsMember', window );">Conversion Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightIssuedDuringPeriod', window );">Class Of Warrant Or Right, Issued During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantsMember', window );">Conversion Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantMember', window );">Unit Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">740,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ProceedsFromWarrantExercisesGross', window );">Proceeds from Warrant Exercises, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember', window );">Pre-Funded Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ManagementWarrantMember', window );">Management Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfWarrantsCalledByEachUnit', window );">Number of Warrants Called by Each Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsMember', window );">Stock Purchase Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215,672<span></span>
</td>
<td class="nump">54,557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock Issued During Period, Shares, Warrants Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,705<span></span>
</td>
<td class="nump">36,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember', window );">June 2020 Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionOfConvertibleDebentureMember', window );">Conversion of Convertible Debenture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember', window );">Unit Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember', window );">Unit Warrants [Member] | Conversion from Convertible Debentures to Conversion Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1', window );">Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2020Member', window );">Representative Warrants 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2021Member', window );">Representative Warrants 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 6.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_Warrants2021Member', window );">Warrants 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding, Ending Balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=govx_CapitalUnitsTrancheOneMember', window );">Capital Units Tranche One [Member] | Capital Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_NumberOfCommonStockSecuritiesCalledByEachUnit', window );">Number of Common Stock Securities Called by Each Unit (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ClassOfWarrantOrRightIssuedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights issued during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ClassOfWarrantOrRightIssuedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt and interest is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredCompensationLiabilityConversionToEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deferred compensation liability being converted into equity in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredCompensationLiabilityConversionToEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredCompensationLiabilityConversionToEquityConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share for the conversion of deferred compensation liability to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredCompensationLiabilityConversionToEquityConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_NumberOfCommonStockSecuritiesCalledByEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock securities into which each unit may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_NumberOfCommonStockSecuritiesCalledByEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_NumberOfWarrantsCalledByEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants into which each unit may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_NumberOfWarrantsCalledByEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of stock issued for services during period recorded as prepaid expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ProceedsFromIssuanceOrSaleOfEquityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ProceedsFromIssuanceOrSaleOfEquityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_ProceedsFromWarrantExercisesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from warrant exercises before deducting costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_ProceedsFromWarrantExercisesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period for the cancellation of accrued compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares of common stock issued during the period upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=govx_StockIncentivePlan2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionByUniqueDescriptionAxis=govx_ConversionFromConvertibleDebenturesToConversionUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ManagementWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_ManagementWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_StockPurchaseWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_June2020WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionOfConvertibleDebentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_ConversionOfConvertibleDebentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_Warrants2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_Warrants2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=govx_CapitalUnitsTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=govx_CapitalUnitsTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CapitalUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CapitalUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430545931944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rates</a></td>
<td class="nump">1.43%<span></span>
</td>
<td class="nump">0.69%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years) (Year)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">84.80%<span></span>
</td>
<td class="nump">38.16%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430550910888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity- Stock Option Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">602,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">360,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">962,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted average remaining contractual term (Year)</a></td>
<td class="text">9 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 499,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">200,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted average remaining contractual term (Year)</a></td>
<td class="text">8 years 11 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 166,549<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430549390232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Stockholders' Equity - Summary of Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 28, 2021</div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Sep. 29, 2020</div></th>
<th class="th"><div>Sep. 24, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="nump">2,816,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_Warrants2020Member', window );">Warrants 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantMember', window );">Unit Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="nump">2,396,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted-Average Remaining Life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2020Member', window );">Representative Warrants 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="nump">128,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted-Average Remaining Life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2021Member', window );">Representative Warrants 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted-Average Remaining Life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_Warrants2021Member', window );">Warrants 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrants (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted-Average Remaining Life (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RemainingLifeOnWarrantsOutstandingMember', window );">Remaining Life on Warrants Outstanding[Member] | Weighted Average [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Weighted-Average Remaining Life (in years) (Year)</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_Warrants2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_Warrants2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_UnitWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_RepresentativeWarrants2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_Warrants2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_Warrants2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_RemainingLifeOnWarrantsOutstandingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_RemainingLifeOnWarrantsOutstandingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430556264200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Retirement Plan (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 36,980<span></span>
</td>
<td class="nump">$ 27,511<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430547672344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">75,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating Loss Carryforwards, Subject to Expiration</a></td>
<td class="nump">$ 48,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430551064584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">$ 18,449,694<span></span>
</td>
<td class="nump">$ 14,737,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforward</a></td>
<td class="nump">1,566,293<span></span>
</td>
<td class="nump">1,189,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation expense</a></td>
<td class="nump">129,475<span></span>
</td>
<td class="nump">4,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredTaxAssetsAccruedSalaries', window );">Accrued salaries</a></td>
<td class="nump">69,940<span></span>
</td>
<td class="nump">72,721<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Total deferred tax assets</a></td>
<td class="nump">20,215,402<span></span>
</td>
<td class="nump">16,003,941<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">30,945<span></span>
</td>
<td class="nump">28,274<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_DeferredTaxAssetsBeforeValuationAllowanceNet', window );">Net deferred tax assets</a></td>
<td class="nump">20,184,457<span></span>
</td>
<td class="nump">15,975,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(20,184,457)<span></span>
</td>
<td class="num">(15,975,667)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset after reduction for valuation allowance</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredTaxAssetsAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredTaxAssetsAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_DeferredTaxAssetsBeforeValuationAllowanceNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances and after deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_DeferredTaxAssetsBeforeValuationAllowanceNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430551764248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate applied to pretax loss</a></td>
<td class="num">$ (3,899,767)<span></span>
</td>
<td class="num">$ (621,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(377,183)<span></span>
</td>
<td class="num">(66,574)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance, net of expired items and other adjustments</a></td>
<td class="nump">4,276,950<span></span>
</td>
<td class="nump">687,703<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Reported income tax expense</a></td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430547572008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Grants and Collaboration Revenue (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 385,501<span></span>
</td>
<td class="nump">$ 1,823,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_govx_UnusedGrantFunds', window );">Unused Grant Funds</a></td>
<td class="nump">81,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=govx_NIHGrantsMember', window );">NIH Grants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="nump">$ 385,501<span></span>
</td>
<td class="nump">1,438,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=govx_ResearchAgreementsMember', window );">Research Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 385,193<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_govx_UnusedGrantFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of grant funds available for use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">govx_UnusedGrantFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>govx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=govx_NIHGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=govx_NIHGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=govx_ResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=govx_ResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430549376584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 11 - Subsequent Events (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 19, 2022</div></th>
<th class="th"><div>Feb. 11, 2021</div></th>
<th class="th"><div>Sep. 29, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,644,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pre-Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">2,360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Warrants Issued in Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">3,067,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 3.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">707,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="nump">$ 9.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=govx_WarrantsIssuedInPrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=govx_WarrantsIssuedInPrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140430547672344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at Beginning Of Period</a></td>
<td class="nump">$ 15,975,667<span></span>
</td>
<td class="nump">$ 18,787,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions Charged to Costs and Expenses</a></td>
<td class="nump">4,208,790<span></span>
</td>
<td class="num">(2,811,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Additions Charged to Other Accounts</a></td>
<td class="nump">(0)<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at End Of Period</a></td>
<td class="nump">$ 20,184,457<span></span>
</td>
<td class="nump">$ 15,975,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>govx20211231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:govx="http://geovax.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="govx-20211231.xsd" xlink:type="simple"/>
    <context id="d_2021-01-01_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2022-03-09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2022-03-09</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantIssuedForTechnologyLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-21</startDate>
            <endDate>2020-01-21</endDate>
        </period>
    </context>
    <context id="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">govx:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-25</startDate>
            <endDate>2020-09-25</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_NatureOfExpenseAxis-UpfrontFeesCOHAndPNPLicensemember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:UpfrontFeesCOHAndPNPLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:EquipmentAndFurnishingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">govx:EquipmentAndFurnishingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="d_2018-02-28_2018-02-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2018-02-28</startDate>
            <endDate>2018-02-28</endDate>
        </period>
    </context>
    <context id="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-02-28</instant>
        </period>
    </context>
    <context id="d_2021-05-01_2021-05-31_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-17</startDate>
            <endDate>2020-04-17</endDate>
        </period>
    </context>
    <context id="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="d_2021-05-01_2021-05-01_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-26</instant>
        </period>
    </context>
    <context id="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">govx:ConvertibleDebenturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-26</startDate>
            <endDate>2020-06-26</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-InsurancePremiumFinancingCostsmember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">govx:InsurancePremiumFinancingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-InsurancePremiumFinancingCostsmember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">govx:InsurancePremiumFinancingCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">govx:OfficeAndLaboratoryLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-06-01_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-01</instant>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="i_2020-09-29_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">govx:CapitalUnitsTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CapitalUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ManagementWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-29</startDate>
            <endDate>2020-09-29</endDate>
        </period>
    </context>
    <context id="d_2021-02-11_2021-02-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
        </entity>
        <period>
            <startDate>2021-02-11</startDate>
            <endDate>2021-02-11</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">govx:ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-09-30_PlanNameAxis-StockIncentivePlan2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">govx:StockIncentivePlan2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:Warrants2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:Warrants2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_RangeAxis-WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-RemainingLifeOnWarrantsOutstandingmember_RangeAxis-WeightedAverageMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RemainingLifeOnWarrantsOutstandingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-26</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:June2020WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-ConversionOfConvertibleDebentureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:ConversionOfConvertibleDebentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-29</instant>
        </period>
    </context>
    <context id="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-24</instant>
        </period>
    </context>
    <context id="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:RepresentativeWarrants2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-11</instant>
        </period>
    </context>
    <context id="i_2021-09-28_ClassOfWarrantOrRightAxis-Warrants2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:Warrants2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-28</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">govx:ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-NIHGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NIHGrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:NIHGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ResearchAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">govx:ResearchAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-19_2022-01-19_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-19</startDate>
            <endDate>2022-01-19</endDate>
        </period>
    </context>
    <context id="i_2022-01-19_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-19</instant>
        </period>
    </context>
    <context id="i_2022-01-19_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:WarrantsIssuedInPrivatePlacementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-19</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsFirstIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:StockPurchaseWarrantsFirstIssuanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-UnitWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">govx:PaycheckProtectionProgramCaresActMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-UnitWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000832489</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">govx:UnitWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">govx:ConversionFromConvertibleDebenturesToConversionUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2021-01-01_2021-12-31"
      id="thunderdome-EntityCentralIndexKey">0000832489</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2021-01-01_2021-12-31"
      id="thunderdome-EntityRegistrantName">GeoVax Labs, Inc.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2021-01-01_2021-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2021-01-01_2021-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2021-01-01_2021-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2021-01-01_2021-12-31">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2021-12-31"
      id="c81558299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2020-12-31"
      id="c81558300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558304"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558305"
      unitRef="USDPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c81558308"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c81558309"
      unitRef="Share">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c81558306"
      unitRef="USDPerShare">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c81558307"
      unitRef="USDPerShare">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="c81558310"
      unitRef="Share">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="c81558312"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c81558311"
      unitRef="Share">100</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2020-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c81558313"
      unitRef="Share">100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558316"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558317"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558318"
      unitRef="Share">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558319"
      unitRef="Share">600000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558320"
      unitRef="Share">6381541</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558322"
      unitRef="Share">6381541</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558321"
      unitRef="Share">3834095</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558323"
      unitRef="Share">3834095</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"
      id="c81558630">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"
      id="c81558633">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtInstrumentTerm
      contextRef="d_2018-02-28_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"
      id="c81558703">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      id="c81558762">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="d_2020-01-01_2020-12-31" id="c81558801">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      id="c81558815">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      id="c81558825">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-Warrants2021Member"
      id="c81558842">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:IncomeTaxesPaid
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81558934"
      unitRef="USD">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2022-01-19_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_SubsequentEventTypeAxis-SubsequentEventMember"
      id="c81558984">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"
      decimals="INF"
      id="c81558559"
      unitRef="Share">149705</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsFirstIssuanceMember"
      decimals="INF"
      id="c81558560"
      unitRef="Share">36902</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558562"
      unitRef="Share">716790</us-gaap:ConversionOfStockSharesIssued1>
    <govx:WarrantsIssued
      contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-UnitWarrantsMember"
      decimals="INF"
      id="c81558564"
      unitRef="Share">300001</govx:WarrantsIssued>
    <govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558566"
      unitRef="Share">300001</govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation>
    <govx:DeferredCompensationLiabilityConversionToEquityAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558568"
      unitRef="USD">1500000</govx:DeferredCompensationLiabilityConversionToEquityAmount>
    <us-gaap:DebtConversionConvertedInstrumentSharesIssued1
      contextRef="d_2020-01-01_2020-12-31_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c81558570"
      unitRef="Share">177626</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
    <govx:ExtinguishmentOfDebtIncludingInterestAmount
      contextRef="d_2021-01-01_2021-12-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c81558571"
      unitRef="USD">172056</govx:ExtinguishmentOfDebtIncludingInterestAmount>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c81558574"
      unitRef="Share">126042</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-UnitWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c81558576"
      unitRef="Share">303668</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="d_2020-01-01_2020-12-31_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c81558578"
      unitRef="USD">1200000</us-gaap:DebtConversionOriginalDebtAmount1>
    <govx:DebtConversionAccruedInterestAmount
      contextRef="d_2020-01-01_2020-12-31_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c81558580"
      unitRef="USD">14667</govx:DebtConversionAccruedInterestAmount>
    <dei:DocumentType contextRef="d_2021-01-01_2021-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2021-01-01_2021-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2021-01-01_2021-12-31">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2021-01-01_2021-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2021-01-01_2021-12-31">001-39563</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2021-01-01_2021-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="d_2021-01-01_2021-12-31">1900 Lake Park Drive, Suite 380</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2021-01-01_2021-12-31">Smyrna</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2021-01-01_2021-12-31">GA</dei:EntityAddressStateOrProvince>
    <dei:EntityTaxIdentificationNumber contextRef="d_2021-01-01_2021-12-31">87-0455038</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressPostalZipCode contextRef="d_2021-01-01_2021-12-31">30080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2021-01-01_2021-12-31">678</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2021-01-01_2021-12-31">384-7220</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">Common Stock $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">GOVX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-CommonStockMember">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">Warrants to Purchase Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">GOVXW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2021-01-01_2021-12-31_StatementClassOfStockAxis-WarrantMember">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2021-01-01_2021-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2021-01-01_2021-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2021-01-01_2021-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2021-01-01_2021-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2021-01-01_2021-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2021-01-01_2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2021-01-01_2021-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2021-01-01_2021-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="d_2021-01-01_2021-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="i_2021-06-30" decimals="INF" unitRef="USD">30365310</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2022-03-09" decimals="INF" unitRef="Share">7089025</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId contextRef="d_2021-01-01_2021-12-31">344</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2021-01-01_2021-12-31">WIPFLI LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2021-01-01_2021-12-31">Atlanta, Georgia</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558270"
      unitRef="USD">11423870</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558271"
      unitRef="USD">9883796</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:GrantsReceivable
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558272"
      unitRef="USD">49006</us-gaap:GrantsReceivable>
    <us-gaap:GrantsReceivable
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558273"
      unitRef="USD">182663</us-gaap:GrantsReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558274"
      unitRef="USD">156240</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558275"
      unitRef="USD">168689</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558276"
      unitRef="USD">11629116</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558277"
      unitRef="USD">10235148</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558278"
      unitRef="USD">156938</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558279"
      unitRef="USD">147741</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepositsAssets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558280"
      unitRef="USD">11010</us-gaap:DepositsAssets>
    <us-gaap:DepositsAssets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558281"
      unitRef="USD">11010</us-gaap:DepositsAssets>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558282"
      unitRef="USD">11797064</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558283"
      unitRef="USD">10393899</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558286"
      unitRef="USD">2057534</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558287"
      unitRef="USD">267702</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558288"
      unitRef="USD">3377826</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558289"
      unitRef="USD">359281</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558290"
      unitRef="USD">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558291"
      unitRef="USD">183326</us-gaap:NotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558292"
      unitRef="USD">5435360</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558293"
      unitRef="USD">810309</us-gaap:LiabilitiesCurrent>
    <govx:AccruedExpensesNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81559022"
      unitRef="USD">2000000</govx:AccruedExpensesNoncurrent>
    <govx:AccruedExpensesNoncurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81559023"
      unitRef="USD">0</govx:AccruedExpensesNoncurrent>
    <us-gaap:LongTermNotesPayable
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558294"
      unitRef="USD">0</us-gaap:LongTermNotesPayable>
    <us-gaap:LongTermNotesPayable
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558295"
      unitRef="USD">14738</us-gaap:LongTermNotesPayable>
    <us-gaap:Liabilities
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558296"
      unitRef="USD">7435360</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558297"
      unitRef="USD">825047</us-gaap:Liabilities>
    <us-gaap:PreferredStockValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558302"
      unitRef="USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558303"
      unitRef="USD">76095</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558314"
      unitRef="USD">6382</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558315"
      unitRef="USD">3834</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558326"
      unitRef="USD">68731220</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558327"
      unitRef="USD">55294504</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558328"
      unitRef="USD">-64375898</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558329"
      unitRef="USD">-45805581</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558330"
      unitRef="USD">4361704</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558331"
      unitRef="USD">9568852</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558332"
      unitRef="USD">11797064</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558333"
      unitRef="USD">10393899</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558334"
      unitRef="USD">385501</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558335"
      unitRef="USD">1823658</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558337"
      unitRef="USD">15554171</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558338"
      unitRef="USD">2444459</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558339"
      unitRef="USD">3577153</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558340"
      unitRef="USD">2196014</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558341"
      unitRef="USD">19131324</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558342"
      unitRef="USD">4640473</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558343"
      unitRef="USD">-18745823</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558344"
      unitRef="USD">-2816815</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558346"
      unitRef="USD">4736</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558347"
      unitRef="USD">2271</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558348"
      unitRef="USD">1286</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558349"
      unitRef="USD">143524</us-gaap:InterestExpense>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558350"
      unitRef="USD">172056</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558351"
      unitRef="USD">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558352"
      unitRef="USD">175506</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558353"
      unitRef="USD">-141253</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558354"
      unitRef="USD">-18570317</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558355"
      unitRef="USD">-2958068</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558357"
      unitRef="USDPerShare">-3.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558358"
      unitRef="USDPerShare">-2.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558359"
      unitRef="Share">6099933</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558360"
      unitRef="Share">1383829</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558361"
      unitRef="Share">2486</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558362"
      unitRef="USD">1932433</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558363"
      unitRef="Share">14992</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558364"
      unitRef="USD">15</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558365"
      unitRef="USD">39340509</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558366"
      unitRef="USD">-42847513</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c81558367"
      unitRef="USD">-1574556</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558368"
      unitRef="Share">300</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558369"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558370"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558371"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558372"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558373"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558374"
      unitRef="USD">300000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558375"
      unitRef="Share">-2686</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558376"
      unitRef="USD">-2156338</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558377"
      unitRef="Share">716790</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558378"
      unitRef="USD">717</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558379"
      unitRef="USD">2155621</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558380"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558381"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558383"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558385"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558386"
      unitRef="USD">457833</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558387"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558388"
      unitRef="USD">457833</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558389"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558390"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558391"
      unitRef="Share">286902</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558392"
      unitRef="USD">287</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558393"
      unitRef="USD">2213</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558394"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558395"
      unitRef="USD">2500</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodSharesDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558396"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558397"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodSharesDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558398"
      unitRef="Share">177626</govx:StockIssuedDuringPeriodSharesDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558399"
      unitRef="USD">177</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558400"
      unitRef="USD">569340</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558401"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodValueDebentureConversion
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558402"
      unitRef="USD">569517</govx:StockIssuedDuringPeriodValueDebentureConversion>
    <govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558403"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558404"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558405"
      unitRef="Share">300001</govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558406"
      unitRef="USD">300</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558407"
      unitRef="USD">1499700</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558408"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558409"
      unitRef="USD">1500000</govx:StockIssuedDuringPeriodValueCancellationOfAccruedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558410"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558411"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558412"
      unitRef="Share">2310000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558413"
      unitRef="USD">2310</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558414"
      unitRef="USD">11156186</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558415"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558416"
      unitRef="USD">11158496</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558417"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558418"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558419"
      unitRef="Share">26581</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558420"
      unitRef="USD">27</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558421"
      unitRef="USD">94373</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558422"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558423"
      unitRef="USD">94400</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558428"
      unitRef="USD">18730</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558430"
      unitRef="USD">18730</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558431"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558432"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558433"
      unitRef="Share">1203</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558434"
      unitRef="USD">1</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558435"
      unitRef="USD">-1</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558436"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <govx:StockIssuedDuringPeriodValueReverseStockSplits
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558437"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueReverseStockSplits>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558439"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558441"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558442"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558443"
      unitRef="USD">-2958068</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558444"
      unitRef="USD">-2958068</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558445"
      unitRef="Share">100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558446"
      unitRef="USD">76095</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558447"
      unitRef="Share">3834095</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558448"
      unitRef="USD">3834</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558449"
      unitRef="USD">55294504</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558450"
      unitRef="USD">-45805581</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558451"
      unitRef="USD">9568852</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558452"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558453"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558454"
      unitRef="Share">1644000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558455"
      unitRef="USD">1644</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558456"
      unitRef="USD">9407276</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558457"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558458"
      unitRef="USD">9408920</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558459"
      unitRef="Share">0</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558460"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558461"
      unitRef="Share">889739</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558462"
      unitRef="USD">890</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558463"
      unitRef="USD">3403266</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558464"
      unitRef="USD">0</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <govx:StockIssuedDuringPeriodValueWarrantExercise
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558465"
      unitRef="USD">3404156</govx:StockIssuedDuringPeriodValueWarrantExercise>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558466"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558467"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558468"
      unitRef="Share">13707</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558469"
      unitRef="USD">14</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558470"
      unitRef="USD">71827</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558471"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558472"
      unitRef="USD">71841</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558474"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558476"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558477"
      unitRef="USD">209825</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558478"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-WarrantIssuedForTechnologyLicenseMember"
      decimals="INF"
      id="c81558479"
      unitRef="USD">209825</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558480"
      unitRef="Share">100</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558481"
      unitRef="USD">76095</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558482"
      unitRef="Share">-0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558483"
      unitRef="USD">-0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558484"
      unitRef="USD">-75095</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558485"
      unitRef="USD">-0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558486"
      unitRef="USD">1000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558488"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558490"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558491"
      unitRef="USD">269427</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558492"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558493"
      unitRef="USD">269427</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558495"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558497"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558498"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558499"
      unitRef="USD">-18570317</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558500"
      unitRef="USD">-18570317</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558501"
      unitRef="Share">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-PreferredStockMember"
      decimals="INF"
      id="c81558502"
      unitRef="USD">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558503"
      unitRef="Share">6381541</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81558504"
      unitRef="USD">6382</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c81558505"
      unitRef="USD">68731220</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c81558506"
      unitRef="USD">-64375898</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558507"
      unitRef="USD">4361704</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558509"
      unitRef="USD">-18570317</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558510"
      unitRef="USD">-2958068</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558512"
      unitRef="USD">38521</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558513"
      unitRef="USD">19656</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558514"
      unitRef="USD">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558515"
      unitRef="USD">124185</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558516"
      unitRef="USD">369987</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558517"
      unitRef="USD">64463</us-gaap:ShareBasedCompensation>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558518"
      unitRef="USD">209825</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558519"
      unitRef="USD">0</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558520"
      unitRef="USD">172056</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558521"
      unitRef="USD">-0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558523"
      unitRef="USD">-133657</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558524"
      unitRef="USD">114060</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558525"
      unitRef="USD">16270</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558526"
      unitRef="USD">24702</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558527"
      unitRef="USD">6810233</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558528"
      unitRef="USD">137956</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558529"
      unitRef="USD">7373897</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558530"
      unitRef="USD">207498</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558531"
      unitRef="USD">-11196420</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558532"
      unitRef="USD">-2750570</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558534"
      unitRef="USD">47718</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558535"
      unitRef="USD">156791</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558536"
      unitRef="USD">-47718</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558537"
      unitRef="USD">-156791</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <govx:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558539"
      unitRef="USD">9408920</govx:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <govx:ProceedsFromIssuanceOfCommonStockAndWarrants
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558540"
      unitRef="USD">11158496</govx:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558541"
      unitRef="USD">3404156</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558542"
      unitRef="USD">2500</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558543"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558544"
      unitRef="USD">300000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558545"
      unitRef="USD">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558546"
      unitRef="USD">170200</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558547"
      unitRef="USD">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558548"
      unitRef="USD">888500</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558549"
      unitRef="USD">1000</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558550"
      unitRef="USD">-0</us-gaap:PaymentsForRepurchaseOfConvertiblePreferredStock>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558551"
      unitRef="USD">27864</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558552"
      unitRef="USD">11880</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558553"
      unitRef="USD">12784212</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558554"
      unitRef="USD">12507816</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558555"
      unitRef="USD">1540074</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558556"
      unitRef="USD">9600455</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558557"
      unitRef="USD">9883796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c81558558"
      unitRef="USD">283341</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558581"
      unitRef="USD">11423870</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558582"
      unitRef="USD">9883796</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:NatureOfOperations contextRef="d_2021-01-01_2021-12-31" id="c2049117">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Description of Business and Recent Developments&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;GeoVax Labs, Inc. (&#x201c;GeoVax&#x201d; or the &#x201c;Company&#x201d;), is a clinical-stage biotechnology company developing immunotherapies and vaccines against infectious diseases and cancers using novel vector vaccine platforms. GeoVax&#x2019;s product pipeline includes ongoing human clinical trials in COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; and head and neck cancer. Additional research and development programs include preventive vaccines against&#160;Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for solid tumors. Certain of our vaccine development activities have been, and continue to be, financially supported by the U.S. Government. This support has been both in the form of research grants and contracts awarded directly to us, as well as indirect support for the conduct of preclinical animal studies and human clinical trials.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;GEO-&lt;em style="font: inherit;"&gt;CM04S1&lt;/em&gt; License&lt;/i&gt; -- In &lt;em style="font: inherit;"&gt; November 2021, &lt;/em&gt;GeoVax entered into a license agreement with City of Hope (the &#x201c;COH License&#x201d;), granting GeoVax exclusive rights to further develop and commercialize GEO-&lt;em style="font: inherit;"&gt;CM04S1&lt;/em&gt; (formerly referred to as &lt;em style="font: inherit;"&gt;COH04S1&lt;/em&gt;). GEO-&lt;em style="font: inherit;"&gt;CM04S1,&lt;/em&gt; a synthetic, attenuated modified vaccinia Ankara (sMVA) vector expressing Spike and Nucleocapsid antigens of the SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; virus, was initially developed at COH for immunocompromised patients.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;GEO-&lt;em style="font: inherit;"&gt;CM04S1&lt;/em&gt; is being studied in an ongoing Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; clinical trial to evaluate its safety and immunogenicity, compared to the Pfizer mRNA-based vaccine, in patients who have previously received either an allogeneic hematopoietic cell transplant, an autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy. GEO-&lt;em style="font: inherit;"&gt;CM04S1&lt;/em&gt; is the only COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; vaccine that includes both SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; spike and nucleocapsid proteins to advance to a Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; trial in cancer patients. Such vaccines also tend to produce an immune response quickly &#x2013; in less than &lt;em style="font: inherit;"&gt;14&lt;/em&gt; days &#x2013; with only mild side effects. The trial is also the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; to compare an investigational multi-antigenic COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; vaccine to the current Food and Drug Administration (FDA)-approved mRNA vaccine from Pfizer/BioNTech in people who are immunocompromised. Such patients have often shown a weak antibody response after receiving currently available COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; vaccines.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2021, &lt;/em&gt;patient enrollment began for the Phase &lt;em style="font: inherit;"&gt;2&lt;/em&gt; portion of a Phase &lt;em style="font: inherit;"&gt;1/2&lt;/em&gt; trial of GEO-&lt;em style="font: inherit;"&gt;CM04S1,&lt;/em&gt; to study its use as a universal booster vaccine to current FDA-approved vaccines. GeoVax believes that the GEO-&lt;em style="font: inherit;"&gt;CM04S1&lt;/em&gt; vaccine, when administered as a heterologous booster, will provide additional recognition elements to the immune system over a homologous boost from mRNA vaccines such as those developed by Moderna or Pfizer, which are directed only toward SARS-CoV-&lt;em style="font: inherit;"&gt;2&lt;/em&gt; Spike protein. The &lt;em style="font: inherit;"&gt;COH04S1&lt;/em&gt; vaccine&#x2019;s MVA backbone &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be more effective at inducing COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; immunity since MVA strongly induces T cell responses even in a background of immunosuppression. In addition, GEO-&lt;em style="font: inherit;"&gt;CM04S1&lt;/em&gt; targeting of both Spike and Nucleocapsid antigens, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer greater protection against the significant sequence variation observed with the Spike antigen.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Gedeptin&lt;/i&gt;&#xae;&lt;i&gt; License&lt;/i&gt; -- In &lt;em style="font: inherit;"&gt; September 2021, &lt;/em&gt;GeoVax entered into an Assignment and License Agreement with PNP Therapeutics, Inc. (the &#x201c;PNP License), whereby GeoVax expanded its immuno-oncology pipeline and added a new technology platform through the acquisition of exclusive rights to Gedeptin&#xae;, a novel patented product for the treatment of solid tumors through a gene therapy strategy known as GDEPT (Gene-Directed Enzyme Prodrug Therapy). In GDEPT, a vector is used to selectively transduce tumor cells with a nonhuman gene, which expresses an enzyme that can convert a nontoxic prodrug into a potent antitumor compound. A Phase &lt;em style="font: inherit;"&gt;1/2&lt;/em&gt; clinical trial is currently enrolling to evaluate the safety and efficacy of repeat cycles of Gedeptin therapy in patients with recurrent head and neck squamous cell carcinoma (HNSCC), with tumors accessible for injection and &lt;em style="font: inherit;"&gt;no&lt;/em&gt; curable treatment options. The FDA has granted Gedeptin Orphan Drug status for the treatment of HNSCC and the initial stage of the ongoing clinical trial is being funded by the FDA pursuant to its Orphan Products Clinical Trials Grants Program. GeoVax&#x2019;s license to Gedeptin includes rights to expand its use to all human diseases and/or conditions including, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, cancers.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;GeoVax is incorporated under the laws of the State of Delaware and our principal offices are located in the metropolitan Atlanta, Georgia area.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049118">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 21, 2020, &lt;/em&gt;we effected a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-2000 reverse split of our common stock and on &lt;em style="font: inherit;"&gt; September 25, 2020, &lt;/em&gt;we effected a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-20 reverse split of our common stock. Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;-month period following the issue date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We believe that our existing cash will be sufficient to continue our planned operations into the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; We intend to fund future operations through additional private and/or public offerings of debt or equity securities.&#160; In addition, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek additional capital through arrangements with strategic partners or from other sources. There can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;&lt;/p&gt;&lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from those estimates.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We consider all highly liquid investments with a maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Fair Value of Financial Instruments and Concentration of Credit Risk&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from &lt;span style="-sec-ix-hidden:c81558630"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c81558633"&gt;five&lt;/span&gt; years. We amortize leasehold improvements using the straight-line method over the term of the related lease.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02,&lt;/em&gt; &lt;i&gt;Leases&lt;/i&gt; (ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt;), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months, we made an accounting policy election to &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be&lt;b&gt; &lt;/b&gt;recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been billed by our &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, calculated using the treasury stock method, totaled 213,831 and 1,001,948 shares at &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize revenue in accordance with FASB Accounting Standards Update &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (ASU &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;), which created a new Topic, Accounting Standards Codification Topic &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; The standard is principle-based and provides a &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Grant revenue&lt;/i&gt; &#x2013; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Research collaborations&lt;/i&gt; &#x2013; From time to time, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; and revenue is recognized accordingly.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Research and Development Expense&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development (R&amp;amp;D) expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred. During &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; we also recorded $10,513,825 of R&amp;amp;D expense for upfront license fees and warrant expense associated with the COH License and the PNP License.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt; &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Period-to-Period Comparisons&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be relied upon as predictive of the results for future periods.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of the deferred tax assets will be realized.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#x2019;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; for additional stock-based compensation information.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Other Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Except as discussed above, there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet effective, accounting standards if currently adopted would have a material effect on our financial statements.&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81562663">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements include the accounts of GeoVax Labs, Inc. together with those of our wholly-owned subsidiary, GeoVax, Inc. All intercompany transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81562664">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 21, 2020, &lt;/em&gt;we effected a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-2000 reverse split of our common stock and on &lt;em style="font: inherit;"&gt; September 25, 2020, &lt;/em&gt;we effected a &lt;em style="font: inherit;"&gt;1&lt;/em&gt;-for-20 reverse split of our common stock. Unless otherwise noted, the accompanying consolidated financial statements, and all share and per share information contained herein, have been retroactively restated to reflect the reverse stock splits.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt;-month period following the issue date of these consolidated financial statements. We are devoting substantially all of our present efforts to research and development of our vaccine and immunotherapy candidates. We expect to incur future net losses and require substantial funds as we continue our research and development activities. Our transition to profitability will be dependent upon, among other things, the successful development and commercialization of our product candidates. We &lt;em style="font: inherit;"&gt; may &lt;/em&gt;never achieve profitability or positive cash flows, and unless and until we do, we will continue to need to raise additional funding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;We have funded our activities to date from sales of our equity securities, government grants and clinical trial assistance, and corporate and academic collaborations. We believe that our existing cash will be sufficient to continue our planned operations into the &lt;em style="font: inherit;"&gt;second&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt; We intend to fund future operations through additional private and/or public offerings of debt or equity securities.&#160; In addition, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek additional capital through arrangements with strategic partners or from other sources. There can be &lt;em style="font: inherit;"&gt;no&lt;/em&gt; assurance that we will be able to raise additional funds or achieve or sustain profitability or positive cash flows from operations.&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2020-01-21_2020-01-21_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c81558616"
      unitRef="Pure">2000</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="d_2020-09-25_2020-09-25_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember"
      decimals="INF"
      id="c81558620"
      unitRef="Pure">20</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:UseOfEstimates contextRef="d_2021-01-01_2021-12-31" id="c81562665">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81562666">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We consider all highly liquid investments with a maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less when purchased to be cash equivalents. Our cash and cash equivalents consist primarily of bank deposits and money market accounts. The recorded values approximate fair market values due to the short maturities.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2021-01-01_2021-12-31" id="c81562667">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Fair Value of Financial Instruments and Concentration of Credit Risk&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Financial instruments that subject us to concentration of credit risk consist primarily of cash and cash equivalents, which are maintained by a high credit quality financial institution. The carrying values reported in the balance sheets for cash and cash equivalents approximate fair values.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81562668">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Expenditures for maintenance and repairs are charged to operations as incurred, while additions and improvements are capitalized. We calculate depreciation using the straight-line method over the estimated useful lives of the assets which range from &lt;span style="-sec-ix-hidden:c81558630"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c81558633"&gt;five&lt;/span&gt; years. We amortize leasehold improvements using the straight-line method over the term of the related lease.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize leases in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02,&lt;/em&gt; &lt;i&gt;Leases&lt;/i&gt; (ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02&lt;/em&gt;), which requires lessees to classify leases as either financing or operating leases based on the principle of whether or &lt;em style="font: inherit;"&gt;not&lt;/em&gt; the lease is effectively a financed purchase by the lessee. This classification determines whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months regardless of their classification. In the case of our facility lease agreement which has an effective term of less than &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months, we made an accounting policy election to &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recognize lease assets and liabilities and record lease expense on a straight-line basis over the lease term.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81562669">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Impairment of Long-Lived Assets&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We review long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the future net cash flows expected to be generated by such assets. If we consider such assets to be impaired, the impairment to be&lt;b&gt; &lt;/b&gt;recognized is measured by the amount by which the carrying amount of the assets exceeds the expected future net cash flows from the assets.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <govx:AccruedLiabilitiesPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81562670">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Accrued Expenses&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As part of the process of preparing our financial statements, we estimate expenses that we believe we have incurred, but have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been billed by our &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party vendors. This process involves identifying services and activities that have been performed by such vendors on our behalf and estimating the level to which they have been performed and the associated cost incurred for such service as of each balance sheet date.&lt;/p&gt;</govx:AccruedLiabilitiesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81562673">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Basic and diluted loss per common share are computed based on the weighted average number of common shares outstanding. Common share equivalents consist of common shares issuable upon conversion of convertible preferred stock, and upon exercise of stock options and stock purchase warrants. All common share equivalents are excluded from the computation of diluted loss per share since the effect would be anti-dilutive. The weighted average number of common share equivalents which were excluded from the computation of diluted loss per share, calculated using the treasury stock method, totaled 213,831 and 1,001,948 shares at &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558654"
      unitRef="Share">213831</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558655"
      unitRef="Share">1001948</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81562671">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We recognize revenue in accordance with FASB Accounting Standards Update &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09,&lt;/em&gt; &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt; (ASU &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt;), which created a new Topic, Accounting Standards Codification Topic &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; The standard is principle-based and provides a &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-step model to determine when and how revenue is recognized. The core principle is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Grant revenue&lt;/i&gt; &#x2013; We receive payments from government entities under non-refundable grants in support of our vaccine development programs. We record revenue associated with these grants when the reimbursable costs are incurred and we have complied with all conditions necessary to receive the grant funds.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Research collaborations&lt;/i&gt; &#x2013; From time to time, we &lt;em style="font: inherit;"&gt; may &lt;/em&gt;enter into collaborative research and development agreements for specific vaccine development approaches and/or disease indications whereby we receive &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party funding for preclinical research under certain of these arrangements. Each agreement is evaluated in accordance with the process defined by ASU &lt;em style="font: inherit;"&gt;2014&lt;/em&gt;-&lt;em style="font: inherit;"&gt;09&lt;/em&gt; and revenue is recognized accordingly.&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2021-01-01_2021-12-31" id="c81562672">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Research and Development Expense&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Research and development (R&amp;amp;D) expense primarily consists of costs incurred in the discovery, development, testing and manufacturing of our product candidates. These expenses consist primarily of (i) salaries, benefits, and stock-based compensation for personnel, (ii) laboratory supplies and facility-related expenses to conduct development, (iii) fees paid to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers to perform, monitor and accumulate data related to our preclinical studies and clinical trials, (iv) costs related to sponsored research agreements, and (v) costs to procure and manufacture materials used in clinical trials. These costs are charged to expense as incurred. During &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; we also recorded $10,513,825 of R&amp;amp;D expense for upfront license fees and warrant expense associated with the COH License and the PNP License.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31_NatureOfExpenseAxis-UpfrontFeesCOHAndPNPLicensemember"
      decimals="INF"
      id="c81558668"
      unitRef="USD">10513825</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="d_2021-01-01_2021-12-31" id="c81563825">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our expenditures relating to obtaining and protecting patents are charged to expense when incurred and are included in general and administrative expense.&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2021-01-01_2021-12-31" id="c81565271">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Period-to-Period Comparisons&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Our operating results are expected to fluctuate for the foreseeable future. Therefore, period-to-period comparisons should &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be relied upon as predictive of the results for future periods.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81565272">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We account for income taxes using the liability method. Under this method, deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted rates in effect for the year in which temporary differences are expected to be recovered or settled. Deferred tax assets are reduced by a valuation allowance unless, in the opinion of management, it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; that some portion or all of the deferred tax assets will be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2021-01-01_2021-12-31" id="c81565273">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We account for stock-based transactions in which the Company receives services from employees, directors or others in exchange for equity instruments based on the fair value of the award at the grant date. Stock-based compensation cost for awards of common stock is estimated based on the price of the underlying common stock on the date of issuance. Stock-based compensation cost for stock options or warrants is estimated at the grant date based on each instrument&#x2019;s fair value as calculated by the Black-Scholes option pricing model. We recognize stock-based compensation cost as expense ratably on a straight-line basis over the requisite service period for the award. See Note &lt;em style="font: inherit;"&gt;7&lt;/em&gt; for additional stock-based compensation information.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81566659">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Other Recent Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Except as discussed above, there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; recent accounting pronouncements or changes in accounting pronouncements which we expect to have a material impact on our financial statements, nor do we believe that any recently issued, but &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet effective, accounting standards if currently adopted would have a material effect on our financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049119">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment as shown on the accompanying Consolidated Balance Sheets is composed of the following as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Equipment and furnishings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;591,554&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;543,836&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;707,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;659,441&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(550,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(511,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;156,938&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;147,741&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Depreciation expense was $38,521 and $19,656 during the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively.&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049120">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 9pt; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Equipment and furnishings&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;591,554&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;543,836&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;115,605&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;707,159&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;659,441&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(550,221&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(511,700&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;156,938&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;147,741&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember"
      decimals="INF"
      id="c81558682"
      unitRef="USD">591554</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-EquipmentAndFurnishingsMember"
      decimals="INF"
      id="c81558683"
      unitRef="USD">543836</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="INF"
      id="c81558684"
      unitRef="USD">115605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="INF"
      id="c81558685"
      unitRef="USD">115605</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558686"
      unitRef="USD">707159</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558687"
      unitRef="USD">659441</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558688"
      unitRef="USD">550221</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558689"
      unitRef="USD">511700</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558690"
      unitRef="USD">156938</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558691"
      unitRef="USD">147741</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558679"
      unitRef="USD">38521</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558680"
      unitRef="USD">19656</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049121">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accrued expenses as shown on the accompanying Consolidated Balance Sheets is composed of the following as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020:&lt;/em&gt;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 18pt; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;Accrued license fees&#160;&#x2013; current&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,000,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;Accrued license fees&#160;&#x2013; noncurrent&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,000,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;269,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;279,696&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;108,826&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;79,585&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;5,377,826&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;359,281&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049122">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 18pt; margin-right: auto;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;Accrued license fees&#160;&#x2013; current&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,000,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt;Accrued license fees&#160;&#x2013; noncurrent&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,000,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;269,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;279,696&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;108,826&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;79,585&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total accrued expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;5,377,826&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;359,281&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <govx:AccruedLicenseFeesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81559283"
      unitRef="USD">3000000</govx:AccruedLicenseFeesCurrent>
    <govx:AccruedLicenseFeesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81559284"
      unitRef="USD">0</govx:AccruedLicenseFeesCurrent>
    <govx:AccruedLicenseFeesNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81559285"
      unitRef="USD">2000000</govx:AccruedLicenseFeesNoncurrent>
    <govx:AccruedLicenseFeesNoncurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81559286"
      unitRef="USD">0</govx:AccruedLicenseFeesNoncurrent>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558695"
      unitRef="USD">269000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <us-gaap:AccruedSalariesCurrentAndNoncurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558696"
      unitRef="USD">279696</us-gaap:AccruedSalariesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558697"
      unitRef="USD">108826</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558698"
      unitRef="USD">79585</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558699"
      unitRef="USD">5377826</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558700"
      unitRef="USD">359281</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049123">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Debt&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;GRA Note&lt;/i&gt; &#x2013; On &lt;em style="font: inherit;"&gt; February 28, 2018, &lt;/em&gt;we entered into a Senior Note Purchase Agreement with Georgia Research Alliance, Inc. (GRA) pursuant to which we issued a &lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c81558703"&gt;five&lt;/span&gt;&lt;/em&gt;-year Senior Promissory Note (the &#x201c;GRA Note&#x201d;) to GRA in exchange for $50,000. The GRA Note bore an annual interest rate of 5%. During &lt;em style="font: inherit;"&gt; May 2021, &lt;/em&gt;we repaid the remaining principal balance of $22,737 and retired the GRA Note.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;CARES Act Paycheck Protection Program Loan &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;On &lt;em style="font: inherit;"&gt; April 17, 2020, &lt;/em&gt;we received a $170,200 bank loan backed by the United States Small Business Administration (SBA) pursuant to the Paycheck Protection Program (PPP) provisions of the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The loan bore an annual interest rate of &lt;em style="font: inherit;"&gt;one&lt;/em&gt; percent. During &lt;em style="font: inherit;"&gt; May 2021, &lt;/em&gt;upon receiving payment from the SBA, the lender forgave the full principal balance of $170,200 together with $1,856 of accrued interest, and we recorded a $172,056 gain on debt extinguishment.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;i&gt;Convertible Debentures&lt;/i&gt; &#x2013; On &lt;em style="font: inherit;"&gt; June 26 2020, &lt;/em&gt;we issued convertible debentures in the aggregate principal amount of $1,200,000 and warrants to purchase an aggregate of 120,000 shares of our common stock for gross proceeds of $1,050,000. As discussed in Note &lt;em style="font: inherit;"&gt;7,&lt;/em&gt; in &lt;em style="font: inherit;"&gt; September 2020, &lt;/em&gt;the convertible debentures and accrued interest were fully converted into our equity securities and were retired.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Interest expense recorded for the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2019&lt;/em&gt; was as follows:&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;GRA Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,727&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;PPP Loan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;653&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,203&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Insurance premium financing costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,743&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible debentures (including $124,185 of debt discount amortization)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;138,851&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total interest expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;1,286&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;143,524&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2018-02-28_2018-02-28"
      decimals="INF"
      id="c81558704"
      unitRef="USD">50000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i_2018-02-28_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="2"
      id="c81558705"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="d_2021-05-01_2021-05-31_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c81558706"
      unitRef="USD">22737</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="d_2020-04-17_2020-04-17_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c81558707"
      unitRef="USD">170200</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c81558709"
      unitRef="USD">170200</us-gaap:ExtinguishmentOfDebtAmount>
    <govx:GainLossFromInterestForgiven
      contextRef="d_2021-05-01_2021-05-31_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c81558710"
      unitRef="USD">1856</govx:GainLossFromInterestForgiven>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="d_2021-05-01_2021-05-01_DebtInstrumentAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c81558711"
      unitRef="USD">172056</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c81559494"
      unitRef="USD">1200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c81559495"
      unitRef="Share">120000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <govx:ProceedsFromConvertibleDebtGross
      contextRef="d_2020-06-26_2020-06-26_ShortTermDebtTypeAxis-ConvertibleDebenturesMember"
      decimals="INF"
      id="c81559496"
      unitRef="USD">1050000</govx:ProceedsFromConvertibleDebtGross>
    <govx:InterestExpenseDisclosureTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049124">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;GRA Note&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;633&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,727&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;PPP Loan&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;653&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,203&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Insurance premium financing costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,743&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible debentures (including $124,185 of debt discount amortization)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;138,851&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total interest expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;1,286&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;143,524&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </govx:InterestExpenseDisclosureTableTextBlock>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c81558713"
      unitRef="USD">633</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-SeniorNotesMember"
      decimals="INF"
      id="c81558714"
      unitRef="USD">1727</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c81558717"
      unitRef="USD">653</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-PaycheckProtectionProgramCaresActMember"
      decimals="INF"
      id="c81558718"
      unitRef="USD">1203</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-InsurancePremiumFinancingCostsmember"
      decimals="INF"
      id="c81558719"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-InsurancePremiumFinancingCostsmember"
      decimals="INF"
      id="c81558720"
      unitRef="USD">1743</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="INF"
      id="c81558721"
      unitRef="USD">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31_LongtermDebtTypeAxis-ConvertibleDebtMember"
      decimals="INF"
      id="c81558722"
      unitRef="USD">138851</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558725"
      unitRef="USD">1286</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558726"
      unitRef="USD">143524</us-gaap:InterestExpense>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049125">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Commitments&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Operating Lease&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We lease approximately 8,400 square feet of office and laboratory space pursuant to an operating lease which expires on &lt;em style="font: inherit;"&gt; December 31, 2022. &lt;/em&gt;Rent expense for the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was $166,242 and $166,577, respectively. Future minimum lease payments total $176,356 in &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; although the lease &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated at any time by either party with &lt;em style="font: inherit;"&gt;ninety&lt;/em&gt; days written notice.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;License Agreements&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We have entered into license agreements with City of Hope, PNP Therapeutics, Inc., University of Alabama at Birmingham, Southern Research Institute, Emory University, and with the U.S. Department of Health and Human Services (HHS), as represented by National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), for various technologies and patent rights associated with our product development activities. These agreements &lt;em style="font: inherit;"&gt; may &lt;/em&gt;contain provisions for upfront payments, milestone fees due upon the achievement of selected development and regulatory events, minimum annual royalties or other fees, and royalties based on future net sales. Aggregate unrecorded future minimum payments under these agreements (excluding milestone and royalty payments due upon contingent future events, and assuming neither party terminates the agreements) are approximately $174,000 in &lt;em style="font: inherit;"&gt;2022,&lt;/em&gt; $128,000 in &lt;em style="font: inherit;"&gt;2023,&lt;/em&gt; $128,000 in &lt;em style="font: inherit;"&gt;2024,&lt;/em&gt; $28,000 in &lt;em style="font: inherit;"&gt;2025&lt;/em&gt; and $28,000 in &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Other Commitments&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In the normal course of business, we enter into various firm purchase commitments related to production and testing of our vaccine, conduct of research studies, and other activities. As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;there were approximately $407,000 of unrecorded outstanding purchase commitments to our vendors and subcontractors, which we expect will be due in &lt;em style="font: inherit;"&gt;2022.&lt;/em&gt;&lt;/p&gt;
  </us-gaap:CommitmentsDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2021-09-30_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c81558728"
      unitRef="SquareFoot">8400</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2021-01-01_2021-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c81558730"
      unitRef="USD">166242</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2020-01-01_2020-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c81558731"
      unitRef="USD">166577</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2021-12-31_LeaseContractualTermAxis-OfficeAndLaboratoryLeaseAgreementMember"
      decimals="INF"
      id="c81558732"
      unitRef="USD">176356</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <govx:LicensingAgreementFutureMinimumPaymentsReceivableCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558735"
      unitRef="USD">174000</govx:LicensingAgreementFutureMinimumPaymentsReceivableCurrent>
    <govx:LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558737"
      unitRef="USD">128000</govx:LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears>
    <govx:LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558739"
      unitRef="USD">128000</govx:LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears>
    <govx:LicensingAgreementFutureMinimumPaymentsReceivableInFourYears
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558741"
      unitRef="USD">28000</govx:LicensingAgreementFutureMinimumPaymentsReceivableInFourYears>
    <govx:LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558743"
      unitRef="USD">28000</govx:LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558745"
      unitRef="USD">407000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:PreferredStockTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049126">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Stockholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Preferred Stock&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2021, &lt;/em&gt;we repurchased the remaining 100 shares of our Series B convertible preferred stock for a total price of $1,000. As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;there are no shares of our preferred stock outstanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Public Offering &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;On &lt;em style="font: inherit;"&gt; September 29, 2020, &lt;/em&gt;we closed an underwritten public offering (the &lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Offering&#x201d;) of an aggregate of 2,560,000 units of our equity securities (the &#x201c;Units&#x201d;) with gross proceeds to us of approximately $12.8 million. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $11.2 million. Each Unit sold in the offering consisted of one share of our common stock (or a pre-funded warrant to purchase one share of common stock, all of which were fully exercised during &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;), and a warrant to purchase one share of common stock (&#x201c;Unit Warrant&#x201d;), exercisable at an exercise price of $5.00 per share and with a &lt;span style="-sec-ix-hidden:c81558762"&gt;five&lt;/span&gt;-year expiration date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;From &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; through &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;to help conserve the Company&#x2019;s cash resources, our executive officers and non-employee directors agreed to defer receipt of all or a portion of their respective cash compensation. Upon consummation of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Offering, $1,500,000 of accumulated deferrals were converted at the $5.00 offering price, resulting in the issuance of 300,001 units substantially similar to the units sold in the public offering, with each unit consisting of one share of our common stock and one warrant substantially similar to a Unit Warrant.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Upon consummation of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Offering, we issued an aggregate of 177,626 shares of our common stock, 126,042 pre-funded warrants to purchase common stock, and 303,668 warrants substantially similar to a Unit Warrant upon the mandatory conversion of $1,214,667 of convertible debentures and accrued interest.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Public Offering &lt;/i&gt;&#x2013;&lt;i&gt; &lt;/i&gt;On &lt;em style="font: inherit;"&gt; February 11, 2021, &lt;/em&gt;we closed an underwritten public offering of 1,644,000 shares of our common stock, with gross proceeds to us of approximately $10.3 million. Net proceeds after deducting underwriting discounts and commissions and other offering expenses were approximately $9.4 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Warrant exercises&lt;/i&gt; &#x2013; During &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; 740,034 Unit Warrants were exercised for cash, resulting in gross proceeds to us of approximately $3.7 million; net proceeds after deducting commissions owed to the underwriter of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Offering were approximately $3.4 million. During &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; an aggregate of 215,672 warrants were exercised using the cashless exercise feature of the warrants, resulting in the issuance of an aggregate of 149,705 shares of our common stock. During &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; 54,557 warrants were exercised using the cashless exercise feature of the warrants, resulting in the issuance of an aggregate of 36,902 shares of our common stock&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Other Common Stock Transactions&lt;/i&gt; &#x2013; During &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; we issued 13,707 and 26,581 shares, respectively, of our common stock pursuant to consulting agreements. During &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; we issued an aggregate of 716,790 shares of our common stock, pursuant to the conversion of Series H and Series I convertible preferred stock.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock Option Plan&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We have a stock-based incentive plan (the &lt;em style="font: inherit;"&gt;&#x201c;2020&lt;/em&gt; Plan&#x201d;) pursuant to which our Board of Directors &lt;em style="font: inherit;"&gt; may &lt;/em&gt;grant stock options to our employees. A total of 1,500,000 shares of our common stock are reserved for issuance pursuant to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan. The exercise price for any option granted &lt;em style="font: inherit;"&gt; may &lt;/em&gt;&lt;em style="font: inherit;"&gt;not&lt;/em&gt; be less than fair value (110% of fair value for ISO&#x2019;s granted to certain employees). Options have a maximum &lt;span style="-sec-ix-hidden:c81558801"&gt;ten&lt;/span&gt;-year term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We use the Black-Scholes model for determining the grant date fair value of our stock option grants. This model utilizes certain information, such as the interest rate on a risk-free security with a term generally equivalent to the expected life of the option being valued and requires certain other assumptions, such as the expected amount of time an option will be outstanding until it is exercised or expired, to calculate the fair value of stock options granted. The significant assumptions we used in our fair value calculations were as follows:&lt;/p&gt;
   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average risk-free interest rates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.69&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;84.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;38.16&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;A summary of stock option activity under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan as of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;and changes during the year then ended is presented below.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Number&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;of Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Weighted-&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Weighted-&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Remaining&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Contractual&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Term (yrs)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Aggregate&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Intrinsic&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;602,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;360,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3.82&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited or expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;962,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;3.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;9.31&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;499,660&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;200,661&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;2.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;8.93&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;166,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The weighted-average grant date fair values of options granted during &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; were $2.87 and $1.12, respectively. Total stock option compensation expense recognized in the consolidated statement of operations for the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was $269,427 and $18,730, respectively. As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;there is $1,420,144 of unrecognized compensation expense that will be recognized over a weighted-average period of 2.2 years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Stock Purchase Warrants&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Summary of Warrants Outstanding &lt;/i&gt;&#x2013; The table below presents summary information about our warrants outstanding as of &lt;em style="font: inherit;"&gt; December 31, 2021. &lt;/em&gt;Additional information concerning the warrants follows the table.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 55.6%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant Description&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Number&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;of Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Expiration&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020 Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;120,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Jun 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020 Unit Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,396,631&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Sep 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020 Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;128,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Mar 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021 Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;72,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6.875&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Aug 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021 Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;13.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Sep 2026&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total Warrants Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;2,816,631&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-Average Exercise Price&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-Average Remaining Life (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Warrants&lt;/i&gt; &#x2013; In &lt;em style="font: inherit;"&gt; June 2020, &lt;/em&gt;in connection with the issuance of convertible debentures, we issued warrants to purchase 120,000 shares of common stock, with a &lt;span style="-sec-ix-hidden:c81558815"&gt;five&lt;/span&gt;-year term and an exercise price of $10.00. As a result of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Public Offering, in &lt;em style="font: inherit;"&gt; September 2020 &lt;/em&gt;the exercise price was reduced to $5.00.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Unit Warrants&lt;/i&gt; &#x2013; In &lt;em style="font: inherit;"&gt; September 2020, &lt;/em&gt;in connection with the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Public Offering, we issued 303,668 warrants upon the conversion of convertible debentures, 300,001 warrants upon the conversion of amounts owed to current and former executive officers and directors, and 2,560,000 warrants to other investors in the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Public Offering, with each of the warrants having a &lt;span style="-sec-ix-hidden:c81558825"&gt;five&lt;/span&gt;-year term and an exercise price of $5.00. During &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; 740,034 of these warrants were exercised for cash and 27,004 were exercised using the cashless exercise feature of the warrant.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Representative Warrants&lt;/i&gt; &#x2013; In &lt;em style="font: inherit;"&gt; September 2020, &lt;/em&gt;we issued 128,000 warrants to the underwriter of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Public Offering, with a 42-month term and an exercise price of $5.50.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Representative Warrants&lt;/i&gt; &#x2013; In &lt;em style="font: inherit;"&gt; February 2021, &lt;/em&gt;we issued 72,000 warrants to the underwriter of the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Public Offering, with a 42-month term and an exercise price of $6.875.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Warrants&lt;/i&gt; &#x2013; In &lt;em style="font: inherit;"&gt; September 2021, &lt;/em&gt;in connection with a technology licensing agreement, we issued 100,000 warrants, with a &lt;span style="-sec-ix-hidden:c81558842"&gt;five&lt;/span&gt;-year term and an exercise price of $13.00.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Additional Stock-Based Compensation Expense&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In addition to stock-based compensation expense related to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan (see &lt;i&gt;Stock Options&lt;/i&gt; above), during the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; we recognized $100,560 and $45,733, respectively, of expense related to the issuance of our common stock pursuant to consulting and investment banking agreements. As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;there is $19,947 recorded as a prepaid expense for these arrangements, which will be recognized as expense during &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; over the term of the related agreement.&lt;/p&gt;
  </us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-06-01_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c81558748"
      unitRef="Share">100</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      id="c81558749"
      unitRef="USDPerShare">1000</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i_2021-12-31_StatementClassOfStockAxis-SeriesBConvertiblePreferredStockMember"
      decimals="-3"
      id="c81558750"
      unitRef="Share">0</us-gaap:PreferredStockSharesOutstanding>
    <govx:ClassOfWarrantOrRightIssuedDuringPeriod
      contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember"
      decimals="INF"
      id="c81558754"
      unitRef="Share">2560000</govx:ClassOfWarrantOrRightIssuedDuringPeriod>
    <govx:ProceedsFromIssuanceOrSaleOfEquityGross
      contextRef="d_2020-09-29_2020-09-29"
      decimals="-5"
      id="c81558755"
      unitRef="USD">12800000</govx:ProceedsFromIssuanceOrSaleOfEquityGross>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2020-09-29_2020-09-29"
      decimals="-5"
      id="c81558756"
      unitRef="USD">11200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <govx:NumberOfCommonStockSecuritiesCalledByEachUnit
      contextRef="i_2020-09-29_StatementClassOfStockAxis-CapitalUnitsTrancheOneMember_StatementEquityComponentsAxis-CapitalUnitsMember"
      decimals="INF"
      id="c81558757"
      unitRef="Share">1</govx:NumberOfCommonStockSecuritiesCalledByEachUnit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c81558758"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember"
      decimals="INF"
      id="c81558760"
      unitRef="Share">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c81558761"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <govx:DeferredCompensationLiabilityConversionToEquityAmount
      contextRef="d_2020-09-29_2020-09-29"
      decimals="INF"
      id="c81558765"
      unitRef="USD">1500000</govx:DeferredCompensationLiabilityConversionToEquityAmount>
    <govx:DeferredCompensationLiabilityConversionToEquityConversionPrice
      contextRef="i_2020-09-29"
      decimals="INF"
      id="c81558766"
      unitRef="USDPerShare">5.00</govx:DeferredCompensationLiabilityConversionToEquityConversionPrice>
    <govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation
      contextRef="d_2020-09-29_2020-09-29"
      decimals="INF"
      id="c81558767"
      unitRef="Share">300001</govx:StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation>
    <govx:NumberOfCommonStockSecuritiesCalledByEachUnit
      contextRef="i_2020-09-29"
      decimals="INF"
      id="c81558768"
      unitRef="Share">1</govx:NumberOfCommonStockSecuritiesCalledByEachUnit>
    <govx:NumberOfWarrantsCalledByEachUnit
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember"
      decimals="INF"
      id="c81558769"
      unitRef="Share">1</govx:NumberOfWarrantsCalledByEachUnit>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-09-29_2020-09-29"
      decimals="INF"
      id="c81558771"
      unitRef="Share">177626</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c81558772"
      unitRef="Share">126042</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
      contextRef="d_2020-09-29_2020-09-29_ClassOfWarrantOrRightAxis-ConversionWarrantsMember_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c81558773"
      unitRef="Share">303668</us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1>
    <govx:DebtConversionConvertedInstrumentPrincipalAndInterestAmount
      contextRef="d_2020-09-29_2020-09-29_DebtConversionByUniqueDescriptionAxis-ConversionFromConvertibleDebenturesToConversionUnitsMember"
      decimals="INF"
      id="c81558774"
      unitRef="USD">1214667</govx:DebtConversionConvertedInstrumentPrincipalAndInterestAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-02-11_2021-02-11"
      decimals="INF"
      id="c81558776"
      unitRef="Share">1644000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-02-11_2021-02-11"
      decimals="-5"
      id="c81558777"
      unitRef="USD">10300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-02-11_2021-02-11"
      decimals="-5"
      id="c81558778"
      unitRef="USD">9400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c81558780"
      unitRef="Share">740034</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:ProceedsFromWarrantExercisesGross
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="-5"
      id="c81558781"
      unitRef="USD">3700000</govx:ProceedsFromWarrantExercisesGross>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="-5"
      id="c81558783"
      unitRef="USD">3400000</us-gaap:ProceedsFromWarrantExercises>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"
      decimals="INF"
      id="c81558785"
      unitRef="Share">215672</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"
      decimals="INF"
      id="c81558786"
      unitRef="Share">149705</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"
      decimals="INF"
      id="c81558788"
      unitRef="Share">54557</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2020-01-01_2020-12-31_ClassOfWarrantOrRightAxis-StockPurchaseWarrantsMember"
      decimals="INF"
      id="c81558789"
      unitRef="Share">36902</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558792"
      unitRef="Share">13707</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558793"
      unitRef="Share">26581</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="d_2020-01-01_2020-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember"
      decimals="INF"
      id="c81558795"
      unitRef="Share">716790</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i_2021-09-30_PlanNameAxis-StockIncentivePlan2020Member"
      decimals="INF"
      id="c81558797"
      unitRef="Share">1500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="d_2020-01-01_2020-12-31"
      decimals="1"
      id="c81558800"
      unitRef="Pure">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049127">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average risk-free interest rates&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.69&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected life of option (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;7.0&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;84.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;38.16&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="4"
      id="c81558862"
      unitRef="Pure">0.0143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="4"
      id="c81558863"
      unitRef="Pure">0.0069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81558864"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81558865"
      unitRef="Pure">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2021-01-01_2021-12-31" id="c81558866">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2020-01-01_2020-12-31" id="c81558867">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c81558868"
      unitRef="Pure">0.8480</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="4"
      id="c81558869"
      unitRef="Pure">0.3816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049128">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Number&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;of Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Weighted-&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Weighted-&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Average&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Remaining&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Contractual&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Term (yrs)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Aggregate&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Intrinsic&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Value&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;602,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;360,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3.82&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited or expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;962,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;3.18&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;9.31&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;499,660&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;200,661&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;2.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;8.93&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;166,549&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558870"
      unitRef="Share">602000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558871"
      unitRef="USDPerShare">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558874"
      unitRef="Share">360300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558875"
      unitRef="USDPerShare">3.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558878"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558879"
      unitRef="USDPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558882"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558883"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558886"
      unitRef="Share">962300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558887"
      unitRef="USDPerShare">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2021-01-01_2021-12-31" id="c81558888">P9Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558889"
      unitRef="USD">499660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558890"
      unitRef="Share">200661</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558891"
      unitRef="USDPerShare">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2021-01-01_2021-12-31" id="c81558892">P8Y11M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558893"
      unitRef="USD">166549</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558806"
      unitRef="USDPerShare">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558807"
      unitRef="USDPerShare">1.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81558809"
      unitRef="USD">269427</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81558810"
      unitRef="USD">18730</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c81558811"
      unitRef="USD">1420144</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c81558812">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049129">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 55.6%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Warrant Description&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Number&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;of Shares&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Exercise&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Price&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 14.4%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Expiration&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020 Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;120,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Jun 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020 Unit Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,396,631&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Sep 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020 Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;128,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.50&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Mar 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021 Representative Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;72,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;6.875&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Aug 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021 Warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;100,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;13.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;em style="font: inherit;"&gt;Sep 2026&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total Warrants Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;2,816,631&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-Average Exercise Price&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5.35&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-Average Remaining Life (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2020Member"
      decimals="INF"
      id="c81558894"
      unitRef="Share">120000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2020Member"
      decimals="INF"
      id="c81558895"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c81558897"
      unitRef="Share">2396631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c81558898"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member"
      decimals="INF"
      id="c81558900"
      unitRef="Share">128000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member"
      decimals="1"
      id="c81558901"
      unitRef="USDPerShare">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member"
      decimals="INF"
      id="c81558903"
      unitRef="Share">72000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member"
      decimals="INF"
      id="c81558904"
      unitRef="USDPerShare">6.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2021Member"
      decimals="INF"
      id="c81558906"
      unitRef="Share">100000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-Warrants2021Member"
      decimals="INF"
      id="c81558907"
      unitRef="USDPerShare">13.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558909"
      unitRef="Share">2816631</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_RangeAxis-WeightedAverageMember"
      decimals="INF"
      id="c81558912"
      unitRef="USDPerShare">5.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-RemainingLifeOnWarrantsOutstandingmember_RangeAxis-WeightedAverageMember"
      id="c81558915">P3Y8M12D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c81558814"
      unitRef="Share">120000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-06-26_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c81558816"
      unitRef="USDPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-June2020WarrantsMember"
      decimals="INF"
      id="c81558818"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ConversionOfConvertibleDebentureMember"
      decimals="INF"
      id="c81558821"
      unitRef="Share">303668</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-ManagementWarrantMember"
      decimals="INF"
      id="c81558822"
      unitRef="Share">300001</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantsMember"
      decimals="INF"
      id="c81558823"
      unitRef="Share">2560000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c81558826"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <govx:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c81558828"
      unitRef="Share">740034</govx:ClassOfWarrantOrRightExercisedDuringPeriod>
    <govx:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="d_2021-01-01_2021-12-31_ClassOfWarrantOrRightAxis-UnitWarrantMember"
      decimals="INF"
      id="c81558829"
      unitRef="Share">27004</govx:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member"
      decimals="INF"
      id="c81558831"
      unitRef="Share">128000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-09-29_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member"
      id="c81558833">P42M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-09-24_ClassOfWarrantOrRightAxis-RepresentativeWarrants2020Member"
      decimals="INF"
      id="c81558834"
      unitRef="USDPerShare">5.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member"
      decimals="INF"
      id="c81558836"
      unitRef="Share">72000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member"
      id="c81558838">P42M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-02-11_ClassOfWarrantOrRightAxis-RepresentativeWarrants2021Member"
      decimals="INF"
      id="c81558839"
      unitRef="USDPerShare">6.875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-Warrants2021Member"
      decimals="INF"
      id="c81558841"
      unitRef="Share">100000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-09-28_ClassOfWarrantOrRightAxis-Warrants2021Member"
      decimals="INF"
      id="c81558843"
      unitRef="USDPerShare">13.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember"
      decimals="INF"
      id="c81558847"
      unitRef="USD">100560</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_NatureOfExpenseAxis-ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember"
      decimals="INF"
      id="c81558848"
      unitRef="USD">45733</us-gaap:AllocatedShareBasedCompensationExpense>
    <govx:PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558849"
      unitRef="USD">19947</govx:PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049130">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Retirement Plan&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We participate in a multi-employer defined contribution retirement plan (the &lt;em style="font: inherit;"&gt;&#x201c;401k&lt;/em&gt; Plan&#x201d;) administered by a &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service provider, and the Company contributes to the &lt;em style="font: inherit;"&gt;401k&lt;/em&gt; Plan on behalf of its employees based upon a matching formula. During the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; our contributions to the &lt;em style="font: inherit;"&gt;401k&lt;/em&gt; Plan were $36,980 and $27,511, respectively.&lt;/p&gt;
  </us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558924"
      unitRef="USD">36980</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558925"
      unitRef="USD">27511</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049131">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;At &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;we have a consolidated federal net operating loss (&#x201c;NOL&#x201d;) carryforward of approximately $75.2 million available to offset against future taxable income of which approximately $48.9 million expires in varying amounts in &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2037.&lt;/em&gt; Additionally, we have approximately $1.6 million in research and development (&#x201c;R&amp;amp;D&#x201d;) tax credits that expire in &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2041&lt;/em&gt; unless utilized earlier. &lt;span style="-sec-ix-hidden:c81558934"&gt;No&lt;/span&gt; income taxes have been paid to date. Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; of the Internal Revenue Code contains provisions that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;limit our utilization of our NOL and R&amp;amp;D tax credit carryforwards in any given year as a result of significant changes in ownership interests that have occurred in past periods or &lt;em style="font: inherit;"&gt; may &lt;/em&gt;occur in future periods.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred income taxes reflect the net effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred tax assets and liabilities included the following at &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62.2%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Net operating loss carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,449,694&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;14,737,240&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Research and development tax credit carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,566,293&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,189,110&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;129,475&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Accrued salaries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;69,940&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;72,721&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20,215,402&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,003,941&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;30,945&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;28,274&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20,184,457&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(20,184,457&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net deferred tax asset after reduction for valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We have established a full valuation allowance equal to the amount of our net deferred tax assets due to uncertainties with respect to our ability to generate sufficient taxable income to realize these assets in the future. A reconciliation of the income tax benefit on losses at the U.S. federal statutory rate to the reported income tax expense is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. federal statutory rate applied to pretax loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(3,899,767&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(621,194&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Permanent differences&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(377,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(66,574&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance, net of expired items and other adjustments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;4,276,950&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;687,703&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reported income tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c81558927"
      unitRef="USD">75200000</us-gaap:OperatingLossCarryforwards>
    <govx:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c81558928"
      unitRef="USD">48900000</govx:OperatingLossCarryforwardsSubjectToExpiration>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-5"
      id="c81558931"
      unitRef="USD">1600000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049132">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62.2%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Net operating loss carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,449,694&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;14,737,240&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Research and development tax credit carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,566,293&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,189,110&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;129,475&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Accrued salaries&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;69,940&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;72,721&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20,215,402&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;16,003,941&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Depreciation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;30,945&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;28,274&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20,184,457&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(20,184,457&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;(15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td colspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net deferred tax asset after reduction for valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558939"
      unitRef="USD">18449694</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558940"
      unitRef="USD">14737240</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558941"
      unitRef="USD">1566293</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558942"
      unitRef="USD">1189110</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558943"
      unitRef="USD">129475</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558944"
      unitRef="USD">4870</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <govx:DeferredTaxAssetsAccruedSalaries
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558945"
      unitRef="USD">69940</govx:DeferredTaxAssetsAccruedSalaries>
    <govx:DeferredTaxAssetsAccruedSalaries
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558946"
      unitRef="USD">72721</govx:DeferredTaxAssetsAccruedSalaries>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558947"
      unitRef="USD">20215402</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558948"
      unitRef="USD">16003941</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558952"
      unitRef="USD">30945</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558953"
      unitRef="USD">28274</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <govx:DeferredTaxAssetsBeforeValuationAllowanceNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558954"
      unitRef="USD">20184457</govx:DeferredTaxAssetsBeforeValuationAllowanceNet>
    <govx:DeferredTaxAssetsBeforeValuationAllowanceNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558955"
      unitRef="USD">15975667</govx:DeferredTaxAssetsBeforeValuationAllowanceNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558956"
      unitRef="USD">20184457</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81558957"
      unitRef="USD">15975667</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81558958"
      unitRef="USD">-0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81558959"
      unitRef="USD">-0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049133">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2021&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;2020&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. federal statutory rate applied to pretax loss&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(3,899,767&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(621,194&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Permanent differences&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(377,183&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(66,574&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance, net of expired items and other adjustments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;4,276,950&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;687,703&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reported income tax expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0); margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558960"
      unitRef="USD">-3899767</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558961"
      unitRef="USD">-621194</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558962"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558963"
      unitRef="USD">65</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558964"
      unitRef="USD">377183</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558965"
      unitRef="USD">66574</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81558966"
      unitRef="USD">4276950</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81558967"
      unitRef="USD">687703</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81558968"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81558969"
      unitRef="USD">-0</us-gaap:IncomeTaxExpenseBenefit>
    <govx:GovernmentGrantsandContractsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049134">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Grants and Collaboration Revenue&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;We receive payments from government entities under our grants from the National Institute of Allergy and Infectious Diseases (NIAID) and from the U.S. Department of Defense in support of our vaccine research and development efforts. We record revenue associated with government grants as the reimbursable costs are incurred. During &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; we recorded $385,501 and $1,438,465, respectively, of revenue associated with these grants. As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;there is an aggregate of $81,526 in remaining grant funds available for use during &lt;em style="font: inherit;"&gt;2022.&lt;/em&gt; During &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; we recorded $385,193 of revenues associated with a research collaboration agreement.&lt;/p&gt;
  </govx:GovernmentGrantsandContractsTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-NIHGrantsMember"
      decimals="INF"
      id="c81558973"
      unitRef="USD">385501</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NIHGrantsMember"
      decimals="INF"
      id="c81558974"
      unitRef="USD">1438465</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <govx:UnusedGrantFunds
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81558975"
      unitRef="USD">81526</govx:UnusedGrantFunds>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ResearchAgreementsMember"
      decimals="INF"
      id="c81558978"
      unitRef="USD">385193</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049135">
   &lt;table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 45pt;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: auto;"&gt; &lt;p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 19, 2022, &lt;/em&gt;we closed a private placement of 707,484 shares of common stock, 2,360,000 pre-funded warrants to purchase common stock, and accompanying warrants to purchase an aggregate of up to 3,067,484 shares of common stock. The warrants are exercisable immediately at an exercise price of $3.26 per share and will expire &lt;span style="-sec-ix-hidden:c81558984"&gt;five&lt;/span&gt; years from the date of issuance. Net proceeds after deducting placement agent commissions and other offering expenses were approximately $9.2 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2022-01-19_2022-01-19_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81558980"
      unitRef="Share">707484</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-01-19_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c81558981"
      unitRef="Share">2360000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2022-01-19_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c81558982"
      unitRef="Share">3067484</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2022-01-19_ClassOfWarrantOrRightAxis-WarrantsIssuedInPrivatePlacementMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c81558983"
      unitRef="USDPerShare">3.26</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2022-01-19_2022-01-19_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c81558985"
      unitRef="USD">9200000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049136">
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"&gt;&lt;b&gt;GEOVAX LABS, INC.&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;SCHEDULE II &lt;/b&gt;&#x2013;&lt;b&gt; VALUATION AND QUALIFYING ACCOUNTS&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;For the Years Ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Additions (Reductions)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Description&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Balance at&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Beginning&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Of Period&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Charged to&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Costs and&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Charged to&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Other&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Accounts&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Deductions&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Balance at&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;End&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Of Period&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Allowance for Deferred Tax Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Year ended December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,208,790&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20,184,457&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Year ended December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,811,563&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
  </srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:SummaryOfValuationAllowanceTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2049137">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Additions (Reductions)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 40%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Description&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Balance at&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Beginning&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Of Period&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Charged to&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Costs and&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Expenses&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Charged to&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Other&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Accounts&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Deductions&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Balance at&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;End&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;Of Period&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reserve Deducted in the Balance Sheet From the Asset to Which it Applies:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Allowance for Deferred Tax Assets&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Year ended December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;4,208,790&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;20,184,457&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Year ended December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;18,787,230&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(2,811,563&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;-0-&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;15,975,667&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:SummaryOfValuationAllowanceTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c81558990"
      unitRef="USD">15975667</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c81558991"
      unitRef="USD">4208790</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="c81558992"
      unitRef="USD">-0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="c81558993"
      unitRef="USD">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2021-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c81558994"
      unitRef="USD">20184457</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c81558995"
      unitRef="USD">18787230</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c81558996"
      unitRef="USD">-2811563</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="c81558997"
      unitRef="USD">-0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="c81558998"
      unitRef="USD">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="INF"
      id="c81558999"
      unitRef="USD">15975667</us-gaap:ValuationAllowancesAndReservesBalance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MD*89>.>6KX74E8QP("TS++%=SS+RFC$J<@=+ZSJHHB3\]N%#7>2L+KNT8>1
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MR"DNOULV>?7+>Y9*1C40.F90! [()1>P*K!^CUH]I[CZ;GF-(YF0R:B2%HY
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M([4],;)Q+W4>I#&R<H<;SB  "X#K:PD:MSNQ[XGV[P67_P%02P,$%     @
MUWUI5$$)M([A @  ; H  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RU
MEEMOFS 4Q[^*A?;02EVXA5RJ!&E)-6T/E:)&VQZF/3AP$JP:F]DFZ?KI9P.E
M4'+MM#P$VYS+[^\;9[+CXE$F  H]I93)J94HE=W:MHP22+'L\0R8?K/F(L5*
M=\7&EID '!=.*;4]QQG8*2;,"B?%V$*$$YXK2A@L!))YFF+Q9P:4[Z:6:[T,
M/)!-HLR '4XRO($EJ&_90NB>74>)20I,$LZ0@/74^N3>SMW"H;#X3F G&VUD
MI*PX?S2=K_'4<@P14(B4"8'U8PMSH-1$TAR_JZ!6G=,X-MLOT3\7XK68%98P
MY_0'B54RM486BF&-<ZH>^.X+5(("$R_B5!;_:%?:!MHXRJ7B:>6L"5+"RB=^
MJB:BX>#V#SAXE8-WKH-?.?B%T)*LD'6'%0XG@N^0,-8ZFFD4<U-X:S6$F65<
M*J'?$NVGPCEGDE,28P4QFF&*601H:<))=+7  IA*0)$(4WF-/J(/R$8RT<-R
M8BN=W@2QHRK5K$SE'4AU!U$/^>X-\AS/W>,^/]_=:;O;6G2MW*N5>T6\_H%X
M"[U?0 @M6T]R]'B#,BS0%M,<T!5A*.:48B%1!J)4?+U/<9EB6*0P)V8;.CU'
MB]LV=9TP:M'[-;U_E'[.TU2?@G] +^./VE0=]E-6+?A^#=^_ ![G*N&"/.N5
M,/3E]MJ+7$8=-& &3O5[@WV.90L]J-&#"]")E/EI[* +XX_<H/]VKKMV_LCO
M.^-@/_*@1AY<@*RO<JDPBPG;G.(>G,G=M3O*/:RYAT>YER (2#1#^H[:@E!D
M10&]GMJET8-^WD.Z O'KR(4PJO.-_O^%4*8(&G/A=G?G":,6_;BF'U]&7R[L
M!:=KW%E&=__A.L.P)<%U7C]&SKM$G'?.JN!-L+?H>TS<@]B-;ZC[+NP+SEJ5
MX2A[UZ3+;C=* 5.'W6.Q(4PB"FOMY?2&>M>)LK0I.XIG176PXDK7&D4ST>4@
M"&.@WZ\Y5R\=4W#4!6;X%U!+ P04    " #7?6E4[?J'BA $   V#0  &
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(V77X^;.!# OXH5W4,K70.V,9!5
M$JF[>W\J7:^KW?;Z[ 0GH +.V4ZR]^UO; C)@D'-0P S,_[-V)X9EF>I?NA<
M"(->J[+6JUENS.$N"/0V%Q77<WD0-;S9255Q X]J'^B#$CQS2E49D#",@XH7
M]6R]=&-/:KV41U,6M7A22!^KBJO_[D4ISZL9GET&GHM];NQ L%X>^%Z\"//M
M\*3@*>BL9$4E:EW(&BFQ6\T^XKL'G%@%)_%/(<[ZYAY95S92_K /G[+5++1$
MHA1;8TUPN)S$@RA+:PDX_FV-SKHYK>+M_<7Z[\YY<&;#M7B0Y?<B,_EJELY0
M)G;\6)IG>?Y3M XQ:V\K2^W^T;F1C18SM#UJ(ZM6&0BJHFZN_+4-Q(T"CD<4
M2*M ^@K1B )M%:ASM"%S;CURP]=+)<](66FP9F]<;)PV>%/4=AE?C(*W!>B9
M]8.LM2R+C!N1H1<#%U@CHY'<H2\'H;B-M48?T+>71_3NE_?+P,"D5C78MA/<
M-Q.0D0DP09]E;7*-?JLSD;TU$ !MATPNR/=DTN*CV,X1Q;\B$A+L 7KX>?5P
M H=V$:3.7C1B[P_%:X-XG2%8BY)O9!,TV.,G41^%+V*-0>8,VG-V6M.4L1"<
M.=WZ,13#*:$Q2SNY-\!1!QPY13H"W*YKO4?B%;*!%OIN(@RLL\HFP_ LM.!J
MF[M(9.![*0]V*_G\;RS%MXXQQB*<]",P%"01_-C"'X&X8XVGETS4$(+2H?(,
M3E6AC0W)R;M:\0""LB3!C/9@AW($+^(01W[8I(--)F&_2@.H<K!H/M1D&-@%
MIIB2J,<Z%(SB*(P2ZF=-.]9TDO4OJ37:*5E=>"%Y^#C3P?0?<)I$#+9W#]0C
M25(<IYCY21<=Z6+Z$)A<*%346UD)]*Z-Z?NI@X##:TH-)Z/PJ39""6U:\]Z<
M&0X7(*%QSWF/%"$WA^0MWTW*QS_'U[KM!<2>)2+I@- G%E%&1C8])E=(,GU&
MH05!D$8SL;&@=NL?"YV/I936VINMGY"0#8"'<N$(ZK4 X.D*T)Y0[X[RLE(/
M*^3_ >M0#H*+"1LYI?A: 7 T2?PW](<EG%4O730H.W X61)2G/0!/:)DP=(P
M'BE1^%I-,)L\G_=<%]NFEA3E$9J3R:-Y3?QX.O-?'$>0GJ!>5Q7L,)US!2L&
MVRVS!5PU+]VH?_F:*9);K^D\[*=8GQB9CU4#?"T'>+H>?'>=*71K_ 0I=B\:
M4NC8CD8;")BM$=:99MCOP3#]Q^%BL:#][.L1Q#2E*>D7X."F ZV$VKO&7$.$
MC[5I.KMNM&O^/[J6MS=^;S\*7&=[-=-\47SF:E] +UJ*'9@,YPEL(-4TZ<V#
MD0?7YVZD@:[9W>;P82.4%8#W.RG-Y<%.T'TJK?\'4$L#!!0    ( -=]:53P
MXQY)"0@  "DK   8    >&PO=V]R:W-H965T<R]S:&5E=#4N>&ULK9K;;MLX
M$(9?13 6V!98UR(IZE D 5JG7=O9+H*DW5XL]D*1F5BH++J2G+1OOZ2L6!:'
M!R=-+QK+_F<XG.'A(^V3!UY]JU>,-=Z/=5'6IZ-5TVS>3B9UMF+KM'[#-ZP4
MG]SR:ITVXK&ZF]2;BJ7+UFA=3+#OAY-UFI>CLY/VO<OJ[(1OFR(OV67EU=OU
M.JU^OF<%?S@=H='C&U?YW:J1;TS.3C;I';MFS9?-926>)GLORWS-RCKGI5>Q
MV]/1._3V@D32H%7\D[.'^N"U)[MRP_DW^3!?GHY\&1$K6-9(%ZGX<\^FK"BD
M)Q'']\[I:-^F-#Q\_>C]8]MYT9F;M&937GS-E\WJ=!2/O"6[3;=%<\4?9JSK
M$)7^,E[4[?_>0Z?U1UZVK1N^[HQ%!.N\W/U-?W2).#"(3 :X,\"*01@9#$AG
M0!0#8TA!9Q"H(6&# >T,J&(0A :#L#,(%0-,#0919Q"I!J:0XLX@5@R(*:2D
M,TC4%DQI1?YCY7S%!!&3R;[8NT&W&R7M$#M/F_3LI.(/7B7UPI]\T8[3UEZ,
MK+R44^JZJ<2GN;!KSJ:\K'F1+].&+;WK1OP1\Z6I/7[K35=I><=J+R_%!SS[
MMN+%DE7U[]Z'[]N\^>F].F>W>9:S,OOYVAM[7Z[/O5>_O3Z9-"(LZ7R2=2&\
MWX6 #2%\3:LJ+1MO7M=;$818)KS/+%N5O.!W/[V_\DQ,8/;O)[:^8=5_EV+&
ML:IJ@Q4Q>8_O:YJ=OF"S4[Y>\]+=YOD+MOENN<SELI,6WF6:+\>B#M-TDS?B
MV1+!AQ>,X(HU8E$6L@]I5>;E76UK^.,+-JQQ_Z?=_1/&Q<SNZ=A2S^UNGE>]
MA=WIDPIR8??UF8M8AF83L7CL5Q"\7T%PZR<P^'F?%FF9,>^5Z&&]2BM6O_;2
MQCMGV1N/H#\\[*-$5\^=U[#U*C?^^S,<Q.')Y/ZP5%"$@B3!>]4@8K*/F!P5
M\3%1[CS1PP 2@@-"E$ U.CJ4S*&$)"3PJ9\,A0LH' <X#B**E%8O-$I$HX#2
M4)^A8)^AP)JAZ[1@<@O(>'G/JB:_$8^;_0RKVZDA9W"6UJO#PNLR&( 2$M]7
ML@<UOKX#=-\!^F(=T 5-8:U\^4^)&\H4Q9Q:>K:KME-Q 15*,(,4A?L4A=84
M3=O4M&@L$J4FI^$B=^U"N'MV%#D$(8YQ"&8S5$4HC!)#1Z)]1Z*7ZX@N^ C.
M(HQH2$BLQ ^%$8J4@D=P64-B/F*DE!WJU++;%(-$Q?M$Q=9$=5NP(+K='BQ*
M>E/ERSOFW>:E6!'%AJ)+3^P:Y#.G8AZ#O@0TBM55= %E:E*<C@:92?:921Q#
MZ&"H=]EQC/C$%>H,*G <)KYA\T)^3^R^-5A)4.W^U:YO!X%O-^+E0\=9[ >K
MLKQF6I3RG2752'"LCO5.-.@B5C>IA4:E5E7GB)H6.'1PMD&_D*DENQ%'G6W%
MNEVB74$<5>\:M)5=(T%1%&+#EHQZSD)VT'IZ;[0]P.[:0XGH@5I[B&8TE#RC
M5A_J0/5A>\(5/5A:AQGK.0_904\WK7>[ODAC4:1-MV>D65;)ST16-^(8LGO?
M-1*(>R1 2;MQ([7_3MVP_SW%(3O&V4?,,5G0]CQPCR H = W1Y#Z)-Q'JG"A
M$8(A!!M$U ))J =)="Q)'N3O6/9%3KB;:228($OD/=\A.^!9(]=&&[H+"R4R
M6K6R$/00$D2%5")<:)2@M+!)Z2P.$M.*VH,CLI.C<7[(+-6LNL\S5CMK["2Y
MF4:"0QJ#=< E&W:SQSYDY[ZCNJGMFAO]-!(,M@H(;4E (L );OK3M)8$@7&J
M]/B'[/RWN^SAFW8I9#_D\J<#ISF"3(?BB( P7;+A14M/?MA.?E=\6RZW&UG'
MW8 4%2P*_B# W:N8W/195]EZ4^2-:^1B)YC--!*$?0-MXQ[,L!W,GM@1;?#(
M.38U$F7*S3&$M;%Z4M-HU();)<,<'5RKV7'O;]9X!:^U$Q.[(<XMF6,GFBTT
MDC%.:.R'L9J"(Y3#3/08AX^[KS/?,&)?FR7(50A<X6A$)!88FU!#V#U]83M]
MZ:\9#:%"?HG"PQBZ8#5<)8)5ZPIYB5*<!-0/U/)"Y3@0-:-P<])($QK&,36<
M9W%/6-A.6,^[EGB/G9=O4[?D7"/!?A)C)?,?W*X^NET-$]2#'';=U#WY=@([
MN6JFD<1Q$I'$$&Y/5?B95'7T_02&%VT@>BB)$[# 0: 2,YO@4,50C1 L\5I?
M 3)=M>,>S[ =SW[IA(&=T#332% HJ<FT1?78A!W8]-031N?/6E@HD=&JE86$
ME01^A"-06><]W86F1>$K3K A/Z3G-?+,F[JGG"^(F](T$D0B7^'P"Z=LV,V>
MYL@SK]E<YPOB9CB-!*F#@4#ZBE"L'D,6&IDZ%#2M"4^!X01&>I8C=I8[\GSQ
M)W$2V<PMF6LD.$P"F!#WU9S;U3 C!U_!VIG.1K<$?JT)LN"4S(GS@FZAD8Q1
M3".?J%_K7!PE'>:B!T5B!\4KMME6V2JMF>X++-?RH$$X2+D:E6EUZ[F-V+G-
M&K8V5 A(8QWE:G2@N/#6+*+ TT(C R,<2F3^3-GIH8W8H>V(0PO2)LE-;AI)
M2&)$C>M4CV[$CFZ&(XL^4#>D:20B4*S64J.*(X(P!O-5\TUM&)"(QHEZ'-5(
M Q*BZ. (M,O1Y."W<_)'I)_2ZBXO:Z]@M\+2?Q,)%]7N=YF[AX9OVI_3W?"F
MX>OVY8JE2U9)@?C\EO/F\4'^0F__Z]BS_P%02P,$%     @ UWUI5"YB02 *
M!@  4A<  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6R5F-MRVS80AE\%
MH^E%.U-'./#HL3UCRTV;BV0\<=-<0R0DH2$)!8 LNT_?!2F3L@#2MB\LBEH
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M%+^!0)H%^'PC\!!0#TR YJMJ]C=02P,$%     @ UWUI5(D%T)J% P  60<
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M.N;5*!'Y0Q"(PMD21Z<(HT7J6Z/#3GB5-8[7CF#:&C81.F()-R:E,\0V0M?
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M$50KEO1'0.T,Z'ZE:,=V!Q>@_\?,_@-02P,$%     @ UWUI5&,J\1+0 @
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M /MK@R;93L(!I_\,)G\ 4$L#!!0    ( -=]:52CLU#;YP4  "@.   9
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M*:10L"1!,6E_@3_L^,/('Y[AGY1PA@;7DCS\^(H'5I4MMC]?JNEEXJCW_[W
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MT,Z"T#FP1"4VAD0(W!T^H6YP$CN^SWO%68>]:+'3#["'*5P;[4H+WW6.^5N
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ME8LN,Z\\5.:]0'7A%6&C#*3/Y59\4O$DBXIR!WL79_!(,5A!*A +9W.PKH.
M%JDOE0Y;X55:.5X[PM'6.!-I1RSA:;70*<R%O&?@?:1!'$=#BSC^*+ZVKK2.
M>-"=3&6F<IWBL3%R3B_(6<<DYAQ^JM8J*I=%N ,EUJ;TJZCK.114+1:482 %
MI&^53QN@X((B!K6V)DSQ8:->%99FY!"G8U9,80=\_UGK^\\&7?-#-,!KR)F3
M<1_J^(/4"4G\[$N9JI=');F^6ZNC;UBR;T<7;7WJ0&8B;1$ (<-RTEFJ II"
MJJ'@H,#)FIQ%:B^[S/CHU]GL^C%<%UX!243%KI/+STJH5A V,(5(&77/AI2+
M!8 #FP R6L<\\C8M]KR_[^ETGVF?&NLKQ^>-AEZ2V0_MB5S8G[&!KO?JH8FT
M?>(X.""\*2Y2=\!L'C<90H"COMG$VE%.VPQ9. T5&$ K #">76O L9ZWCO5\
MN."1RY,0?/$::E\C.B'E0SWL!]E00%*.U!DR*3Q$K #+X"=&8PW5D37L'O7)
MGB1Q\$"98AMU[Y0:T,)9JX6S0?'>2.W$1VDJMNB;UIIO"T"+*O\1??S?#*.Z
M*+\7H8NX2]0''<2-]I][VW1O&T<#:OD_% XQ?M*OJ:21BB,JK'T?* J!\[5A
MQ::-O?A"]=TB5AK4*4%-1, _N/8<D<VF:TA_@:^2D18[,NI0,1K@7))*Y[A&
MKDD/OHN3NOS,I:'T+A@LQYIS4"PAR]+9.TX08D'*C42'<,>+UCE>? >X49X/
M0$77AF W\2</+DG?#W6+^[':Y2%V'JOV,=F \TU&.2FU'M(8*L_(K55>&7Z3
M*>1L&"#V5 5G(226B O&XC7E'ABLHFQ+*F:CJH(U3\LIX6OGF5FZDFX)FG"I
M7NF3#$8K!\.S=QALS$ RO@0)G<,VZR8K$AU9ZD#@1&5<D5'54Q9W5UI"&S$;
M$L"G=NV8%"9RP%F+Z@N4P&^;RI!AAUI4!LEC'0$&@^.8Q:/; DXL:Q3"N0/^
M"23PB?)M:M%9_:N@0>DC!J(2Y3+6!.>>+MYZ?<@M,$@F7>;%A<4?\>C-[/;B
M\?X5'THN&H]FMQ\>B_=V#)20/!.3Z4B\BTSK>V"&(-"-)7PUX,+)I&L;)X.>
M]38G,[+;P,A7VI<6,(QT],X6R^-W4$,F9JRJA[KT,.?]X*(OSAX1HD76-"0P
M],[PN]J2Y*6ZV[]9 5R0*U!)I>KJR$]AYHA$M$,L1*!(#S) R%!CO]!/0K$X
M,U0H(J<:O86A,IOT^O9DT !P"%?A$.]Z2.*^"KX?Y=<-C)AY 9 6F@! \*64
M%7 ;X1L=EV#L/M0RHG:C":@.F32-2(.=-S7:[P)_7H7XB#065MH-S0^2::>V
MZ>#A7DM70%XOKF'A6^0?]6#W'&;P'H9^9WV/@: ^,*VAH:DHKQA:@(R'))OG
MR$R>UW$J0ZO'2VC4A)P42]>&ATODLG!,B8Q35-PJ,K[L*, F52#?S'#$,8I]
MCWB_N#4E^IOM&BA8SI%PJ](RZ@8[W]1XO@N:7L/N"T5V@J6AI]@Q\1YUA[9>
M1ZC/[Y#9N\P=GY250T1AS0;!0OU8' FDA\3E^SL>3V1-KFTTU4*0;U0;Z2#E
MIW&HH2*@W]C*9-2/@;$^YEU(!A%!W%/-.\+%.K!1/R[CJ*M76:]&!?3;:"*V
MM=)BD1JA5J+28>$T.1V=G2:LUF0TF22C%T_.&CLBN*Y4&L<)S;@LSA2&@JB;
MFB6G@SY^$[N->$Y 2AZ7Q9IVR2-+L+UO--V/TTTLIZS(G>I:-SY[RRL*YV#=
M1'5\(B8O1F+O>?SN@7RS7#R;/!O'.O\K>6\KP@V*D70\->G/"#CM<P)K* S9
MH!LL)L/COY8;.< 51# VHK@Z;3\XK0VRVU]UOR>#V%F0]18\NOE)YN4O5X^;
MDM!K%^KLY&/8^=#!P0;)4X=-: T0ND<4L:'BW(6XY;*H:!P56^!Z.(32E55P
MU912)/F Y\#WO<JTMWUYI!_3E GW-"J9 R L--6V-J<=QW1-\0XR,> )5R#(
MO2T*94:@ 2*U7U@*ZZHL33,S@*14Q+?'3L4\T%5*;K=8ZIVS@ASH+92BXJP9
M0S=.1F/%(1_K!J3)\ #S+=JQ8LD9OX%RP*PZJ BN'NQBP]RN<7"XQB6;_ ^>
MH_5Z"58,YT8T"W-J$QM+PZB!OO'0;(-)?--<-#Y&T*YS)FY>G&HFW^Q=]6 I
MOLMR,/'<YJY;#QGJ )-N_)8,S]^0SPQ-'.G+2_PT<$DS7A>QW%;,LG^J.*>X
MMW*'&5[SU.<XV.-X5?/3GC(4*;MNP*#$9B(4RVX)U48M+DQ%(R-JB.MQ+?XB
M=A0CAD5%=N)P CBP5-;*EF>\XO!H>/H5%^+O]"/=V"D9'@B]+4!<B3_I(\,#
MO?*^A!6W$?6<,78-\5W@=UWE;H9[V[IHC\6'(N/>4ONVCF<-@L+N@Y-!URMU
M6:OVKC^-2F<2E+> 2Q3W)3($IX&@V3(T*]< /RZ^FZNPH:\#!^:,7W<PG(;;
MB?; V!/TM"/G(8^A@"&I*"TBQU[=\[ Y0YX6!JE"LO,Y'M,B/&L,URABB^)"
MCR,&HR\52*Y(K?WC?NW%\ZA25 ^"UX!@*@1#<X.],K(!D'R;D11-@>K1AS%V
MPV"C*FA(,FJ*DRV1-2+>0PT"BHSY6@=!UD=@X-2?E2%,@,[P._[?#1R3X0$@
M=QIU%;J66[;DS/%XXD%9Y#M<N-9=,)?+?JW[*C#Z-7'GXUYG+&CJLO[\!WLH
MGK 0K-!D- 9B].');A55W$QC#:HF=^.6/CY&=[B+G3GSK#_\]$>7.SU4-\5K
M)SD;&K#4C3M_&>(A_%C<'BKI!$>8&6_U_<: 03HLW 7G#G? B;1E3)^TG*F_
MY_6VUVN;+P'<C<'#[B/0;J^%!TUOM2O3-X?MI%029NFT]]-_SJ;)\U]\7V_2
M]UN5^99I71@)V6[3E>6O<"P!'Y>.E]M,F?$N9#\(F/@PX-&4:X0]$MB6A)-?
MC>SF\=-J,['C[SL>P*1QH;KVM)F"[04]*B7> RV(YT-!UPURD^'QZGNUV?G1
MA+,%KE/U0P/^[_#Z@S^Y S>HKWZIL<,4R)N^AY$6"217GI0,S+E&.28"JO=Y
MN+"'LL])[_<D:'V6_*L9@L;@&7]:TCYM?YDSB[]'Z9;'G_7\#A &IQ)&+;!U
M,GX.#.CB+V7B3; E_SIE;@/Z++Y<*8GXH 5XO["P5WU##-K?*[WZ'U!+ P04
M    " #7?6E4_S]/G)<"  !W!0  &0   'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q]5-MNVS ,_17"Z$,+>/4]ER(QT+0=-F =@K;;'H8]*#83"Y4E5Y*;
M=E\_RDZ\%&CS8E$2SSDD97*V5?K15(@67FHAS=RKK&TN@L 4%=;,G*L&)=VL
ME:Z9I:W>!*;1R,H.5(L@#L-14#,NO7S6G2UU/E.M%5SB4H-IZYKIUP4*M9U[
MD;<_N..;RKJ#()\U;(/W:'\T2TV[8& I>8W2<"5!XWKN7487B]3Y=PX_.6[-
M@0TNDY52CV[SM9Q[H0L(!1;6,3!:GO$*A7!$%,;3CM,;)!WPT-ZS?^YRIUQ6
MS."5$K]X::NY-_&@Q#5KA;U3VR^XRR=S?(42IOO"MO=-IQX4K;&JWH$I@IK+
M?F4ONSH< ";A!X!X!XB[N'NA+LIK9ED^TVH+VGD3FS.Z5#LT!<>E>Y1[J^F6
M$\[FWY5%2. 3+#4]M+:OP&0)-T\M;ZCT%DX?V$J@.9L%EM0<)BAVS(N>.?Z
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M\'R<>:#[-N\W5C5=:ZV4I4;MS(HF(VKG0/=K1;_8;N,$AEF;_P-02P,$%
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M3IS @Y)V8^!6EEC^#PA)5*\L.2B;)R>)"RPN(8T'D$1)?(*7]IFFGI>>R-1
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MJ)T O6\5#=SMQ1G8?6_,_P-02P,$%     @ UWUI5#M$UGWK @  -P8  !D
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MC:'8\B52:/<?=LW>P(.DTD;F#9@4Y+RH?]F^2<0!(!R< $0-(#H7T&\ _1>
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MRN'@"VDR89."@;KQPWBOD4;;'ROZ^8!Q 72_UC20G>$2]+^S_#=02P,$%
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MYM[,?<5I[]4:7>>_4;$I:TD8Y"AT)A$ZB+9VMAW%&U-^[KC"8F::!?YN0.@
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M!7U?P+@ >M]HFKG.< GZ+U;Z"E!+ P04    " #7?6E4>I>]'8(#  #G"@
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M;@H   T\   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;,V;6V_;.A*
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M_(<N-@5;?Q4\0XHR&",+8MQCA>0NTG/W':TH [Z("^7EHM+I \#,H!HJXC]
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M@W77#0OLC*#L!ES/)5;+=F(/Z'KM_ ]02P,$%     @ UWUI5 ;MLS"  P
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M(L\&D<W1O$)F084TC"63QW6;G:H;\;I3U/NO3H?&TV[X6>CW9CK9.<G)_WY
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MB9<ID,8 O\\%]M=F8MIU>ST;_P502P,$%     @ UWUI5%54*V<  P  M <
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M.OR-O9^9XRN4,/X)ASXV"J#8&:N:'DP*&BZ[-WOI\W $B+,+@*0')*> Z05
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M>C<Q8JFJ1503(Q?E*SN3!M_L<IAC5P5E#7 _D])L)O8#39_N_P%02P,$%
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
M" #7?6E49M8GI!<$  "8'@  #P   'AL+W=O<FMB;V]K+GAM;,696V_C*!2
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M*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>EMGLX1 ;T.]C4!O0[V-0&]#O8U
M;T.]C4!O0[V-0&]#O8U ;X]Z>P*]/>KM"?3VJ+<GT-NCWIY ;]_9[";0VZ/>
M_IUZQW2M0GSV/-;X_'=2G6[WAN?C[\O'R<X+=<?9P>^QQ2]02P,$%     @
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M_I.L[UJO_OHW3[O&M2J;HS_K_J7-/P%02P$"% ,4    " #7?6E4!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( -=]:51B/$*Q[P   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( -=]:5297)PC$ 8  )PG   3
M          "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
MUWUI5*#@/DAU!@  ,QT  !@              ("!#@@  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( -=]:53'C]EA:P4  ",4   8
M          " @;D.  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4
M    " #7?6E400FTCN$"  !L"@  &               @(%:%   >&PO=V]R
M:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ UWUI5.WZAXH0!   -@T
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M965T."YX;6Q02P$"% ,4    " #7?6E4(/YN*_@*  "E&@  &
M    @($*,@  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @
MUWUI5$(&V33^ @  ;P8  !D              ("!.#T  'AL+W=O<FMS:&5E
M=',O<VAE970Q,"YX;6Q02P$"% ,4    " #7?6E48RKQ$M "   ,!@  &0
M            @(%M0   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4
M Q0    ( -=]:52+M1(G!P,  #$&   9              " @71#  !X;"]W
M;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ UWUI5)WF.@;; P
M)0@  !D              ("!LD8  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX
M;6Q02P$"% ,4    " #7?6E4H[-0V^<%   H#@  &0              @('$
M2@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( -=]:507
M?E5"0P(  .D$   9              " @>)0  !X;"]W;W)K<VAE971S+W-H
M965T,34N>&UL4$L! A0#%     @ UWUI5%Q6%^/(!   A@H  !D
M     ("!7%,  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -=]:53_/T^<EP(  '<%   9              "
M@=AM  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ UWUI
M5!</Y,)[ @  704  !D              ("!IG   'AL+W=O<FMS:&5E=',O
M<VAE970R,BYX;6Q02P$"% ,4    " #7?6E4PT@\N)$"  !"!0  &0
M        @(%8<P  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0
M   ( -=]:52B\WB'$P0  /P)   9              " @2!V  !X;"]W;W)K
M<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ UWUI5+&1(6+3 P  >P@
M !D              ("!:GH  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q0
M2P$"% ,4    " #7?6E4.T36?>L"   W!@  &0              @(%T?@
M>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( -=]:51+>RN^
M<P,  $@*   9              " @9:!  !X;"]W;W)K<VAE971S+W-H965T
M,C<N>&UL4$L! A0#%     @ UWUI5(- ,%XV @  V@0  !D
M ("!0(4  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #7
M?6E4*N'O'ZT"  "^!P  &0              @(&MAP  >&PO=V]R:W-H965T
M<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( -=]:50!RQ:1;0(  ,P&   9
M          " @9&*  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#
M%     @ UWUI5,9WO8P2!   T0X  !D              ("!-8T  'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #7?6E4R]N_]M4"  "#
M"   &0              @(%^D0  >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM
M;%!+ 0(4 Q0    ( -=]:51FNDZ.) (  +T$   9              " @8J4
M  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ UWUI5'J7
MO1V" P  YPH  !D              ("!Y98  'AL+W=O<FMS:&5E=',O<VAE
M970S-"YX;6Q02P$"% ,4    " #7?6E4CS.!*&X*   -/   &0
M    @(&>F@  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    (
M -=]:53R3/';J0(  '<'   9              " @4.E  !X;"]W;W)K<VAE
M971S+W-H965T,S8N>&UL4$L! A0#%     @ UWUI5 ;MLS"  P  !@T  !D
M             ("!(Z@  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"
M% ,4    " #7?6E49IT$DOD#  !#$@  &0              @(':JP  >&PO
M=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( -=]:53XDK/V,@(
M -H$   9              " @0JP  !X;"]W;W)K<VAE971S+W-H965T,SDN
M>&UL4$L! A0#%     @ UWUI5.9X20V1 @  >@8  !D              ("!
M<[(  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #7?6E4
M$$_V\#0#  "J"0  &0              @($[M0  >&PO=V]R:W-H965T<R]S
M:&5E=#0Q+GAM;%!+ 0(4 Q0    ( -=]:5155"MG  ,  +0'   9
M      " @::X  !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%
M  @ UWUI5%!I_D*Q @  AP<  !D              ("!W;L  'AL+W=O<FMS
M:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #7?6E4<$L$Z'4#  #R"@
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M+G)E;'-02P$"% ,4    " #7?6E49M8GI!<$  "8'@  #P
M@ '$R0  >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ UWUI5+@VQ-RI 0
M+AL  !H              ( !",X  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ UWUI5%/9*RFR 0  4QL  !,              ( !
MZ<\  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     #4 -0!J#@  S-$

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>123</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>51</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficiency)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Deficiency)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 1 - Description of Business and Recent Developments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments</Role>
      <ShortName>Note 1 - Description of Business and Recent Developments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 2 - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 3 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-3-property-and-equipment</Role>
      <ShortName>Note 3 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 4 - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-4-accrued-expenses-</Role>
      <ShortName>Note 4 - Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 5 - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-5-debt</Role>
      <ShortName>Note 5 - Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 6 - Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-6-commitments</Role>
      <ShortName>Note 6 - Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 7 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-7-stockholders-equity</Role>
      <ShortName>Note 7 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 8 - Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-8-retirement-plan</Role>
      <ShortName>Note 8 - Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 9 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-9-income-taxes</Role>
      <ShortName>Note 9 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 10 - Grants and Collaboration Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue</Role>
      <ShortName>Note 10 - Grants and Collaboration Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 11 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-11-subsequent-events</Role>
      <ShortName>Note 11 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 3 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables</Role>
      <ShortName>Note 3 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-3-property-and-equipment</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 4 - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables</Role>
      <ShortName>Note 4 - Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-4-accrued-expenses-</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 5 - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-5-debt-tables</Role>
      <ShortName>Note 5 - Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-5-debt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 7 - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables</Role>
      <ShortName>Note 7 - Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-7-stockholders-equity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 9 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-9-income-taxes-tables</Role>
      <ShortName>Note 9 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-9-income-taxes</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 2 - Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 3 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual</Role>
      <ShortName>Note 3 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details</Role>
      <ShortName>Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details</Role>
      <ShortName>Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 5 - Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-5-debt-details-textual</Role>
      <ShortName>Note 5 - Debt (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-5-debt-tables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 5 - Debt - Interest Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details</Role>
      <ShortName>Note 5 - Debt - Interest Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 5 - Debt - Interest Expense (Details) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals</Role>
      <ShortName>Note 5 - Debt - Interest Expense (Details) (Parentheticals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 6 - Commitments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-6-commitments-details-textual</Role>
      <ShortName>Note 6 - Commitments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-6-commitments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 7 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual</Role>
      <ShortName>Note 7 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details</Role>
      <ShortName>Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 7 - Stockholders' Equity- Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details</Role>
      <ShortName>Note 7 - Stockholders' Equity- Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 7 - Stockholders' Equity - Summary of Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details</Role>
      <ShortName>Note 7 - Stockholders' Equity - Summary of Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 8 - Retirement Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual</Role>
      <ShortName>Note 8 - Retirement Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-8-retirement-plan</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 9 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual</Role>
      <ShortName>Note 9 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-9-income-taxes-tables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details</Role>
      <ShortName>Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 10 - Grants and Collaboration Revenue (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual</Role>
      <ShortName>Note 10 - Grants and Collaboration Revenue (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 11 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual</Role>
      <ShortName>Note 11 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-note-11-subsequent-events</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="govx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="govx20211231_10k.htm">govx20211231_10k.htm</File>
    <File>ex_339970.htm</File>
    <File>ex_339971.htm</File>
    <File>ex_339972.htm</File>
    <File>ex_343680.htm</File>
    <File>ex_344528.htm</File>
    <File>ex_344529.htm</File>
    <File>ex_344530.htm</File>
    <File>ex_344531.htm</File>
    <File>govx-20211231.xsd</File>
    <File>govx-20211231_cal.xml</File>
    <File>govx-20211231_def.xml</File>
    <File>govx-20211231_lab.xml</File>
    <File>govx-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img01.jpg</File>
    <File>img02.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="446">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "govx20211231_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 123,
   "dts": {
    "calculationLink": {
     "local": [
      "govx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "govx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "govx20211231_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "govx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "govx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "govx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 389,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 35,
    "http://geovax.com/20211231": 7,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 48
   },
   "keyCustom": 38,
   "keyStandard": 302,
   "memberCustom": 31,
   "memberStandard": 18,
   "nsprefix": "govx",
   "nsuri": "http://geovax.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://geovax.com/20211231/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 3 - Property and Equipment",
     "role": "http://geovax.com/20211231/role/statement-note-3-property-and-equipment",
     "shortName": "Note 3 - Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 4 - Accrued Expenses",
     "role": "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-",
     "shortName": "Note 4 - Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 5 - Debt",
     "role": "http://geovax.com/20211231/role/statement-note-5-debt",
     "shortName": "Note 5 - Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 6 - Commitments",
     "role": "http://geovax.com/20211231/role/statement-note-6-commitments",
     "shortName": "Note 6 - Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 7 - Stockholders' Equity",
     "role": "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
     "shortName": "Note 7 - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 8 - Retirement Plan",
     "role": "http://geovax.com/20211231/role/statement-note-8-retirement-plan",
     "shortName": "Note 8 - Retirement Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 9 - Income Taxes",
     "role": "http://geovax.com/20211231/role/statement-note-9-income-taxes",
     "shortName": "Note 9 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "govx:GovernmentGrantsandContractsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 10 - Grants and Collaboration Revenue",
     "role": "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
     "shortName": "Note 10 - Grants and Collaboration Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "govx:GovernmentGrantsandContractsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 11 - Subsequent Events",
     "role": "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
     "shortName": "Note 11 - Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "role": "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://geovax.com/20211231/role/statement-consolidated-balance-sheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 3 - Property and Equipment (Tables)",
     "role": "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables",
     "shortName": "Note 3 - Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 4 - Accrued Expenses (Tables)",
     "role": "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables",
     "shortName": "Note 4 - Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "govx:InterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 5 - Debt (Tables)",
     "role": "http://geovax.com/20211231/role/statement-note-5-debt-tables",
     "shortName": "Note 5 - Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "govx:InterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 7 - Stockholders' Equity (Tables)",
     "role": "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables",
     "shortName": "Note 7 - Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 9 - Income Taxes (Tables)",
     "role": "http://geovax.com/20211231/role/statement-note-9-income-taxes-tables",
     "shortName": "Note 9 - Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SummaryOfValuationAllowanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)",
     "role": "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SummaryOfValuationAllowanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "role": "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
     "shortName": "Note 2 - Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 3 - Property and Equipment (Details Textual)",
     "role": "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual",
     "shortName": "Note 3 - Property and Equipment (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "role": "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
     "shortName": "Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "govx:AccruedLicenseFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "role": "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
     "shortName": "Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "govx:AccruedLicenseFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2018-02-28_2018-02-28",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 5 - Debt (Details Textual)",
     "role": "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
     "shortName": "Note 5 - Debt (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2018-02-28_2018-02-28",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromNotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 5 - Debt - Interest Expense (Details)",
     "role": "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details",
     "shortName": "Note 5 - Debt - Interest Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "govx:InterestExpenseDisclosureTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_LongtermDebtTypeAxis-SeniorNotesMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:InterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 5 - Debt - Interest Expense (Details) (Parentheticals)",
     "role": "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals",
     "shortName": "Note 5 - Debt - Interest Expense (Details) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "govx:LicensingAgreementFutureMinimumPaymentsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 6 - Commitments (Details Textual)",
     "role": "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual",
     "shortName": "Note 6 - Commitments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "govx:LicensingAgreementFutureMinimumPaymentsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2020-09-29_2020-09-29",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "govx:ProceedsFromIssuanceOrSaleOfEquityGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 7 - Stockholders' Equity (Details Textual)",
     "role": "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
     "shortName": "Note 7 - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2020-09-29_2020-09-29",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "govx:ProceedsFromIssuanceOrSaleOfEquityGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)",
     "role": "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
     "shortName": "Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note 7 - Stockholders' Equity- Stock Option Activity (Details)",
     "role": "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details",
     "shortName": "Note 7 - Stockholders' Equity- Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note 7 - Stockholders' Equity - Summary of Warrants Outstanding (Details)",
     "role": "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details",
     "shortName": "Note 7 - Stockholders' Equity - Summary of Warrants Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Note 8 - Retirement Plan (Details Textual)",
     "role": "http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual",
     "shortName": "Note 8 - Retirement Plan (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "role": "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Note 9 - Income Taxes (Details Textual)",
     "role": "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual",
     "shortName": "Note 9 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31_TaxCreditCarryforwardAxis-ResearchMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCreditCarryforwardAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "role": "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details",
     "shortName": "Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details)",
     "role": "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details",
     "shortName": "Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Note 10 - Grants and Collaboration Revenue (Details Textual)",
     "role": "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual",
     "shortName": "Note 10 - Grants and Collaboration Revenue (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "govx:GovernmentGrantsandContractsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "govx:UnusedGrantFunds",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PreferredStockTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-02-11_2021-02-11",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Note 11 - Subsequent Events (Details Textual)",
     "role": "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
     "shortName": "Note 11 - Subsequent Events (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2022-01-19_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)",
     "role": "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfValuationAllowanceTextBlock",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-ValuationAllowanceOfDeferredTaxAssetsMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficiency)",
     "role": "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficiency)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-PreferredStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows (Parentheticals)",
     "role": "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
     "shortName": "Consolidated Statements of Cash Flows (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 1 - Description of Business and Recent Developments",
     "role": "http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments",
     "shortName": "Note 1 - Description of Business and Recent Developments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 2 - Summary of Significant Accounting Policies",
     "role": "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
     "shortName": "Note 2 - Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "govx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 51,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20211231/role/statement-document-and-entity-information",
      "http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals",
      "http://geovax.com/20211231/role/statement-note-5-debt-tables",
      "http://geovax.com/20211231/role/statement-note-6-commitments",
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables",
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan",
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-tables",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20211231/role/statement-document-and-entity-information",
      "http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals",
      "http://geovax.com/20211231/role/statement-note-5-debt-tables",
      "http://geovax.com/20211231/role/statement-note-6-commitments",
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables",
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan",
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-tables",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "govx_AccruedExpensesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents noncurrent accrued expenses.",
        "label": "Accrued expenses \u2013 noncurrent"
       }
      }
     },
     "localname": "AccruedExpensesNoncurrent",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_AccruedLiabilitiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding accrued liabilities.",
        "label": "Accrued Liabilities [Policy Text Block]"
       }
      }
     },
     "localname": "AccruedLiabilitiesPolicyTextBlock",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "govx_AccruedLicenseFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents current accrued license fees.",
        "label": "Accrued license fees \u2013 current"
       }
      }
     },
     "localname": "AccruedLicenseFeesCurrent",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_AccruedLicenseFeesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents long-term accrued license fees.",
        "label": "Accrued license fees \u2013 noncurrent"
       }
      }
     },
     "localname": "AccruedLicenseFeesNoncurrent",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_CapitalUnitsTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the tranche one capital units.",
        "label": "Capital Units Tranche One [Member]"
       }
      }
     },
     "localname": "CapitalUnitsTrancheOneMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during period.",
        "label": "govx_ClassOfWarrantOrRightExercisedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_ClassOfWarrantOrRightIssuedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights issued during period.",
        "label": "govx_ClassOfWarrantOrRightIssuedDuringPeriod",
        "terseLabel": "Class Of Warrant Or Right, Issued During Period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringPeriod",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_ConversionFromConvertibleDebenturesToConversionUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion of convertible debentures to conversion units.",
        "label": "Conversion from Convertible Debentures to Conversion Units [Member]"
       }
      }
     },
     "localname": "ConversionFromConvertibleDebenturesToConversionUnitsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfConvertibleDebentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to conversion of convertible debenture.",
        "label": "Conversion of Convertible Debenture [Member]"
       }
      }
     },
     "localname": "ConversionOfConvertibleDebentureMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about conversion of series H, Series I, and Series J preferred stock into common stock.",
        "label": "Conversion of Series H, Series I, and Series J Preferred Stock into Common Stock [Member]"
       }
      }
     },
     "localname": "ConversionOfSeriesHSeriesIAndSeriesJPreferredStockIntoCommonStockMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConversionWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the conversion warrants.",
        "label": "Conversion Warrants [Member]"
       }
      }
     },
     "localname": "ConversionWarrantsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ConvertibleDebenturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to convertible debenture.",
        "label": "Convertible Debentures [Member]"
       }
      }
     },
     "localname": "ConvertibleDebenturesMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_DebtConversionAccruedInterestAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the debt accrued interest being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Related accrued interest"
       }
      }
     },
     "localname": "DebtConversionAccruedInterestAmount",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt and interest is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "govx_DebtConversionConvertedInstrumentPrincipalAndInterestAmount",
        "terseLabel": "Debt Conversion, Converted Instrument, Principal and Interest, Amount"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentPrincipalAndInterestAmount",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_DeferredCompensationLiabilityConversionToEquityAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deferred compensation liability being converted into equity in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Deferred compensation",
        "terseLabel": "Deferred Compensation Liability Conversion to Equity, Amount"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityConversionToEquityAmount",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_DeferredCompensationLiabilityConversionToEquityConversionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share for the conversion of deferred compensation liability to equity.",
        "label": "govx_DeferredCompensationLiabilityConversionToEquityConversionPrice",
        "terseLabel": "Deferred Compensation Liability Conversion to Equity, Conversion Price (in dollars per share)"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityConversionToEquityConversionPrice",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "govx_DeferredTaxAssetsAccruedSalaries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued salaries.",
        "label": "Accrued salaries"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccruedSalaries",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_DeferredTaxAssetsBeforeValuationAllowanceNet": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances and after deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "govx_DeferredTaxAssetsBeforeValuationAllowanceNet",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsBeforeValuationAllowanceNet",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_EquipmentAndFurnishingsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents equipment and furnishings.",
        "label": "Equipment and Furnishings [Member]"
       }
      }
     },
     "localname": "EquipmentAndFurnishingsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of expense related to consulting and investment banking agreements.",
        "label": "Expense Related To Consulting And Investment Banking Agreements [Member]"
       }
      }
     },
     "localname": "ExpenseRelatedToConsultingAndInvestmentBankingAgreementsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ExtinguishmentOfDebtIncludingInterestAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount extinguishment of debt including interest amount.",
        "label": "Extinguishment of debt"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtIncludingInterestAmount",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_GainLossFromInterestForgiven": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents gain (loss) from interest forgiven.",
        "label": "govx_GainLossFromInterestForgiven",
        "terseLabel": "Gain (Loss) from Interest Forgiven"
       }
      }
     },
     "localname": "GainLossFromInterestForgiven",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_GovernmentGrantsandContractsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.",
        "label": "Government Grants and Contracts [Text Block]"
       }
      }
     },
     "localname": "GovernmentGrantsandContractsTextBlock",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "govx_InsurancePremiumFinancingCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance Premium Financing Costs[Member]"
       }
      }
     },
     "localname": "InsurancePremiumFinancingCostsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_InterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest expense, including, but not limited to, interest expense from investments, loans, and securities.",
        "label": "Interest Expense Disclosure [Table Text Block]"
       }
      }
     },
     "localname": "InterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "govx_June2020WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to June 2020 warrants.",
        "label": "June 2020 Warrants [Member]"
       }
      }
     },
     "localname": "June2020WarrantsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future payments receivable within one year of the balance sheet date under a licensing agreement.",
        "label": "govx_LicensingAgreementFutureMinimumPaymentsReceivableCurrent",
        "terseLabel": "Licensing Agreement, Future Minimum Payments Receivable, Current"
       }
      }
     },
     "localname": "LicensingAgreementFutureMinimumPaymentsReceivableCurrent",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future payments receivable within the fifth year from the balance sheet date under a licensing agreement.",
        "label": "govx_LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears",
        "terseLabel": "Licensing Agreement, Future Minimum Payments Receivable, in Five Years"
       }
      }
     },
     "localname": "LicensingAgreementFutureMinimumPaymentsReceivableInFiveYears",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future payments receivable within the fourth year from the balance sheet date under a licensing agreement.",
        "label": "govx_LicensingAgreementFutureMinimumPaymentsReceivableInFourYears",
        "terseLabel": "Licensing Agreement, Future Minimum Payments Receivable, in Four Years"
       }
      }
     },
     "localname": "LicensingAgreementFutureMinimumPaymentsReceivableInFourYears",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future payments receivable within the third year from the balance sheet date under a licensing agreement.",
        "label": "govx_LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears",
        "terseLabel": "Licensing Agreement, Future Minimum Payments Receivable, in Three Years"
       }
      }
     },
     "localname": "LicensingAgreementFutureMinimumPaymentsReceivableInThreeYears",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future payments receivable within the second year from the balance sheet date under a licensing agreement.",
        "label": "govx_LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears",
        "terseLabel": "Licensing Agreement, Future Minimum Payments Receivable, in Two Years"
       }
      }
     },
     "localname": "LicensingAgreementFutureMinimumPaymentsReceivableInTwoYears",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_ManagementWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the management warrant.",
        "label": "Management Warrant [Member]"
       }
      }
     },
     "localname": "ManagementWarrantMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_NIHGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grants from the National Institutes of Health (NIH).",
        "label": "NIH Grants [Member]"
       }
      }
     },
     "localname": "NIHGrantsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_NumberOfCommonStockSecuritiesCalledByEachUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock securities into which each unit may be converted.",
        "label": "govx_NumberOfCommonStockSecuritiesCalledByEachUnit",
        "terseLabel": "Number of Common Stock Securities Called by Each Unit (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockSecuritiesCalledByEachUnit",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_NumberOfWarrantsCalledByEachUnit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants into which each unit may be converted.",
        "label": "govx_NumberOfWarrantsCalledByEachUnit",
        "terseLabel": "Number of Warrants Called by Each Unit (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsCalledByEachUnit",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_OfficeAndLaboratoryLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to office and laboratory lease agreement.",
        "label": "Office and Laboratory Lease Agreement [Member]"
       }
      }
     },
     "localname": "OfficeAndLaboratoryLeaseAgreementMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments",
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward subject to expiration, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "govx_OperatingLossCarryforwardsSubjectToExpiration",
        "terseLabel": "Operating Loss Carryforwards, Subject to Expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_PaycheckProtectionProgramCaresActMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents loan designed to provide funds for small businesses to keep their employees on the payroll.",
        "label": "Paycheck Protection Program CARES Act [Member]"
       }
      }
     },
     "localname": "PaycheckProtectionProgramCaresActMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the pre-funded warrants.",
        "label": "Pre-Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of stock issued for services during period recorded as prepaid expense.",
        "label": "govx_PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod",
        "terseLabel": "Prepaid Expense, Value of Stock Issued for Services During Period"
       }
      }
     },
     "localname": "PrepaidExpenseValueOfStockIssuedForServicesDuringPeriod",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_ProceedsFromConvertibleDebtGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to gross proceeds from convertible debt.",
        "label": "govx_ProceedsFromConvertibleDebtGross",
        "terseLabel": "Proceeds from Convertible Debt, Gross"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebtGross",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of common stock and warrants.",
        "label": "Net proceeds from sale of common stock and warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_ProceedsFromIssuanceOrSaleOfEquityGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "govx_ProceedsFromIssuanceOrSaleOfEquityGross",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquityGross",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_ProceedsFromWarrantExercisesGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from warrant exercises before deducting costs.",
        "label": "govx_ProceedsFromWarrantExercisesGross",
        "terseLabel": "Proceeds from Warrant Exercises, Gross"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercisesGross",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_RemainingLifeOnWarrantsOutstandingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Remaining Life on Warrants Outstanding[Member]"
       }
      }
     },
     "localname": "RemainingLifeOnWarrantsOutstandingMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_RepresentativeWarrants2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2020 representative warrants.",
        "label": "Representative Warrants 2020 [Member]"
       }
      }
     },
     "localname": "RepresentativeWarrants2020Member",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_RepresentativeWarrants2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2021 representative warrants.",
        "label": "Representative Warrants 2021 [Member]"
       }
      }
     },
     "localname": "RepresentativeWarrants2021Member",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ResearchAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Agreements [Member]",
        "label": "Research Agreements [Member]"
       }
      }
     },
     "localname": "ResearchAgreementsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_ReverseStockSplitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The conversion of a reverse stock split where there is a reduction in the shares outstanding.",
        "label": "Reverse Stock Split [Member]"
       }
      }
     },
     "localname": "ReverseStockSplitMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Series B Convertible Preferred Stock.",
        "label": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_StockIncentivePlan2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to 2020 stock incentive plan.",
        "label": "Stock Incentive Plan 2020 [Member]"
       }
      }
     },
     "localname": "StockIncentivePlan2020Member",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period for the cancellation of accrued compensation.",
        "label": "Common stock issued for cancellation of accrued compensation (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Cancellation of Accrued Compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCancellationOfAccruedCompensation",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_StockIssuedDuringPeriodSharesDebentureConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of debenture conversion.",
        "label": "Issuance of common stock upon debenture conversion (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesDebentureConversion",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares of common stock issued during the period upon exercise of warrants.",
        "label": "Common stock issued (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Warrants Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_StockIssuedDuringPeriodValueCancellationOfAccruedCompensation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cancellation of accrued compensation.",
        "label": "Issuance of common stock upon cancellation of accrued compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCancellationOfAccruedCompensation",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockIssuedDuringPeriodValueDebentureConversion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon Debenture Conversion.",
        "label": "Issuance of common stock upon debenture conversion"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueDebentureConversion",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockIssuedDuringPeriodValueReverseStockSplits": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in value of shares as a result of reverse stock split.",
        "label": "Roundup of shares following reverse stock split"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueReverseStockSplits",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockIssuedDuringPeriodValueWarrantExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the exercise of warrants.",
        "label": "Issuance of common stock upon warrant exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantExercise",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_StockPurchaseWarrantsFirstIssuanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock purchase warrants, first issuance.",
        "label": "Stock Purchase Warrants First Issuance [Member]"
       }
      }
     },
     "localname": "StockPurchaseWarrantsFirstIssuanceMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_StockPurchaseWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to stock purchase warrants.",
        "label": "Stock Purchase Warrants [Member]"
       }
      }
     },
     "localname": "StockPurchaseWarrantsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_UnitWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the unit warrant.",
        "label": "Unit Warrant [Member]"
       }
      }
     },
     "localname": "UnitWarrantMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_UnitWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the unit warrants.",
        "label": "Unit Warrants [Member]"
       }
      }
     },
     "localname": "UnitWarrantsMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_UnusedGrantFunds": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of grant funds available for use.",
        "label": "govx_UnusedGrantFunds",
        "terseLabel": "Unused Grant Funds"
       }
      }
     },
     "localname": "UnusedGrantFunds",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "govx_UpfrontFeesCOHAndPNPLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents upfront fees for COH and PNP license.",
        "label": "Upfront Fees for COH and PNP License[Member]"
       }
      }
     },
     "localname": "UpfrontFeesCOHAndPNPLicenseMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_WarrantIssuedForTechnologyLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents warrant issued for technology license.",
        "label": "Warrant Issued for Technology License[Member]"
       }
      }
     },
     "localname": "WarrantIssuedForTechnologyLicenseMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_Warrants2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2020 warrants.",
        "label": "Warrants 2020 [Member]"
       }
      }
     },
     "localname": "Warrants2020Member",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_Warrants2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2021 warrants.",
        "label": "Warrants 2021 [Member]"
       }
      }
     },
     "localname": "Warrants2021Member",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_WarrantsIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in noncash financing activities.",
        "label": "Warrant issued (in shares)"
       }
      }
     },
     "localname": "WarrantsIssued",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "govx_WarrantsIssuedInPrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the warrants issued in the private placement.",
        "label": "Warrants Issued in Private Placement [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInPrivatePlacementMember",
     "nsuri": "http://geovax.com/20211231",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "govx_statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Property and Equipment - Schedule of Property and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-3-property-and-equipment-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Property and Equipment"
       }
      }
     },
     "localname": "statement-statement-note-3-property-and-equipment-tables",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Accrued Expenses - Schedule of Accrued Expenses (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-4-accrued-expenses-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Accrued Expenses"
       }
      }
     },
     "localname": "statement-statement-note-4-accrued-expenses-tables",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-5-debt-interest-expense-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Debt - Interest Expense (Details)"
       }
      }
     },
     "localname": "statement-statement-note-5-debt-interest-expense-details",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-5-debt-interest-expense-details-parentheticals": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Debt - Interest Expense (Details) (Parentheticals)"
       }
      }
     },
     "localname": "statement-statement-note-5-debt-interest-expense-details-parentheticals",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-5-debt-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 5 - Debt"
       }
      }
     },
     "localname": "statement-statement-note-5-debt-tables",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity - Significant Assumption Used in Fair Value Calculation (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-7-stockholders-equity-stock-option-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity- Stock Option Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-stockholders-equity-stock-option-activity-details",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity - Summary of Warrants Outstanding (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-7-stockholders-equity-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stockholders' Equity"
       }
      }
     },
     "localname": "statement-statement-note-7-stockholders-equity-tables",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes - Reconciliation of Income Tax Benefit (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-note-9-income-taxes-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Income Taxes"
       }
      }
     },
     "localname": "statement-statement-note-9-income-taxes-tables",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule II - Valuation and Qualifying Accounts (Details)"
       }
      }
     },
     "localname": "statement-statement-schedule-ii-valuation-and-qualifying-accounts-details",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "govx_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://geovax.com/20211231",
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r178",
      "r211",
      "r245",
      "r246",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r385",
      "r387",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r178",
      "r211",
      "r245",
      "r246",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r385",
      "r387",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r144",
      "r229",
      "r230",
      "r364",
      "r384",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r144",
      "r229",
      "r230",
      "r364",
      "r384",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r178",
      "r211",
      "r232",
      "r245",
      "r246",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r385",
      "r387",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r178",
      "r211",
      "r232",
      "r245",
      "r246",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r385",
      "r387",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r353",
      "r355",
      "r358",
      "r397",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance.",
        "label": "Weighted Average [Member]"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r27",
      "r349"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r370",
      "r381"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrentAndNoncurrent": {
     "auth_ref": [
      "r370",
      "r381"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.",
        "label": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r25",
      "r154"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r274",
      "r275",
      "r276",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r248",
      "r250",
      "r280",
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock option expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r174",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Warrants issued in bridge financing"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.",
        "label": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Total adjustments"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r250",
      "r271",
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r53",
      "r63",
      "r198",
      "r329"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 7.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Debt discount amortization"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "us-gaap_AreaOfRealEstateProperty",
        "terseLabel": "Area of Real Estate Property (Square Foot)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r79",
      "r133",
      "r136",
      "r142",
      "r148",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r309",
      "r312",
      "r319",
      "r347",
      "r349",
      "r366",
      "r376"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r41",
      "r79",
      "r148",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r309",
      "r312",
      "r319",
      "r347",
      "r349"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r251",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalUnitsMember": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of ownership interest in a corporation. Class of capital units or capital shares.",
        "label": "Capital Units [Member]"
       }
      }
     },
     "localname": "CapitalUnitsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r22",
      "r65"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r6",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r59",
      "r65",
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r59",
      "r320"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r77",
      "r79",
      "r104",
      "r105",
      "r106",
      "r108",
      "r110",
      "r115",
      "r116",
      "r117",
      "r148",
      "r162",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r209",
      "r210",
      "r212",
      "r213",
      "r319",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20211231/role/statement-document-and-entity-information",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r218",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Exercise price (in dollars per share)",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Number of warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r36",
      "r160",
      "r371",
      "r380"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments (Note 6)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.",
        "label": "Commitments Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance",
        "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r92",
      "r93",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r349"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $.001 par value: Authorized shares \u2013 600,000,000 Issued and outstanding shares \u2013 6,381,541 and 3,834,095 at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockByUniqueDescriptionAxis": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of stock conversions.",
        "label": "Stock Conversion Description [Axis]"
       }
      }
     },
     "localname": "ConversionOfStockByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConversionOfStockNameDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unique name of a noncash or part noncash stock conversion.",
        "label": "Conversion of Stock, Name [Domain]"
       }
      }
     },
     "localname": "ConversionOfStockNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Shares issued (in shares)",
        "terseLabel": "Conversion of Stock, Shares Issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r173",
      "r175",
      "r176",
      "r178",
      "r188",
      "r189",
      "r190",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r202",
      "r203",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionByUniqueDescriptionAxis": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.",
        "label": "Debt Conversion Description [Axis]"
       }
      }
     },
     "localname": "DebtConversionByUniqueDescriptionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentSharesIssued1": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or payments in the period.",
        "label": "Shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Pre-funded stock purchase warrants (in shares)",
        "terseLabel": "Debt Conversion, Converted Instrument, Warrants or Options Issued (in shares)"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_DebtConversionNameDomain": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Name [Domain]"
       }
      }
     },
     "localname": "DebtConversionNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r68",
      "r70"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Convertible debentures"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r192",
      "r199",
      "r200",
      "r201",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r78",
      "r82",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r202",
      "r203",
      "r204",
      "r205",
      "r332",
      "r367",
      "r368",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r175",
      "r202",
      "r203",
      "r330",
      "r332",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r34",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "us-gaap_DebtInstrumentInterestRateStatedPercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r35",
      "r78",
      "r82",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r188",
      "r189",
      "r190",
      "r191",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r202",
      "r203",
      "r204",
      "r205",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_DebtInstrumentTerm",
        "terseLabel": "Debt Instrument, Term (Year)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r292"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred tax asset after reduction for valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r295",
      "r297",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research and development tax credit carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r291"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r297",
      "r298"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "govx_DeferredTaxAssetsBeforeValuationAllowanceNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssets": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.",
        "label": "Deposits"
       }
      }
     },
     "localname": "DepositsAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r63",
      "r152"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "us-gaap_DepreciationAndAmortization",
        "terseLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r63",
      "r131"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 6.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-6-commitments",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per common share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and diluted:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r45",
      "r46",
      "r47",
      "r92",
      "r93",
      "r94",
      "r96",
      "r101",
      "r103",
      "r114",
      "r149",
      "r214",
      "r216",
      "r274",
      "r275",
      "r276",
      "r300",
      "r301",
      "r314",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r388",
      "r389",
      "r390",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "us-gaap_ExtinguishmentOfDebtAmount",
        "terseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r63",
      "r206",
      "r207"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain on debt extinguishment",
        "negatedLabel": "Gain on debt extinguishment",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt, Total"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grant funds and other receivables"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r151",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r80",
      "r287",
      "r289",
      "r294",
      "r302",
      "r304",
      "r306",
      "r307",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r81",
      "r102",
      "r103",
      "r132",
      "r285",
      "r303",
      "r305",
      "r383"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "totalLabel": "Reported income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r44",
      "r283",
      "r284",
      "r289",
      "r290",
      "r293",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance, net of expired items and other adjustments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "U.S. federal statutory rate applied to pretax loss"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Permanent differences"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "us-gaap_IncomeTaxReconciliationTaxCreditsResearch",
        "negatedLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r60",
      "r67"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "us-gaap_IncomeTaxesPaid",
        "terseLabel": "Income Taxes Paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
        "verboseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInReceivables",
        "negatedLabel": "Grant funds and other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r74",
      "r150",
      "r361",
      "r362",
      "r363",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Finite-Lived, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r48",
      "r130",
      "r328",
      "r331",
      "r373"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "GRA Note",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterimPeriodCostsNotAllocableDomain": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.",
        "label": "Interim Period, Costs Not Allocable [Domain]"
       }
      }
     },
     "localname": "InterimPeriodCostsNotAllocableDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r51",
      "r129"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Warrant issued for technology license fee"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments",
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments",
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r336"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "terseLabel": "Lessee, Operating Lease, Liability, to be Paid, Year One"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r31",
      "r79",
      "r137",
      "r148",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r310",
      "r312",
      "r313",
      "r319",
      "r347",
      "r348"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r79",
      "r148",
      "r319",
      "r349",
      "r369",
      "r378"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r79",
      "r148",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r310",
      "r312",
      "r313",
      "r319",
      "r347",
      "r348",
      "r349"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Note payable, net of current portion"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r35",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfExpenseAxis": {
     "auth_ref": [
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cost or expense.",
        "label": "Nature of Expense [Axis]"
       }
      }
     },
     "localname": "NatureOfExpenseAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r118",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r59",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r42",
      "r43",
      "r47",
      "r49",
      "r64",
      "r79",
      "r95",
      "r97",
      "r98",
      "r99",
      "r100",
      "r102",
      "r103",
      "r107",
      "r133",
      "r135",
      "r138",
      "r141",
      "r143",
      "r148",
      "r162",
      "r163",
      "r164",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r315",
      "r319",
      "r372",
      "r382"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonmonetaryTransactionTypeAxis": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.",
        "label": "Nonmonetary Transaction Type [Axis]"
       }
      }
     },
     "localname": "NonmonetaryTransactionTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonmonetaryTransactionTypeDomain": {
     "auth_ref": [
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies the nature of the nonmonetary transaction or group of similar transactions, such as a barter or exchange.",
        "label": "Nonmonetary Transaction Type [Domain]"
       }
      }
     },
     "localname": "NonmonetaryTransactionTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "us-gaap_OperatingExpenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r133",
      "r135",
      "r138",
      "r141",
      "r143"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r370",
      "r381"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.",
        "label": "us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock",
        "negatedLabel": "Repurchase of preferred stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r251",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value (in dollars per share)",
        "terseLabel": "Preferred Stock, Par or Stated Value Per Share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding (in shares)",
        "terseLabel": "Preferred Stock, Shares Outstanding, Ending Balance (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r349"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, $.01 par value: Authorized shares \u2013 10,000,000 Series B convertible preferred stock, $1,000 stated value; -0- and 100 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Net proceeds from bridge financing"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "us-gaap_ProceedsFromIssuanceOfCommonStock",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.",
        "label": "Net proceeds from sale of preferred stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r55"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Net proceeds from issuance of note payable",
        "terseLabel": "Proceeds from Notes Payable, Total"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Net proceeds from warrant exercises",
        "terseLabel": "Proceeds from Warrant Exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r25",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r157",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r24",
      "r153"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r7",
      "r8",
      "r155",
      "r349",
      "r374",
      "r379"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r23",
      "r155",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r7",
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r7",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "us-gaap_RepaymentsOfNotesPayable",
        "negatedLabel": "Principal repayment of note payable",
        "terseLabel": "Repayments of Notes Payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r282",
      "r360",
      "r399"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development",
        "terseLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r216",
      "r277",
      "r349",
      "r377",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r92",
      "r93",
      "r94",
      "r96",
      "r101",
      "r103",
      "r149",
      "r274",
      "r275",
      "r276",
      "r300",
      "r301",
      "r314",
      "r388",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r127",
      "r128",
      "r134",
      "r139",
      "r140",
      "r144",
      "r145",
      "r146",
      "r228",
      "r229",
      "r364"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Grant and collaboration revenue",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r75",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r255",
      "r261",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r218",
      "r249"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Weighted average risk-free interest rates"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Exercisable, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r257",
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
        "periodEndLabel": "Outstanding (in shares)",
        "periodStartLabel": "Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r249",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted, weighted average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r251",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r266",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected life of option (in years) (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r273"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Exercisable, weighted average remaining contractual term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Outstanding, weighted average remaining contractual term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r72",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r77",
      "r79",
      "r104",
      "r105",
      "r106",
      "r108",
      "r110",
      "r115",
      "r116",
      "r117",
      "r148",
      "r162",
      "r166",
      "r167",
      "r168",
      "r171",
      "r172",
      "r209",
      "r210",
      "r212",
      "r213",
      "r214",
      "r319",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20211231/role/statement-document-and-entity-information",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r39",
      "r45",
      "r46",
      "r47",
      "r92",
      "r93",
      "r94",
      "r96",
      "r101",
      "r103",
      "r114",
      "r149",
      "r214",
      "r216",
      "r274",
      "r275",
      "r276",
      "r300",
      "r301",
      "r314",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r388",
      "r389",
      "r390",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals",
      "http://geovax.com/20211231/role/statement-note-5-debt-tables",
      "http://geovax.com/20211231/role/statement-note-6-commitments",
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables",
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan",
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-tables",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r114",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-cash-flows-parentheticals",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations",
      "http://geovax.com/20211231/role/statement-note-1-description-of-business-and-recent-developments",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue",
      "http://geovax.com/20211231/role/statement-note-10-grants-and-collaboration-revenue-details-textual",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies",
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-details-textual",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-schedule-of-property-and-equipment-details",
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-schedule-of-accrued-expenses-details",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20211231/role/statement-note-5-debt",
      "http://geovax.com/20211231/role/statement-note-5-debt-details-textual",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details",
      "http://geovax.com/20211231/role/statement-note-5-debt-interest-expense-details-parentheticals",
      "http://geovax.com/20211231/role/statement-note-5-debt-tables",
      "http://geovax.com/20211231/role/statement-note-6-commitments",
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-significant-assumption-used-in-fair-value-calculation-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables",
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan",
      "http://geovax.com/20211231/role/statement-note-8-retirement-plan-details-textual",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-reconciliation-of-income-tax-benefit-details",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-tables",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r38",
      "r193",
      "r214",
      "r215",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Conversion of preferred stock to common stock (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Issuance of common stock for services (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, Issued for Services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Sale of common stock for cash (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Sale of convertible preferred stock for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.",
        "label": "Roundup of shares following reverse stock split (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r214",
      "r216",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r39",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Conversion of preferred stock to common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Issuance of common stock for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r214",
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Sale of common stock for cash",
        "terseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Sale of convertible preferred stock for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r13",
      "r14",
      "r214",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "us-gaap_StockRepurchasedDuringPeriodShares",
        "negatedLabel": "Repurchase of preferred stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r13",
      "r14",
      "r214",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "us-gaap_StockRepurchasedDuringPeriodValue",
        "negatedLabel": "Repurchase of preferred stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r17",
      "r18",
      "r79",
      "r147",
      "r148",
      "r319",
      "r349"
     ],
     "calculation": {
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets",
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-deficiency"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1",
        "terseLabel": "Stockholders' Equity Note, Stock Split, Conversion Ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r327",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r327",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r327",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r350",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events",
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfValuationAllowanceTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance.",
        "label": "Summary of Valuation Allowance [Table Text Block]"
       }
      }
     },
     "localname": "SummaryOfValuationAllowanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-3-property-and-equipment-tables",
      "http://geovax.com/20211231/role/statement-note-4-accrued-expenses-tables",
      "http://geovax.com/20211231/role/statement-note-5-debt-tables",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-tables",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-tables",
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-9-income-taxes",
      "http://geovax.com/20211231/role/statement-note-9-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).",
        "label": "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
        "terseLabel": "Unrecorded Unconditional Purchase Obligation, Total"
       }
      }
     },
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-6-commitments-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward.",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]"
       }
      }
     },
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r83",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "us-gaap_ValuationAllowancesAndReservesBalance",
        "periodEndLabel": "Balance at End Of Period",
        "periodStartLabel": "Balance at Beginning Of Period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "Additions Charged to Costs and Expenses"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.",
        "label": "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts",
        "terseLabel": "Additions Charged to Other Accounts"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "us-gaap_ValuationAllowancesAndReservesDeductions",
        "negatedTerseLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r83",
      "r84",
      "r85",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-Average Remaining Life (in years) (Year)",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-note-11-subsequent-events-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-details-textual",
      "http://geovax.com/20211231/role/statement-note-7-stockholders-equity-summary-of-warrants-outstanding-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average shares outstanding (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://geovax.com/20211231/role/statement-consolidated-statements-of-operations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e639-108305"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29470-108402"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29502-108402"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123368017&loc=d3e29515-108402"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=123385986&loc=d3e32049-108421"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "845",
   "URI": "http://asc.fasb.org/extlink&oid=6457341&loc=d3e32102-108422"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04.16)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r401": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r402": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r403": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r404": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r405": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r406": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r407": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r408": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r409": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001437749-22-005677-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-005677-xbrl.zip
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MF7>4R@WGL=14I4_R%GG^A0O"-&DK75 R@(C86ZO173HK=$F&E*NQW"$6PTA
M@A:<[#S)9_0E'K1*K+D!QM58YY53N]TJ5#MK)KJS1\=/JF/%*H!LQ0]I >.8
MDQ4(AST0[?T"1V 4@P#!C^&]A@9'*[&F'S*1?> L6CH<O'?@BLZ::"?FFL'7
MX/D61J+G.B^(L\1>GC5@T:4):RKMGJI=O0=+SK6]3'>36N]Q6&0\!^/B$Z2$
MECKI+/04MM5FN T8/9>UA_,KUQU)5&ENP7S7\A>T5L"N<R+ZB=H=[:'(N#.D
M ]<,94UODA6&3<Z@1R[VT)8CP<_GILRPG I*A[RF!H*]':\P%X6 C70SH ?>
M;/]7_VT>+CRBBR6J=^K>_B"Y]#"E="^BM3532BTE3V:=M!(P]74"UOP(*\[
M,>&6:TPEOE(+K$.3U@V7JYJ#J6 K'NK$%M@JKDI3I4 <WJ!RNN J95JFA,>H
M(G<UCC/;4TBX-#;-I2;:>C+I^K'C6E/QM9C]X@V!Y< \440F@62@2?CMG^=
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MF'"'?V1R R>%;D'75P0MP#"I)I/OEBP_CYC"+_=158)%4H7#*E82202@QOT
MV\]T+?'/N8], ]NL(M;@TP6:+][U\UU)%]1?UV2Z8 I2X0P_0;%L<4^[3JS9
MM6F-3HDO0A+X.%)+27A2P(1#RA&THBV'$JZ.G[<.%E^KO+795V/B>=_#]"HW
M1:;>MTC"5= L.GU"B17X<I*/<O;OX/$X9],&U\Y[43@!"PO/8)P629%N)6.P
M&VOZR@@&@:HG$I87[1@4?; (:>02"B^3U99Z!]H-SG!2:=S0=C8BX'A2$3Q2
M!!RZ8C!_V6,".B"@1&+&TRD, )&]_Q)QS@2 ;CQ.=&:/Q%RG('YRO=]>@\;0
M(9.%[]1I>0<G!K7[]A^G>_(@?V="\5X$Q' "VX2\B/D4+#"[+RJ',4-2^D+\
M=N+@89\<SG)P.NMFLVJS8A5]8@E* (SP,\/'JZW-]0DJB=$GH202U>J%GIH0
ML0SMD6J(\J:\;]U?]]"'.Z<HNC 7"/.9R<[#;G!7$SG:+;#X-J84S&IQ[J+@
M[*H!@N*(%SOV!9)3>"H9KSZ/':5R],4ZY!(#JB1C=E/8:@OWV,(]_D/@'ILG
MIM,_F)@. A<M/7(7UUA>@CQRZ(QJM!2\8WENHC!O:]P/A&6YQ%ZG.D'WN!M;
M_!U#GZL%@#6>%SD53\5&$(B;=$XHOFJ 3_F@LB0X78Y1,:32)^3+L#,VX]B2
M&H*26K70'_6TE#%S^0>P*<MZ$F)CT?+AF,6328-9!U FIV54+"B/JCG/<UN(
MXS6&TLZI/JH+IA^BURGNIXX/$WJH:DIR,,H[*PZ%]GHFA"5G[0PI(CQ<*9;7
M@HXH-"T>' QDUVT,%G*#A=EOZN?;\%LK7F.V!X/?7PIN>2B&M@KD[Q^-J,(Q
MH[!A!/NUY8RX?AZM)'5('JVW$E>=!-&X4&[6'+1("4O,6553K@H02G@XSII@
M]N*_.R=X<?IS1:> C".<?W202RW6-T1N)3 '(Y7[V;;4D6^,WVK37'U4WI_#
ML9W!Y%X\H/M(9(BUW#>?D*7?IG#TL]TN$$:8Y;XT PD@B9EX3#U/J1541T^B
MH!-5OO&I"KV(Q6[7')<$0;?'X'3NI2>H,'48WTHI43J$:BZBC"-*6Z*\!^Q/
M]M;YW.I,D$6#CJ061A[J((U,O<#J8RLHAR$O5#093UQ;Z;E9TG/#J\5>4L&5
MX.\9DIP2Q@U>/!:?"6+J\! =A6>)6QB=T%8YPIHB&))D')W4)ERI.1WG3U$"
MTV#1 &*&7@(^^56Y"V]NM4Y@*:9$B:^=0@8"Z)%A,MI@V<FOZ]=4D#-_B +E
MW3HE7=%[7^#3EXZ*QB,>7JS9N-9U[IN)DZ0D-6E@]JV=+>6D?+%<F%YJ9R'+
M.,(LKB8<^\K48>M9<:XBI[K 2 ),Q]O6J\!U;[YS6QRL@]Z2<EY= H!E]&BN
MJ)39FDU*5#  :.>I>%\J,KJ3P==IC;8!"*-Q=5OWZY[M[<-:.!PB=8CZZ:N5
M]PGWCCR-:S.T/X;^XDJ6(U/8\E9X['[NV"J+#5,6&UZQ]LH@?AC>H-NZ7A!+
M?FQ]FXX=**A1?PMH5SI4)@+5>(=O&R+Q\J)3D )#\,1N _C0^'H2K._%E0.G
M8I=%.)-0=EP*=C%R>VTA03PS\(TM'5A+,\*I$\<2RB>@G[ 0*29I>W,.-(#E
MFJ-=;#0-@7M-^O#OCFT<Q8DJOS.='-:0]9*TL1\R5!DXY&-+L?B.TR5_H#M;
MYKA&16[&3SLUVV"!:O$*:.#<,COHWQTU)A7NKXX1]T/67\71DM0FS;S0BY5)
M]N:W4H4W0J'[U[FL:Q(E:GKK.K(S9$&ZMS+H95!>@T@D+"]+&JV'@NQC$N.B
MKFV!#D&JN2_4V(BSQA>SWPKBS1+$&UZ&\9*"[E%. '_ )\-U=CS+QU&M5W !
MOM &704U)QL"11/']MU$;.7H4@64E+-V#.(&%@.$1#ZG>KNUX'S5<\#(A8S
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M? K$<P\W3PHCZ3C))D8@XT&X6["\-+S2R+\.M=;\[9^D_0<R&Y1"KBR::41
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M ES^1""ZB(+A/U^"+_WE=&]E9)=]YY?X0"['+8K%0%]!#P/E7NMTX47?LEC
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M=1L)QVV@G2$WCXL/XZW7'X$.0W,;[#8:'ORJ'!NSG"W'>2M\)_L&E4]2&.!
M&&1,H%!KTV$[>3#0UHYN.L#'@/"A)C$>\' $\@=F K-!BBK/$\V_RH1"_J0/
M\%T8#>RX?E4:&S B?>7Y(F0XS$I!5B.TV<]$[!C<0I?(N9[3&ER+IRJ8YH4
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M?99&>:ZE+&[T/=1W^!Y\5AX\OB @N]4ZI,I%+B(M\?#03.=?<UD%D($^L2P
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MO&8"<G\JT.9Q)O@%;][;V5X9E6FR\_]02P,$%     @ UWUI5$*976@D!0
M^BP   T   !E>%\S,SDY-S(N:'1M[9IM4^,V$,=?'Y]BF[MRW$R<.*$4B$-F
M<AQEK@7*<&G?=F1[@S6U)9\DAZ2?OBLYY DH'!0NS/B5L:R'E?3;_6N#NHG)
MTEXW01;W-MYT#3<I]G#\U_;V_OYNNT%?N\VR<.,-??_!\^ 8!2IF,(9P H.D
M$#&J3S)#.)?*L!0\:#?;.\VVWVY#N_-3J[/=@OXI>%ZOFZ%A$"5,:30'M<(,
MO;W:M%2P# ]J0ZDR9KP8#4:&2U&#2 J#@FH;3#%/I, #(6N]C6ZSM+D;RG@"
MVDQ2UUP83_-_L-/R<Q.XUR'+>#KIO!_P##6<X15<R(R)]T'.XIB+RX[/!31:
M7 2VU_RZJXRI2RZ\4!HCLP[X^3@ @V/CL91?B@XH?IF8 *;5C,Q='9J-'73)
MGJD!<,.".KB2.FA4?!C W'JPYE-?8>]HG/"0&RIHM/QN,^QUF[8:/?+>QC>8
MF^+PN:W=%*'.@SOL6^Q[I>?@MET;,<69,!UA@4B#A:E$1 .JH)Q*QS9P"W6,
M\D\VAA,6DHF?1=0H%^N%K?A29%0T 3F$3UP1PU+!H<QR%)I9GN$\9<)9%BK+
M;N]H.+2DCQ"8MJU^9:*P';3J8!WHODG<I/H!TU@R^GK7ON\8C]B,I1$^"V "
M<$CQPX"1P(Q1+#)4&(.B\$(N?H5IZGTM:/N&G&)7/-T>HL4D"!\E4_'BMFG8
MLN6;;_?:;3]PG]W?K>"#K78#MZ7J=LN9F,P:)+2Y+,^5'-'(#'*"P'82+9)!
MICM+%MJV=@,-0@H/LSR5$\2YU4O#6:BNQVI '_2<0EN+(BJY+$5F>F3ZNM0V
M JXM=T.9IO)*=UX[!=VB5^[C*68A*IWPO-LL7M*!# M3A% JTL2#FD_R1=1-
MA6;VKG,67;]/3;KBL4EH0/_'X!L6I.9$F52;8LD;^XQ7^MM;LM#$J]5&J R/
M6#H-:J0+P5)+5_VYUNWM_L^[^^7"V6$>9MY_V?14?(Y8E-SN;J 3EJ8422)T
MH=I&&XK3*41,)], @\IZUKOV3MWW?>?-))0C'KG(SB!S2%X[G\.TL3IW>MJ=
MI+.-XZB"MH+V7HOZR\0>)HRKG&*?%$NLW4(P[:\5'J+X'I@K3BM._X\3FH61
MSDLH*"827>QAY-97*\Z"<HR:+'>9*(58V^"$4L+YP?M1R+?\"OD*^>]UGKA4
MU)GE4.865&USF;Q0$240:!LIG)W?5_,$2B8R<AUM9/1W P9S]RER*J:AZ#N*
MN$PV%OJ8)2#TDG%C$.M3\^RO,"HCSR@]-Y.%*#.J61ZA"YJALUD#VME.D*EU
M\9WG2C'Z!461^6I5&485$5XTP]BM[_A^_;X,8X72=7'*"M]7C._@)E=+Q[9'
M';@<SK#UKE4FSD8:EGY8HIN+4F@B9KDPDW5A^;D$YG95KG2F<M07U1GGC_?J
MS.VPKHN+5A2_8HH'=^+U=-4IQ69KFNY7JE/TSB2E>K3.XA(V698'<"QIOP6S
MO]94(E2Y[SJ+T(/871<'KJ!^Q5 /'DK;TR6J/4V,R@2I4JC>[^3JJE*@RED?
M_+]1YW2,/-#M(H[M49)ZY"(JE"HO,-YQO8:[?U=Q-7,N*SO.VTI?#I%ZYEE8
M*%WVL_"3_+KX8<7N*V;W<%$/])RZG/'8TLGBD1,<;F^.%0J^%DP95.F$2C1)
M19JA,'I=4(SY"**4:7U0.^E_&7CG_>,C[^/%4?\W>^EVX>OY\2^#BY6R9.@I
M>76ST.(+Y\=G?YS.1Z,:]F[P+0^RHFGO"I-ZN#O/_P)02P,$%     @ UWUI
M5.F4!GN? @  0PH   T   !E>%\S-#,V.# N:'1MY59-;YM $#W'OV+J0]-*
MQMB0M"G&2$Z,+12;(.PTQVJ!P6P%NVA9)W9_?1><J'7BJI4B-4I[ >U\['LS
MC!YC9[+('3M#DCBM(UM2F:.#FR_FB?GAK-=57EO?&5M'RO]&TV"*# 61F$"T
MA66V9@F*,2\0 BXDR4$#4S_5C9YA@&'U3BVC#Z,Y:)IC%R@)Q!D1%<IA>RU3
M[:Q];V6DP&$[Y:(@4DM08BPI9VV(.9/(5+3$',N,,QPRWG9:MKZC;$<\V4(E
MMWF3SJ16T6]H]7NE'#3'E!0TWUK'2UI@!3[>0<@+PHX')4D2RE96CS+H]BD;
MU+>6>U?=YSY*'1R"N26"$B8M5E>0#R1NI$9RNF*6H*M,#@HB5I19=;PJ.7+<
M348C*L$PNWU;CQQ;+YW6+_"?<O\#!GN ;UE4E8.7QGA>'V,U!BB>-/+BRE^X
M_A*N)N#Y8S=PU4,=0W?J+99NZ(XAN#Z?>1<PNKBXNO:7GC^%B1?._Y>F_RL8
MSQN>K^M*TG2[#WJ#M;Q4:JY <I 9 F4Q%R57ZJ;$IY8W@2D*9''M:B)"7-%*
MW@<LI)+!HLY7AXD"A85FPKL)S1%\W@73-#7CU#@Q/[X'GBKAY)_)!F8DJCK@
ML;A;&_E:*!2%*2%I1'5.1)S!IP[4"MI1OER!L=4#Q9HQS^DN-J6,L)@JT:T>
MJ%0'D3I RA)5>]1%326T@A%C:Y49[L ?*NCWM,O#9)4X-PRVZAY I?H)C#'&
M(D(!9K_AV^^^PC'90] K'6Z\8#+S8#8+7F$UOQOZD<Q5-.G4'UB9R5^&WYON
MEV[O*\1(Z"W$.:FJ87LV6BRU8#1UM?/0'5W6Z\M/WF Z68:/;%FJ"7[WU!AC
MGD,P]:_G/]!41+UE'7@I%GJ]=:G?9[,\?@=02P,$%     @ UWUI5/(O8L)!
M"   -SD   T   !E>%\S-#0U,C@N:'1M[5MM;]LX$OZ\_15S/EPW >PXSLMN
M:CL&O(F;#;9-@]0YW+<#+5$648I42<J.]]??#*GX+6[K8M/6WC,0Q!8UY Q'
M\_"9(>5VZC+9::><Q9T7/[6=<))W^,-_CT].3H_.#O!NNQX:7_R$]_]1J\$5
M5]PPQV,83*"?%BKFYE)G'&ZU<4Q"#8[K9_6CPZ,C^*5YV&@>OX+;MU"K==H9
M=PRBE!G+W7FE<$GMK%*V*I;Q\TJB3<9<+>:.1TYH58%(*\<52CLN>9YJQ<^5
MKG1>M.O!Y/9 QQ.P;B)]=^5J5OS)F] XS%T+?$/",B$G37CYL="NU1<9MW##
MQW"G,Z9"8PMR%L="#9MP*!0<'C2$:D%4&*M-$UCA=(MTY@N*RG&7!FS-C/ V
M^,L1,X(IUU0T/]ER_,'5F!1#U31BF+I6QLQ0J";)5SHOU<#FK78][[SX7BK;
M@T[O(14#X>"X<=!HUP>=S^G_><F G]>QX+O.,<*8X>;))"]Z=_WKU]<7W?[U
MNYLOS?*;6'![?_?^OGO3A_X[N+M_TX/&,:LU3O;8/F@#C=,X7/P0V]Z]AO[O
M/?@ANM_W+N[OKOO7O??0^\_%[]V;JQYT+_J -C5>'9]L:40N:+BNPB4;B1BZ
M!W"IX[@*$3=.)!-P*7/-[S@]QP:2PT ;7+G/*X>XRG(IRQ5P>FUS%CU>ER:-
M1>Q25'CXK]97.*;BJ0.YQ> 7^HR7QCM;L-#%RV(C<E/$9!E!3N>MA9Y>_)L\
MLKW&OG<9*5C/L&]IS36D;,3!\)'@8Z1?EPH+3*D"2=?P'-D7M(+7V!/IK_8'
MZ 2Y6O^;/< ;-K!5N%;106MY/OA)SP4)U4?%+@0W+02/-BD$?V,6 P^C+)O
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MY]J2N&;T<+&1RAJXN;R^^_BH#27HYW)+/M"*.OU\KMVJ^U\!_@]02P,$%
M  @ UWUI5*T*@(J\!   8QH   T   !E>%\S-#0U,S N:'1M[5EM;]LV$/[<
M_(J;@+4)8/DU*1++-J#:3F8TB0U;&;9/ R51%C&)5"G:L??K=Y1DQR]IFV&)
MTV$!C"@Z'GG/'9\['J%6J.*HTPHI\3M'[UJ*J8AVZ.*/QNGI6:-:QM%6)1<>
MO</QGTP3KBBGDBCJ@[L$)YQQG\J>B"F,A%0D A,:E?-*O5JOP\=F5?]@= .F
MV6G%5!'P0B)3JMK&3 7FN5%(.8EIVPB$C(DR?:JHIYC@!GB"*\I16]&()J'@
MM,V%T3EJ57+(+5?X2TC5,LJF<V6F["_:A%HU419D@H#$+%HVX?V7F5"6PV*:
MPBV]A[&("<^%%B3$]QF?-J'*.%3+-<8M\&8R%;()9*:$I6TF6X:*=7<6M!Y
M9!BRUSF1C'#5Y-J_R%)TH4P2L2EO2C8-E143.66\J?6-SGONIHG5JB2=HT.9
M;+F=_B)D+E/0J)=KK8K;^9;]#SL /CP%P4%]]) S5.XYV>V/G<'EH&L[@^'M
M][Q\$02CN_'DSKYUP!E"[1SNRI-RMPR3?E<C@EKCK JO@LN>@-T;CIQ^#S8A
MKH!=5#^^"JSA)3B_]&%BCS_9M_V).?SMNO\[V%T'<*1>K=;_HU3=LC#@NLSQ
MO.3!/5,AJ) "X7R&Y532!.LJB  +K_B5+.":N&D)!MPKP['6,[HB3@A?&B>
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M2+2?G-K_LYQ]R]>W?/T1H_V6KX]':X2W Z8;U.RJT T9#?#NB_=@Q>84AD'
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MT[A*O,=32U87IX@Y@D]]#=)?,KK$S"=@VDRA*0G,&9Z>]405:\<UQ.\N&A]
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M/(EE!3Z[SC[]\8C3'YWY5* Z :84NJ-)[ZS7P:E!#<:$ '*^TS8:&TJP,$V
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MD9*%U&%<RZX#. 1/GMD>'LV%=?(AN>:A(<DD0F\LZ2C"5*I5NK"<H3D2!/H
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M,UD.2L=2VK9CI!W!7O"OP#5$AF#MQOH*G'0<R0-!0W!=DP$IU7)+?:-Q4(N
MBU_Z.,T%;K6M!ZGH$3+R*>0DEM)=;*^P2KM@\G&*,HKR:?W<YCI<E_<=I<OI
MV>^4Q:"UZ_*G_,S9_A2"O?.4%+3KI=)5\S&U'Q+#GHK$(3AT?7R*N4\Q]RGF
MHT@Q-\LE"H\CH :H%5C4RM;%B+,^E$;[5&$P3HN==Y+:^@$Q0K:. U"0FWH$
MP(VQMD-99@YI843ZJMZ>K?5(4)@78+2WG8#V KK[!QH5@;9(MD)U1<:1[G0D
MUYLL,QVP<JSV(*!6*<@HF=75X7AL];_@_@QTG*NW5':7TY"UAI)AW1AN&(2L
MFV,3?OD'*SJ0B#4D\O8K:!QC UT@ ")T5*'.,4+0?8U^$3JN;FJ9ZH3NT##Z
M-0YUG7;W]E >+L[=0JW.F>]1[F7P[8Y^4;HT61IES*+;TA"GW>&N=G@%%.46
M[\@-VFJC_X!N"ZC3?="QN<+/1ZVOR*%D5SLO9RLN_!$=%VKN@:%CPT[C:+OF
M+"QG&"4S#Q*,Q""9':M@D*OX_6[ZSARJ\.H:0, _H01LNB4,!/<S2G!VI0B
M4#^."VKMQ6NHD,89]7"$SM&&=*AV&)/ST2D?5A'][?JYK$&#4MUPF [12HEP
M))5]S4E?<_*(:TZ"+I(\@^RZV.3/ 2-YPJI/5L*BV!("+#2I[-]#D4G#;_L"
MDZ^EP*2_G_WR9EMUV@CU9IHO"+L69_WS1OE$,K$!;9X=:3N<OP_C[\/X^S#C
M3\[U6K77JM%JU4[.J/[4[H]!DHE&),C#1V+[6E]]YQX4;MT/>VW;:]NO4ML6
M"TUXGD0GM,ARMM960M*V':16C=S.=^'CI,@7E-6S#:PQ"NH-U77TS<>+ $%%
MB"?2X'8EI,L 2&X()T(16&@W<GTC;^D.:^EV1*U@T1-&XB0_"1E;SR@K,S'4
M@M+8'@L&8_D:8*]CP6,C1[U7Q7M5@%>X#8H3M551,&(TRSS:4*R,SD]FHR^C
M\[L8.9!:63.H7(+N]B.&>Y4..16HL*!C5J@<H3#%'26SNA2L1W)[W0<BK!'Y
M0$1/@0BX4Z._8,/[;X-YF<(:A%D<1#1-JQ>V)<LR\D"RYYD#1B L1NPA+&%-
MC8]5O)98A>)!L5_I V&9Y*!?2\81?+-]@YVKW);V'1T0>G7QMU\-+Z\IFCCX
M\:VN!'GIT]2VO8N(LWS'/23^M>\:$A_]<<UH7$3YE-T2]I!$=:7>3<WZI917
M%X\E$;QVEX+:CHEF!,&*8PD]>N<_'CW1.V3Q.RN-HI]:R=O1>29A1Q\:$PRV
M%!2B!Z'R"+1F0PSN1V?K!M,<1^=;]4XJ[Z3"YJ1J:L+VZ*IZ'_#BGI,OA?Q(
M^FYRV^Q8W1!].*.,/^^]3Z_<^V0HA+GK5@'5S&Q%S';@"\X+$E]DURQY$ Q]
MG891R=5JVNQZ#F!H^M?*_6OEWH5DN"L*V>ZPQD.XDL*4[-0HG,YD:6@N9E0<
MY%KF@G<\+E0(=HYW6O9 [9,&>O9@VM3:ML/3OE]'3T]]?17%H>G7;UI3^S%C
MP"!O7M*FC.^"VP^$(8F3D*UW1+QA5VC;^T"*#Z3X-^<LD)K.&6HMT+&BU,L-
MVER''EVXS$K'0.<3-K.A&N+P$1CH,TD.MB6&:)IC;@6<_?CX%2Y.J)U+ BWG
M.A2U1Y+:;^F*1<?$0[V']0I?4\3Y@%N3H @0,)X7P7QN@S4BG]O0TP4<H/NF
MEY0&GLRS9)9$0B $813):[))-@]6-$VBA/"G/[:DF3,<;$?L-N&A&34^_^&5
MYS],HDC(BO@R">^35/ @X=>24=;:FS?@3@.X9R=/O'^]X7A#+-C<80 4GT*>
M"#5GC[:U?FV:=1XB 2'DBTD6R__(IY(?A$4E3@<8.*N^0V"C&1?$Q.651R D
M0)<!D)R%+!/,PZ\)*Q_ @H$!]AH SWF8L'^$:2%,]O,D"[,H"=.+3&SU8OG,
M0@I45GV'*/FV7 D*)2U3)I2T%>5A.IU=TFQ^F3R0>,(Y@6ZP-D,-6>P.B,[0
M?! $>9C-Y6-CU=R>2V60E).MY4EPOP$P79&O.\</HYGXLS*ZN<U)UG28(9*W
M7E)B4#H,K8=)/J.L>I#HAD32RU):$Z6I&?]W43W,M/-@K0I8PV$&04Q7A.5K
M^79C+E0*J4ZL)'DPWK3M/F#Y3$'=*7D@*2WIV[Q-I94M%CT'P546DMB\!E_N
MG-^3?'$BV$L(=P9;OV:##)%P4OM":?4.:_ELVLY#PWHMIL5(/CGQ*),3/W/Y
M6!W/DZ4@2#6_]8U&G[8$.H,Q98:,*&7)!S9\8&-,@0V3+*#V_D)T& &$TR9.
M*70Q8CN@3;RE_>9R.(>L.]#[#8"[9UM[]S 0\?=($3=P30(1_X 4<3/+&PCZ
M1Z2@V[ME@1/@Z'%T9Q/0).((A.KHE6SG:VT50P%B_8@4:QLW#%3SP*IC67O9
MH("QZEJ6(0LH7*QZ5CMG.!0]5E4,%FJ#HL2J?K7VJ4(G *LVUBY&UTON7UD,
MZ+M@M=$;R]+49*LT!KGT3]A6-@*.UD.1(RM*?+[?:\GWZSI(VC@\BB*DYD-+
MG5-;_KZ)2^H;C3ZTI(/E(TH^HN0C2D<?45*( (@;<W!5^7MY@T3ZVP)2^2)X
M,R79.$X/ZC&0!J\8>\783AF+%B0NY%7P0]\T2/6Q'\ KREY1]HJR5Y2]HNP5
MY=>D*#<]*?M3F'\03'7?T)-<V[<'Q5CSNUX9?BW*L.)6^(408XSP;2AZI^R#
M3E=ITM7KM%ZG]3JMUVF]3NMUVM>@TS8_(_O39G\*N*QNN*"IF#9>9A3DZV;*
M+62H'G1=.!E>]7TMJJ]S/W!])EA9*+1*!^.3*$\>!,F6_N&V R.9E>MP+7?D
MY&O(XEWBY>6%*B>2\V)9?=9XAMK_R+"SM2.FSDHI=27DU[:0Y:;<I?G9A+;C
M>:O,6V7>*O-6F;?*O%7V&JRR/C2*GCFYJ^EHHX("IZ"_ZSQ64]!&E>K/>/\8
M).6]&V'=/C;-V]*.T8.Y#OA];Z=[.[VAC75*9H0Q$M^%C]4MQ$G6(GFKT6B#
MXC^;S8@4UN3I@MZ-V'TW1*@4D:"ZE.R6D]!\2&]I>DO36YK>TO26IK<T7Z>E
MV4*!&+5)V59GZ,6DXAMR@R0)'K8&?WG/^DL1ILEL+=]8V3RW8F]LM1F]X]=D
M6E/F#31OH'FU')E:?ELLER%;3V?/SLLTI5_#+#(;>Q9=O<'A#0YO<'B#PQL<
MB!1O:_G=7\SB0\ KZ@(Z,SYD&),\3%*A= JJA2YJ&=IP\5,]1$#<D>GU\->B
MARON\L@"FXR3,GQYNTJ3O6>/=^_N&)HZ(.;S2LBM+#\GA)],_S;)XNNKZ\LD
MDEG0:K(TG9:-":S7.SG+=W1.\:]]?5-\],=OX6.R+):U!"N_[XLV(8"TM-5]
MWQ-M-V$V)S7\7_M=GS0I9ZOF6VQT.9-D+9Y<%6(K3M)".O-N252PTG%Y]ABE
MA3AXJLJ^RU615Y4Q9_O5C2=+>:(I3#:G8P\P-^55CV19%8$]H3SG5S27FE<D
M-;;:LZI)U^-#AH"OK\*\8-)375W3J9%<@)9#T$VS)<V$4LC6=RS,>!B5OG1!
MB X"J!,J-%H>@W8['D0(=HRRI-EG3F9%>IG,5"Y2BYX#X-(6:E<@ O7Q?O;C
M]+/7YHH^VU4G-).6EMB^-U)Q>:_$TVR8P3S:Q^+^U0.IMU>HP63 A "BM] V
MFBA*L# -AS;5(487H6BB^J'S?(/7B-HXN5#%9KICX&[".+TSLL:!A(9?56<#
M-?KE4/$B].S#P%DM5D/MP>WW#I-+*6_R4:#9*HW4#MHL6(!J<W6@EK7:AXY>
MEO+)%!TF4RBWX[$E4_27Q0R%U,8X[_<8<0;:VDW7KZ1QAK.#L!-P)OI[YPXV
M$Q9NS/X2AI1OGK5+#K(=MH=$H&8D^:2?UY+TX\AA?4I6C$35I1NQTX7\8GGR
MKW#W4=(]WS2@AP]N#!O<\*Y^;YQXX^15&B=@Z=R?SK9Y;Z"=AJ8?I =]#$*
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MM=Z3!-L:/^B2!UL HB 3"F'&'>B>8N?Q:'2LT"GDE[>=+(-FZ(1%7U-EF0Z
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M- "J\6#BDS/6^,9^.\0>,=#7B"XYJ0'2UE=9L:5I-XI=H1.WMBC@$X!<_+8
M[L(UTDNJ1D9S$GP,DG+C!7GX2+BTF\MT-_G/("PO'@6"WB!]OG4CVN1ADEHD
M<3CZH6[3.YP2Z1,_7DOBA^)5A^U5OKOP<?-T9W5[[39,0W98U-"J3Q?D?2(S
MRHA\NZG,8YJD*?TJT\-W'GK5D@KH/TB1\3TR=RX/'B*S[(4!SY.-*O6F\OEK
ML0Q?0Q:KXB<-1L" T[9$H?T &%"*/T[$OY/\Q3IL'6=0J+!1D.#=N_*\6TA"
MK-(GDHFC/>?UE29.J#(IILN?PC!SAX(6.A'JGL/BVI&Q+3:[S2@^S.T+^OE
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MZIJ+6[!U(RK]>[HKG_8$=9DAR7RS$J?NQVA#3U]2E8X;&H)EFMY4SCF%_XL
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M35K-K<L8I3D(PR5'JLGUN^3K2)_I86A=>SRJ"N/(O%ZN%6,(F%=<M+H:Q,4
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MAF\,WJ$=)K?"!=<S']OBOU# $)I7HF/''IJG#V551+$J\P(_$;[D@"% Y^8
M1X>L,_:I[+<]$<516ER^#U4& +LYS![%K9B;)3='KM=#!_J4Y:G[)=X(G8+@
MQQXM:__VH'4ZUSBUOT2W=FI#C&59K=JLR&80W_<;Z8&7,H./PO0_P+Z25D[L
MRVI48X!JB&EQ/8C*"<>OV60,66=!KEYZ3[,.,Z>?9X'9E^/Q-]^C8Y%B,CBG
M9Y=)X,?@XV1E1K3RS#W\HE'0J.3HR/]>Y:=Q##Q=WD2O$*>&%&\9N_V01@]I
M-N8DF#<9DO]P0,T9E&_< S-5>@TJ$#(447_Q9* .Z-?-#5$7>E^KQAU<..R"
MR.Y,GF5VM\1V M)[D;'RYR9%Y;3)4#E^^H#^WDIBT@@<+T6J3!":G\5D=;7(
M6H+'Z4D6TK.L+FQ.JM;*(%=+J.0UMVCW:9+5,OJZ,L_FZN=PP?1Q5!2O'!_1
M,GPE*N6R747^MBO2,DE%/D:4P;,5L#"7D-^E(_?*7"]M+O!OZ[ -Y6C6/7??
MTYRN4]6]<F(TWEH9FM7CP3P$'FF!V%D)0H'=TBTKP$&3"B2$4-;65"@C8I17
MF"'9/ O&W1.GYKW>4XC1L4BA&)S3?2TZ#G1)KR'&*<N,R!6:@29:B(Z.ML5$
M?IY$*-@H;$_/<?J.L=*<5Q&6F*F-;=8:4J6)E..0#'0TGZ]#^0@PYCBV@#TZ
M3,\:V)HN#4=\KV8(IDTGS[PNZX"552%N.B"("F97#T1R^_&$OMC]&#*&WVW@
MCXAB"&=S!Y>K>]#\;Z!QQY=!F'Z$,9@^M;RS_3K-H15T+J_0\!Z!D[DNIEN<
MIV5<B (C4?':'S0:"+0S*5J<Y@#W)WISL,2)J5^ZH$1:H$CZX D@N2(-FF0/
MS_V1 >.7ECB>N=DNSSKE!WZ1+J(,G.S))LU32!V":FCU.:]0&II?(;7"Q.RN
MQ;X&+SV<>P@$85==6C,D 7T'WJ/RB2,&_X%:*L]1!GE$I]49.'NY@0D.4!7;
M&7V+#<SKP/"2S"A=X/P'VN$1)E!O1'8VBY8S0WFBH< 57U$._ Y*>+QJK\YX
M3*AN;%[GOA6 35K@XE">6:K7[G)<)1V*-99B]6F[^BV?)$!L2(NQF#%Y?3^1
MD7% FH@6).^A \D9V\ A(H@_;B28?8Q]UJ(%Q-N#%2UL4$]1'*T38?E/MJ/1
M6J:KMR=F3,?F47AVQ3?(*Y9=<.ZV63I2<F-B**Z>V^"4[LNW";!$'E,"\)S*
MV);6@#N3[I_H0:I[Q \DN3YY$)5B?9^>:$&A" ;_W[04@T36 _^FZ?T+3%<2
MUM5Z"U)!>YS)F G544=52>.O.(BO$YJ*4^J7W\"/)_)'(3C\GW\]Y3N5B.[
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M:'QABQG]Q2(&[?'P\0@=6H]QW$*B$C(Q_&Q7%/R2K?(:#XW!>HC[<_DRBO>
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M*UT 'K"F3OIU<9L^/E7EU$/NV?-A[^!8N,ZOYC5B[?6\1NW71")' +M5US&
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M.]1=%WG%U3P<PP67$%%91^2GU)KTC"6'A9,,OT)H-HW9G8?=!0ID#X<5$5C
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M"3LX>''W;,.6]M>,:6 T(%'^(*%L:C2[#X%#9>(QH(>A[.E7RO2F2:NO<=Y
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M)O9E;C&1>CW;(+70 7C*+T.%OZ$FGV1(^];(.E*"\[?(V#G-?C^.RZ?*)D%
MLGWA3DQXW1%;W5Q24K8+\\5FH<W,T0CM$[\UK:KO,D#S%HCBM[52U!,V:I<
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M)>N0XD3DDQ61!:1.UXC;K)/%#:;TW"=D,\<D-\;<9X__C8+T ;_:M:LHUAK
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M;O)(\SP<%1^ KO;$T(W<+0J9*Q>,<CK!*.J3]-@X)M1/K -%;:277T"V>/U
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MN_JFDOH#F>'ZU8(C9NBXC8E,67^3&Z#8W7:'UAEA6A/-39ALWY"\WN"^)U?
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M@R@OT"KP_-S+QRI .R3THL0#!=P+AJ 3JVP3-NE';DKA@V'@]=(,-.7?GK2
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MB9K])X)$)Z8(%W[\L]LA9GC<.6V?'G3 Z#PX.SUD]%OAJ7@IT.ZGCY=T)7I
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M1/E%X0=#*JZ6>0S3O"#"'!>$Y07'!P[!!$51RC]2Y3(/U_*>B&NX1_Z_B*L
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MAQ0-&1ZV+9T5UVD3:*&H$%Q>3W%(NJ!3H/^=#TZ5^X(Z&A4HEK5[P4[I$#'
MCW*XE(F]"TQ]@F,ZTOR9- G+G]]%;!J2^G"D?8;\'/(MDA[40"U7JS[$4YB9
M.$?QL^;6^KB1K(;%.F/W]>5U"EOX+S8AJ4=#9<MAB!]$E6BC*N%]3N,2!#XL
ML@& -*+*:AFHYIQ]^-'G827:[MSTCF\+L7IPU.2MZP8^C]/ I]ZG-4/@M^;#
MS$4_QRG_&/[_3F(.50W)C4!AD ,M8/0?$<3L$(OO? Z*X,*6V/EE2FFQ3EY2
MH70<J:)&5?P)QK[036N(T_M5I8%XE6;UUU%,.+I7J.#X%H/8JBCL!,VU7B)#
MS"=P^TC@]4FDH&+0RU)L)C ]#V;\5A9ID6&Q@($-$Z7WT#E/"/^H58%=19%"
M$__Q2*T$?DEOU&$<L$)!Y\-'P*)S"Q!:\0P4?W04<?!/M%F[MAB(DF&;,T;1
M8M*(\G*L8WAL2X:ZI8"SR3C2E'P2.G&']D6<T;)WY&P#0L!P(VK>W)0D4+:Q
MCY?V@+A1LI+:68D7,@ATF>E(G!X@62",WQH))K/KFT&U 59D);2K2Z/^;+OJ
M3V&T\&O?.6Q$WB'(_*:RNH-8<3FI$.1T8_F, 0D@_1*!NGNJN%;B'$6 6WS'
M]DLD)4P#9V,MM)XPQVAC=[+>/C?F@D,?"Q!;2FUE(CR5U^AZ="U-HA$:(RA$
M::PR-_!:M3OUU%U>8R=T950-&C&]R'>U&,?\Q],T'37&A0/&>:5P02A<E?FC
M,@^(/6UT3C;A*U%\ML V043@9CD6@]NX=YQ14+Y BAZ,4MB$:6@""XY'!L0+
MVF%(XWIKI_D@V"1!1%VI*"9@@^W2RH-2/ZR#M7 (ABG$]+?!% &P?Q,Y(IRX
M@2D?*W92=@R')YJG_D?"+GCW?1W^$.](@T6!1I9_WJH[(PT\$!-8-%IFQ.RG
M&'<,&]JP].:<#/TNE[6A]4!DEJD!S)<VG/)">.,JEH:CE%=LC0:ZU4L,JY<9
M.^C$7^*8']A+ '7SBO4A'. V?L%4@U)$\D3(IJ@YKA21B.(9WY\<5+$Y*C*7
M!\+7BKWB2*61\O.2#VHE.XH'7MDC_)J.ZE1085[\5 NDFC0&BL9(7M3&YS/,
MRZCV+3P;10'(4P]^JS0!,'DTE\VJ>%V)\V3M^AW>PG,_:=8D\U6M^V-T!#71
M92<<K2Z>02=%Y\,YOFYL$,$^P13U$PQK(N5QI,/&))7$_6U@94L4\1.,K)L<
ME/[T6*H#<%54SH^838:J]=>;TSQ(V7ENU#(*Q(H$@>_G$..6]R&]QBA?0Q1B
M/&^VP1C?ZF=@C6#C- QO42? 9&IXR,][F$5%3Q^CVTT[SRD#D--_A,8#?TP^
M*'@TM9KB,PV'GO#[S4!YG7J3F;PA.WJ../LY:P(Y_L<LB#XI\MJIJ)N3QV3V
M:":E(P&"K3NDU N+>R<Z^1X8>P$YC$D4E%N%B8LC7VP#8#,469##O1"G\H'R
M%C[EVI7%?5QLY(I61<)63?GS(\:GSG'; R"!C?>?FP+Y\28OS2BG*D.P, 2S
MS)IBH6_O@+ENQXI.C\N3-T_A 6\W3>L88X,-22LU!UO.FD=VF!I,JMD\;A*"
M&"P58XK245@B,&?6R84Z3MW I"=5B*3"5FUL4<#K2I228FHF\(/]QEB1IC6A
MI+R,_6*(@DPLMP=>++-6%8--)VF".18ST)1Q,5>,Y T6-?FFXWEV3"T3N&=^
MYDCEW.$UL83\C2&IF!,HTB6F6<>6=S2;T6D/J E^@EJB1KW,AZ=MG&Q*VA=3
M@+=QM&G7&UZ"]BH:F6#0<#"%^M8">[U*,=\-R6-D%&(^Z#&^9BPTG(.@_GB>
M;QHK4*@&/065A9N1S-BY*<W&J=6WI16J&*;-^U)/Q8F@_05(WM.OYFWF!$N:
M<P^[[Q1#X6Q)8.;+YZ)92=FL& 34:MF<)7DY+V3/Q];(^'XM]Z@]B_5S:\9.
M/-LOJ1\IQHZ-(,* 5 PR+-+*7J\$HX5&)JDH3I([M6",^2T.6\9!?DHB6-)*
MH)"7VK)\K>EBCC0UT70ZM;#4$'8R$_UG:P8?I_KH):FHJJY@-^X=PU(HP07O
MP>S+9DP!1Z-):A?&E;*LIT9UE/Z80VHU*O>8ZV:%+UR.6O)5&AF=TJZW&UXS
MR2!\0,V\R\):Q/"5&E//RX40:-\=PIYJ-18CP-[,?H/0$EUTT^2R3FE#_(4Y
M_<+,?<FM/Z%/1_;<PO5R0N702H2FFLS<;4S?Z>:W&Q8VQ;Z -SDLC,S$,29Z
MQU-6$CG7\A'F??H)_2Z^!"9^Z1IFS2+-)?2#*MY2"D#ZDG_,O@SN&:K"B(Q0
MQSU'(L])'4U"(_7@[%23%>N=>G2"\*S'J'2^4X6OR7T5B!*VY6]@8Z/GBD.4
M..53'<CNP")$1<EM9=O *S/)>YM%F0)!==II=PXW&R2[M/R<?10IK%+T [=\
MP)1';(PK7BOA@[[7)6IY)XU?X7[0_WSB5Q>Z<]Y&]UWG8I-S9]!@$BK5[Y[I
M1:</F]LF"_@1$C:?">U.HB?JH&7#1"V!^!T\BTH/-(S"&OW)(&YY;2$D4S;E
M%F^B7B1#ULQ2)[$P8V^0AD>BV!"O\_X"DP[07N(F8#.LQ$Y<!X4I?9.<FK!'
M?&8IX;:NI>$W>.-0O<W0V5,XSCBQ0%'\9!S_-+I;M6++C#]-3--JR;]'TIQ^
M*Z46.DZ^G^'>6_82T]U5"7+^,B6F-3#3]Z@Q_=Y1_"AOG*#LTH2^RQ;5.+UH
MC^I"!N/!TZ_A-K72)I9:@[(.@1D;3YU>M3I)I]+(T6V!:FQWGVP2DZYN#!BV
M@D$A>P\_-P]U#<M1\N_)B&J%L6B/<M;QMHWWAT?GEYND.W5AI+=FF.*C46[0
MV)!=SLDX/3\]EY=0_<5,EU_XW13_W)2::A-2YR>BZD46'X-><F=9KRL>%!H@
MJ'^DDFF!;AP71IW0!\$H*!NG!YUIW:/S8;;!KUX2&+3=?YW#2*519E(@SK12
M+:6&=OAD.HK@=!MX/L6,2]V8/K?:98-*3#&LJ&L0BK0A9J+N^;DB^B11+>9?
M219G1%EHG!^A8K8YL:@8LU3)F4&'A\O$Q%A'T<)KB^=(^S[$'E%2B$AGQIB1
ML.C('OC>(OW*945TGB3]FBI ^!<D:'DKZ(@HD1IBV>3P/>IH6U[;"R9!7-GV
M[^-%'K,AS110M:-2*J)6+G^&-6D6DC(2.:EG#N61!]CG\)H_\5#A2E$!PA@M
M>RK VC%^0U\O0L/K R'Z&'$&QC0>IOEX2+4%Z#%&MZ6O^1M%BD'.XPIH?9@#
M>3[7<$JHT4DT= )E]$ZQS&;63S-$C%/J4G"]')Q@3P$G#HT3<@K[^-&O@<.D
MAP.[$WT8'TB;B$M<S;G&VRK-J5?A;+7K,T%W7^P]V]_=W9RW)5+5S34TL(2@
M_"L\-!-R+]9LS^Q2@IR2#-%J6_/\K](?H1%([H4 C+(H@:EY&Q].NP<87N1X
M"6[!1KY)#AVI!:*Z#DWAXG7$-%0*W3@"=DPG@(I:;*(QI\^2OX]Z;2;PM!#=
M<.CY0^\1YI7#%7Y/>S]I'$<CK':SE[DIWN*VCY*K-,;<#5FDJ:0JCD^9]7)/
M':=*(=2 /6<-#B>"UHSDC::@FWP5)=9S,D;T'"-SZ/06*5K%>#^5,9L4>1ZP
MA)>YC@8!AVR1F@E^<^HIRE(>HL3=P8C*\M+G*F8,K ATD72!S3V#ZW_)O>W?
M9^3;$S63WXS/P= '97#I+NP/RB=3'E7H "II!:S**"OJF _F9#H2]ZA#;R8+
M#QZ:39*!0H@0EKNN#TB^TDL91V/,U$D&)49>RA%RT32EYM] ]L6P 6<,#%OT
MG@QB<ED:, !Z8>!?P0:Q,][UL^S R<#0Q0"V+?0.VI=G7O>DBS)S$*<]W[C9
MZ4W&+L^TWP,X6RGG AO#P9P'JN(^F.(37%1*=6(H<FP4TU*;^QXX&P)Y@@L8
M*QM!J,E?)^YBW L+P6<?KF(:^P1(XOA49Q\W$T Z+*"?GBLHF(EA$&08]2)V
M(Z*KUFJA0*447*GF6?8F8G9P#A7=C"Q+@"68FQA0DFH*%>PKTBXB;6"$@.G?
M<6->BH)%"I/O!!+X5)$<-?5[THG>^Q+%^IBX2 ;]2,5.$F43= A6Y1E/1VJ;
M,+X]2I%(RI$E.6Q!GY(J5K45@,N5":;RF$D%0Q Q8Z#GPJY%[FUT#CH8#O,)
M^H1/8I(&L<EGE328C1._EV_J= F\R4$KD.5'O)< Q0IG+8BR,!V.LN,@;S66
M,2+;%]ZJW=1F?5/V&/?+F J]\H)0<'18$_8WCOIRI!H@A(OT"VEDS'RU,,2%
M%]>>HQVOTNGZE%"<D]3V1-;05+![&VIKL 4:9QCIA1JJ46K41QW[ &HO@JW-
M1@5-0.C5!-\HT:8:B;)Q:"=HB0<##32J!V/OI<[""1QL&THH!M4)9+SHI&+\
MHX%'XM!DZ$ZE?XT4*2#&9-')Q]JQ>T72G;9;*UR!VD)@'?@E4G2Z=?HH6??I
M-=LSDH8V/?& @G8C_PM-'\,@Q*>9.:5,JSVEK5^JHY2\DZCB7Z+HI0\[D+-B
M9>-&=*KI;!$304%,RB?KW-Z!UMAX@QA6BI;7]_I /VP@JG!FY*RYH'^;AU7[
MS@:9X @ 1-8AE;DEDNMI91EJ1BMU</[@912/"3&),G."#RADMG=V7AM_NDG#
MX'I-ISJ<PH@]E:'Z%J,*,PG2?!)3# WO,'H0J?=YF8$@4DU0(M*  VTH'ZLH
M.HRT06:Z%*!SZ3+8CLK2:$7GPNR O&B0NQA.>LKS)Q0(U/L0#\*G; (N8D?"
M+SF3=2HY+?.C7&P?B_("![YII9O.D<2$B>E*@9IB5+.AA)HJCN_?GK2>T+UC
M5.:3@?D['_N!_KLN$$ ^;. [*B&O_U>-8OS&XK-6()7K$&SK@(\UMN^+&\%H
MYUN?WIUI?&<OZ-_8]4R&@O7)CSF4/Y1)GY2D/<]M[52'H1 "\TW8$1M2V-J1
MN)@,A(XI3.BCO#Y048#OL;5'#Y1H=HI%P@4H5>31(SR*(1F 1/M(BYBLHT\
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MIP95,_&B&T(V?."Y;DV'@R7=KR:-PXX['Y9%$6O7?VXJ7W4*0S";B\%<E]"
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M?!AYEW[B]^ %EW P0I^% B?,-[Q.$FR]]D912.LR_ZV4IZH9Y3PF;X=V.$E
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MQQ<D;7E6=2'AK1IU'9W(EKEF"@-C*C!4,9_/=\ BN2+Q:@7&SPBALL]K*KE
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MJH#=BK*I]!"!L'])&$/T"O<?[>ZA2$S-E^L=#;XM'Z>>E1J(*(.SJ4*+P05
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M??G3-BL+MTH.=Y-W1=5>XHGQYL5O^L[O&(A?V9>,RR;O7%DVJ^(J@_,^!;-
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M<+F63E>"K),13H5UM?<EEL$><?L?DJ'BK8J6"AQT-HLSU$44&IQYWWEEN<
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MR<U^!D<]2IT272>MZX83VOWH^;S+9[25)A#T+$PV&]<0LFK D(&]:KH&=Y"
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M)C0E.Y_V<,D6O3QB6$=IE.[Y'F+K]F54#S?(\E0#U#ORM_5(@M6#(<C^BH\
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M_M=_XX,@2]KK:H<$Z3BY)[)$72V%UCOE$3_"0\L3X/-H_8N.:7W&W>2E[Z*
MS\*(?YTF'UP-]KREY4J6 ],^X::Z .)3R2!8Q0?B X.Z>QL::GU[YEB50=H
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MXJ83DK$<Z,9TW!\N7@NE%*E:'O-GA6@?,7"P2;QC MY6UO:FMH?,;UQ_#*S
M)B>XB1&)-P3LYQT<VFXA:>W2G5=MKN#W634E?3BO0C=J2*T^1 2?Z&UN[^R!
MJ\<,5WT!T+7+-- D76L?[!U-^3H> >JK(#Y@V&*%=HR/[>P>R%SPZVS'-I+;
ML@I;LZ>Q*^0*M?&80X?=IIU4=AQ,'V$4=_.H@!-&_[ #0[AJHYX>M*%"J_)
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M-8]:FNV7#28&TVZ2Z[EV\L9E= &?0_,FQC^+,N!2OH"N@;$-"@J34+3N9[U
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M.=FTO-6PBKH6,$=T3->*LFHK>C-"-"^QF\U_FO3D>X=9DYY!/>V6>)(G1^S
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MT2@SB,-LAH1'"RGTCU*<IGZ!>"49B](WS(91EU=(R]P$UQ<MG+CID'5?&*Z
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M\V"[,&8]J71DQJP)9\2TR$04:7QSPAZNB%PC]: KF@$8;HHDPU6EX6%-&E5
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MPGHA'+]3PDS.0#P?9>IT@8;3:3=YA8@?5@\9?VK[P"22@RGOLL5V Z16E7-
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M5];)P?>%Y8GB"#.OF,@%4'D^?0#TM/*Z875<7A],-(,5:!%2@L\OL-=[1R8
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MKE:*ORT1<\/85!1TLY!.%NEH_;WEB56!*A6H4H&J'+U?H4,%I_8F.+4X$?5
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MYR4-!CF0#ON(Z)<BI1TL=.2.>S@@XC'X.>Y-YUTFN"U!L=<>UJ0)+V?D[Y?
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MJ,'W1!K0#F\JP&F<>9\4+I([Z#7H\CXH%WQ#10>!N%$8'W6?=-7$V&G< ;9
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M><%T.0[M4>*,ZKZU/MBP?I"8QQ#9K+P8'\D+,55T OX^FR*MMNB\)L3S(Z_
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M,T8_-2(^TKRGQY."KN$_IRNHTM6R(\[ LDA:RWRJ\[(F\.1J%TC+[7JOJ;8
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M(_W$R.H&N$4$&05M);_!'H)(NC.7NJJUQ\,A9K&)AL33WJ9+VP.A N()JY5
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M)\:O,K:O-1QG3+F>(]>#:XRC4?6543C[@[(3PL[OP@86G9;A T:J,0O7I44
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M9>M<JXL%OM7[M-/*59;8Z;^/+2]@WN UY5S_76QVR(!1W<.3K1QF*]KA@GK
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MRQ9II6O*-89C+F<:F& :5/1BS=#+I<FE6=)",)>S$,PBU@#6BB5^/)-O4I;
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M!>84#J]XC(4_<MWJSGH1\+R96F.%YWV3Q\6U(<QS0+8OC(V27J^;"KU*&D]
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M*1XOHJ!A#SS>J8/_U]A75>8!<!.K5L1C,O[<U)L"Y1N[]<GL8SL2_8!H-R_
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MKXYF*H 2$-(-_Q"?X\W; O$VS+\@"T*P0M^';V6I$J=R:3XRV(NZOS#1(U:
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M@I7")Z2=Z?N[N[L/B!K[8GI\\/-(3-9V'5M[,=T 7F(:*AA&RV0CE<\JA.,
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M4E'%<4<24J2D.WUU.U^CVU6;[>;&,Y][K:2D7%+6X9@HT>DMUSBI\\.;E:L
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M()6P(PK)L=G+<W23!)4VCWUWX)\9@>Z#0@&5ZTR) *@\7J@)C_ 6YD\NDU9
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M3Y-[I1+M\O;),I_)4_W,@:P>QHQMA0S5KO>2I1;H%7._P.7W?* MX6\E':.
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MQU0"..@V]W@_G?4<#NNGY^3:HE-XV9>UM]+#7<E1\E2;4RE1;)TU^I6 '5S
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M1P6=4@&DCFCS$GW>"_'S39OS"V'G/SD!F.# !4,H'NS$J]\VUX5G7!<.(7+
M-X"O$'\?R*#.7%N"Y8<O'3F@^%\]^B4M_KA!\I$GQXX%L:QW^5=@^C.0:R:/
M[M:]1Y7E)6/C#RIL_,VQ'CMGW;]O#4&ZQWM#P0H@/9[NFF182H)96T''?JQF
M 50,>& &K!#R]W3RTABVS]K;&Y!=\(%L3XN=2]6VD6Q4,1<1\_^/LO(FRY2^
M0@5@TYN4=DKVXAP]SMN1. +AYE(@+4\%CV@IA9&8,$U\5BSFR9F+:-8K3.63
MY,M.\7R9DLY/?.)<B4GXQS#<RWGCUSDK'[_NVBSOT<*FY#;^$=B8T>B(QLRB
M[._)%L.2_?T&TE,9X1TKNY2.K!1EAT<C?GU(&]Q46X.NVFWMJUBULL+[8\Q^
MX8Q9&>&W;80?V'071OBT@^![)BY]-+S4KLSQ3K7>H)[2/I*B]>8/J3P1<K^*
MD$^22]/J3@KATN)-=2:V;:!Y[I2.8]^&>?Y=<]$\MZL8.;-Y;E3F>;^*+Z7X
M/X_B:QS2//>JF8"GR:3Y[E4V8-)R!-+=LWZO4S;V?1NF>A@\[\)4GW(DW3AV
MVUP0R''AVG$G",.#Q<ZFS2\!#VK;&_7J<OHTC7N^^YHC,.>-5I48/VQBO%M%
MWMG,.>];3&R?J)";]F[Q"^KL'RRV9VX"W;2KZ^U^8Y_7VWEZ],LZM^C4)B'M
M?P_%!W,+&RK%/RL;MZ*M2/;""F  17I]RNK:_B.P:0G:;!4BS<%]_48SQ=>_
M1[0'[MO/(SB4U+WOG+5*EZPKEVZN+%;Y+-:)ZO(0B$WY:HZ8\MZT>2O_AR-5
MZV7*VB1U?6>^@A''@J=R:X>:-XHC)J3<URO_>34O'S2T#:[#8T]$_+UW<U:G
MDP("T3KK[0=]K]+A;UJ'OPW,MU_---)$P%)Q(!(E!.>XME/1-/X1V S33W6!
M*&028H;-N)OY:OIC0L@P/2_0;)TA.(>.J#)@,C&58K G9M-H0U5YY1]C1@2R
MX3O*5.*DI"$4)=U%UVOU;JW935&$N';\H-SX%E<IO/_^=O3 ]  H8S+O7+,L
M9GR>+3JVQ;8!*AZUX'.R3B9 %L(Y4SGE->57[$R7AX=*MF;^J(U-PV#V+Y)X
MG7>?1N8+Q%KXV4\U5,%@>=P)X6QI"&LD0K(INNKXJE2TJ*0KK0+.HASQ1:.>
M='U $%P:HG(%%L'#(<MGDKF[X,D"*WX[&C%$5E01>2Y-W![8U.=I7RJ;EB!>
MBV>$&'$N,P(=A ED*/6\DCH@X+P&M>;@^,\KL0WB=*"D,O'80H/;!LI]GMO2
M-7P^=H]T?@J+-I,*@=>SZ#G9&0\>=CLZCVS.A30Y)5;WK7I+[7:7IWQ%EC&8
M.B%&I=AEFFU-HVY2_F<]=7_7;(T#@6[?H;=[<J+U7+[?6$M.;0+A.R*,O7)%
M"LMS$0$4+2.^'B0#-*\>4%6L,QJ!ZG(]^JMANB AC@NT)V3/%/HG57NNIW^L
M!:W,CDM3[717N"YQ+\]!)$I0&0@W"$23 *PYE0KJ)*;I8VF*PS>-M1>Z/LWB
M%S6+]8N:*_RB[,=\5"96N<@$%:WR(TRC6S\;G&T!7<3/SLN/=,H9?%?I8]?7
MU$.W01Q:R="BP*M>C%L)&%MR&2D<1=>\\5J%DA$ N"B*$7;@-5GQ.'DX.)AD
MLI"".=5(#W1( M$62!1X$J<1"64QSXND=,0T-(8+.N&-^8(K&SFV]0HS.7*M
M?([<3OH.=Q^Q)[<ESID]9,3 -IC["DL @FX5.LJ0?TV"N AZYT_\]ENMQ,3O
M!)8Y?O>IO83^6Z._;&%X6RN20T"$=EG;"//9X826PK>BWAK%J;<K]N0&B#H<
MPTG/IMV2B[GKS5IC[VU;N]9N*[JZME=NC>V46Q'DWD:Y)8\?WJ%R2ZXF+)#G
MRJ'<DKNPWIAVV]Y;:ZS.X6G A?K8=BSG>:: [#&;?&GMV664Y<F8JVLG-^VC
MM>WOOJ-EYT[=BH:74.]M<O'2;A::8&@G=PUO1?ER"']RS\9!\/;9#]T*#"8A
M[@WS1:+6WWVY^?9[*@#T!C#VBQKEW2=ZGZ)<U?B;TT2^P1LFQ1)_AC7*G\=A
MS=+=\,ME[?/]Y?"?M>'5X^7]+XIFO6HS3Y:]8^V/S1;6/*8JD%^4)A9LBY*F
M_ZK3?Y*JG<2?WBD_)Y+KMXO[1')A,<;<B\/-\_-8VA=QQMS!Q$]*'N+29W:E
MRF-S)"@S4J.Q*DI\;HHBI@*=SL@/,$*:V#>Z?G0)7:,1@ZMF;5DT5$NXB=D"
M7@MTXGN/82F &*(B9HV10=2>G!?V094SZO8SDDN5(^SB<WY2M732C+:$Y-P-
M):MN1X)3^' ?_O,]I]VC<PY;#RP?=@O.Z37ESFDPFV9_Q]])RYUX-[O7,59@
M-3O=!*NY;I!7.RGWFS#(ZY2(U>ZHO59KB5;S,[]4= 96R%*\U ;'Y,3K0K":
M!O_JTV562!$Z"#.D">AR(DKD_'D['S+6SM86%3L,RCW?N6RJF8:@.$T2%,-L
M>$+ZRG'%A"MO^]1]8Z .V@GSZ%#T7=0Q&E:!3/F2PN,1\P'A)_*&^)TI.HIC
M4Q\GC0G3O/"[F>9M-KD.HNEB-(T(74@1;$O>"$\R])J2ZMSV8X+0#> F/3+H
MD3G??JK1'88NC@UB?HNL=^=XOLM\T^53*YG-1J;O79B>;CD>J(W$H4:M>N)0
MH\UG&BV4JY(?E6L.D>],YXO%Q2/;G<7R;T'ZY1)B[EFE.II)995/:=%I_TQ4
M53Y]2JOJU@+?V?4J[\-#)E=A84DI%9_'['C]"=&AAIQB3G%^+P3VFC)!K5YC
M?,*?"UIL9-KDB.$\YZ> 5&\D$<J4_*HU;AA/-^@?V_7&]\@=X[\U/GX [V]B
MVJ8'N@?>]#3#"'CUP_RQZ1KTE!HN?J9X7$>#[G1>3! M7C2!2T*[JMFS:/',
MR^ TSJ]2@?T^L;%FC5 M@O K@C;P+.ZC4OD'$$[S]3$J7+0)@:6%M]C[G._*
M;79T5#GVNVZB\J#9SN2%IGM!%YROSF-KQ;>+R9(N:ECD,HB$W%G\0T,JJLE9
MR=-5!_W-/<E!LY/)DRS?AIL]M=-8KEQ:& %[^D;]V@8_ECUJ/]89[D9EN#,9
M[D%Y##<_6P4.%X?)O06K/?1S15*O#"O8()"8GTP^8L#4FJ78S)>#R<%F@9!X
MRGMIMV]NOT;&6H=(9 8ZZ%5S:>RP-@7#^P/4C@_*)%V/I@$#A3(Z#/RQ WN9
M421^ ;_T0"3.40NZLRP!]JW<Q5?8Q'ELM5'>OIM1B]8Z[S[U.F?+8^(5.$F+
M)LJ^:*9%Z@$+$4<C#\BH/6NF[?G***":(5_[01\P.:<"R7CTM@'AT@8-;$\X
M"H974^TA>/I?,!:/3C2>+1<AV_VSP6I",GPXH^)-8/X991!$ 6UZ6T,4Q/IC
MUPF>Q^D?;O6X[E*B5"NF1$+IR'PHB?5(\E#@.,[!F37]."7%[:D'OJ ^SL+)
MR4^9=P@V.8'&67?U 9CHU_.U\2)D!MZ!,R4O/]0$]_]'FTP_7D3: )A;T6F-
M'A]=SL^QV#-KBSO,P*:J//"++$IVP&(MD[EG&2[,!JWVNT\WCK@ND[+HH]7@
M!__$F*U0[@4$&57CF?(@KCA3UM;JRP0*3YE<XVT-9N_O@7IV@"&(077A/JH$
M'J)XW"]'8J7I\8DVXXK;,B<F'UK--\Z3X2)!!ZJ93DL<3.P\YA0U"1&&0L_@
M\_%.:IYPBMJ./+##Y@B<#SAO?8RY)OJ2\VHSUQN;4_@'!FB>/&BBFJ-353LF
M (%XH//X.'I/<=QLFZ,'X+>%LA3?/Y'+>7#ZF2!/C-]<-K* M8AAT.RRT0C_
MB2P$L:7C8OV086+U"K-U##.9_XK<R4M3W7GEB!;8 ZO#.P<L4WL"'L'+:\H=
M0LRAV;H)#.DR>#+9]FG@3AV/>6&8+!\5R$+A:+7AAT$:XOP!@;5C,_%^Y$-#
M[A2_M&)!\%B\0N,OY2/0!1[9;D+B7R*PN".=K"[Y!ZT[T71H&U\CBM*D\^1(
MIEG-52]3EWTUYCDL1BK3P.7]O[ABA#!?62PC+ (#-DB5% BCE@2]$YYFXUT!
M6]@I]&JR7Q)9ZU\*/I#C@"ZIGG@,3RPC *(L,NLVSYI_+P&$UKSV:/:(B#?+
M2;UX5'BD4%I'A9"XHL@^VXW1O/.?(;&Y64E*7VVW!VIWL-P;68'PGQ(/MI-&
M-F:]M=PQ#[;57JNG-MLEP=6O\!DS&Y?[5=GB%3G(([4V90)N3!3NE'N(#84[
M\;[!D^><4\#53K>K-@?+5:F5C3EVSDL&_RD/YS7Z [71. W+<J(H[HF6Y6%-
M!TAE278CSRFC0S>79_D[45X?[W$8VH8LI4YN@CAWO)PE;XWF0&V7;^9BQ9Q;
M,V<R$L=1,6=;[?=.PQJ]I3AGJ.LN-JY[F@7/9,<Z'+/T M[)U<2U?$7.C^M!
MG%9.R CLUBJ)J%9,5B"3)0,I'H;)>DVUU]S7X+0J.BG*'O#1B@D%3Y5AV(W,
MII2-;^CYW;EX&^;/L//&!T?O\J_ I)QESOZ:NMIL=-1V?;E O+(4Q\YUR=#V
M)>"Z1E>MUUO@GYR&Z3C9NII8Z6M56U,]L:1/K!R_S([?!0(?ZB8E@2I?;R=6
MMY,R3S2SU8U5R!=L>EMU,+M5<OGTV"YYC$99V*[95YN]DA1I5=Y>Z.UA=665
M!MB;C"9= .7(#W]F('B$]L6O>[ -#2'/X#1S9P$:_;;:[BRC>U6&X=B9+NE2
M(D>^N'"F:W340:^C=KLE8;H=A!'':A;"4U8T><Q':A*V[*[;F1!G6U:BK+]/
M$_;D&0QY4G[+DGZLMB4S#WPH,PN680U'(P9)]RWY,M]%B<'AK=V*_M(/55"4
M*2A2M!%.<:&QPL1O"#/Q<CJ&<JUPMD X#2= \(4%I;&_KJ&,2TI4&+4TA9$"
M3[6APHCE4/*XQK76.\*Q@9_>?5HNWZGMQ3RLI.M^X[;L'%@)QJX$(ZGW,Y\E
M/4K!6+29+9S]D2F03 1M3, G/6YXJ#\%Z!SS<)NF-T:P=6446%:2;5387X%F
M24!?#MHDX9?LY%2D8@0$3!C UUV$(",<)IHR)"!@";80'L"Y:X;_?&8V]G@R
MQ0MP*+4I6OKB&(;P*9=I",(FT>GYZ\3D98[E=:8,"9G>UN'1(6@931F(\*6>
M>*DUHBQC>SJB4G%@K&]G#V<A."70QP]\QYTIM#!! @YI-8>N%8+?FQ[BFW&0
M*8%M<:084)>$#F:^L!#H\1YH<#]'V!0@J%8%!%6:N_8*_X?3I *"JAA!,L)I
M $$5!B?3JY<!3.;=IS3SJTVGELEG!DU=1J5N8+I/)G0_-)!'6FZN6R]@]D+D
M2,PY$>&O15.<Z((;^E><#1XD%\PY(KD2>E$LTE+[@X':.^0UUFX2UQ731DS;
M*&!^1IF8MMMLJ(U#HB85DW8^T=K-=Y_N&'P:X8GC,,I':I_*7B'1;>[.(MTX
M.# );PP@X%PS&/$_S'4,S1LOW1W5RE$@4?%<@3S7VIU!V83GUO00EZ10N(SA
M3AFLQ$K\,C'/HC(8.W('BY@?MT)Z0QRI+;&C6KV>VN@?$+/L"(.2\C->$7/\
M=LQXW:[:.62I?Q59I-J,<QJ,PX=4+5W0J7R(VDC,0#(4TV<3/@;%P6'"BF;\
M;\"G9!^K<3G!4K@TA='=G:7BG'1M[ZQFKJTV>UUUT-D7BDW&(SAL$4Q5/KIS
MF>GMSLCN7&:Z_9[:J^_+[4NZJ:J"N;S!W,I:D&,UM6^Z=*[;+]+TSE\.'$GU
M7%566LE&LFP,BC2Q1RD;)U19"J]F/V@PIBS-,\P766UW]^7J\3ZU0"A6?B=K
M^^:>,![57.<U_-/BW[#*3[G[<O/M]_5E2"OK^A8+@]Y]$B]3E*N:?'':M,Y&
MAT_1E6O\&189;B;VC[F?QZ$3=#?\<EG[?'\Y_&=M>/5X>?\+Q.2OVLR3(HC.
MA,WF:/51&3,4M5^4)K*.\)'^JT[_27*?Q)_>*3\G'M-O%\G'Q.?:%W%(C[?G
M7TW[>XRVG),V(1HQ^ARWQ=E/<N;"9Y*D Q?(%Q(M(GI/_O)7ZI[^XH!7:V.:
MY(L+4N1IMG$.CT"5XB47N;83BUPWKW%-*FG-59<*WNJ\=RT>V>XL^LM"-RQG
M-#GGI,I9@D/ZZ].G-#FKGXF9N$^?TMQB+?"=72^3GRUEQ\X=R]+@F'@^38S.
M7EACBO8^\A8 E^G,?&%@TV:4&E1&KC-1GD,A4.#_^ !E4$?,I7+]9TX\^B26
MPM]H?)2]<FU[\.' 9YB'A&B8N<\SHO&U367D3N I%Z;'-"RU?W]S/;R^^$!_
M#Q]%E7\7;*JYE*G$YV"\347UMN(%4PRT9-_!BZ:#\+#5D^/9"+P(WSM3^$9!
M%.%_^&ATT&X.HFE!T$8=";$=B^UIGJCS-R=/@>N1-.L.3B#7:,0\GST.JPU<
MG&^7/@Y:S)#/,#=:Y9]\E2N&!?Z4XH[UDFZCEU7<O^]<!^^5;]T'YKZ8.AO^
M,+W:S?5O7!!^IR'7Z3Z;D(PK."JI$/\$RIT''CA!S+VF^=I "4R*P'\Q/Y+S
M^JO?43OU97Q)HEXJ+9+N]I9=TV.B14-MM_IJ.^$V7Y5--""]UDQ%F5C%V[Q+
MAK/UF3*DL>D;#3U7^=1SO$;@S2VVHCT_N^Q9XZ*>>BCYD-6_V3@0GD[D"C1/
M3I#K?D/M-+O+G 2ZQ&43S;11<HDPR@C?HF@OFFF1J&./,"Q!,;*(=Y-;MFRZ
M8&,13\I&9&5K>2$XA.-BI.%+Q=\HZXV$\5PQ=O:6^%F+-+X^9[PUN<DS:3@3
MW<>]F.Q=.:EACU;PY+&_ MCLY0L>:[)OVJE\TVR^::,\OFETL@H_VK?AC-[:
MJ4;I'YH=:.Y,:0S()C6%30(EJEN.1[VK4]=\08LTM32=2?<Q1;'VD_H9FBAY
MC4'\QP51>YQ-N6Y=^#U7K/1ITS!AK0\:ME#2/#'Z_!U?WYU<WI(FII$_2X*.
MW[_VO( 9W+S< 4D<@S[K ;GI3WF'0-1[:KN_7/&A>/1TI)_N3"9 -@]7H:92
M,VD4I"3A.:83;D=_:BX:VUOW'M,?@B@,#3PSQ-^\&!DS$WT=#1-?#\H7O@H'
MQ,"5IQCG7(.8Q?@\DTL1'\Q)W*;:ZM;5>GTY+XF=2[41[5IY%>^BAJ8 ;!H$
M1PM$1[\70AUG,M7L&?H7B=]9=,J"*?XY[<"2X&[7'Y@D#F?):SN9JT_@_%IJ
MO;N1>)PICQ PAH>#82+[P5S=Y,&C.9DP ]T8:X9]YIHM_\I0<^EK/>E^$D[L
MP<\+O$=02-E/[5+L^0ZW'/XQ/*I&SK,Z2W+SIQ##T%&1"+V:EB6JHY1?L?U5
MVIJ:Q_2:^:,V-@UP9GZ1Y&Z_^S2"X.K7G_&SGY09>)RQI(<AQ,P$LN*=_YF"
MX$-3U]$9PT""((=$,3>(;&23M&<J\P6^@:_",N,U6@XVC.#'Q>VQ!T&"2SV/
MKO,#]DN\D\HC256&AS1I"<'%G: 11A?7@GH0M-"3$:O8GX4\T,UZ#]1Y]VEP
MMCP(10'/Q((?S@Z!P9!VL;+NRF,#7(.5]Q_A[4>:W]N-W7V<Q 7'WY:O)X[I
M#L)S_1C\1E1:9!O_-X!-C]#^#\$7"$!G7I@>^KZ!NP)]HYL<_.VZ6B8A%A)L
MS5/OE[=_#/^?\G7X^4%5KF_.S\+PIM#88DWS/\99Y[]=7GS[>JE<7RNX!CC(
M9KW1^@A_4OX8?OTV?+R^O5&&-Q?*__TV_'I]]:_KFR_*\/S\]MO-XT.&19<W
M[EI/FRO')2OW+S)ZE^2I;I0RY-%9AGSW?-A]7# YP01>,(N+J:P 3!;(7@6'
M4R8XG)T]L5@LE:.D1(@PTWW#"#-#D&"?7/SW]Q)\U/M0S>.J!*6B;;[2\J(
MCS*V'\C+B9+@(EV ]^":TY4CP'9.D I(+$G-?]8L@LC4?'XJ^WHM@Y_Q!GNO
M;[T=*?P"HB0<6+'^(5G_? S_(C2VO3+A.:_#LHV]OE44JQ<]4+7B_(KSLZM?
MO"?8ZQMEMK'B^HKKP0.586S%#A4[',KSO=RSX2^5SULU8:]&U')?F,)5%#5C
MTQ6&Y-&',6.^<B7O[ZEW'RMD_AR;^E@Q?65(R,("K_\8,S[5$ZLG5D^LGE@]
M\=B>6#SBV<*"JW]F_6?E7B6[5V%I W5&21 DY5'[P5VIH@/"XQ/BZHG5$ZLG
M5D^LGGB<;I.LJOMR]8]_M6L75]_@PY.::SS7_#&!'QC.A-5T"V<2UESF.8&K
M,Z]V[B'J+OVC-O8G5LTR;7;MLTGMI?E2TT0)T,EX O-IR0&M":M$%49%HDN%
MH"<#@+<:O&MPX(D$@_KJ2:__7JY-]8:V(9)E7MCXL?RQV]$2TF66[H[T]XED
MW+$.8C_>J1I'Q<])(YL2,$W*Q=KB0OC1P>($^/U6XSO::K/>5WN#?>$G5YR^
M.TY/0U,<9!M@5%96IVH$62!P).B-%:L?B-4S(E65B]6C@H<\[%UQ]2EP=1I3
MMU>C6Y6,D[=RO9MUM=%OJ^U.25SO*DM?0&R>//VZ4A"%*H@$^+O&X/041 .B
ME7Y/;;:JB.7X^3EMCMD@:2Q1 AIAN7B[R. \BEF::K_14#O=:E3?4;-[:M22
M;:)06=F]"M K5L_,ZAEQ9LO%ZE6 7G%U&E,/JKNQPP7H.>;=S&%(%2$ *4#0
M,8RQK\.'QUJ$=":QLI:FX23 DRW,3]GOC)NK6J.W;NQ*B$K&?X(??_V9S@4.
M""L6/OWM_P=02P,$%     @ UWUI5!V/#>Y7"P  ! T   D   !I;6<P,2YJ
M<&>=E0DXE%T;Q\]@#.I-4[9LX[5$5-(4)9I/&J+76E$HJ32DS9((35E:;)/U
MS63Y;$EBDC4:DBT1,44HS)!=9LS08#S/]_1^V_75=UW?<C_7N:[G.O<YY_[_
MSCGW?>"/\!!8:VEF8090*!0XB7P 9H+-Q #/LP!860%M ( 8XM,#0LB?!-+D
MD0;,?=S=+_IZ7/(#<#\P!1@T6A0M@A%%BXIA,&(2V%42XN(2TI)K5V/EI.4W
MR$G+R2HH:_ZJH*2A)"NGNE550VN3SF8=>15=O*[V=DUM'>WOBZ P8F(2XA)2
MJU9):2O**6K_SP:_!%@Q8  >"*-4@1 6)8Q%P0T !P *C?K#P-\,)20L@A;%
MB(E+K$(&E*T%0BAA82$1831:1 3QAB!^(()%K_M5ST1TO9T;1M5;:OO-N$PQ
MM7W%==+VG6QU_"F?4'$)&5FY#?(:&S6U-FGOV*EOL&NWH>E^HIGY 0O+0X>/
M.#@>/>9T^HS[69*'YSE?ORO^5P,"KX6%1]RZ?>=N9'Q"8E+R[_=3J%G9.;D/
M\Q[E/WY64EI67E'YO.I5?4-C4_/KEC==C/<?NGL^]O8Q6<,C7T;'QB<F.7-<
MWOS"-_[BTG<N%!!&_=W^+1<6X1(2$1$6P7SG0@E=_3X *X+^54]TG8D=QLU[
MO>KVFV)2^^(RB^O$U?#V;.E3/IT2,NH[F!J<[VA_D/UW8*'_%]D_P/[)U0=6
M"Z.0PQ/& @+@X>Z2U\U31/GQ@S9=,T_<(P\24\L:+KZMK"[:Y=8DY8B#P:KA
M!AAPAW-@,)A"YG_!*1-&KI7 X.DY\GBO5]L4KXVF4W>D[E"^/?5"]I?B@"HV
M3:O)NL<8#\DVWX7!6+,%#&JWPX#SAL ,#LB @OTREKFZ,%"DX;/HNM/G:Z$0
MM0=3E1ECI(?D5WP.0<"?('P;=85VFPMT*>MAT!&; (/K[C 83AKULUN)^1WI
MRL$=1S3M^:]B4/X(H;+T57.Q=R*#76-D X.]AC8KB\A"L78_X06F29%/(]&X
M$Y@>;T)[QV\PB."PR(N<+O)L6ZW A\)W5=:$08:2)B1HA4&S3MMX]K("$BOC
MP-[JNY#_-=*/LA/_%>L$B8C[V$L6+)G,?[+AEC!^4)S]$Q+74 MJ0D*-=4D6
ML<AIZ2D_'\D/5(XIG>8+^JY(S[V0J^L%T_.#D@(/CDP!ZSC>IO)95[="=>6?
M_6,W":-)8'AKX"B]IL:*31)0J)(KX1=@P#O5TWV$XV(1GAE1:+WC5!9U8C(H
MQ?U<DINF08A-!F1$?CU/@L')]S#H?-:3TO,P.  &<9,=4%T^#++=:7A:64OM
MB.O!=VQ.[2Q^?J>1$=6H[X4M__:,A9>."/="VN$&B^5FE1''JQQ)YL#MH;<2
M.JVF^<?I]?>[S)*,*OLWH&M<4KF,KA<U].57AX@<3:9BW\[IL)GDE@6?F1:'
M$Z?)[ZZ;/?<]5W:Y;!/K<$8)/>=%-0R<'YP<ENA,VDB?\K@,"?%/&#DS'\Q8
M3P86#FY1NN>"]A>.[U7"WVS.+ IZ)?]+$8TUSC,^,?"M+=E4=@G_^/Y1DO?)
MER.K<9:\D#U-]P)\6=9IS""+/W4^&9+W364S$A(T>\BXNP4UNQG3 LF]SUD%
MCG;D@OWEY<4WVWST@YMQ-S!3&4Y<&)3J699.V$ G<B86O=SYY]HI!?8C]I2/
MU[_-\]4B&*62HI/I1LI*95"/1]_9"%UT0\!96XL]_GY#7&H4RR"B%(=Q;7[H
M.6:;/C-\++K$,MTI7_TTRL=&VI1)$22^E86J#: ;'VHY'9#Y:\)4(X&WL6CJ
M0UX*HYY;H7R0?O7J("3:)!/^]%G^&UI0<%2--#^(>6D]WRS$&^=0(3-*C)>A
MXN,CY8:FQWV/U:QA5X0)O(+T,SRW%KL%Q&TXU!XPX@!N7-,:BVOT=Q6'P<B]
M<S"8[QZ# 7%+8-'-X1*FEZ/AFAA/-*]8;(2>-&"F5B.5NCJ..I*W^;@GR[,K
M830Z/K9*U_EK#==3>UO,)BN=G44/J%3<3=[=ZRHN?'.G9$Y1O!GVN-/KQQ'[
M+FVPSQE3Y@54UT-KV)0[.,OG%.?*.#5'KEJZRAKFUS+<J^KGL]#68Y\'+!DV
M!NES!YJ33RN<Z1YLM'(T+^&'J9[;JTRQC7.[4UIX1?U,M-]+5EG:;_M]Y=XE
MYFJT^">45Y1<*\N+P\88W+JR[N! .3UV[VC/*V\O?1SI@MFP356Y0YR,1\,[
M2Y=0R=98T&Z\U'.$@V'"X-8+;$Z]84W>%6/&CLL4_6V/7Y*VS(W$IDHPYPM:
MK4R;*ARI/C.EZ=Q@;=F+4A6*_C1'_@H,5$(4H!IU&+PC'K^6E!GUBC$:?XC^
M85F'5DGU#G_T(2DYN9AE*Y?,POL4L6\IGVJJ.TJ[+([!L&E'")+!&C"0X$+K
M.O!'YXPR#*:A\T$EU1?Q%4I!/4FY+[J<6PSWSZS>+ZZ^:B[?&&5<$G8"4:G?
M3IABP,#+H9?NE/@91]I(VRE+ZHP+#7?O:*.=Z3,R],56WNLOR-&(;?1'ARZ(
M1)]A:&71OV09<;WJ,N;V>A 6L!5(ZD:Y'G-LJ5F-I"[7!"GF,;50M-/2F]J]
MK(YA!H^<PCM&8'^9#$;JSS!D7D!8%LV#8I)?M-/QP\T"B@-YX1>;%84M@6DA
M9ZU@H+ITXG9<# P",QXYP"!<<#H_P'!N=/C@W,=/C5^J+,5=;3\I9R]17V;1
MY4LSG=:D$?V6%-^E9F[UJ-;KV!S_&V-/<=S]YSZ!FKL[QIP'-G$>YK/FB^7S
MHU=IE:M$8RM3W=MM#MUT69'*-4O-VU#VQ'^N<E,+L=%8>70L0F =O"58]P*O
M=4]UZ>Y(KYC%J&A%\/+J5^VQ*"-?@VC]UGQ/?;W/*A(5VV;72"G.U)W'=N3Z
M\!PNB1.[%V:"/G]M/?(P<WHV<\ 3)SWK9ZPR03U[.[?>HU=76?W"2/0ZBXN^
M+L=7VAQ_IQG34_7MRO5$-")I2A7KR$XTHM3E1 ^K=FI)T.3\O'AWVOYLS2Q#
MG$1 F4#CRD*U\=;V4?;Z9ZSAP#,B)V\(HY9(5'*4$4DS:E16MN](HFP8^%3W
M J_5\<;DU)ZEL\^KM)9R<1=F9F:_52_3C<+Z;1)Z!_<MQ#UJS!TL;.L+H4,#
M#CJA_2;M)HL'.N:*JIWX!5=86ED4YW<["AHBHLQP;Q4LAGC>+DI2CX?&':CY
MNSX7I@VD4\-U#H>[G.*1S(-8(U6,]=9A^QA/9M!O/K4J*I_D1H8*%6^VWF9C
MZDQFE^L2F#BH'JKKJBTQJM6=_IB@X)M*NGZ-FSI:*:^M>:/>2D-KH'V9OCQ;
MFV+7<"2JDY).3&99J-UU,SOEL$,]7#G,:"@(N6/5#I%-HCUAA)'@=^1IM4O(
M8R!3\XR6$+P!!FJC83!P4R"OR)7-)UT/:<QHSAN' 7[\&9G9^GY8X,QFF'.2
M"V4R'[L,$C?;B@GUOXZL-L631@^U'^V6%6B15Y,[%@IA0,Y"GE,_.U?"P1U-
M7:%YUMD6RHE/$S6W>A)="$Q3_FF(7'9I>446!@K9D!3A%F%L&;F/M9UD3I56
M(:'<5W)QZ?52LL+B6O*KV^QF 0S.#7Y;TH4,S'^*8+[0[@8#PM&0@[\([ORG
MI;.72=N0Y__)WMQ;T'X<.U.@ATSMJUB!HF 0TXDD.*X>QUTI( ^.U_(_2]FM
ME-PG=W3C[.O)JI)\6T@.F3KC#"%E%@9-R*9$2#(IB]"'VEF>J^!BI!;4VT88
MFY+,=ZN-P_PH\P<,HA3Y_"B..W_[_=/!UV$_J/P!(BORK_M1/WGTTHC)#QI_
M8B#B^G??%JRXS6\VF%/M3F&[UE<Y%'H^ZA^8C-F9,V&X.;[I\+.G:KM,FJ7'
M_>Q<CD8?#SYD7ZBYL?H!(]LZOE2: O?^!5!+ P04    " #7?6E4(.KA%7D.
M @ "&0( "0   &EM9S R+FIP9\2Z9U!37QPM&A1%!*1)5Z("TL%"!XF*= 'I
M'41 "%5Z@$B4WE&JTB*]@W2!0.@(B$B7("4!07H"$HZD\/B_]^:^+^_#G7L_
MW)/9,YGL??:<M7]EK97D].?I"HA%1T-; T1#0P-Z?O8"G6)!$NHPZ$L02$\/
M) 8"@2Z=S=T%G3M[=_EL\)X-D*:OL[.7GZNW/^AT :3VW[W_6]=_F_SO[D%S
MV@UBO41C<R[]/,TMT#E6FO.L-*?](# (1'/A_UD ^G\OFG/G:2]<I+M$?YGA
M;$$S"^@<S?GSYVC/7[A 2WLV^_IL'D3+>H'MYMU'%]D-'>AN^5R]]_9]P26!
MQ_4]'$83>,'[+WS#Z2]S<G'S\ K=%A81%9.1E9-74%12>Z*NH:FEK6-L8FIF
M;F%IY>CD_-+%%>KFYQ\0& 0+#HF(C(J.B8V+3TU+S\C,^O QN["HN*2TK+RB
MLJ&QJ;FE]4M;>V]?_\#@T-?AD<FIZ9G9N9_S&"QN=>WW^L:?S2W"P>'?(^(Q
M\._D/UPTH//_ _K_+R[6,USG:&G/T]+]AXOF7-!_"UAI+]R\>Y'MD2&=@P_[
MK7MO+UU]_+Z@OH=>X+X1GN.%[\1E3D$9K!#A/VC_-[+_.6#A_TO(_@>P_P\7
M!L1XGN8L>.=901 0E2I2& _Z/SY*Z8QS^7,12(/!BN;^^F^T;R[Y)?TC]?_%
MH/+)?\]?WRQ!C%/YOO&U+O_+BNL>_B/*VA?^4('N6O*7OY6DWY8//2[%M_A-
MOY^Z'C/%_\O40OI%VV&DNXAU\%.G)OTWN2X"-YP-%+QB>$H+,>T'LR?BF]Y&
M-JDA)V%6Y#H@^^,IB#?AN]YOQ:_$U;E:]WM+?G[W=2],&KR$^-^*O2BN)+\O
MKT7_1VOD?4]5LE38'(]ZI'6PQ_4X5=>P'O."Z\,4T8.#EA+WDL#:*8/J 'LV
MS.A:C^Y'._E%^%1+E6WU\9'D'G]A%J3,WJUR:B'GK:L]%[]]+CLM6(*EH]71
MV^CB_8X%'EF;.(Z\L1%MUN?E28-C;6PWG=?>[RFH\*_IF!_LAFZ'8<*>_W9>
M/K&FK&="Z3'T#RXX+][-%%F+][YU8Y6V;JE'@%L%9,'(/CP^F<D0^5[PUU;K
MLW#!>,54<W5A$=OS3*7JO]5HYB),O_X+SFP)A'JU+(9=F6N<V+N&69@X.8%N
MNF.H9B\_>+Q93%&9W'B@6$U$.7A-,01_B/PEH&HU0E[E"Y*CWUZ8+$M^_L+R
MCGE(N-H[N9/P1P("95:9V23,1%EEJ[>]YM3+:Q/[=4=S[L<[ED6RW.]8M+LQ
M]_JOO:6&AAJ)5_Q6?3Y4!_A,9:O;_R4'"A6F*9R"( :$DC'054/U__-CB%3L
MPH-#FO[VK70R/-94O.%XXI@-&L[>P_3P[UGRS*E:/KL?O:'B+YG\T&MFW/UD
M9G'OPRGHIZMN^T6V%H%?\@Y%CS6>O#FD[NN7MO-U0L;B@UE>%ZP;QKYT(#IY
M:>QX"OQ>>6?^#J(B>4\Y1Y>OH%I"WGCA=2'LYM3J3_Y+S]I[WR=53LHM5BH,
M=W]W;T@K3:W$;2A\EXL(>5"S-V\K_')?$"TTIHK [A3G5\B.S.3]:IZS%I?*
M\QB_1T@90M#"Y5KP>SFK2)8%:';+IYOLI<-"H1;T8G/F(O'?/GN )<IBG(7I
M&,4=J!.K3.9/"-Y19$^O_"O9LY@G\1.SSM,U#=9C;S3^!7S4U7A:OV^<RYC(
M_!V9J$J'1^[:$GA'23K2<:<@^F:PJ@%S5QE_9%;[A:/2_$:EG(2<#EC1U+[3
MC0&^6\,\$D5^X _42$"&?(.2KWH-$.Z1IRK@]V/\$Q@L_N9QD@;S;TXV52VZ
MX;_:!7,<B><X^OA)]E>/7[ML)CD2?VY5M44J?K3B1W:)@J-;;V&%C@G6*-W!
MZCA=&#JUGB)9\'5M#H5)4! QL9C75YW09:;3ZX5^S] 4\Y(S2E@KGVX-TI&<
MMZVY4C? ?V>*S.?,2.2TQ["/!7@A'=VK)$4HV:&Q*_DD^<D%NN29$K7[41Y<
MS_37S[7S=2PDN%?I=FC7-5^84ZERUW)(%N^\-5 4KDV=?]#/9R4>G.Y0=EBL
M@1 U\66"6Y*,8=NXY60R'8&YYQ0$4KUF Z393MR>DEDTMYCU)S'OU(1JS$H:
M;6U36=S_;83J&;G['ZA_6Q;KNR'.>LAQ#1B/0#&3--S!S*I7D)SP9YT 'PY\
M"8@>0SFL\(DO&'JO0A@W?>PZ8V)N-[2WP9['F-:/E4QCS&;:47D"6:_[[ZP6
MYNO1_VZJ;_:QT%'X^$)8HY2S)L":RR@1/[T]4:-TQ\M_-53D8#)%_D&EOGQ3
ML-#'Y@^F/;W18B4<T4E6L/)G_OCZBLM[23K/J@2+%)N#I,-T?Z%N[<V?B$N5
MGF06!+D(QVIDXG\MT+::)$]Z/IM_<J4,ZCI7;;>M'RSTN#7$;>_1>\'=7(9
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MVC$W>T/%^JP"NRF1<(GLOW*JMX&HU3S[7CLA B0:;G^&+^;LN,B:N#'K7B,
M8IBF.WMDSZ96LC#&GU8TX,>X[-+1GL$T[:/R;M!47R&L(#8G\M7?JCG?,M[4
MWP4R16-B[\U"*M1)BK[C6L,50M664T<C=XT"W(R*TW]Q; TL9\JL[;=*S#5I
M]YDUA92&H:=XGSSU>MYV@_%=F[#">4&_H8.ZKVA>1(\WXKG!9<"]MTMJ H[
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MEL/!5LEOHWT]/?=?VXM4F]G2#(RY9YGC/\<6RJ<LZN4-@CF5W@#_>"ZP &M
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MR):C-"'SK)-3#'X5\]:=B5VJNA(?;^D.Y&;"")1[\+.'"=>ECJ!IPB2LX;Z
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M>,("VLK%IC&IZ^C5*B\D^1&5^VVM0/;D'V3''N^V2GP'.).,M;EB$5A7\FW
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M19&]4'_Z9![9E)V475'_'^![WV][IMR!%**O>",<F2#$30"+W8_A#.$HVXU
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M,@W_KD9KUMVU?Y565;GI)HI>E0/C:<B\NI=-YH&VS+O+IZ#;$)+C&>U7A_V
MG%20K>W#T9=.00Z[]L2.L\,6H/91)0'-$+@XR3SL.Y*YJ2Y^N1&1O',*FC@2
M-^#XDQ4DWVK'\J4CQ:/!M4NZM54I8"PWT7,)BUWB$/R8\A=-4,8>QU EX?+
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MEA(=]1DG:1"GBXN#26*/S&.U6/H%=S65*R,LA[R&/%)DSE<GF2B?=7A6D\R
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M?FIBH$>>E]#D6M7Z?I1('7DW:)O5UIL#]XS[N.;3T^\@,6)O,]>H+[//2J+
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M]M^RZ0$-.\?T&Z9>N),U3[99O5I/,-@+5S6N+O/>I:(\F."O>*ELFCM@7=J
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M0B4[W)P\%/(COJBV-HD5[(-*8"Q_.@\1N)K:,9_4-1).X&@%]"=YRJO<4O1
MM+*W7?Z;WNFN/&OXY6KYFMGM.>.#;E+C3CKW,W42;N24/YCVYZ@;3YH/Z#KU
MZ'#/#2AE*"L>!C+VKBQ1]O./3.VK!9-(RO/[EP\<^:#%E7\[IMMG$(=5$4I$
MK'G0HMMTH%\BUT3$8[=T]*=%?3*\E?0/C,L'._/$*9-G_ =W-_"J (('TWP+
MGO=F-5%JG54.I'VJ]YS@YV*0K/WSY.#\D(\^3"X<2-%;_/ZS8^;[Q8BV1^<F
M#$^IU&_+Q)X<- QYBE4"_#H4=1J9A=GO,%<O%"+WSKL4K%+:<5 3A?)? T^M
M531!\E"2D3&0-P[U3#YI=K_IPO[[8%3##\.8_V!(<^QL_I8>>WYX)Y@X<6S\
M* W[RNDI?Q AJB>>A-C2K(91&E@N"^H60!0!1TXK>W3CE;UUT;C16(),0]R$
MB_,AM;**F/R/J2<"$?KHA0Z2*/;@N$4H30")P>VMLO+R83 FX;$DR8I<V@HU
MY5!US9-!1!8R0#G]B<;QI\^L#D)\<]\4^J6:A)<B-];:3R^^KN38X$'BV76N
M@^9O9[(W]?36ZWX=EQ4O_G[]\FQJ68D9<@7,>+,\.%<2JKT1/L-?KK4#-= 8
M3+VUN?@)?EFPW-JB,_5 \R%^+_8,$$[%1_&%:H$+*/HYQ/Z^UV@K>+^>MD0[
M#1%)ICPNI\<M7'Y?$^H1X3 T-31C-7? \$0SA;(/+\=2712AAUNQPW@Y6!DT
MC@8F'KP"5YW)H[3"%-!=O7U7CH$9'JOS9,$*2*$RH#=<2_W-UJQRU1-%9ZB7
M'+.:"IH&A<@G)UW1(4XL#?U,?<0^XV-HW_E>><G2.1E%0U9[=^P,2B_OE#6A
MXE)_Z45%87*1\HU'ZC5-E<S>-*G:8<-@UHX1UV(&X[4DQ@Z(K+=Z:=8>L>9^
MB*SH?> "CSZ0F@@&)NT2;<Z3!@%D=/E%(&B"\'ZSMIB_OW #?XV_]>LF&K1N
MZ*>]_LV^.[=A%EOX8T[.(;)^Y]2'P:!QG[*R.U,7/IOX^VT_8987>7GH0;DE
M\(1S_L.'I!D^2I9K[GHZ?=H39'\\??#@R?QSC_[@J$J]SL/QRX;Z^T\<'.V!
M*?#/<4\ (LQE9^ E'1$W>7K04"]_9UN:03M"7C8_%^DL03[W@"6;,NM6A#E'
MG,+$]3RR^2_LRX#8)SFMA7?JP=?7H%Q9T+I *ZJ<F,LT.*"U(X^&A_J=-6C%
MQQB?9,ZV-IT=[N2J3!X%8FDCHX35NN9>#8VJQ%,(B59/9,%GKRPKGOD5 [R/
M:W#23U>=#PJ93W!33<U[6=*$-\!=5ZY[P]F V' !1(00L\S7!*);'UX9>5V7
M*J\\J*W"TLJ[/;-RP(5VX)JZ[REKJ?1GL?V_A(]"^3AP*%M.KH#FEH]:VN.+
M_[,$ T""KH)5^ZH#C8  -#E"8@!C"B:!I$AC#W!O /UTTM@(]>\YA)0UDJY_
M88JR;_XA*A=C<#= 3LQQF#L X0_6G[+I<B%/?R_!_T@>$Z??P2D:2A:@\ZX
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M%OONTG7,P![*M*M2_[586QU%4;0Z*?O@H>9*)^I@[G$@^=Z#F\F,% N622=
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M%=%--I#-]91UVZ88WC-2)@9#(MZ?1?*B:>801%U0@W\I;'?HT9@>7F9*B=#
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MK<M0[,^>QD8;TB N-^J<] ]_TP"T:,F"F=S].ZGK WW7SQVP=S-X&K1"Y^>
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MMY$76V\L/;0KYKK_0^#39?H!";I3BD]]V]1$^NVD1T[)QB\&$?#X,: ZHMS
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M=J5 O#ZXMSHV'$@5)2'PJ;%5!R:Z-\!;47VMGQZV9R&A,0IG0+U9=Y/2^)I
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MMN.#H]X\"^\@B$GX>&U_:0FF\91'QQ<7W2-GU?+O 3S/;9T 9O<HCN34V!.
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MA'>$T/&VNHQ$_8'/&)]O!N=BS)'Q6Y@VY#RM0G17UD5)^:.!MVBL7Y-?0[Q
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MYK2E;?SCA$T(775+B\*8JK0W6J7#S>?']]1&WN"VGMCX9<95N_/PDF/F <H
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M(G3[9DS]+W/.7L52L>_@^E;S)UI LP//6/X?59Y7&-^!A(%@\@[AH -Y%:I
M]>[($1A2NE[J%IWO<GG5V[JWL+=,VF_G%%INU^JG;Z_QFM484KJ$ \7AN-1_
MU0M3()R1"=YL" A1%/' 4#X>+J)2,9$-%K4!C%^%;^T)K([.P+WUAZ]U0.'8
M(7'Y #?P]8IO^&[^AKAC27AL%W]:D6/ I0S&!@)=OJ\])##>=L=P% 5L"4(^
M'=L"=C>,RFPZ&-TGQ/8';#U,YK8XN#E+U2/O+#P9!#)0.%JU\S2BYP=XX?$T
M[9?E16A4Z9J58UR?4-OG_I(^GK047^C11!LT.U:ZXY%7:^N3\XDBVI4T>6HH
M&=^IFMJ&*LXE9@<:3&PZQV7A UN^[@EI7'67::C*,F^(;VW*_P"YXFZ17/YI
MQJ[M!%"WU[8XUVX\E3!A/("OD-NX4=?A *O3R"JZ\,[QARE6,(Z(/8=1H^)Z
M51-0, IFMO?98!V$79C*U8GAK*8@[GS3*5E7/<ZV_S8']_(8@U4JDFPGL^[.
MZ/!//2J[^Z'T*GV+7KPI5D]E/S*>[I:N,KA44FP@2$Z6B.[)+?1(EN=\I%]R
M7C_^WS&G5'':_UO^G3M&#&]XF\V6T-_:96O/LX<'"U"6HW2C05% 5>#=,@LM
M^Y=%ZO2^?KZX+^# 3Y4^RU&O!%P,(UHL(0YK9+V0OM:$LGT2=<8W\$B89DR]
M@)&8:)6B2*SKU]62T4UY4]/&,"*2U?605)KVD^WQ]SOU8[*[\.4160^)NTK3
MWZXJ"$V%)I)/ )84\_?!PM8ED3+U<U&9LRGT4@J#"1H[_J(F5IL\F>E:S[RU
M!^YAK4BY%VBD.L#U^,L4SOWG%IJ-$T^4[(ZE(L!$DHKN&) E(&\M^-H@KPB[
M'F\94(7W+!N?04OKCM +].6^IHKX[L&+\=ZW8MX\#TA($?COKR8;IBXS$0[?
MO^3QO&(W#&?#$.*N/0H:S)UNI#PU#&$:DW,7'Y,Q68+V13 +X2.OFTEN9YB\
ML#N(V=&M&M_U':89.Q9#G_RL1LV@Z.5\?J:M'A^L9A<=$Z__LVE/?7$Q]R,_
M[2XUE%@9K^J1DSJ_%7H"X$4\?UE"5;$DI\YU!4+7H="VQQ=\(:X.0^Z[\693
M[=.G)LV<H+82X]9@*LUAH\9YQ<!X/X<ZL( -SZT5>7>:E&GV8S=&]BJYUOV$
M[TS4N>RM5NP.<!K+9!<GYMM86[:G3_DDX;-*)6*(L_>Z-QQ;Z^-9;C*ME)!$
M">QG5UCF9>1'.C18AGVPO-"#9K^6"@A5#9=8QGOJ RB5Q^@Q3\5)J]]@HFRQ
M0B3GQVJ?,-IOIE/4Y6I5H/@3XU1$:G,W#B@BN%FF$9J.SX2YK=*8HGE3VTC=
M^IM5_V*KV56_@<5>F<X[]8U01U]XA@H/ B47&2Q!K]S2X(+K+O>< %@+Z7D:
M'-1\(S6K(9BO 4P:X>KLL!"44%BSNB1PI*)\P#K.5Q/A'V$V[6@@ EN53&C5
MGD^<'"'$5T;1U DR*CCCDE6#;[9_XM5(S6'*L0S& >=)QPZCGK*<#PC+R:Z3
MA;K?[W]A?U<W1Q6/Q(F<N@<[0H\BN1]/+:"([$=,T(0(V<Y=WMKE4)5F_TBS
M98/JS/T+[C[=:99^0$HO\ZO!L@)>EV>[NR> /X;X7KN+&&9J8&^.QFCK^1*J
M?Z_5QF'6JK(9NMEZEH6\5"(6J1]"W/V2:5X;I2TT;&-\35M"T[9^EZ\=.35'
MB"3=_3+KTL!G99V6N9G^%3+ />$%F5JSLOD>*/45,_"&2+QU]CL9+"#[]\6%
M90 "=V1UC!.A0)4>4OE0M!=-8["KR1.=Q\(4H]*1##$SI^N9W9+@@':.3\1/
M6[_!@"^7V2=DY"RKQMUO8(<K4;XL]Q=V9+:DBQ.(4SZBI\R=D?1Q[_M]VCH.
M84>)M";#HI$U>^P,ZZH]\1*=S>AX$7S8S=ZEP*@0VOO[ZMZ]9[%J)X#Y;-21
M"T*=?$C3H/:3G48( SC01:T@5>CL];&*"II>H*#^]M508V!Q@,1#R9_Q *$"
MVUL?D!V6M#.5-+UQ!#L9-X_MSKWJQJO:O9D8^-H'&BC \L-G-8>IJ<8O$U)P
MZ6DV+\117H+]YP7%,].(MU0[0F[B''^P(,)\U#<W(;8 H8'.G,'P4:&D*5 $
M[:FO6#203[7N@RU$P<.'0Q^8D5%P3JH[&;HR8VI,Q5+\>$:ND_-I0/+T79GZ
MMEE4X&M?E5 IKIHI7+NOCAJ869!6F&-D.@)R.0'$' @+MXP74L\0P98YHWW%
MKB6_$@(J!(0?F:AI"L8%'23P/?_^8]WN)DV-6GH:,:VHI10S[S*$ %FD8R[L
MLITHQ&8]16H]_:U7AMXGRO0<_=N2ZW5&(S1:\P:)]0T.(.(*1^YKD"]E>#$6
M$-5FP%W-8:SB1SJC(><M=0UNSP'?^]$R.&4U_WK;TK]03=LSG]?*1MH7?WFG
MZ+$?D.9O<N6[B?F.V.WN"2_3NA"FL\VG4;#)QP6E)!7>U)H\")GMYZR[^T.A
M8_$WY99X@:Z3O8C:1WL)K&HKU]%Y.(Z0WHOD19B3020V"J,(*WQX[??1,_*E
M6E^)@F(K:YURB)O*TTFQ&@.7M)&.<VGO"]#HYLN_?HAMRYX28M"1&[RO9_;N
M6.LI?_>"ZAQS<<B8W$N^VC B+#+G9B8$C.3$%8O%7Q]";<5"K*5_5W)':/%[
MB!6&I?)@CZX?CU8'3\Y>;*,Z4K9.DSE+JSE%1:>_)$H1Y^^"A5KH3?Y-,U)?
MA#2*(3]?CS"X(2TV&=^)P=!+D2]. !%8 9@L1LP"@NR\10$;C!1[R'7QLS)*
MCE:F2=Q46K^7+3KZ%/^J-2II.M6<70R?"MWI)6S1N$X 6J/'-Q0SY\*40.%S
M=3GQ>990Y3D.&EM@0!'5O$<&MH@W_K;&_]0_\5%KH_MC<C?091N1+_;W,GM3
M/8PJB=P(FH>QPE-Z,<)4YOD9IAY5IY0 E)4;[P,R/=2TP5CC*NGR]*=G':KE
MU8375UCCS(<.QWZ982[2"V4WQ2U>AK9;6>_\6F;F]J+=K \0]YY\JN6G_DZB
MW H.ZYGEH^>T@O.I1UTF\+(N,XVKXWFYUIDW226M[Y]B^I>[F9-!2B^OV^!X
M/\3W)D/Y>E1-H%C6$X";.J>9Q<*XQA6MHA^BG+R*6*HZ3YG:9:TSYXJBSPG?
M$T5Y"%4ES.T(B",-[P3;_';#"F+7)X[Q%O\..@[CZY=#%0-(OU3RUW%OA6;:
M?LK7UXU+ZM=O_U+(%^K4=8]X(L]\[K-WVZLMORF$?+>'QZ)52U:G17W=>JZ4
M:].S'2Z7"W=TEQG>I K2[(_85T5X@_EI?,,8$=KCA"4RU>J0G9V*-&OR:4PQ
M)7_>KP(76O?8^UNB2$D?$:3M'H#3](7*2H1Q\4QQ4KF%JY1@P[#%#YD8'3_T
MK,=NHP.\Y/4Z5-IRY[VOR\&7,Q:<4E:Y@FT6,NGYM(0*M3]]':SI:<>.T_(!
MYNSW+(5N7*CX>_N?5P8#[P?5N.2L>YK02 HH%J%&7N],MY6:V,M6 Y,'(HCZ
M>Y#^!R[YER;,N;H]S@X$2#]5ZN[>Z:P*^(V!XP61 =!>C/+Q$/("TF$@;,HY
M$>1B)U@<:Q\4Z)BW:LZ2/U .#^VVO071%K,5)J/#"ZUL[:!6I.U.$M3>T<FQ
M6=:20Q,0[$GS;J;7G2KAU[D+-&>R<P>V5B0"Y"0W:4Y$1WI]60?QG X9=;F9
MBB(&<4+ORWHH)9ZA71RL0/G&7]I7RSN_]+Z,&OML9'9X7GKBEH>TQG.G6?J1
M)1;3+8X$'P8[EP7/8>3(#=VPR4JBS$281UTN)Q2MJI'[;=5D)7W*MJS<:L7+
MNO?;VMN2?=^P"<YR?G<6X&'&MF7F\-A'+XDE&@,]$ZA'$:-YC&O<L$"C LDI
M[6A^IWJ*T=Y]A\&7HW7T^V+)0GJ:<6%)I%RSFEI.'4];2/32H^._:L7.-"[<
MO@1ECL:YC#.WX]!012@C!6B/J?B*69K"*(EFY/O54@7''F&ROH37S)Q2"\OY
M*; 5Q3OE,%6,9<Z6]6A5D\TJ;K)08JFU0X.N' ,0ZI3E"-CN3M[*'!L01-R*
MG&C>2^\2B1Q_L\82P(G'XZ!%;E:W[DX6K/ U<+KY/_5 !Y1O+,YP 1.TC59(
M'L@?)P"[L8CR VS&S@D@'.2!?(\4B?\[RS.L%RI;67=+J5^E,[-V[;$2DM,U
M;42YQ-<O*^<G=Y)D>!T!F+;MQF'D+18M&(*5V)6;RC49T[@[.0OWUTPW&/79
MBLX1'!4;@\6W-40HL;-KE;&#CIYZEH@:U52UO5\<#G,4#H3 E[([-*5V]?;O
MTV..A;+F.%9R>5H#BKXW>\9*:S".*3)O[K;T._4(2=S;J@_2U9%@X=&72/']
MDJ "*7%ES^3QH[G^M]97TXN#Q0I?'EJDIB\A5%LQR0LV%)'PW0#8*=_/@O.*
MUC0$C<R@-PO&RPD?BN+X9I&3*+G"-L[._AMWRUK$=R#KR'7:IY9CD8F\_1-
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MCC@1ZED!(LAA<G"X_F+9^GNAII_/HZO'BY^-R,K.M_G)_Q#[*3/Q^K8A$5-
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M ?O<8%#?^+ESY95/"E$2R9DU;0YE\&0B.+ILDSL=RC\3KA2;;CLMX\/?0Q_
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MV#N-EVS;GV< !V2SKKA&Z/;H93^X"P!^<"29(=DV;5F[36DW6-VO3X>CYFS
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M[$KPP)I-1YF1NL.6K4Y31HF-27IVFOK7S]*QJ315XO*O@98("[+WG[@V%=F
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M*<THU,IJ^O&<S=;+#(\T/'Y]G7BIN>YIQK-6U]2X3R(O%N.HR-,:A,&)/J4
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M;[%C"DC?^]%]"SZ:#Y*H;$V)<T"'RCG DY5'>;UUY53K6SX+.;"XQ/-88^B
M:H+%ON55ONM=>Q303 K)8.NB>3^:6"E=DO+TF6 G<DCO''!%_AQ 16M\/K,M
MH-PJS_J#. ?0AB%4=[56L&\=.1!ZI', $16#45]TL1[UALFBY%QKXTV;2%^[
MU] ,U1##[WPPI2$-'XLGLLZWBWN9<7;K9F&Y%!MRT#=!(<I]XCX'Y%5)]:<.
ME4;9K.JM'-U=\#JCW4TTU$A&D0^\6-8XWCY37G+;AN]^<MC?>*D<\@9V)4:K
M02N^#78.8&CL/O4CR"44%CQ!9_[I'")6OG&224H/*2O+XYU$$MB,J"8E<_I9
M1U'F[F(_VIT?QA1"?Z=IS=83HZ/1=G9 .JHTQ833UB,KYZ$*_TQ\XE[>M2!?
MVGFZ+()DZ1N.WR)Y<_3!#[S]TO\?&ZXEJX0,UV0C2;PMIW21D793 ;M :_?I
M-JDBO+VH%;^7;9K>:84WI'2.OBCIV&.\?]7D:WM@JXUQ'U.V5S[-D199M4.J
M@*+OY6^GQ6^]E2] ]BE&KJI?#S'+/T4)3V.DYG-YE06L33#MZ9JQ7M.9$YOU
MP=W>W!?$NEXKG,@01F:WB43*DU] ?KA(A^WI8 WA1SR1*06O0\OS/6Y\JDW8
MY8W,(Y?7%S)B'W.+Z01/8DF/3#GFM\"*T[^THLY8QWX#!;8S^?.;I,]$32X%
M-32H^-J:. _Q1#R-^:W Y!VP'OP9<(LGYW^2,^N,M9 2]L=1EK!K=?#/,'58
M@+"M/_\>@496DGOVHY>9?BWS(#M[F^T<D%9DK1C141F,M9-!0*A:[V!S0QU:
ML3_E;V-$SP-M]H49[KJ4D[FH_7"LAU8D$JT:BQ#R7AVYO!5V)=IL,@',E=P=
M*YN._#123@-JV%C=2<A,[5_IADG5;0G,T^N:M:M39LX!EPK_:Q9)&5@5S%AU
MC!:\0S$EF-+!_4ZNP%@WCI,3E67TS.+V^L=#3!Z$/K!I$SUJ-.-UC1*0L$[I
M948;GL15 !W/ALX!)%,@WH704_S1$\MOUX'DQ@ O2F>&L7S-[;T]WZ=DOO"5
M>MQ0EP8WR72PJ-GS6:4%L=;]5<@4E_<XXCCS=*1H1O\7#A[_A0/C_Q\.!4^H
MEA08X0[L5W*,;2(1@M=[J[16.^[<T B%*&V"[PJG[M;<2.%;(AG6ZK";?-ZY
MLI;$.A)V:Y(J$4#<#@\A# #9/-0",A+P2P5E$/(RI>%((!=>XTV8O'S:.: $
MD<L\R W",^ [#%/!Q>3]H[!3S)ET_#X31$VOBYF3L' $AAVY87$R#R8<FJ>J
M:X1#)-<G5TG%/3DNNC4S;#$VU.YDJ&_Z#S#=:>(YP.L<0+,%5F^?H J1P,%4
MDV('R#&XM *A/X/1,.S9@G=6#QXXP)VFY@1D&F12 9\YE&FNAC"< Y3EJ))=
MYX"#L1,=*D:+9/]/L8%;2]%$U&YQ\1 1F/Q*T1;NWCTMJ$9V[W&,SAF)!-V8
M"50]XQ-D'L4XB#MH/VUIK+O)L67)W1<#VI>W=GN7A<@Y*VL'B4UB&; >'E5N
M^K(_R()1F?7&;_6)[^8V3@0?;O1KQ?C]0G4M1R))>H[S*B.KU']E60:>3%BJ
MP=LJPMT-1Q%!G_1\) HLT,T%CZ<MD5>JLCC%<NR%=6#2"O7!T&\#K$NPV"4F
M<G3R&?!L-.PJZ8K' ;SWR8RTU;UX'(_YW$;=EDH+.%?)UU,U<,S$]W+]^VRP
M?E$0S:6;U5P5 Q=+U8*L6]*R9/1-=&4SE$HE& S$X -!8PT)M\ ^Y=)NU5)2
MW968W>MI$(=*5*Z>!.FG_IAT%?HF^JOJ@V2;R=\.W#/@S*,%HC<W<9UKRMC@
MVBB[TA?1 C<O U9\6Z&T&6=#.\=ITS]JHOF&Y:0*D8L[<_P5X)EGJX:DPUN0
MU2?R-E6]9O-22_K;);:>B5[3B:%K0AR@![HJ)]]^G0/8J32G7W][&W58'2M'
M=R:SW"?P>I>=#6,HX4@_KN%J+MS#13Y9Q(V=6NF+VM="$>.)3=X_;S\]S='R
M07%NO=P2E TGM#>*3:=^AF29]9$ES!)V)G=D=VR$&ASI<UW9JN<-F*(41^MN
MQC^_[+XC09U$DHK^BWN5H_B_GLB5S_F.BX=4OL.RKT2I96ZJ$XDN>A?!2?AJ
M-@PEM;#&2F *'C4VM3L(SYA-R8BT-W@LF$B+$[P7XY/%)=,]=#U/5+MR9).1
M)?!6XN6]2"ZJN<.6RN@<I,[DL^DGR"N]:,OY1\E=60U_!F!N9<L#7/TVIE O
M5PC*B<-4U*\>%84/Z]5J:/^PQ'DBGD4J*8_&%.P:7$0\G)+)'MO)[-$GNI(*
M^M>U% ;C&_T36  T@D,E80..:-&<@)D(#)*18F5(\J^=[_7S)NS'9:4L;$UO
MI)4TB*I&6"C%,$&A#)G?JM*DZ7$^MO]+ *\Z4;&;^[__"H[]QR<\__@$.Y5]
M8-JU3Y&LSE@OY G')$<%L8'G%K<X*=#[HS+I%M,!\;G!PWG%&_6SRB4SK\ 8
M=0;:8O] NTX:8X'LR;,\.WBQR90607 "85[8%4 T&N#=P[R?^=[<1!K?EJ\>
MM'68!RF48-TM+ORX\DV/MH_)Z6V!($EBIX^LOI(?3U3'1B[3G+$O49:?M$_N
M^YLXVI+[9Q-ORL(2\*'Q"[846:/XRA"CEYW!KN+$D%CP?6&F*]\FPBZ=S;4+
MCJ)#M8U&V_D=J8^F,#U3[<*45G-*_">3Z[\3IU:ST:PL<T.$NX437KM>;A[$
MU-0<J\?Z#PS*=\2HDZ^0@SJL<L<A9T8F77C46L4_'?X<C P:(84F:5F?IE5A
MYN7B&E[]3 P8\NL"@\@6V!A_1F9%B B:=#K5]E*:M1AO*TW;;]V)QGJ8;;D5
M2 E_LB>$C2PSM0O#H0359"K?JD"((QT\R(!LC29%E58Y@AW VVJA)45;,U:3
M,$Q%^YBOG^B8B+VMB5+JZ2';-_O02,((3=@X/[BT9&FK'4!!?NYEQBS/-U#U
MVAISU >B'J X6:]PY=\AZD2RQ71Z+17376B7([GO*A"A#F;C?PC[78O.P^>
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MEUI4:;F]C1TT,TPM>._7IIA#RH)=/(JAWX$@.KP>F%$C)NTFX5L\:_KWTSF
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M:,AJA5PUF@Q$?P>8X)OIA'^:N ,@9YC@.<A==*P]] X0B95\!^BOG.$JWRI
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MF S!-WE<WHUJET@[W^F;O=TBSASSH6=[ RN3D]\\<]#&!X'?Y5#)*O]^$%
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M?$59L+>:?O%I28_LH@L9\JUFKFYKTZK7PXG%026A89OY%Y-M4L!ZJ]!99.X
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M9B=,E671B*W'_13 O/GH(!/ RL");5J1>%%0R:(S7,[- _]JXGU>IS]HF]I
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MI@S0LUN0BC<[,=FF%UD3#^OR'A$!I)D$?A$9;!.T9SY?JTE-P[%2,7RT\)'
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MN1[_M<PAC>[8G7"D0P1KZC2_L-Q='_NXE.!X[3-+7A'/,!89,&![Q&9^LH_
M.V;C[:,/7PA%F#YD]>_1V"U'2J\GX6QBTD"!C0T-RF([7/PV-&>EJ:\?"ZP/
M?#AL^_:1U#_!C1-HBRE(VB,URK=HI!#\R 2SAB5&E^T,8U_+-OQ'=9X"6>BD
M BTR$?%T (3/EC8:&-^M[=,Q=T0RY,?>"!U\Z^_88:3)XJ_FMB8P\"AX;JY>
MW2ZH3-7+AEMV_FA>*RB"<^=IB[V0I@B7O+>(9O7N^)/;##0KBNY>T+0X%S V
M_);3\8'W;#2VUT)+\GK3?Y<'?_GMXE*.WT*IRS_+\&)E!4$3KF*U^,(\#G![
MUM02-L9>3)=7W!4_BH?)Z[82$?20ND:-2,.Z'X.BJFA(_U&;RM@N:DG"@+!;
MPCVRA$>)+?7]GX-A"^ (?4[D5SRV=^^SI\,T^7"V2)6(&<W#+V/HCUT#R_H%
M80[K!5W\=%JS<D'E(S8N7Y:U7>QKU<7F@$ZSU5Y!O)@M?$(<?4&,JGK'[[@L
M>@%@]1M[2)=2J$SH3TB#8 _HG2GVX>*&3NP*%C*2Q^2 463B4X?QX>>6-#JU
M&X:^J@+Q#]_"EH;X9N>,_-.H65*+ @Y >N@1IKJ +IT%_1Y+@3JD8I%S#A!"
M!@9]0:D@GKC(%%_G'7:P(!Y\G5/2]&(3D[BH>.CU)+?I'4Q3/F2\FU$&7MWK
M@;]G*09'I>Y_4ZAW%V=@TH4I3FN3-KR@R7HCROWSB8/G8D1B3U&^1AE3QRH!
MS[MMZJOP&L^)%.J8&+E=)V#$;)AT >..X /D>VW6A@C-%M7ELVVE$1G*?BFF
MGM0D><*05]Y>ZX(PW&@IN$)<3Y,7/'_ZS]%4]4L0-Q*VL]Q.N/'%*AN_KW \
MAMUS4LCJ'6-BBG>HQWO;S6I0I0 6F/U&*6ELS>VQWQ^DCK-,?H'^5/5W%Z:K
MB#M S15D+P:2O_+]9] =@.0.,-=YVU2..@T,Z#6R9-;X0WUD#*VXC=;+*&G1
M"IS$ 41I,&XLO*^Q[AV>^ )^@$,#[7\\Y,;V M:X4NTF,^X\1IY>540@4$U_
M-D1B:^U:!9?29]RZFK<RD'$K='J\V"5^-+:2Z^%!9_DD$][C.$?U^&UFV_()
MX;K2\V1>D82$KTKAEAX;XS#]=9VWC8F"/3+-,1SQ1M,[3+]),M)L: R;C>E%
M^&J?B@4*-?WN<@V9%2=#EJ YK^H=P<)W +S[W,-DG,P*.U5/!:JJJG]^WC7#
M#Z?8S:#M>M2YQ*]@'#-H0ROZ,2A7^]6L>(S817YP[DF]V:)*\T4%E-[-,PWW
MS/Y79IP:CZ0F\*L-27'XE.>8XC,WGCN 0</W*0'^HJ:9H]??FI)<_%M/\ZR7
M:/U,1K'6S!J>]^6"[<+Q^F*_@+T*G610K(1ZNSJ16/D3L9^2A<V7Y4I%^2[]
M9T^5ZI\9% AHXA#,AWP1L2WZ*1[BT\-$">:]S2XM+6+O* _"VP^P!P#1(W$0
M'L3DYL\<O8N)8Y_MPN)!VI?MX2!9Y.;Z>,\=(+P&&:#[2ZQV$[_5KS1-ZH3!
MID"G\7'GM4%:#4EF37"R]*P8HV.^"(4Y1?J,'!74R=2BOWQ]_$CZR$\;?R13
MUBQ1^EQ+ZM#]J6N#5JX3)6Q#.]^$]"$6<P#6 P<L")W)"K+H%;P_ZMIZ^A7[
M--N,'UW@#,NW)!V!XP7WKT7$;&9?,H9!2OARE.F9"4USNL0*=X#(&0"",SK3
MA4ZK\DCGY>2Y6:4F&B:.*[9S\\3,HEB3Q-@ZD;_[^8E[&B[%]I #WDKL!G%,
M_H.VN:D>S)?U!;V4L'=Z?46E93)62O$4W[[]J&E(%@NV\6CDL\Y19N.RY8&(
M>?@RQ:PP($^^]E4AW6%N6OTR:C5H:J%Q/QNW]3W,)?FDBKE+CT;!JB(31AC,
M<88,<S3^B.!9: #XR6TQ"Q*$<"?&0XY8M#4BWJS"2FLKNYL9W<.%OAF8G'3\
M[!U^]5!$SK^:-=:XM)]O)TRQB"F&B4F.>PWZQ(,8-&+M(K^RN&P_9BO9C"CN
M%Y>X^-60\!M':2):.*)%(Q3A/%1S6^QKA B(DN/YAMD54,5C.A!<,>*<J;<H
MWY)MVQSMY63#-43BFEB?M;08-77ELCG^V"F4KV9:05 PKG#.]:2CQX6HV*UC
MW*WRF9N-;C==IE:\T7M;OA@!5NVU\%. (G=C :QYX^=W1#XOW8UO$R-C)WH$
MCOHUG#+B04_C(IW%R_.B-@.4\5+N;.;5%\P;IAG"C@C^PTOA/'GM]SK ,\+,
M6$PFV7$R<R$UC0T:+.8X\D?V76-@;$3$15@;PK+6:_T.0+B:ZSOYM5J0+:RU
MN>&[+T'MLHQ*Q1B)!@J)2J-O[7E0+&\3.@RB#.4"ZR!?054WBV4.%GK<>/9A
M[^-2+*FLTHPUT,Z:4DGBI.W"W4.-AI)26.V<&\GO.V2^S_B6"XIEO15L8+ R
M\VA.VUCE.0(^P&6I:\ II";!U8WPHHOY1'@2Q40O;K;Z^, (S3==,NE..S+8
MW-+62-+8ZS^[8AXU*(9EUKW#->=#=9K.'@,T^AU]>+.9J&\ 5_V>L*53GMWH
M]F1X8SN?^(C7Q_.&A6^BN%EDP#["%Z!F\OZ17 ):.M##"*&3A+*\-*6,#:YR
M@;DFAMAYR0Q8%^[!P$*#XK*Q&1=T7SC2;YF!QIEJU@U<%M#K7?C3%[-^(43R
M6A8-26+U4\Q3@OWI=K?Y$P,!LEI!_I&LQ.1#F,=D9A:Q<F5.]/!IC'/M2.C4
M@-<7\;CXP*J7XKQ%'D ],]/<C"2NM&&EM7HVA1\3Y:DVI*34.6,-TP+B=.<9
M5M'/O[TU6;^A;= 0I 0U\+>8^7/S\O3',- ^QP6*;&;P3^YGSDW\KG0H>NJV
MY3P1XWLECJNW?[JQR3&D99D5$*>=VL>F)97NW^=G-3K,=C]Q9L%NG/IIZ@I<
M-<;0!V.R?=8!/L!2N+KX5!"4CU05P\16=X3RSP/=XA0,D.Z-!XHM)R^_G"*O
M9/J;24O"2G&MZ+(IC=4=0"TP5I_K/H'-CF<256=A[]!]J.<IJC=D@:5Z!]0Z
M,9ZUJ5O"/#:;T*S1R?4$ZS>976M6:_3)@PQOS/ 3!4W1D^JL.#G;*:8-;^DJ
M$T5\"#SKS=/<; H(=P8:S=6JMQ\K_?6CUT:&40D(7+LZ82Z -J\CWL/MJW/Z
M2.7RZ.S%M]?JB-+EQ*/>_:H)58^PX_V$)Q%]3H)K?QG[F<[S93+BJUC0G_N.
MW>L%QWO#Z!%(TZ[M^IR-,UU':KH1%\>C,G:Z(UVQSS,K9N],JE@,DT6V>G:V
MPU=FCMR.3XI^N3ZS6$BW'?(*O .X-+:ET=@TYVN<4#]ERMWQVN[C>MS?URVL
MW7AU58;<[9((!<";8P3 ZEB=&U"L22=Q'#&L),>Q.J41AR O-_I)=<R1[1ZI
MUMXZM@X$HW'<C=$/H\L5=GA6M#AWZ%3I'<#)$;X\XN%%4;PQ8_<J..0Y1;RC
M@1IL&.GYPE),RB:[=67,J<RIQES5CRC#]YO\0"J?A+W+[U*'^-U,U2 *@9WD
MF+=?4V5L@C:!A2!C%[+^6I/NSH5*9ZNWXY1P/I[$;$H-.WXO.=>1#Z'6'E%Z
M/>4; OR/<LRT[4+<F^R/V#*YJAA-W(LS0[("1&-SK35C,##4<7#QE&B@?BV3
M]JW?(YYJ-9@)GKLX<21.TV7251\E]>/2/]"3D&,9^;3U<2-,1I'48LRG;#'2
MI<U%NJS!^- ARUJF4)9GM>9TUJ Y;S/0V"ZBR&T)C\R8-JK I\(IJPD*U/1R
MW_.$?_@4[ *JXXD,+$H8\9)]5K_"UZ=[]<RB?6S S5ZM^6S0IJ7A&^4!>6KQ
ML8U]>[[4LBE=T+:P.KY96_:$K:JA:C]BQ[TZ6M&5*4&B@- 7/\]TW++3(E@%
M_OI 4J)KJ[$V1/)YFN'T<1F7PXTJ2@C75H*;VT0W,D9(BIFAH,\#-M+-B/E.
M^8LS#,]YUDT>^J?;V2DT1?RS667EF-IR@K8'@98/P<L?OV(%JIX;_JA5PMY,
M/L*] SS"GX&&LB!E>PVO.^/7X/D[TWYW "PGF-\?:'7L^7FS"4N'AU2%:ID+
M]K#QITB86:3G+CYM";AK;5D  JOL77T,5LF$E6;!YS31(PCU1+ 1Y(NZ7>F^
MFU]%4*:>1.9^VJ)IHB%VW.0"&?ZV:?;6:RH&P2-9N(U)W8P<]F9GI"4;(R<<
MO$(K\Z@J$^9*A3!W,?5/%Y,P^O;\4F!J.&F?S8<4Z#^I,1G%H?08<U\0%]*E
MTJYD#\'[W8$W)T9(/;\<N(12F2J,NMY5,=/<.A-;+.WIH4"7,Z2;+M ,9MNV
MN@2]RA&V6.T!(7D8,Q#*)PTZA,X*S%,H+_&/L*^P@%A7*UJ+Z=GF4!7=19#Y
MD1E4#S;F=FS7V)0B,^9U$?/J;<5<'V4.J&<<;[P"^70CJ;7,TOE-1X9#@%_%
M7E8SY:SWT_+&!KV]6I.G=#$O4F7,Y3>'*+=:(0J<$6.C^4$;B@NS<\;(B$^_
M%;$5Z%>0;3U3QN.A@GI&4XUD0?Q;(DYS33Y]6_N8?I5BZ<YTHQQ:P(0L>WTE
MIBFFPYX-ESM 3"=Q+NA='YTSC*_YS:%1 %JEZ?JKCQ;[?!S-J]*Q&ABE(1[#
MQ(Q/0D&)V-&+H.KSRH_JT'FG5/XV+3?/2N]C-E[^O/D6ED7;=@^\-G);-G<:
M]"N(/2BQ@!)-A]*?1?$B'/HLN7_MP..7G;Y9%F 5\C64TMHM70;0*M1?-.:8
M0:VZ/)/J-8#J":["F* IAW YNT)0X%,5Q/.7YJ:J7_<D%)@E7Q!,/F58.TVU
MRZ%.Y0AN?28V4>SR#D9%L/@#&^K,R.;(1\FONILH3MZ>P^OCX21BUD,78]!6
MUSB>"4U+4V/)&X8ONO#\Q+JQ*YZ]I')SX?E@W49)IBH/4Z-T\#ZM*WNOL/$8
MWU/3N@LJFUZZN/=KA=4"XJCM]S"+W3:LV#.#E"Z0=3Y*)1?;.O-5QJNXE/GR
MAJ"CLID"_0;*6NBHP&S3I 8I#*948GOC?I$UC'FBD=S _3(?1PSC6O0&1^P(
MOKM!!:-X&+%Q$FO@.K1,^QO-0%*?-IYMHF8>Q9RO3G'Y"*QZ@ULT #_9P-,$
MZM4@FS>>V(81L_0X*3!9;V78ZU-CXQFL)849+3;\CR,1Z&N!"$V""D;NU(U4
M(D_$8(D%D70/-X_73V(*U!78_-YEOD#_NK[L.:$.'55X@#CY\5W]PAU!W-M)
M#M: <W0BR'KRQ;(V5KNT"NA<M*L"HP:ZS^Y9O&:BL76C->>8G_(.H"L<'VP6
M03A*FD%0\"LQ:+P?"W$.P4.SC,&K=OJG-K2;(]J5 ]9,_&3%IL5V$-JEV5X^
MA8NK)FW]];#EU3["XGV+9P.B,BG#7+0>95E_RI'%JW -$*V3(AW''!_885V0
M#L6#,$KJH$ ]0>@BQF,51)WRV28;DZ.NU?+*VM^ (N7P-R%$@:*]5))SIN94
M.8;0#64?A32&HYVXZ_DK[/JZ^RW:HAPC>N$H\?0-R1X/I+T+")8-<?[@%XA2
MA$*ZS]+-XU^&F#)A:97+%<Q#;,RN:-CG>AJW<@+-K-UQ5HW15/=72$-9(/O6
MD^=/E)&6';3UR++-50R4"3+^1F/1\O>J6T073+UKC$U_2KQ2RI5V32&=HW8S
MGLW)=<K>\6@3Y\,9IM'T*I:B"W$<TV/%M9S+>^*UK,DAAY"]1MIL5E-V9YJZ
MJ'^NJES?\U.9&KAPS2*M?QHO!?Z=X[,C[/$!,XSBQ&FW<!%T\.U4KMKTK^VX
M9-T!X+HA9A?54Z&LQGN=N'Z\FG)^3-VE-3D!\1<1\=W-'613'6Q:=&J^>QLU
M]:UQ^US&5X7[_/.OM^?ZT(1_'5+0Z0**9J+S]4AF!"*SX/7]'?>.N0>4!"'^
MVJ@=H(],KH)TFX4@I,M"L'M-=[*@V@J)Z]]%59?=/!3?@=FM[4JU'NK;[0:1
M9'7= 6S&D3S51\0(S('5^F)+ 204'KUY!XCJX T$]8>R(\?6(%$0/-3+]7':
MT'%34&2#V;*Q"^W/-L*9E?!R,U$8OEKC>[XYO>':Q<C7QJ&MH0.=<%WBJ-6F
MR)V&3B(PV2:43G7JO/=_T?55<4UX8?]30$5 I*6E54I2.D1*I)0>*3G&0'I(
MHW2#C!*0[H:-[DYI&;F!(.E&#ACP^OO?_-^;]^)<G'-Q/B>>^'[/<S[/,]]0
M30VN1O%>DYC.V'3X$L9/8!"1C5=9!*:&VG(69#C8DOH\&T+.!C:B,D]X45DU
MJIF:.EF[88'1G/S%@U;=IW?%\O;2K<ICPOO(P]>H<[1PH>7+QCB(GS0:PK-!
MAD^EA Z023I5HFN240?=+;> *!>-]/&)*/B-*?CW\E#D9;TR-3'\7/Z[-NXY
MT1CL%L#:P;;"W>B:7Y5<"&79*0HFS39-S6:>L0HSBRHXI 3&4 V(#-%/;C_'
M&C2[^!>N=!F"NS<[JC)9@)VB%>I<RU\O$BU%FB(5D6W8&-;.6\!Z'B+#L_C@
M2]7BVIH"/(!M2H:^8/=2<]FY9@TI&%Y15/]RN;1'D^G&.^V^'%"P9')2RN[+
MCW%?=Y1T)?<\4@,H-KOOS/?6K.=,SE)9F)(YY/7W9@FO;AVU)Y5@/_!-N\XM
M8(;Z%H"*V<$+XCWE3S:CX-F<LR>,:6([U3,#GP52">YG/)L=M=LOW[YH8I?<
MB,RQ?ZW2);%G.ADIUF[K*8XU[X3X0G)EYA=HP86*1T-,Y+7\XPV@3L<OS1'^
ML0D*$[S3/)CW._SE[;$#V1X'2FJT"4M%ME\\;.BS5XF<&A8(_WIU6VJ?U_'R
MO*M)4JMR<ODK*'A:7@3WY1?W/.(3W9.8TVRHS?QV-.8:'/Z0V&XO:J@^%W>G
M>I>%'<N_?-F879D/VMI9I1=0393=?]ZZ?_/&AMB 6)%Q*ECB N$A=DGD6%_9
MY\!A='(:)W)OGC!U%_W:."UUETZ2);_03UML):NJOF#WY42BIF4DX5]&B3@5
MM9%6GM2(0]V) #T"T)/)MY>MW1GYCAFR[?UASF+W8G6+<\Z])M0W?A.6I2W\
M&'#OYOQYO_A^E%JQ^E?XXB<ZH:V7Q?GU+T<_H[PV/Y]9V48I4B^)]P<AK-+?
M>SZUO4>NV48S2;]!/0 >9B;J-N:D^)YX7/*BR:I6;;D-WW:7?#Z'"%E&XO-C
MM?B;G<Y^A<CQ-H_=W(;+>]>E*(!'60RE&G=:7;/^T>:%7\T#G1\AE0W)0;W>
M16J%'X>9DM[^Y<O6T2,\@/["Y.H^<3'UOQ%6[W[*8'O:9=! S#+DS&0S4'!$
M A%8QW\-;EJWL7$3R4C_8>VTQB9$_[8""_]I[;GUG.EW\,HD<]/?KOO;Y >2
M&R3#>&VZ4$\**JC;PNND<Y-Z8VYCP2_.8# D\AQEI\/S;>AM+8>+A*QV;SNX
MU^1OZ$F/4_Y//J?*#3HOUR5W=Q=.5TX[P -O. &K^%1;R44-N/ ZKX&<?-%1
M"!H+8;@YE&57TXP,/LSM0S J+4,TIP>/*:V56ID@_.;$*%\P1+7OTA9+J0@N
M!OU4"^/)F)]?V;!F['>Q9M.\,%@.L1QE41MP56 NCKJA@C+VF_1?W\3^,-E]
M93BE2+@P"7["X)E5HF)-:%/&.^2FUBM2(_/%7&1][2X9+YJV5" 1#';B; W7
M:CA"N<43,'=-=#V!><E[?L,F/=JWZ\A8XIK/\K1"Q4H=JLQF^-=]S?1(\@D2
M.C;<--#1LGXOD@ =HMG+N-]]7 CZM&*RZP9<FX!LIV03]3'E:WZS]4_:3.NR
M_IZDXJ[ THT"@_A._.56KU' )LB&NAUB3^39TR48\]O@[X])6++(G(H77ZMS
M1+ZIY-Y4%U8+]UKY':9=/#H@Q7*J-:K^TBE,IA;T^")Q.)(%DG]>%@L;9?H'
M5\^87$UR0R8(#M(&,T'TWRP[5[N7>F5LCG_:E_#\(/+_^)AO4VA9,.EO<3-Y
MT,3&^SI&Q:<4#=L$\O*%_BL;W:VH[0,)$<1S_\GB_X(MQXF))S(+/0P5?S+\
M=A,CK:]4OD?L:T@D-DH+[]_7H4(\M2XYL(!"]^-QACD-BQR?%GT3%#8#>Z1M
M$]P'M<UEP479./(K\IQ4?.O_B]3< LQ9;S9E0J 1/W.S[_EPF8G_DG&8]J3%
MXJ=(GQH2#1_-";O=TW*3E^I<SP^XCPV/D[>6C[ET^;I_2MS8&D@>" &FQ<#.
M]UOTQ[Q30;;"^6^YDN8$Z*Z9*F*W7L"Z-DXRNI. S/).?M&\%OQ<?-VVXK5!
M'T:EZ3[&"0L=W1D>D/C+M)MA(\?8(=72(QH,$8,7';W)DZPLC/S8%+9.57.1
M2_-PZ >$CS%,;.(\H/I8BG9TBE7\IJ]#$K,=&7 7+SA;X:DI=TA2?1<'XJ\D
M6G:7S5\"&<#<C J 2];&ZBY\(NRU^NE<3KSUUKN5;W<9)="=ZC1 -JV7EOK?
MB"@.Y>S$!Q3YZ,)B50D!\G1X^EL X4T-1O7@U;I@7"=A!P\NL^L60+SO"0'V
M,ZSUR,K=[)Q -/3FUZ%5;/7'7$F,9O?.?#H;JD3[8@80)5SAHZ2*UU%-V0_6
M@5;T33 NM8TH8SI2+[GI[CNJSSGLW>^:/F-Z-LZ6:;<W8?!Q4NB=_]:C2A;R
MD?S?)$DD3$\YA4SMHWI\BJC2WE"H);= O+^IZ>3#,D08:B"HYF4IF.1(%/!)
MU19"F/:>3FFCN0+]A+'QJLS+;IY-!2/ R^(G8@CP[_'G=#KH][D,1L>_G2T2
M7I1(7V@6!CT+C5Q^) GX 5NXAU:)>\[B1C_0LYL8X\I!R*(7'B0/W4&XC  E
MZ Z^)@@)]SY-3W@NN9R$ZH2JD(0/T@_+Q)$Y=H/87N^QOZ'7WR1]I,,F3?7I
MB:U5S%VU=W$2Y=H09_3/H3@#SHFM=97I0TN]6P"EW).R;?H_^4U$KJ2V,:TP
M&V^+%:N4,\1K"J\DI5-Z&?+6X R\[G\E$/Q$KXO;?-%K(6>!CSI!$)YUPZX+
MSSV@1<19*O)KAME9T_3R#PVP$MCQO"6F(O^:Y>>J"? BT\1_B/?L3#46HL3^
MH*<IT11^X1Y'7>5&P/(PJXUE#I?RCWLBKK\%L-_,W@+NMI'FD)Y"7O<:XWRQ
MK&I8V6M8JK?L-R0L8^<,E*_.O_QV!BD:@A95VV2<4C0@^(?@ES#GZG!,9^_:
M0^AG,H-MXWCEGQY[U'-%Z56"GF2P$N[V;-07UH85R5?20-<[4?F/)6;@;3-D
M$P<*JM3+T?I-KSL4_I"Z-9A;VJ.6G_4Z<\B"Q^6(=Y!K83=D?F)38GOI]G,-
MG80X:ZTYS5%I\]&211#M/$)$6Q1,(M:7],;$RTUX?W\X.6JNC7+-XG[DXF(T
M]W1P$"!.!Z9W!W!UE?I';9.@<,XE5S]M4!!6WOXQ3IS[54I:<L.#Q3261S)U
MI4.<XKQ;+E&!]7][79 DVO4S<L^@MI[E_ S@9*O?:\M&-6 <J:$:47F/&4]L
M1)*D?DKZA_C4[SE1G61R@HX=7+58E]X<9O6/+;)9#8:K="T)MP";73G3B2.7
M%X7Y&5Y"7SC$?U/$KU+.[<F3BKE$T-4,6VV0W\N2 WK#8ZL]VK56#^D13F3B
MW+',>N$P'>K60]+6.-H@*7DBG(@BSAMU+=(C1U^KR=N;H5_8'AK:Q&8PL8HD
MBENEX:ODH(A/DX1L<^('>1)QQ5B6&515JFOI+D*H[RFB*1NY-FG4,0LK9S35
M8*B/!(ZHZ[4Y5M9(N0 L67]P31^:B(>QOTO.^G/(*31P16@SS)!8&[GN/+$O
M8LFT\ W7B[+XVL$^!@\0FTK6256!SU4<V'HE_7HZEQO"__KE*/O]J-TG'U4Y
MD^ZRJ1"P!\DX+J"YXOL"0Y.A&[WKC7&EA2L7B2^O][G%C!;K@GC)!G.^ 3ZI
M[UD44KFCY.,OB((Q*N$I?[0"J$UL[&ME>8\#+?X-8+:[D6>A*.DG#>V4_-PJ
M4+^QI6YJ%X:/RZ,O?SV:GDYL_G[@K+Y]$O!>'D6)P[NG_%>W_;7D[H-;0*@V
M:%+W>[SK*4W=TOU;@-6IS"U@BR5'*3NP+W#=(L6BZ<971O-L'G.2#,S<8O C
M<2\$#8NMPW;U@P,],!>ZRX*POH-T3FB/WU0^$P-^ #O8Q5A-BYL^WN")/]7D
M?7W3(^^D(:V>&-N-^.I#*T2/E4@RU#,$1T1'TL,'6.]U&OUE3SIP8ME20U*1
MQ;PW >Y+5RBW: CF\(DD,H3V%JA82*9]DD3ZN:-=NN+O^[VM;YYR9CF4^%L%
M\>1,U>Q<>@Y45_FSPIQU/E+6:JT2>;$-8MJ6C[- IVZ-;V &IP)4$T%RS\/[
MY1Y/>9(3[N8L#KO0=(;_%;T%- 0.R1NVQ=Y)R2<5] 8.1+?RLJ8]3/D]:PA%
M!L9  AB@7[0[9[5JH7!#@87YTOOCA(^2@,!!5U?2@C&VL%VU=]M^X8Z1>B\.
M=N58_40P/+U+:AXK=^>7WH?LHNP3!;C1R,M5>HK?34G*7_:G8XX;TKY_84PW
MNF=V"V &PY "J66[E]R5N<O*5F!!/*>(Z3 I@VW[+"UA+T@FTL,IMMO85C7$
M^EM$Y-W0?K7)K6-T\8%G/I1G\%4.)@&OMF SUR;[ L3-RPVS 2I,U/8_>P?4
M*$%>9S^!)QWYZ%)PU+^I';XTQJR='> T4!;!V0]PN1L6E(.@TCTZ5U"R!4FI
M8)'_3"_$1:0K_4J4]K4!70"DE;^A_N I;TWU[\Z-P6@9'O0DDJYO&H3D+O?S
MU'Z\MM;^_=6KQR;P0O%\V?Y>XT'2]_6@I)%]-D"I[<11&6U'=!/&,#9WVH"5
M^D\MR)P9=JSU3\"LU3J,@VMG3AV"H]"^OBD^!.^XX6WN3112^=)6;@#Y?$$D
MR<96; 54WS.>:!DGMZVS()J9>4"@EUXI8-5D7-D#.B@:FU9^WM+PN %AT$6D
M7L2G0Q;3.93:%QA^\PH[V-?NXUD\YZE-:[%[;H$4J?R3)K8^&[UD+II0/TJ%
M_^O*7-?6S&(3X'S]ZSJD'L>Z$=%&CKIJLGB?HPJG\\:"*$0IE&W^L"$0M*1H
MA[SZ5FA_WSAIW3[(C$FE9*!#%GL+.*!#58?042A98XY&];!F<4T+TWLMA7WN
M[Q".[$>HD >$\+_.OUG0/MDJS?;?OS!!D0#I\LF(EO#>G*_9CW&2/L6KQHJD
M-6:.&?UCVN)5R*^N-9&TM(U)*WSS.E%JV>^G7X+T%:KKY>TGO\C7352O7\G'
MY["(/A=M-]3XIL'./]Y>6?FGWBSO3%9@+K!AJSW#LMZ4J_[;G<QMO9&%[<'_
M,@+< LCE>!=W6,2O'BJCXQ\O#?J7@(8Y$X"_'+U<6)<J_7[60*B^LMHH1\CV
MTLF+/Y+49L+-]%G0^8FA4C#]*:N1A3B6GTNK?P9\QBNGFC+]$&YT,-E8[E>U
MWD@F6XHC1<!-P0V!G_MU9L=S4"H8X[BG#6]&U H-YXDGBJ<S)2UMR<N![81X
MVQ)5:"6[!(B)@CZ:=[[HD/8SONG'Q59#HS]@[Y46*((J-.S+04G71<RR[&&J
M1A7%=6SKO!Z9UK%I""0!8&S,_<,MH%LVX$GDUFP;L 07-J,"X5!O:I^JK#Q=
MHL.2K73!W88?I=K+I++:J7<E1BE39U(7C.0VG51Z]V837N??/(%.JF'#HJWR
MH)W*\YSAVMCO1V; HM8 0=,W" JS CA&'3 V$Z&D_02I1$J@P"I/CGMVDV@K
MGFZ-^@L ?7YS[G#&,';Y8>GCS?0O:A$^WP.#D0,:OPM:/1O.V&('Q^LDG,C5
M:[S,? <CSL( \R.VLLJI7F+^T&F]K;F%]A8 :C=:?T4J1J^1]MY0<[16ZRUF
M#E\-G;PA'K]2_&,N 1Q7TDZ"W#ONIX7!4L4S0KM@9@([88N5&U%DDV?Y[)G6
MOPD^-?EPZ3&6G[>B#+MO >$61#?,.&D%+&=&5:%O_DZ]J:FJS_/FUOKVEKJC
M\R7>=]$<PO3(W\8/>2\4"8-%%%C=]E@;M!(+=UOTX9'Y9K(G=?RAJ&:86L.>
M<55_F\'-V\C?Q'7^TRV]A'G<GX):DWA7&PZD@48'['/.E7V(NM& #^I-5[J1
M=OJ@CZ%D!=,#[#:)SD]C\U>)+PP#M/O_"1B> !7/:+*3$9>.EFYU:+B8\R23
M_@"/ H=&5F6K6_K,G+OQU:K\1-X""M["CQ]\=^N_OVKR!O.O;_\GX[LA0V&;
M@953P# #2:O+BWFC2OYJ&'35WIA0P_5W;2R%KFY\6G\$D>^*ME9K75M+8L$,
M9[)B4RR_F?/'5Y3*MGS/XA]^2^![3_?K*Z?#8W=VH<'=Z@/^]2N+"'F,EDMT
M!U&'SEF X,)?O+1'H4888JY#W&1Q]"B$Q*\NN?M#MEYI-VOLY^V($V8I38U>
M[X4:[?(E8 D<D0%V00Q<IK7X>"$?K,!%5)NMR:Y""=.)^P-F\'Y8K93U>!S/
M=E_GD[U40?L\G'5_*L-6L4?B1:6+=;&?2T-3MFU, M,@ RT@0?B>VMV&5 PH
M<&%W[=(Y,1S?5WV)N06<H.43<F)8:V\!@X&+6:>5UBBZ2*=&5@)<QOS1_ @Y
M1:"CXT'1WG-_SK/X<O^X@RJVH_2,Z14OF1<AR%>$B?&@Z^3.]=S+K<QJ',>9
M+^XO:JF:R-'$,T;*O'&#9+"Y<=I3NC6?(@J-)-GWC]=*H'87_>$SS<KO%6SA
MB[N_81".W7X[=R!*;#W+5U%5L56?\JL#]Z2_A,X QG;WC5GB7R_1RJV7"L.(
MK:-JI/>9'LYZ@SQ<CF=!T$.M$O^FFG0*5P;E>35M[O/QKW;(@%IA+'*Q*N^%
M]C?,DU\<-E\'[+9G#;/E9I27$>*?$>':H4["L(SOB'N7_GI+([9J[&I%;FL=
M\GR9>7JDD7 #B6H+3#M^X5*S=3*7_WO&5S<SI)E99J2S^*H-/?S-ENV+"ID4
M>+P'(/ZE,U,@_S\,?2.%.U:?W\*89[IZ>Q?N(.C4-YY4]1^;+6D2#45KAZLA
M8"H/&=2PK](R^1/;!I%RCM>X?\JI!F7L,PF(YBZL6 9EQ&6"P06.7H8]HB%'
M%[/\%093$ZWIP2SOSJL2@:.]P/K@K9_W?[)PM<Z>!)*GO\F (FI:DKR2^XR.
MVOKU*<PFO1OMXY;'E$9%ZU6RWQ-^ZC,\CKX"X1VPQ0>L/BC!8(98>##JP/\T
MR\6TK0VSZ,OK;Z@<@G3PN 6\TDV^9T9Y,K"YU(A6]5@U4E $W )4+"C7WF*]
MOWC.SQU4Y4V)F0EL:,ZRS0AP)!G4&9WGJW]+=6M+-WY\SS+S/?<3HDY88%2+
MX1?/O\CP/KF[TYZ^X]S(I0^8PK#T<K.=F15S1K$0L[=(ZG823BF#X:?038OZ
MBB'V],S?1 X$BW)".,F&ZD5&$TQ.;PZ5<OGN*PM,C ,+YQ>-*#'8W,?6*,F3
MUK 9?5<(S1C,A=="FBNC?;9>G6U"7K:#H/]*4:"V?+ <W"&.S0F2(2;)(E>,
MVYI@?J704=L4A<1T^Q6/QCVS%,D]:EM/VO^]]>+T4G>],_3R1.I5WQKU.+K4
M?MH9<LIV'6P9[T*4W<E<H%Z\*Q6:LNQX#GN1L#S.WY<_G-#U9VAGBQ<?N9&#
M]$57?VF31=\"OA1W27E^/<^P2SDSTUI3 E'UF>OICE^7%Q@-UZVJ?KHZY-*S
MIAE3%^[QSG]Z/U-U0YX,MS;0DAH#\6.'?68-?3K30%+Y_DH/MJW?/B<689EJ
M&F:CBH#[:@#3_%)F!>$^E0W!YT8!L)O)6T#C30X*(MBKC;H%A"';K]LRVAB4
MYTOYSFBE2N -'[F:9S;2"[[OO#0W-59VUL]@S!7K8GU!*4\KQX"#GQ:EZF #
MLJK,?ID::;NC'3SVGGDTY5PI>[6%=4G$^>9Z@YOYMWX1OCOR"6./DAO#$3/I
M0J=[WV,N1PO6S*#>>I&,ANR32K M*C>X1M'S2'2T;JQR;IMN!%)?L<^W\"D3
M^4$L5EXO_BQTWL^=.UP67O^/_--LY18LCKHP-_9OM5F+5&0D+<I@-8L':/B=
M#U@A_2<QK<AGK^TOF?_Q67_\I]D 03_Q&<;^<Q/N1%!)=Z$I%*P]8YUBC\@@
M&LBU(FI<4HOGRNJ1>!;-KA+$0<B;C)_ 6^)4L51],_#:$NB@#C8F(RZ_<-*]
MS$&<?6M-(72S29U[[E1-O(LMT43B;-AMX..#-VX4O'\%<5S546W:*/FH#$3H
M:26#=)H?/?I;7?25X<%CN6BK:B6'OYX%.Q48'[A4Z%1Z85/LN\PCO[J@G_=/
M7YV-JMOY,V>3/5,-9#X_F^:,Y^J!4"JU4_F1OWK$P$4Q$.2.J#1 :&@L^6NA
MC1G\I2>S74O'?R^EY1Z+IUD!)0FGTR..L]ZY%6B,Q?BJHGF93?QCR7['D 3
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M4"G3FW,"GJ\ZX&J6=6'R<L"D=S\N>!\+>'^](\GV^3'Y=LZ&(9ZZ\ZP4,WA
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M=0F]OU^P2P?ID9Y@9*W1<;'NC"8K;R[;W-7$-,7]::\K8(?[KY#<TU6%0O=
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MN@2V@=?53K,EJ?V>K:24-*9$)19&)M+S3TOH1!JU7M.O_UV\!2@VI:I ;SB
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M]DJ5BZQ<6E*W%4[0WS 0^FOPVIK34@I_D#QLE73/U2+S+!#S=FW1Y8;*WWY
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M(NJZV:N*8 B#%8YI0&8N*H"H^ ;@Z,1B?B;5^*Z;C 7)+H-<8SQD:(D$Q<6
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MF:HUF,KP,ZS5#O5II6.OGKG$G-EH>V[++V?W2=7>(,L9K6:35'/\GRZ&-&S
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M*J!@GU6A6C;']Y8%WVP_>(S:CJ*&M?S]H]>"X_QQ&\I"KVV_M-7\%/STL!P
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MKIF>H%<;0X1:"9<@QF$=J<9*/.0G+>"A5<6):+\-[TM76C)'GH92:F#V +-
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M-0-4W%SYO;FD:WC4HX;Y1=VY'ZQ_J>$O^K@_UZF86!V0::Q($"1@U3]'4S[
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MK"A(;QF=T.\]C'1,XD@>T7FV;?(JQTOW!V/4S.+4Y+@3'V(<&"O^S #B907
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MM<:?U'%W *U(@XLSQ&5GQSD-PWXL5<<$:#RH_93C JDW,06?=O'I>G@VV&D
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MK9=V!]J_5]<JBW!8JI];TKO^9<50_PG+=B'=;17/E,0#D8[:<[]FPE5^@\^
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MI: W (W#S_%@N?YS'/#1G?<P2R="9\$A.8<U-] +;%)/-?5\5\DO!_3HNQN
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MD?<W7_#>N-)-2!N.A:[ZGP?\//YO4$L! A0#%     @ UWUI5#\?QQ=?)@
MKM@   T              ( !     &5X7S,S.3DW,"YH=&U02P$"% ,4
M" #7?6E49890<&D=   DN@  #0              @ &*)@  97A?,S,Y.3<Q
M+FAT;5!+ 0(4 Q0    ( -=]:51"F5UH) 4  /HL   -              "
M 1Y$  !E>%\S,SDY-S(N:'1M4$L! A0#%     @ UWUI5.F4!GN? @  0PH
M  T              ( !;4D  &5X7S,T,S8X,"YH=&U02P$"% ,4    " #7
M?6E4\B]BPD$(   W.0  #0              @ $W3   97A?,S0T-3(X+FAT
M;5!+ 0(4 Q0    ( -=]:50A?.!_* @   PX   -              "  :-4
M  !E>%\S-#0U,CDN:'1M4$L! A0#%     @ UWUI5*T*@(J\!   8QH   T
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M,#(Q,3(S,5]D968N>&UL4$L! A0#%     @ UWUI5,GP$0TT5@  VJT$ !4
M             ( !M,$  &=O=G@M,C R,3$R,S%?;&%B+GAM;%!+ 0(4 Q0
M   ( -=]:50%O>,IF4(  !FK!0 5              "  1L8 0!G;W9X+3(P
M,C$Q,C,Q7W!R92YX;6Q02P$"% ,4    " #7?6E4WEY/IJ>\ 0!#&Q  %
M            @ 'G6@$ 9V]V>#(P,C$Q,C,Q7S$P:RYH=&U02P$"% ,4
M" #7?6E4'8\-[E<+   $#0  "0              @ ' %P, :6UG,#$N:G!G
M4$L! A0#%     @ UWUI5"#JX15Y#@(  AD"  D              ( !/B,#
@ &EM9S R+FIP9U!+!08     $  0 -,#  #>,04    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
